<SEC-DOCUMENT>0001104659-25-086669.txt : 20250903
<SEC-HEADER>0001104659-25-086669.hdr.sgml : 20250903
<ACCEPTANCE-DATETIME>20250903070552
ACCESSION NUMBER:		0001104659-25-086669
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250903
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250903
DATE AS OF CHANGE:		20250903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRECIGEN, INC.
		CENTRAL INDEX KEY:			0001356090
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36042
		FILM NUMBER:		251287732

	BUSINESS ADDRESS:	
		STREET 1:		20374 SENECA MEADOWS PARKWAY
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20876
		BUSINESS PHONE:		301-556-9900

	MAIL ADDRESS:	
		STREET 1:		20374 SENECA MEADOWS PARKWAY
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20876

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTREXON CORP
		DATE OF NAME CHANGE:	20060313
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2524946d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:PGEN="http://precigen.com/20250903">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_PGEN_precigen.com_20250903 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20250903_20250903 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001356090 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000004" name="dei:EntityCentralIndexKey">0001356090</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pgen-20250903.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-03</xbrli:startDate>
        <xbrli:endDate>2025-09-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>



<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_906_edei--DocumentType_c20250903__20250903_zS0QDlI7p3H5"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_909_edei--DocumentPeriodEndDate_c20250903__20250903_zWOrz3sRqggf"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 3, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_909_edei--EntityRegistrantName_c20250903__20250903_zcq8jWiAXD76"><b><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000011" name="dei:EntityRegistrantName">PRECIGEN,
INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center; width: 34%"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20250903__20250903_z2U7TfomcxEb"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Virginia</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20250903__20250903_zng7tuCdlXZ1"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000013" name="dei:EntityFileNumber">001-36042</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20250903__20250903_zBqcfv6bpuP6"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-0084895</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of incorporation)&#160;</b></p></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)&#160;</b></p></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20250903__20250903_zb65lcYBff66"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000015" name="dei:EntityAddressAddressLine1">20374 Seneca Meadows Parkway</ix:nonNumeric></span></b><b>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20250903__20250903_zzzd4kFOJJ48"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000016" name="dei:EntityAddressCityOrTown">Germantown</ix:nonNumeric></span></b><b>,
<span id="xdx_90B_edei--EntityAddressStateOrProvince_c20250903__20250903_zejPT3m5yefe"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span></b><b> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20250903__20250903_zirHvo6dkycb"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000018" name="dei:EntityAddressPostalZipCode">20876</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices) (Zip
Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90F_edei--CityAreaCode_c20250903__20250903_zY58mdj8JjQ2"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000019" name="dei:CityAreaCode">301</ix:nonNumeric></span></b><b>)
<span id="xdx_90D_edei--LocalPhoneNumber_c20250903__20250903_zDJGH1OfliA4"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000020" name="dei:LocalPhoneNumber">556-9900</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed since last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration: underline">see</span> General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 4%; font-size: 10pt"><span id="xdx_90A_edei--WrittenCommunications_c20250903__20250903_zBlLUjOAYP4" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the
    Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 4%; font-size: 10pt"><span id="xdx_90C_edei--SolicitingMaterial_c20250903__20250903_zuk8ZAnpFNDe" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 4%; font-size: 10pt"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20250903__20250903_zNoP5zykZ6pl" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 4%; font-size: 10pt"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20250903__20250903_zs6PjrJutbM6" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities registered pursuant to 12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 1pt; white-space: nowrap; font-size: 10pt; text-align: center; width: 34%"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Trading</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Symbol(s)&#160;</b></p></td>
    <td style="padding: 0.25pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name of each exchange</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>on which registered&#160;</b></p></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--Security12bTitle_c20250903__20250903_z7BYHG0h1yt3"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000025" name="dei:Security12bTitle">Common Stock, No Par Value</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--TradingSymbol_c20250903__20250903_zofvoysHmV38"><ix:nonNumeric contextRef="AsOf2025-09-03" id="Fact000026" name="dei:TradingSymbol">PGEN</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--SecurityExchangeName_c20250903__20250903_z9pAirly7Yc5"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20250903__20250903_zfjcDzSGENVc" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-09-03" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01.</b></span></td>
    <td style="font-size: 10pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pharmakon Loan Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">On September 3, 2025 (the
&#8220;<b>Closing Date</b>&#8221;), Precigen, Inc<b>.</b> (&#8220;<b>we</b>&#8221; or the &#8220;<b>Company</b>&#8221;) and certain
of our subsidiaries party thereto as guarantors entered into a loan agreement (the &#8220;<b>Loan Agreement</b>&#8221;) with
BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders thereunder (the &#8220;<b>Lenders</b>&#8221;)
and BioPharma Credit PLC as the collateral agent, each of which are investment entities managed by Pharmakon Advisors, LP, which
provides for a 5-year senior secured term loan facility of up to $125.0 million, composed of two committed tranches: (i) an initial
tranche in an aggregate principal amount of $100.0 million, which was funded on the Closing Date; and (ii) a delayed draw tranche in
an aggregate principal amount of $25.0 million, which is available, subject to certain conditions, until June 29, 2027 (such
tranches, collectively, the &#8220;<b>Term Loans</b>&#8221;). The Term Loans mature on September 3, 2030 (the &#8220;<b>Maturity
Date</b>&#8221;). The Term Loans bear interest at Term SOFR (three-month tenor), subject to a 3.75% floor, plus 6.50%, payable
quarterly. The Term Loans amortize in eight equal quarterly installments beginning on September 29, 2028 through the Maturity Date.
The Term Loans may be voluntarily prepaid in whole (but not in part), and are subject to make-whole, prepayment premium and exit
fees, and must be prepaid upon a Change in Control (as defined in the Loan Agreement). Proceeds of the Term Loans will be used to
fund the Company&#8217;s general corporate and working capital requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our obligations under the Loan Agreement are secured
by substantially all of our U.S. assets, including intellectual property. Certain of our subsidiaries will, on and after the
Closing Date, be required to guarantee our obligations under the Loan Agreement and, in connection with such guarantee, pledge substantially
all of their assets, including intellectual property, to secure such guarantee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loan Agreement contains customary affirmative
and restrictive covenants and representations and warranties. We and our subsidiaries are bound by certain affirmative covenants, including,
without limitation, (i) information delivery requirements, (ii) obligations to maintain insurance, (iii) preservation of intellectual
property and regulatory approvals, and (iv) compliance with applicable laws. Additionally, we and our subsidiaries are subject to certain
restrictive covenants, including, without limitation, (i) limitations on the incurrence of additional indebtedness, (ii) limitations on
the incurrence of liens, (iii) restrictions on the payment of dividends and other restricted payments, (iv) restrictions on investments,
(v) restrictions on asset transfers, (vi) restrictions on mergers and similar transactions, (vii) restrictions on amendments to organizational
documents and material contracts, in each case subject to specified exceptions, (viii) minimum net sales and (ix) minimum liquidity. The
Loan Agreement also contains customary representations and warranties, including, without limitation, with respect to (i) organization,
authority and enforceability, (ii) financial condition, (iii) compliance with laws, (iv) intellectual property and regulatory matters,
and (v) the absence of a material adverse change.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loan Agreement also contains the following
events of default: (i) failure to pay principal, interest or other amounts when due, (ii) the breach of covenants under the Loan Agreement,
(iii) the occurrence of a material adverse change or a withdrawal event, (iv) certain attachments, levies or restraints on the credit
parties&#8217; assets or business, (v) certain insolvency, liquidation, bankruptcy or similar events, (vi) certain cross-defaults of third-party
indebtedness and hedging agreements, (vii) the failure to pay certain judgments, (viii) material misrepresentations, (ix) the loan documents
ceasing to create a valid or perfected security interest in a material portion of the collateral, (x) the occurrence of certain ERISA
events, and (xi) the occurrence of a default under any subordination or intercreditor agreement, in each case subject to the grace periods,
cure periods and thresholds set forth in the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other
things, accelerate the Company&#8217;s obligations under the Loan Agreement (including all obligations for principal, interest, premiums,
makewhole amounts, exit consideration and other additional consideration), terminate further advances, and exercise remedies with respect
to the collateral, including taking possession of, collecting, and selling collateral and applying proceeds to the obligations; provided
that upon an event of default relating to certain insolvency, liquidation, bankruptcy or similar events, all outstanding obligations will
be immediately accelerated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Loan Agreement
does not purport to be complete and are qualified in their entirety by reference to the complete text of the Loan Agreement, filed herewith
as Exhibit 10.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 10%; text-align: left"><b>Item 2.03.</b></td><td style="text-align: justify; width: 90%"><b>Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant.</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information
set forth under Item 1.01 above is hereby incorporated by reference into Item 2.03.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.01.</b></span></td>
    <td style="font-size: 10pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of Precigen&#8217;s press release announcing the financing transaction
described in this Report is furnished as Exhibit 99.1 to this Report and is incorporated by reference into this Item 7.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This information, including the Exhibit attached hereto, shall not
be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by
reference in any filing under the&#160;Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="font-size: 10pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; width: 10%"><b>Exhibit</b> <b><br/>
No.</b></td>
    <td style="text-align: center; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: justify; vertical-align: bottom; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><a href="tm2524946d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#8224;</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2524946d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement dated as of September 3, 2025, among Precigen, Inc., the guarantors signatory thereto, Biopharma Credit PLC as Collateral Agent, BPCR
Limited Partnership and Biopharma Credit Investments V (Master) LP as Lenders</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><a href="tm2524946d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2524946d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release of Precigen, Inc. dated September 3, 2025, announcing up to $125 million of non-dilutive senior secured loan financing</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 100%">&#8224; Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is
the type that the Company treats as private or confidential.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">SIGNATURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Precigen, Inc.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td>
    <td style="width: 50%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom">/s/ Donald P. Lehr</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald P. Lehr</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Legal Officer</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: September 3, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LppGBe2jRYtYRYqIr8GuEmyzZRP/juQtjS3isrAsM9+MELHIaWlqZDjOywL22LS19gglnpHRnjA4stU6hXBLvBjnWVvfvT8wo8BgYCYDNdJB6Kx347BKQU6HcjxUY5CjVM1gtxHRV8/Ink2F1htdg7YV7JhaNug1v/qEvX6SpebVVR2QnSGbQjKQvfwGJRMFW7rrB/HVQVFkIoq7iUTOdGuDa/H0aL8kLGpsQp3r6f9GHwp7SpM= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2524946d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II)
IS THE TYPE OF</B> <B>INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED AS &ldquo;[***]&rdquo;.</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>LOAN
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dated as of September&nbsp;3, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">among</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>PRECIGEN,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(as <B><I>Borrower</I></B> and a <B><I>Credit
Party</I></B>),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>THE
GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(as additional <B><I>Credit Parties</I></B>),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>BIOPHARMA
CREDIT PLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(as <B><I>Collateral Agent</I></B>),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>BPCR
LIMITED PARTNERSHIP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(as a <B><I>Lender</I></B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>BIOPHARMA
CREDIT INVESTMENTS V (MASTER) LP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(as a <B><I>Lender</I></B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCOUNTING AND OTHER TERMS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting</FONT></TD>
    <TD STYLE="text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined Terms.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SOFR</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LOANS AND TERMS OF PAYMENT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promise to Pay</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Loans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Interest on the Credit Extensions.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requirements of Law; Increased Costs</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes; Withholding, Etc.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Consideration; Exit Consideration</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence of Debt; Note Register; Term Loan Notes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDITIONS TO TERM LOANS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions Precedent to Tranche A Loan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions Precedent to Tranche B Loan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Conditions Precedent to Term Loans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenant to Deliver</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Procedures for Borrowing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS AND WARRANTIES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due Organization, Existence, Power and Authority</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Interests</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization; No Conflict</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government Consents; Third-Party Consents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Binding Obligation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse Proceedings, Compliance with Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Act Documents; Financial Statements; Financial Condition; No Material Adverse Change; Books and Records</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solvency</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Compliance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Margin Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries; Capitalization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full Disclosure</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Corruption Laws; Anti-Money Laundering Laws; Sanctions; Export and Import Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Care Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Approvals or Licensures</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply and Manufacturing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity and Data Protection</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Representations and Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AFFIRMATIVE COVENANTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance of Existence</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements, Notices</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Accounts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protection of Intellectual Property Rights</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Books and Records</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access to Collateral; Audits</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further Assurances</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Collateral; Guarantors</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formation or Acquisition of Subsidiaries; Designated Guarantors</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-Closing Requirements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory; Returns; Maintenance of Properties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Obligations; Maintenance of Regulatory Approval or Licensure; Licensure and Designation; Manufacturing, Marketing and Distribution</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts; Collateral Documents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protection of Regulatory Materials</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEGATIVE COVENANTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dispositions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fundamental Changes; Location of Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mergers, Acquisitions, Liquidations or Dissolutions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indebtedness</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Encumbrances</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Further Negative Pledges; Negative Pledge</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance of Collateral Accounts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions; Investments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Restrictions on Subsidiary Distributions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subordinated Debt</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments or Waivers of Organizational Documents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Sanctions, Export and Import Laws, Anti-Corruption Laws and Anti-Money Laundering Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TTM Net Sales</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum Liquidity</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVENTS OF DEFAULT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment Default</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenant Default</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withdrawal Event; Material Adverse Change</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attachment; Levy; Restraint on Business</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insolvency</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Agreements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Misrepresentations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Documents; Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ERISA Event</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intercreditor Agreements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RIGHTS AND REMEDIES UPON AN EVENT OF DEFAULT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights and Remedies</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of Payments and Proceeds Upon Default</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral Agent&rsquo;s Liability for Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Waiver; Remedies Cumulative</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demand Waiver; Makewhole Amount; Prepayment Premium; Exit Consideration</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHOICE OF LAW, VENUE, AND JURY TRIAL WAIVER</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENERAL PROVISIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors and Assigns</FONT></TD>
    <TD STYLE="text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability of Provisions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Correction of Loan Documents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments in Writing; Integration</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival; Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorneys&rsquo; Fees, Costs and Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of Set-Off</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marshalling; Payments Set Aside</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic Execution of Documents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Captions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction of Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Parties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Advisory or Fiduciary Duty</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit Parties&rsquo; Agent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COLLATERAL AGENT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment and Authority</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights as a Lender</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exculpatory Provisions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliance by Collateral Agent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delegation of Duties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resignation of Collateral Agent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Reliance on Collateral Agent and Other Lenders</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral and Guaranty Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement by Lenders</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices and Items to Lenders</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;A</U>:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Advance Request Form</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;B-1</U>:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Tranche A Term Loan Note</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;B-2</U>:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Tranche B Term Loan Note</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;C</U>:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Security Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;D</U>:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments; Notice Addresses</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;E</U>:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Compliance Certificate</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>LOAN
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>THIS
LOAN AGREEMENT</B></FONT> (this &ldquo;<B>Agreement</B>&rdquo;), dated as of September&nbsp;3, 2025 (the &ldquo;<B>Effective Date</B>&rdquo;)
by and among PRECIGEN,&nbsp;INC., a Virginia corporation (as &ldquo;<B>Borrower</B>&rdquo; and a Credit Party), the Guarantors signatory
hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated
under the laws of England and Wales with company number 10443190 (as the &ldquo;<B>Collateral Agent</B>&rdquo;), BPCR LIMITED PARTNERSHIP,
a limited partnership established under the laws of England and Wales with registration number LP020944 (as a &ldquo;<B>Lender</B>&rdquo;)
and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma
Credit Investments V GP LLC (as a &ldquo;<B>Lender</B>&rdquo;), provides the terms on which each Lender shall make, and Borrower shall
repay, the Credit Extensions (as hereinafter defined).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>ACCOUNTING
AND OTHER TERMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Accounting</B>.
Except as otherwise expressly provided herein, all accounting terms not otherwise defined in this Agreement shall have the meanings assigned
to them in conformity with GAAP. Calculations and determinations must be made following GAAP. If at any time any change in GAAP would
affect the computation of any financial requirement set forth in any Loan Document (including for purposes of measuring compliance with
any provision of <U>Section&nbsp;6</U>), and either Borrower or the Collateral Agent shall so request, the Collateral Agent and Borrower
shall negotiate in good faith to amend such requirement to preserve the original intent thereof in light of such change in GAAP; <U>provided</U>,
<U>that</U>, until so amended, (x)&nbsp;such requirement shall continue to be computed in accordance with GAAP prior to such change therein
and (y)&nbsp;all financial statements, Compliance Certificates and similar documents provided, delivered or submitted hereunder shall
be provided, delivered or submitted together with a reconciliation between the calculations and amounts set forth therein before and
after giving effect to such change in GAAP. Notwithstanding any other provision contained herein, all terms of an accounting or financial
nature used herein shall be construed, and all computations of amounts referred to herein, including in <U>Section&nbsp;5</U> and <U>Section&nbsp;6</U>
shall be made, without giving effect to any election under ASC 825-10 (or any other Financial Accounting Standards Board Accounting Standards
Codification (&ldquo;<B>ASC</B>&rdquo;) or Financial Accounting Standard or Applicable Accounting Standard (including IFRS 9) having
a similar result or effect) to value any Indebtedness or other liabilities of any Credit Party or any Subsidiary of any Credit Party
at &ldquo;fair value&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Defined
Terms.</B> Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in <U>Section&nbsp;13</U>. All
other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms
are defined therein. All references to &ldquo;<B>Dollars</B>&rdquo; or &ldquo;<B>$</B>&rdquo; are United States Dollars, unless otherwise
noted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Currency</B>.
For purposes of <U>Sections 5</U> and <U>6</U> hereof and solely with respect to the amount of any Indebtedness,&nbsp;Investment or other
transaction made or consummated in a currency other than Dollars, no Default or Event of Default shall be deemed to have occurred after
the time such Indebtedness,&nbsp;Investment or other transaction is incurred, made or consummated (so long as such Indebtedness,&nbsp;Investment
or other transaction, at the time incurred, made or consummated, was permitted hereunder) solely as a result of changes in rates of currency
exchange occurring over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;SOFR</B>.
The Collateral Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a)&nbsp;the continuation
of, administration of, submission of, calculation of or any other matter related to the Term SOFR Reference Rate or Term SOFR, or any
component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto
(including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement
rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same
volume or liquidity as, the Term SOFR Reference Rate, Term SOFR or any other Benchmark prior to its discontinuance or unavailability,
or (b)&nbsp;the effect, implementation or composition of any Conforming Changes. The Collateral Agent and its affiliates or other related
entities may engage in transactions that affect the calculation of the Term SOFR Reference Rate, Term SOFR, any alternative, successor
or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to Borrower.
The Collateral Agent may select information sources or services in its reasonable discretion to ascertain the Term SOFR Reference Rate,
Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no liability to Borrower, any
Lender or any other Person for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages,
costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any
such rate (or component thereof) provided by any such information source or service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>LOANS
AND TERMS OF PAYMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Promise
to Pay</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower hereby unconditionally
promises to pay each Lender the outstanding principal amount of the Term Loans advanced to Borrower by such Lender and accrued and unpaid
interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Term
Loans</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Availability</U>.
Subject to the terms and conditions of this Agreement (including <U>Sections 3.1</U>, <U>3.2</U>, <U>3.3</U>, <U>3.4</U> and <U>3.5</U>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
agrees to request in accordance with <U>Section&nbsp;3.6</U>, and each Lender severally agrees to make a term loan to Borrower on the
Tranche A Closing Date in an original principal amount equal to such Lender&rsquo;s Applicable Percentage of the Tranche A Loan Amount
requested by Borrower, but, for the avoidance of doubt, not greater than such Lender&rsquo;s Tranche A Commitment (collectively, the
 &ldquo;<B>Tranche A Loan</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
Borrower&rsquo;s election pursuant to <U>Section&nbsp;3.6</U> each Lender severally agrees to make a term loan to Borrower on the Tranche
B Closing Date in an original principal amount equal to such Lender&rsquo;s Applicable Percentage of the Tranche B Loan Amount requested
by Borrower, but, for the avoidance of doubt, not greater than such Lender&rsquo;s Tranche B Commitment (collectively, the &ldquo;<B>Tranche
B Loan</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>After
repayment or prepayment (in whole or in part), no Term Loan (or any portion thereof) may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Repayment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
shall make eight (8)&nbsp;equal quarterly payments of principal of each Term Loan commencing on the Initial Payment Date and continuing
quarterly on each Payment Date thereafter through the Term Loan Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Term Loans, including all unpaid principal thereunder (and, for the avoidance of doubt, all accrued and unpaid interest, all due and
unpaid Lender Expenses and any and all other outstanding amounts payable under the Loan Documents), are due and payable in full on the
Term Loan Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Term Loans may be prepaid only in accordance with <U>Section&nbsp;2.2(c)</U>, except as provided in <U>Section&nbsp;8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Prepayment
of Term Loans</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
shall have the option, at any time after the Tranche A Closing Date, to prepay, in whole and not in part, outstanding principal amounts
under the Term Loans advanced by Lenders under this Agreement; <U>provided</U> that (A)&nbsp;Borrower provides written notice to the
Collateral Agent of its election to prepay in whole the Term Loans at least five (5)&nbsp;Business Days prior to such prepayment (which
notice shall include the amount of the outstanding principal amount of the Term Loans to be prepaid), and (B)&nbsp;the prepayment of
such principal amount shall be accompanied by any and all accrued and unpaid interest thereon through the date of prepayment, any and
all amounts payable in connection with such prepayment pursuant to <U>Section&nbsp;2.2(e)</U>, <U>Section&nbsp;2.2(f)</U>&nbsp;and <U>Section&nbsp;2.7(b)</U>&nbsp;(as
applicable) and any and all other amounts payable and not yet paid under this Agreement and the other Loan Documents (including pursuant
to <U>Section&nbsp;2.4</U>). The Collateral Agent will promptly notify each Lender of its receipt of such notice, and the amount of such
Lender&rsquo;s Applicable Percentage of such prepayment. Borrower may rescind any notice of prepayment under this <U>Section&nbsp;2.2(c)(i)</U>&nbsp;if
such prepayment would have resulted from a refinancing of the Term Loans or other contingent transaction, which refinancing or transaction
shall not be consummated or shall otherwise be delayed (in which case, the date of prepayment may be extended with the consent of the
Collateral Agent (not to be unreasonably withheld, conditioned, or delayed) or a new notice shall be required to be sent in connection
with any subsequent prepayment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
shall promptly, and in any event no later than ten (10)&nbsp;Business Days prior (or immediately if known fewer than ten (10)&nbsp;Business
Days prior) to the consummation of such Change in Control, notify the Collateral Agent in writing of the occurrence (or anticipated occurrence)
of a Change in Control, which notice shall include reasonable detail as to the nature, timing and other circumstances of such Change
in Control (such notice, a &ldquo;<B>Change in Control Notice</B>&rdquo;). Borrower shall prepay in full all of the Term Loans advanced
by Lenders under this Agreement, immediately upon (and concurrent with) the consummation of such Change in Control, in an amount equal
to the sum of (A)&nbsp;all unpaid principal and any and all accrued and unpaid interest thereon through the date of prepayment (such
interest to be calculated based on Term SOFR for the Interest Period during which such Change in Control is consummated), and (B)&nbsp;any
and all amounts payable with respect to the prepayment under this <U>Section&nbsp;2.2(c)(ii)</U>&nbsp;pursuant to <U>Section&nbsp;2.2(e)</U>,
<U>Section&nbsp;2.2(f)</U>&nbsp;and <U>Section&nbsp;2.7(b)</U>&nbsp;(as applicable), together with any and all other amounts payable
or accrued and not yet paid under this Agreement and the other Loan Documents (including pursuant to <U>Section&nbsp;2.4</U>). The Collateral
Agent will promptly notify each Lender of its receipt of the Change in Control Notice, and the amount of such Lender&rsquo;s Applicable
Percentage of such prepayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Prepayment
Application</U>. Any prepayment of the Term Loans pursuant to <U>Section&nbsp;2.2(c)</U>&nbsp;or as a result of the acceleration of the
maturity of the Term Loans pursuant to <U>Section&nbsp;8.1(a)</U>&nbsp;(together with the accompanying Makewhole Amount, Prepayment Premium
and Exit Consideration that is payable pursuant to <U>Section&nbsp;2.2(e)</U>, <U>Section&nbsp;2.2(f)</U>&nbsp;and <U>Section&nbsp;2.7(b)</U>&nbsp;(as
applicable)), shall be paid to Lenders in accordance with their respective Applicable Percentages for application to the Obligations
in the following order: (i)&nbsp;first, to due and unpaid Lender Expenses; (ii)&nbsp;second, to accrued and unpaid interest at the Default
Rate incurred pursuant to <U>Section&nbsp;2.3(b)</U>, if any; (iii)&nbsp;third, without duplication of amounts paid pursuant to <U>sub-clause
(ii)</U>&nbsp;above, to accrued and unpaid interest at the Term Loan Rate; (iv)&nbsp;fourth, to accrued and unpaid Additional Consideration,
if any; (v)&nbsp;fifth, to accrued and unpaid Exit Consideration, if any; (vi)&nbsp;sixth, to the Prepayment Premium; (vii)&nbsp;seventh,
to the Makewhole Amount, if applicable; (viii)&nbsp;eighth, to the outstanding principal amount of the Term Loans being prepaid (in such
order as the Collateral Agent or the Required Lenders may direct); and (ix)&nbsp;ninth, to any remaining amounts then due and payable
under this Agreement and the other Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Makewhole
Amount</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
prepayment of the Tranche A Loan by Borrower (A)&nbsp;pursuant to <U>Section&nbsp;2.2(c)</U>&nbsp;or (B)&nbsp;as a result of the acceleration
of the maturity of the Term Loans pursuant to <U>Section&nbsp;8.1(a)</U>, in each case occurring prior to the 3<SUP>rd</SUP>-year anniversary
of the Tranche A Closing Date shall, in any such case, be accompanied by payment of an amount equal to the Tranche A Makewhole Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
prepayment of the Tranche B Loan by Borrower (A)&nbsp;pursuant to <U>Section&nbsp;2.2(c)</U>, or (B)&nbsp;as a result of the acceleration
of the maturity of the Term Loans pursuant to <U>Section&nbsp;8.1(a)</U>, in each case occurring prior to the 3<SUP>rd</SUP>-year anniversary
of the Tranche B Closing Date shall, in any such case, be accompanied by payment of an amount equal to the Tranche B Makewhole Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Prepayment
Premium</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
prepayment of the Tranche A Loan by Borrower (A)&nbsp;pursuant to <U>Section&nbsp;2.2(c)</U>&nbsp;or (B)&nbsp;as a result of the acceleration
of the maturity of the Term Loans pursuant to <U>Section&nbsp;8.1(a)</U>, shall, in any such case, be accompanied by payment of an amount
equal to the Tranche A Prepayment Premium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
prepayment of the Tranche B Loan by Borrower (A)&nbsp;pursuant to <U>Section&nbsp;2.2(c)</U>, or (B)&nbsp;as a result of the acceleration
of the maturity of the Term Loans pursuant to <U>Section&nbsp;8.1(a)</U>, shall, in any such case, be accompanied by payment of an amount
equal to the Tranche B Prepayment Premium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
Makewhole Amount, Prepayment Premium or Exit Consideration payable as a result of any prepayment of the Term Loans pursuant to <U>Section&nbsp;2.2(c)</U>&nbsp;or
as a result of the acceleration of the maturity of the Term Loans pursuant to <U>Section&nbsp;8.1(a)</U>, shall be presumed to be the
liquidated damages sustained by each applicable Lender as the result of the early redemption and repayment of such Term Loan Notes and
Borrower agrees that it is reasonable under the circumstances currently existing. BORROWER EXPRESSLY WAIVES (TO THE FULLEST EXTENT IT
MAY&nbsp;LAWFULLY DO SO) THE PROVISIONS OF ANY PRESENT OR FUTURE REQUIREMENTS OF LAW THAT PROHIBITS OR MAY&nbsp;PROHIBIT THE COLLECTION
OF ANY MAKEWHOLE AMOUNT, PREPAYMENT PREMIUM, TRANCHE A EXIT CONSIDERATION OR TRANCHE B EXIT CONSIDERATION IN CONNECTION WITH ANY SUCH
PREPAYMENT OR ACCELERATION OR OTHERWISE. Borrower expressly agrees that (to the fullest extent it may lawfully do so) that: (i)&nbsp;each
Makewhole Amount, Prepayment Premium and Exit Consideration is reasonable and is the product of an arm&rsquo;s-length transaction among
sophisticated business people, ably represented by counsel; (ii)&nbsp;each Makewhole Amount, Prepayment Premium and Exit Consideration
shall be payable notwithstanding the then-prevailing market rates at the time payment thereof is made; (iii)&nbsp;there has been a course
of conduct among Lenders and Borrower giving specific consideration in this transaction for such agreement to pay each Makewhole Amount,
Prepayment Premium and Exit Consideration; and (iv)&nbsp;Borrower shall be estopped hereafter from claiming differently than as agreed
to in this <U>Section&nbsp;2.2(g)</U>&nbsp;and <U>Section&nbsp;8.6</U>. Borrower expressly acknowledges that its agreement to pay the
Makewhole Amount, Prepayment Premium and Exit Consideration, as the case may be, to applicable Lenders as herein described is a material
inducement to such Lenders to make any Credit Extension. Without affecting any of any Lender&rsquo;s rights or remedies hereunder or
in respect hereof, if Borrower fails to pay the applicable Makewhole Amount, Prepayment Premium or Exit Consideration when due, then
the amount thereof shall thereafter bear interest until paid in full at the Default Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
of Interest on the Credit Extensions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interest
Rate</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to <U>Section&nbsp;2.3(b)</U>&nbsp;below, the principal amount outstanding under each Term Loan shall accrue interest at a <I>per annum</I>
rate equal to Term SOFR for the Interest Period therefor <I>plus</I> the Applicable Margin (the &ldquo;<B>Term Loan Rate</B>&rdquo;),
which interest shall be payable quarterly in arrears in accordance with this <U>Section&nbsp;2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Interest
shall accrue on each Term Loan commencing on, and including, the day on which such Term Loan is made, and shall accrue on such Term Loan,
or any portion thereof, through and including the day on which such Term Loan or such portion is paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Interest
is due and payable quarterly on each Interest Date, as calculated by the Collateral Agent (which calculations shall be deemed correct
absent manifest error, <U>provided</U> that the Collateral Agent shall provide evidence of such calculation upon Borrower&rsquo;s written
request); <U>provided</U>, <U>however</U>, that if any such date is not a Business Day, the applicable interest shall be due and payable
on the immediately preceding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Default
Rate</U>. In the event Borrower fails to pay any of the Obligations when due (after giving effect to any applicable grace or cure period),
or upon the commencement and during the continuance of an Insolvency Proceeding of Borrower, or upon the occurrence and during the continuance
of any other Event of Default, immediately (and without notice or demand by any Lender or the Collateral Agent for payment thereof to
Borrower), such past due Obligations shall accrue interest at a rate <I>per annum</I> which is three percentage points (3.00%) above
the rate that is otherwise applicable thereto (the &ldquo;<B>Default Rate</B>&rdquo;), and, notwithstanding anything to the contrary
in <U>Section&nbsp;2.3(a)</U>&nbsp;above, such interest shall be payable entirely in cash on demand of the Collateral Agent; <U>provided</U>,
<U>however</U>, that, with respect to any Event of Default of the type described in <U>Section&nbsp;7</U>, other than <U>Sections 7.1</U>
and <U>7.5</U>, the Collateral Agent shall notify Borrower in writing regarding the accrual of interest at the Default Rate in respect
of any such Obligations as promptly as practicable following the occurrence of such Event of Default; provided, further, that the failure
of the Collateral Agent to deliver such notice to Borrower shall not constitute a waiver of any such Event of Default or affect the right
of any Lender or the Collateral Agent to collect or demand such accrued interest with respect to any time prior to the giving of such
notice or otherwise prejudice or limit any rights or remedies of the Collateral Agent or any Lender. Payment or acceptance of the increased
interest rate provided in this <U>Section&nbsp;2.3(b)</U>&nbsp;is not a permitted alternative to timely payment of any Obligations and
shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of the Collateral Agent
or any Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>360-Day
Year</U>. Interest payable under each Term Loan shall be computed on the basis of a year of 360 days, and in each case shall be payable
for the actual number of days elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payments</U>.
Except as otherwise expressly provided herein, all Term Loan payments and any other payments hereunder by (or on behalf of) Borrower
shall be made on the date specified herein to such bank account of each applicable Lender as such Lender (or the Collateral Agent) shall
have designated in a written notice to Borrower delivered on or before the Tranche A Closing Date (which such notice may be updated by
such Lender (or the Collateral Agent) by written notice to Borrower from time to time after the Tranche A Closing Date on two (2)&nbsp;Business
Days&rsquo; notice). Except as otherwise expressly provided herein, interest is payable quarterly on each Interest Date <U>provided</U>,
<U>however</U>, that if any such date is not a Business Day, the applicable interest shall be due and payable on the immediately preceding
Business Day. Payments of principal or interest received after 11:00 a.m.&nbsp;New York City time on such date are considered received
at the opening of business on the next Business Day. When any payment is due on a day that is not a Business Day, such payment is due
on the immediately preceding Business Day. All payments to be made by Borrower hereunder or under any other Loan Document, including
payments of principal and interest made hereunder and pursuant to any other Loan Document, and all fees, expenses, indemnities and reimbursements,
shall be made without set-off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conforming
Changes</U>. In connection with the use or administration of Term SOFR, the Collateral Agent will have the right to make Conforming Changes
from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such
Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan
Document. The Collateral Agent will promptly notify Borrower and the Lenders of the effectiveness of any Conforming Changes in connection
with the use or administration of Term SOFR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Benchmark
Replacement Setting</U>. Notwithstanding anything to the contrary herein or in any other Loan Document:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Benchmark
Replacement</U>. If a Benchmark Transition Event and its related Benchmark Replacement Date have occurred prior to any setting of the
then-current Benchmark, then (x)&nbsp;if a Benchmark Replacement is determined in accordance with <U>clause (a)</U>&nbsp;of the definition
of Benchmark Replacement for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes
hereunder and under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to,
or further action or consent of any other party to, this Agreement or any other Loan Document and (y)&nbsp;if a Benchmark Replacement
is determined in accordance with <U>clause (b)</U>&nbsp;of the definition of Benchmark Replacement for such Benchmark Replacement Date,
such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark
setting at or after 5:00 p.m.&nbsp;(New York City time) on the fifth (5<SUP>th</SUP>) Business Day after the date notice of such Benchmark
Replacement is provided to Lenders without any amendment to, or further action or consent of any other party to, this Agreement or any
other Loan Document so long as the Collateral Agent has not received, by such time, written notice of objection to such Benchmark Replacement
from Lenders comprising the Required Lenders. For the avoidance of doubt, if the Benchmark Replacement is Daily Simple SOFR, all interest
payments will be payable on a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conforming
Changes</U>. In connection with the implementation and administration of a Benchmark Replacement, the Collateral Agent will have the
right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document,
any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to
this Agreement or any other Loan Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices;
Standards for Decisions and Determinations</U>. The Collateral Agent will promptly notify Borrower and the Lenders of (A)&nbsp;the implementation
of any Benchmark Replacement and (B)&nbsp;the effectiveness of any Conforming Changes in connection with the use, administration, adoption
or implementation of a Benchmark Replacement. The Collateral Agent will notify Borrower of (x)&nbsp;the removal or reinstatement of any
tenor of a Benchmark pursuant to <U>sub-clause (iv)</U>&nbsp;below and (y)&nbsp;the commencement of any Benchmark Unavailability Period.
Any determination, decision or election that may be made by the Collateral Agent or, if applicable, any Lender (or group of Lenders)
pursuant to this <U>Section&nbsp;2.3(f)</U>, including any determination with respect to a tenor, rate or adjustment or of the occurrence
or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action, will be conclusive and
binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement
or any other Loan Document, except, in each case, as expressly required pursuant to this <U>Section&nbsp;2.3(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Unavailability
of Tenor of Benchmark</U>. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection
with the implementation of a Benchmark Replacement), (A)&nbsp;if the then-current Benchmark is a term rate (including the Term SOFR Reference
Rate) and either (1)&nbsp;any tenor for such Benchmark is not displayed on a screen or other information service that publishes such
rate from time to time as selected by the Collateral Agent in its reasonable discretion or (2)&nbsp;the regulatory supervisor for the
administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark
is not or will not be representative, then the Collateral Agent may modify the definition of &ldquo;Interest Period&rdquo; (or any similar
or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and
(B)&nbsp;if a tenor that was removed pursuant to <U>sub-clause (A)</U>&nbsp;above either (1)&nbsp;is subsequently displayed on a screen
or information service for a Benchmark (including a Benchmark Replacement) or (2)&nbsp;is not, or is no longer, subject to an announcement
that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Collateral Agent may modify
the definition of &ldquo;Interest Period&rdquo; (or any similar or analogous definition) for all Benchmark settings at or after such
time to reinstate such previously removed tenor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Expenses</B>.
Borrower shall pay to or reimburse (or pay directly on behalf of) each Lender and the Collateral Agent, as applicable, all of such Person&rsquo;s
reasonable and documented Lender Expenses incurred through and after the Effective Date, promptly after receipt of a written demand therefor
by such Lender or the Collateral Agent (with, in the case of any Lender, a copy of such demand to the Collateral Agent), setting forth
in reasonable detail such Person&rsquo;s Lender Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Requirements
of Law; Increased Costs</B>. In the event that any applicable Change in Law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;does
or shall subject any Lender to any Tax of any kind whatsoever with respect to this Agreement or any other Loan Documents or the Term
Loans made hereunder (except, in each case,&nbsp;Indemnified Taxes, Taxes described in <U>clause (b)</U>&nbsp;through <U>(d)</U>&nbsp;of
the definition of Excluded Taxes, and Connection Income Taxes);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;does
or shall impose, modify or hold applicable any reserve, capital requirement, special deposit, compulsory loan, insurance charge or similar
requirements against assets held by, or deposits or other liabilities in or for the account of, advances or loans by, or other credit
extended by, or any other acquisition of funds by, any Lender; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;does
or shall impose on any Lender any other condition (other than Taxes, which are addressed in <U>clause (a)</U>&nbsp;above); and the result
of any of the foregoing is to increase the cost to such Lender (as determined by such Lender in good faith using calculation methods
customary in the industry) of making, renewing or maintaining the Term Loans or to reduce any amount receivable in respect thereof or
to reduce the rate of return on the capital of such Lender or any Person controlling such Lender, then, in any such case, Borrower shall
promptly pay to the applicable Lender, within ten (10)&nbsp;days of its receipt of the certificate described below, any additional amounts
necessary to compensate such Lender for such additional cost or reduced amounts receivable or rate of return as reasonably determined
by such Lender with respect to this Agreement or the Term Loans made hereunder. If any Lender becomes entitled to claim any additional
amounts pursuant to this <U>Section&nbsp;2.5</U>, it shall notify Borrower in writing of the event by reason of which it has become so
entitled (with a copy of such notice to the Collateral Agent), and a certificate as to any additional amounts payable pursuant to the
foregoing sentence containing the calculation thereof in reasonable detail submitted by such Lender to Borrower (with a copy of such
certificate to the Collateral Agent) shall be conclusive in the absence of manifest error. The provisions hereof shall survive the termination
of this Agreement and the payment of the outstanding Term Loans and all other Obligations. Failure or delay on the part of any Lender
to demand compensation for any increased costs or reduction in amounts received or receivable or reduction in return on capital under
this <U>Section&nbsp;2.5</U> shall not constitute a waiver of such Lender&rsquo;s right to demand such compensation; <U>provided</U>
that Borrower shall not be under any obligation to compensate such Lender under this <U>Section&nbsp;2.5</U> with respect to increased
costs or reductions with respect to any period prior to the date that is 180 days prior to the date of the delivery of the notice required
pursuant to the foregoing provisions of this paragraph; <U>provided</U>, <U>further</U>, that if the Change in Law giving rise to such
increased costs or reductions is retroactive, then the 180-day period referred to above shall be extended to include the period of retroactive
effect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Taxes;
Withholding, Etc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
sums payable by any Credit Party hereunder and under the other Loan Documents shall (except to the extent required by Requirements of
Law) be paid free and clear of, and without any deduction or withholding on account of, any Tax imposed, levied, collected, withheld
or assessed by any Governmental Authority. In addition, the Credit Parties shall pay, in a timely manner, to the relevant Governmental
Authority in accordance with Requirements of Law, Other Taxes, and Borrower shall furnish, in a timely manner, to each Lender (as applicable,
with a copy to the Collateral Agent) the original or a certified copy of a receipt evidencing payment thereof or other evidence reasonably
satisfactory to the Collateral Agent of such payment and of the remittance thereof to the relevant taxing or other Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any Credit Party or any other Person (in either case, a &ldquo;<B>Withholding Agent</B>&rdquo;) is required by Requirements of Law to
make any deduction or withholding on account of any Tax (as determined in the good faith discretion of such Withholding Agent) from any
sum paid or payable by any Credit Party to any Lender under any of the Loan Documents: (i)&nbsp;such Withholding Agent shall make any
such withholding or deduction; (ii)&nbsp;such Withholding Agent shall timely pay the full amount deducted or withheld to the relevant
Governmental Authority in accordance with Requirements of Law; (iii)&nbsp;if the Tax is an Indemnified Tax, the sum payable by such Withholding
Agent in respect of which the relevant deduction, withholding or payment of Indemnified Tax is required shall be increased to the extent
necessary to ensure that, after the making of that deduction, withholding or payment (including any deductions for Indemnified Taxes
applicable to additional sums payable under this <U>Section&nbsp;2.6(b)</U>), such Lender receives on the due date a net sum equal to
what it would have received had no such deduction, withholding or payment of Indemnified Tax been required or made; and (iv)&nbsp;Borrower
shall (or shall cause such Withholding Agent, if not Borrower, to) deliver to such Lender (with a copy to the Collateral Agent) the original
or a certified copy of a receipt evidencing payment thereof or other evidence reasonably satisfactory to such Lender of such deduction,
withholding or payment and of the remittance thereof to the relevant taxing or other Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Credit Parties shall jointly and severally indemnify each Lender for the full amount of any Indemnified Taxes (including Indemnified
Taxes imposed or asserted on or attributable to amounts payable under this <U>Section&nbsp;2.6(c)</U>) paid by such Lender and any liability
(including any reasonable expenses) arising therefrom or with respect thereto whether or not such Indemnified Taxes were correctly or
legally imposed or asserted by the relevant Governmental Authority. Any indemnification payment pursuant to this <U>Section&nbsp;2.6(c)</U>&nbsp;shall
be made to the applicable Lender within thirty (30) days from written demand therefor. A certificate as to the amount of such payment
or liability delivered to the Credit Parties by a Lender (with a copy to the Withholding Agent, if not a Credit Party), or by the Withholding
Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall
deliver, as soon as practicable, to Borrower, at the times reasonably requested in writing by Borrower, such properly completed and executed
documentation as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, such Lender,
if reasonably requested in writing by Borrower, shall deliver, as soon as practicable, such other documentation prescribed by Requirements
of Law or otherwise reasonably requested by Borrower to enable Borrower to determine whether or not such Lender is subject to backup
withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion,
execution and submission of such documentation (other than such documentation set forth in Section&nbsp;<U>2.6(d)(i)</U>, <U>(ii)</U>&nbsp;or
<U>(iv)</U>&nbsp;below) shall not be required if in such Lender&rsquo;s reasonable judgment such completion, execution or submission
would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position
of such Lender. For the avoidance of doubt, for the purposes of this <U>Section&nbsp;2.6(d)</U>, the term &ldquo;Lender&rdquo; shall
include each applicable assignee thereof. Without limiting the generality of the foregoing, each Lender shall deliver, and shall cause
each applicable assignee thereof to deliver, to Borrower, on or prior to the Tranche A Closing Date or on or prior to the applicable
date of assignment, as applicable, and at such other times as may be necessary in the determination of Borrower, upon reasonable request
in writing by Borrower:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
such Lender or applicable assignee is organized under the laws of the United States, two (2)&nbsp;executed copies of IRS Form&nbsp;W-9
certifying that such Lender is exempt from U.S. federal backup withholding tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
such Lender or assignee is a Foreign Lender:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="color: #010000">(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x)&nbsp;with respect
to payments of interest under any Loan Document, a properly completed and duly executed copy of IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E
establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &ldquo;interest&rdquo; article of such
tax treaty and (y)&nbsp;with respect to any other applicable payments under any Loan Document, a properly completed and duly executed
copy of IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax
pursuant to the &ldquo;business profits&rdquo; or &ldquo;other income&rdquo; article of such tax treaty;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="color: #010000">(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
completed and duly executed copy of IRS Form&nbsp;W-8ECI;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="color: #010000">(3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the extent that such Foreign Lender is not the beneficial owner, a properly completed and duly executed copy of IRS W-8IMY and a withholding
statement, along with IRS Form&nbsp;W-9, W-8BEN-E, W-8BEN, W-8ECI or other certification documents from each beneficial owner, as applicable;
provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming
the portfolio interest exemption, such Foreign Lender may provide a certificate referenced in <U>Section&nbsp;2.6(d)(ii)(4)</U>&nbsp;below
on behalf of each such direct and indirect partner; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><FONT STYLE="color: #010000">(4)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
the case of a Foreign Lender claiming the benefits of the exemption for &ldquo;portfolio interest&rdquo; under Section&nbsp;881(c)&nbsp;of
the IRC, a properly completed and duly executed copy of IRS Form&nbsp;W-8BEN-E or IRS Form&nbsp;W-8BEN, as applicable, and a certificate
reasonably satisfactory to Borrower to the effect that such Foreign Lender is not a &ldquo;bank&rdquo; within the meaning of 881(c)(3)(A)&nbsp;of
the IRC, a &ldquo;10 percent shareholder&rdquo; of Borrower within the meaning of Section&nbsp;871(h)(3)(B)&nbsp;of the IRC, or a &ldquo;controlled
foreign corporation&rdquo; related to Borrower as described in Section&nbsp;881(c)(3)(C)&nbsp;of the IRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any Lender is a Foreign Lender it shall, to the extent it is legally entitled to do so, deliver to Borrower (in such number of copies
as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a party to this Agreement (and from
time to time thereafter upon the reasonable request of Borrower), executed copies of any other form prescribed by applicable law as a
basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation
as may be prescribed by applicable law to permit Borrower to determine the withholding or deduction required to be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
a payment made to any Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender
were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section&nbsp;1471(b)&nbsp;or
1472(b)&nbsp;of the IRC, as applicable), such Lender shall deliver to Borrower at the time or times prescribed by law and at such time
or times reasonably requested by Borrower such documentation prescribed by applicable law (including as prescribed by Section&nbsp;1471(b)(3)(C)(i)&nbsp;of
the IRC) and such additional documentation reasonably requested by Borrower as may be necessary for Borrower to comply with their obligations
under FATCA and to determine that Lender has complied with its obligations under FATCA or to determine the amount to deduct and withhold
from such payment. Solely for purposes of this <U>sub-clause (iv)</U>, &ldquo;FATCA&rdquo; shall include any amendments made to FATCA
after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Lender agrees that if any form or certification it previously delivered pursuant to this <U>Section&nbsp;2.6</U> expires or becomes obsolete
or inaccurate in any respect, it shall update such form or certification or promptly notify Borrower and Collateral Agent in writing
of its legal inability to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any party hereto determines, in its discretion exercised in good faith, that it has received a refund of any Taxes as to which it has
been indemnified pursuant to this <U>Section&nbsp;2.6</U> (including by the payment of additional amounts pursuant to this <U>Section&nbsp;2.6</U>),
it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made, or additional
amounts paid, under this <U>Section&nbsp;2.6</U> with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses
(including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority
with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party
the amount paid over pursuant to this <U>clause (e)</U>&nbsp;(plus any penalties, interest or other charges imposed by the relevant Governmental
Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding
anything to the contrary in this <U>clause (e)</U>, in no event will the indemnified party be required to pay any amount to an indemnifying
party pursuant to this <U>clause (e)</U>&nbsp;if the payment of such amount would place the indemnified party in a less favorable net
after-Tax position than the indemnified party would have been in if the indemnification payments or additional amounts giving rise to
such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect
to such Tax had never been paid. This <U>clause (e)</U>&nbsp;shall not be construed to require any indemnified party to make available
its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
is currently treated as a corporation for U.S. federal income tax purposes. Borrower shall provide the Required Lenders with a prior
written notice before taking any affirmative action (including making any election under Section&nbsp;301.7701-3(c)&nbsp;of the Treasury
Regulations (or any successor provision) by way of filing an IRS Form&nbsp;8832) to change its U.S. entity tax classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
shall use reasonable best efforts to furnish upon reasonable request any information to assist any Lender (i)&nbsp;in the computation
of accruals with respect to any &ldquo;original issue discount&rdquo; or &ldquo;market discount&rdquo; arising with respect to the Term
Loans for U.S. federal income tax purposes and GAAP, and (ii)&nbsp;with its compliance with any associated tax reporting or filing requirements
of such Lender or its partners, members or beneficial owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
party&rsquo;s obligations under this <U>Section&nbsp;2.6</U> shall survive any assignment of rights by, or the replacement of, a Lender,
the termination of the Term Loan Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Additional
Consideration; Exit Consideration</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
additional consideration for the obligation of each Lender to fund (deemed or otherwise) its Applicable Percentage of the Term Loans
pursuant to <U>Section&nbsp;2.2(a)</U>&nbsp;and <U>Section&nbsp;3.6:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(x)&nbsp;on
the Effective Date, Borrower shall pay to each Lender an amount equal to the product of (A)&nbsp;the sum of such Lender&rsquo;s Tranche
A Commitment, <I>multiplied by</I> (B)&nbsp;0.0125, and (y)&nbsp;on the Tranche A Closing Date, Borrower shall pay to each Lender an
amount equal to the product of (i)&nbsp;the sum of such Lender&rsquo;s Tranche A Commitment, <I>multiplied by</I> (ii)&nbsp;0.0125 (each
such product, separately or together as the context dictates, the &ldquo;<B>Tranche A Additional Consideration</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>on
the Tranche B Closing Date, Borrower shall pay to each Lender an amount equal to the product of (A)&nbsp;the sum of such Lender&rsquo;s
Tranche B Commitment, <I>multiplied by</I> (B)&nbsp;0.0250 (each such product, the &ldquo;<B>Tranche B Additional Consideration</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
additional consideration for the funding (deemed or otherwise) by each Lender of its Applicable Percentage of the Term Loans pursuant
to <U>Section&nbsp;2.2(a)</U>&nbsp;and <U>Section&nbsp;3.6</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
prepayment or repayment of the Tranche A Loan by Borrower (A)&nbsp;pursuant to <U>Section&nbsp;2.2(c)(i)</U>&nbsp;or <U>Section&nbsp;2.2(c)(ii)</U>,
(B)&nbsp;as a result of the acceleration of the maturity of the Term Loans pursuant to <U>Section&nbsp;8.1(a)</U>, or (C)&nbsp;pursuant
to <U>Section&nbsp;2.2(b)</U>&nbsp;or otherwise (including, for the avoidance of doubt, on the Term Loan Maturity Date), shall, in any
such case, be accompanied by payment of an amount equal to the Tranche A Exit Consideration; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
prepayment or repayment of the Tranche B Loan by Borrower (A)&nbsp;pursuant to <U>Section&nbsp;2.2(c)(i)</U>&nbsp;or <U>Section&nbsp;2.2(c)(ii)</U>,
(B)&nbsp;as a result of the acceleration of the maturity of the Term Loans pursuant to <U>Section&nbsp;8.1(a)</U>, or (C)&nbsp;pursuant
to <U>Section&nbsp;2.2(b)</U>&nbsp;or otherwise (including, for the avoidance of doubt, on the Term Loan Maturity Date), shall, in any
such case, be accompanied by payment of an amount equal to the Tranche B Exit Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any and all Tranche A Additional
Consideration shall be fully earned on the Effective Date and shall not be refundable for any reason whatsoever, and any and all Tranche
B Additional Consideration, Tranche A Exit Consideration and Tranche B Exit Consideration shall be fully earned when paid and shall not
be refundable for any reason whatsoever. All Tranche A Additional Consideration and Tranche B Additional Consideration shall be treated
as original issue discount with respect to the applicable Term Loan for U.S. federal income tax purposes, unless otherwise required by
Requirements of Law. The Tranche A Additional Consideration described in <U>clause (a)(i)(y)</U>&nbsp;of this <U>Section&nbsp;2.7</U>
payable hereunder shall be deducted, as applicable, from the proceeds of the Tranche A Loan to be advanced to Borrower pursuant to <U>Section&nbsp;2.2(a)</U>&nbsp;and
<U>Section&nbsp;3.6</U>, and the Tranche B Additional Consideration payable hereunder shall be deducted, as applicable, from the proceeds
of the Tranche B Loan to be advanced to Borrower pursuant to <U>Section&nbsp;2.2(a)</U>&nbsp;and <U>Section&nbsp;3.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Evidence
of Debt; Note Register; Term Loan Notes</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Evidence
of Debt; Register</U>. Borrower will maintain at all times at its principal executive office, a register that identifies each beneficial
owner that is entitled to a payment of principal and stated interest on each Term Loan (the &ldquo;<B>Note Register</B>&rdquo;) and provides
for the registration and transfer of Term Loan Notes so that each Term Loan is at all times in &ldquo;registered form&rdquo; within the
meaning of Section&nbsp;5f.103-1(c)&nbsp;of the United States Treasury Regulations (or any amended or successor version) and Section&nbsp;163(f),
871(h)(2)&nbsp;and 881(c)(2)&nbsp;of the IRC and any related regulations (and any other relevant or successor provisions of the IRC or
such regulations). Each Term Loan: (i)&nbsp;shall, pursuant to this <U>clause (a)</U>, be registered as to both principal and any stated
interest with Borrower or its agent, and (ii)&nbsp;shall be transferred or exchanged by any Lender only through a book entry system maintained
by Borrower. Any Term Loan Note issued in exchange for any other Term Loan Note or upon transfer thereof shall carry the rights to unpaid
interest and interest to accrue that were carried by the Term Loan Note so exchanged or transferred, and neither gain nor loss of interest
shall result from any such transfer or exchange. Any stamp, documentary, transfer or similar tax or governmental charge or fee relating
to such transaction shall be paid by the party requesting the exchange. The entries in the Note Register shall be conclusive and binding
for all purposes, including as to the outstanding principal amount of the Term Loan Note and the payment of interest, principal and other
sums due hereunder absent manifest error and Borrower, Lenders and any of their respective agents shall treat the Person recorded in
the Note Register as the sole and exclusive record and beneficial holder and owner of such Term Loan Note or any other Loan Document
(including this Agreement), and a Lender hereunder, for all purposes whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Term
Loan Notes</U>. Borrower shall execute and deliver to each Lender to evidence such Lender&rsquo;s Term Loan, (i)&nbsp;on the Tranche
A Closing Date, a Tranche A Note, and (ii)&nbsp;on the Tranche B Closing Date (if any), a Tranche B Note. All amounts due under the Term
Loan Notes shall be repayable as set forth in this Agreement and interest shall accrue on the principal amount of the Term Loans represented
by the Term Loan Notes, in each case, in accordance with the terms of this Agreement. All Term Loan Notes shall rank for all purposes
<I>pari passu</I> with each other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>CONDITIONS
TO TERM LOANS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions
Precedent to Tranche A Loan</B>. Each Lender&rsquo;s obligation to advance its Applicable Percentage of the Tranche A Loan Amount is
subject to the satisfaction (or waiver in Lenders&rsquo; sole discretion in accordance with <U>Section&nbsp;11.5</U> hereof) of the following
conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Collateral Agent&rsquo;s and each Lender&rsquo;s receipt of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>on
the Effective Date, copies of the Loan Agreement, the Disclosure Letter, the Perfection Certificate for Borrower and its Subsidiaries
and the Advance Request Form&nbsp;for the Tranche A Loan, in each case (x)&nbsp;dated as of the Effective Date, (y)&nbsp;executed (where
applicable) and delivered by each applicable Credit Party, and (z)&nbsp;in form and substance reasonably satisfactory to the Collateral
Agent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>on
the Tranche A Closing Date, copies of the other Loan Documents (including the schedules thereto), including the Tranche A Notes executed
by Borrower, the Collateral Documents (but excluding any Control Agreements, Collateral Access Agreements and any other Loan Document
described in <U>Schedule 5.14</U> of the Disclosure Letter to be delivered after the Tranche A Closing Date), in each case (x)&nbsp;dated
as of the Tranche A Closing Date, (y)&nbsp;executed (where applicable) and delivered by each applicable Credit Party, and (z)&nbsp;in
form and substance reasonably satisfactory to the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Collateral Agent&rsquo;s receipt of (i)&nbsp;true, correct, complete and up-to-date copies of the Operating Documents of each of the
Credit Parties and (ii)&nbsp;a Secretary&rsquo;s Certificate, dated the Tranche A Closing Date, certifying that the foregoing copies
are true, correct and complete (such Secretary&rsquo;s Certificate (as applicable) to be in form and substance reasonably satisfactory
to the Collateral Agent); <U>provided</U> that to the extent that the requirements of the foregoing clause (i)&nbsp;of this <U>Section&nbsp;3.1(b)</U>&nbsp;are
not satisfied on the Tranche A Closing Date, the Borrower may satisfy such requirements within five (5)&nbsp;days of the Tranche A Closing
Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Collateral Agent&rsquo;s receipt of a good standing certificate for each Credit Party (where applicable in the subject jurisdiction),
certified (where available) by the Secretary of State (or the equivalent thereof) of the jurisdiction of incorporation, formation or
organization of such Person as of a date no earlier than thirty (30) days prior to the Tranche A Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Collateral Agent&rsquo;s receipt of a Secretary&rsquo;s Certificate in relation to each Credit Party, dated the Tranche A Closing Date,
certifying that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>attached
to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing and
ratifying the execution, delivery, and performance by such Credit Party of the Loan Documents to which it is a party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
name(s)&nbsp;and title(s)&nbsp;of the officers or other signatories of such Credit Party authorized to execute the Loan Documents to
which such Credit Party is a party on behalf of such Credit Party, together with a sample of the true signature(s)&nbsp;of each such
signatory; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Collateral Agent and each Lender may conclusively rely on such certificate with respect to the authority of such officers unless and
until such Credit Party shall have delivered to the Collateral Agent a further certificate canceling or amending such prior certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Credit Party shall have obtained all Governmental Approvals, if any, and all consents of other Persons, if any, in each case that are
necessary in connection with the transactions contemplated by the Loan Documents and each of the foregoing shall be in full force and
effect and in form and substance reasonably satisfactory to the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Collateral Agent&rsquo;s receipt on the Tranche A Closing Date of an opinion of (i)&nbsp;Davis Polk&nbsp;&amp; Wardwell LLP, in its capacity
as special New York counsel to the Credit Parties and (ii)&nbsp;Hogan Lovells LLP, in its capacity as special Delaware and Virginia counsel
to Borrower, in each case in form and substance reasonably satisfactory to the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>subject
to <U>Section&nbsp;5.14</U> the Collateral Agent&rsquo;s receipt of (i)&nbsp;evidence that any products liability and general liability
insurance policies maintained regarding any Collateral are in full force and effect and (ii)&nbsp;appropriate evidence showing the Collateral
Agent, for the benefit of Lenders and the other Secured Parties, having been named as additional insured or loss payee, as applicable
(such evidence to be in form and substance reasonably satisfactory to the Collateral Agent) with respect to any products liability and
general liability insurance policies maintained in the United States regarding any Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Collateral Agent&rsquo;s receipt prior to the Tranche A Closing Date of Borrower&rsquo;s U.S. tax forms and all documentation and other
information required by bank regulatory authorities under applicable &ldquo;know-your-customer&rdquo; and anti-money laundering rules&nbsp;and
regulations, including the U.S.A. Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26, 2001)) (the &ldquo;<B>Patriot
Act</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>concurrent
with the funding of the Tranche A Loan, payment of (i)&nbsp;Lender Expenses then due as specified in <U>Section&nbsp;2.4</U> hereof for
which Borrower has received an invoice at least one (1)&nbsp;Business Day prior, and (ii)&nbsp;payment of the Tranche A Additional Consideration
described in <U>Section&nbsp;2.7(a)(i)(y)</U>&nbsp;hereof, which such payments shall be deducted from the proceeds of the Tranche A Loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[reserved];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Lenders&rsquo; receipt of the Tranche A Additional Consideration described in <U>Section&nbsp;2.7(a)(i)(x)</U>&nbsp;hereof on the Effective
Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Collateral Agent&rsquo;s receipt of a certificate, dated the Tranche A Closing Date and signed by a Responsible Officer of Borrower,
confirming: (i)&nbsp;there is no Adverse Proceeding pending or, to the Knowledge of Borrower, threatened, that, individually or in the
aggregate, could reasonably be expected to result in a Material Adverse Change, except as set forth on <U>Schedule 4.7</U> of the Disclosure
Letter; (ii)&nbsp;[reserved]; and (iii)&nbsp;assuming the Collateral Agent&rsquo;s and each Lender&rsquo;s satisfaction with any matter
as to which such satisfaction is required, the satisfaction of the other conditions precedent set forth in this <U>Section&nbsp;3.1</U>
and in <U>Section&nbsp;3.3</U>, <U>Section&nbsp;3.4</U> and <U>Section&nbsp;3.5</U> (such certificate to be in form and substance reasonably
satisfactory to the Collateral Agent); and (iv)&nbsp;that the organizational structure and/or list of the names of Borrower and each
of its Subsidiaries and the ownership therein held by the Borrower or its applicable Subsidiary is as described on <U>Schedule 4.15</U>
of the Disclosure Letter as at the Tranche A Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions
Precedent to Tranche B Loan</B>. Each Lender&rsquo;s obligation to advance its Applicable Percentage of the Tranche B Loan Amount is
subject to the satisfaction (or waiver in accordance with <U>Section&nbsp;11.5</U> hereof) of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Collateral Agent&rsquo;s and each Lender&rsquo;s receipt, on the Tranche B Closing Date, of the Tranche B Note executed by Borrower,
and, if and to the extent any update thereto is necessary between the Tranche A Closing Date and the Tranche B Closing Date, an updated
Disclosure Letter or Perfection Certificate (<U>provided</U>, <U>that</U>, in no event may the Disclosure Letter or the Perfection Certificate
be updated in a manner that would reflect or evidence a Default or an Event of Default (with or without such update)), in each case (x)&nbsp;dated
as of the Tranche B Closing Date, (y)&nbsp;executed (where applicable) and delivered by each applicable Credit Party, and (z)&nbsp;in
form and substance reasonably satisfactory to the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Collateral Agent&rsquo;s receipt of a Secretary&rsquo;s Certificate in relation to each Credit Party, dated the Tranche B Closing Date,
certifying that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(A)&nbsp;the
Borrowing Resolutions adopted as of the Tranche A Closing Date authorizing the Term Loans and previously delivered to the Collateral
Agent pursuant to <U>Section&nbsp;3.1(d)</U>&nbsp;have not been modified and remain in full force and effect or, alternatively, (B)&nbsp;attached
to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing the
Tranche B Loan; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Collateral Agent and each Lender may conclusively rely on such certificate with respect to the authority of such officers unless and
until such Credit Party shall have delivered to the Collateral Agent a further certificate canceling or amending such prior certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Tranche A Loan has been funded on the Tranche A Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;concurrent
with the funding of the Tranche B Loan, payment of Lender Expenses then due as specified in <U>Section&nbsp;2.4</U> hereof for which
Borrower has received an invoice at least one (1)&nbsp;Business Day prior, and payment of the Tranche B Additional Consideration in accordance
with <U>Section&nbsp;2.7</U>, which such payments shall be deducted from the proceeds of the Tranche B Loan; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Collateral Agent&rsquo;s receipt of a certificate, dated the Tranche B Closing Date and signed by a Responsible Officer of Borrower,
confirming: (i)&nbsp;as of the date of the Advance Request Form&nbsp;for the Tranche B Loan, the Tranche B Net Sales Trigger has been
achieved; (ii)&nbsp;there is no Adverse Proceeding pending or, to the Knowledge of Borrower, threatened, that, individually or in the
aggregate, could reasonably be expected to result in a Material Adverse Change, except as set forth on <U>Schedule 4.7</U> of the Disclosure
Letter delivered in accordance with <U>Section&nbsp;3.1(a)(i)</U>&nbsp;or <U>Section&nbsp;3.2(a)</U>, as applicable; and (iii)&nbsp;assuming
the Collateral Agent&rsquo;s and each Lender&rsquo;s satisfaction with any matter as to which such satisfaction is required, the satisfaction
of the conditions precedent set forth in this <U>Section&nbsp;3.2</U> and in <U>Section&nbsp;3.3</U>, <U>Section&nbsp;3.4</U> and <U>Section&nbsp;3.5</U>
(such certificate to be in form and substance reasonably satisfactory to the Collateral Agent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Additional
Conditions Precedent to Term Loans</B>. The obligation of each Lender to advance its Applicable Percentage of each Term Loan is subject
to the following additional conditions precedent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
representations and warranties made by the Credit Parties in <U>Section&nbsp;4</U> of this Agreement and in the other Loan Documents
are true and correct in all material respects on the applicable Closing Date, unless any such representation or warranty is stated to
relate to a specific earlier date, in which case such representation or warranty shall be true and correct in all material respects as
of such earlier date (it being understood that any representation or warranty that is qualified as to &ldquo;materiality,&rdquo; &ldquo;Material
Adverse Change,&rdquo; or similar language shall be true and correct in all respects, in each case, on the applicable Closing Date (both
with and without giving effect to the Term Loans) or as of such earlier date, as applicable); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>there
shall not have occurred any Default, that is then continuing, or any Event of Default (including, for the avoidance of doubt, any Material
Adverse Change or Withdrawal Event).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Covenant
to Deliver</B>. The Credit Parties agree to deliver to the Collateral Agent or each Lender, as applicable, each item required to be delivered
to Collateral Agent or each Lender, as applicable, under this Agreement as a condition precedent to any Credit Extension; <U>provided</U>,
<U>however</U>, that any such items set forth on <U>Schedule 5.14</U> of the Disclosure Letter shall be delivered to the Collateral Agent
within the time period prescribed therefor on such schedule. The Credit Parties expressly agree that a Credit Extension made prior to
the receipt by the Collateral Agent or any Lender, as applicable, of any such item shall not constitute a waiver by the Collateral Agent
or any Lender of the Credit Parties&rsquo; obligation to deliver such item, and the making of any Credit Extension in the absence of
any such item required to have been delivered by the date of such Credit Extension shall be in the applicable Lender&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Procedures
for Borrowing</B>. Subject to the prior satisfaction of all other applicable conditions to the making of each Term Loan set forth in
this Agreement, to obtain any Term Loan, Borrower shall deliver to the Collateral Agent and Lenders by electronic mail or facsimile a
completed Advance Request Form&nbsp;(but for the funds flow to be attached thereto) for such Term Loan executed by a Responsible Officer
of Borrower (which notice shall be irrevocable on and after the date on which such notice is given and Borrower shall be bound to make
a borrowing in accordance therewith), in which case each Lender agrees to advance its Applicable Percentage of such Term Loan to Borrower
on the Tranche A Closing Date or Tranche B Closing Date, as applicable, by wire transfer of same day funds in Dollars, to such account(s)&nbsp;in
the United States as may be designated in writing to the Collateral Agent by Borrower at least two (2)&nbsp;Business Days prior to the
Tranche A Closing Date or the Tranche B Closing Date, as applicable; <U>provided</U>, <U>however</U>, that, with respect to the Tranche
B Loan, Borrower shall deliver to the Collateral Agent and Lenders by electronic mail or facsimile, at its option should it wish to obtain
the Tranche B Loan, such completed Advance Request Form&nbsp;no later than April&nbsp;30, 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>REPRESENTATIONS
AND WARRANTIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to induce each Lender
and the Collateral Agent to enter into this Agreement and for each Lender to make the Credit Extensions to be made on each applicable
Closing Date, each Credit Party, jointly and severally with each other Credit Party, represents and warrants to each Lender and the Collateral
Agent that the following statements are true and correct as of the Effective Date and each applicable Closing Date on which a Term Loan
is made (both with and without giving effect to the Term Loans) except as otherwise specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Due
Organization, Existence, Power and Authority</B>. Borrower and each of its Subsidiaries (a)&nbsp;is duly incorporated, organized or formed,
and validly existing and, to the extent the concept is applicable in such jurisdiction, in good standing, under the laws of its jurisdiction
of incorporation, organization or formation identified on <U>Schedule 4.15</U> of the Disclosure Letter, (b)&nbsp;has all requisite power
and authority to (i)&nbsp;own, lease, license and operate its assets and properties and to carry on its business as currently conducted
and (ii)&nbsp;execute and deliver the Loan Documents to which it is a party and to perform its obligations thereunder and otherwise carry
out the transactions contemplated thereby, (c)&nbsp;is duly qualified and, to the extent the concept is applicable in such jurisdiction,
in good standing, under the laws of each jurisdiction where its ownership, lease, license or operation of assets or properties or the
conduct of its business requires such qualification, and (d)&nbsp;has all requisite Governmental Approvals to operate its business as
currently conducted; except in each case referred to <U>clauses (a)</U>&nbsp;(other than with respect to Borrower and any other Credit
Party), <U>(b)(i)</U>, <U>(c)</U>&nbsp;or <U>(d)</U>&nbsp;above, to the extent that failure to do so could not, individually or in the
aggregate, reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Equity
Interests</B>. All of the outstanding Equity Interests in each Subsidiary of Borrower which are required to be pledged pursuant to the
Collateral Documents have been duly authorized and validly issued, are (where required by Requirements of Law to be) fully paid and,
in the case of Equity Interests representing corporate interests, are non-assessable, and all such Equity Interests owned directly by
Borrower or any other Credit Party are owned free and clear of all Liens except for Permitted Liens. <U>Schedule 4.2</U> of the Disclosure
Letter identifies each Person, the Equity Interests in which as of the Effective Date or applicable Closing Date are required to be pledged
on the applicable Closing Date pursuant to the Collateral Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Authorization;
No Conflict</B>. Except as set forth on <U>Schedule 4.3</U> of the Disclosure Letter, the execution, delivery and performance by each
Credit Party of the Loan Documents to which it is a party, and the consummation of the transactions contemplated thereby, (a)&nbsp;have
been duly authorized by all necessary corporate or other organizational action and (b)&nbsp;do not and will not (i)&nbsp;contravene the
terms of any of such Credit Party&rsquo;s Operating Documents, (ii)&nbsp;conflict with or result in any breach or contravention of, or
require any payment to be made under (A)&nbsp;any provision of any security issued by such Person or of any agreement, instrument or
other undertaking to which such Credit Party is a party or affecting such Credit Party or the assets or properties of such Credit Party
or any of its Subsidiaries or (B)&nbsp;any order, writ, judgment, injunction, decree, determination or award of any Governmental Authority
by which such Credit Party or any of its properties or assets are subject, (iii)&nbsp;result in the creation of any Lien (other than
under or otherwise permitted under the Loan Documents) or (iv)&nbsp;violate any Requirements of Law, except, in the cases of <U>clauses
(b)(ii)</U>&nbsp;and <U>(b)(iv)</U>&nbsp;above, to the extent that such conflict, breach, contravention, payment or violation could not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Government
Consents; Third-Party Consents</B>. Except as set forth on <U>Schedule 4.4</U> of the Disclosure Letter, no Governmental Approval or
other approval, consent, exemption or authorization, or other action by, or notice to, or filing with, any Governmental Authority or
any other Person (including any counterparty to any Company IP Agreement or other Material Contract) is necessary or required in connection
with (a)&nbsp;the execution, delivery or performance by, or enforcement against, any Credit Party of this Agreement or any other Loan
Document, or for the consummation of the transactions contemplated hereby or thereby, (b)&nbsp;the grant by any Credit Party of the Liens
granted by it pursuant to the Collateral Documents, (c)&nbsp;the perfection or maintenance of the Liens created under the Collateral
Documents (including the priority thereof) to the extent required pursuant to the terms thereof or (d)&nbsp;the exercise by the Collateral
Agent or any Lender of its rights under the Loan Documents or the remedies in respect of the Collateral pursuant to the Collateral Documents,
except in each case of <U>clause (a)</U>&nbsp;through <U>(d)</U>&nbsp;above, for (i)&nbsp;filings or registrations necessary to perfect
the Liens on the Collateral granted by the Credit Parties to the Collateral Agent for the benefit of Lenders and the other Secured Parties,
(ii)&nbsp;the approvals, consents, exemptions, authorizations, actions, notices and filings which have been duly obtained, taken, given
or made and are in full force and effect, (iii)&nbsp;filings under state or federal securities laws, (iv)&nbsp;notices required to be
delivered by the Collateral Agent or any Lender in connection with, or the cooperation of any third Person (that is not an Affiliate
of any Credit Party) that is required for, any exercise of any of the rights or remedies by the Collateral Agent or any Lender, and (v)&nbsp;those
approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Binding
Obligation</B>. This Agreement has been duly executed and delivered by Borrower and each other Credit Party that is a party hereto and
each other Loan Document has been duly executed and delivered by each Credit Party that is a party thereto, constitutes a legal, valid
and binding obligation of Borrower or such Credit Party (as applicable), enforceable against Borrower or such Credit Party (as applicable)
in accordance with its respective terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium
or similar laws relating to or limiting creditors&rsquo; rights generally, by general principles of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Collateral</B>.
In connection with this Agreement, Borrower has delivered to the Collateral Agent a completed certificate signed by a Responsible Officer
of Borrower (as may be updated from time to time in accordance with the terms herein, the &ldquo;<B>Perfection Certificate</B>&rdquo;).
Each Credit Party, jointly and severally, represents and warrants to the Collateral Agent and each Lender that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;Its
exact legal name is that indicated on the Perfection Certificate and on the signature page&nbsp;thereof; (ii)&nbsp;it is an organization
or company of the type and is organized or incorporated in the jurisdiction set forth in the Perfection Certificate; (iii)&nbsp;the Perfection
Certificate accurately sets forth its organizational identification or registration number or accurately states that it has none; (iv)&nbsp;the
Perfection Certificate accurately sets forth its place of business or registered office address, or, if more than one, its chief executive
office or registered office address, as well as its mailing address (if different than its chief executive office or registered office
address); (v)&nbsp;except as set forth in the Perfection Certificate, it (and each of its predecessors) has not, in the five (5)&nbsp;years
prior to the Effective Date or applicable Closing Date, changed its jurisdiction of formation, organizational structure or type, or any
organizational number assigned by its jurisdiction; and (vi)&nbsp;all other information set forth on the Perfection Certificate pertaining
to it and each of its Subsidiaries is accurate and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;It
has good and valid title to, has the rights it purports to have in, and subject to Permitted Subsidiary Distribution Restrictions, Permitted
Negative Pledges and the occurrence of the applicable Closing Date, the power to transfer, each item of the Collateral (including each
item of Covered Company IP included therein) upon which it purports to grant a Lien under any Collateral Document, free and clear of
any and all Liens except Permitted Liens and except for such irregularities or defects in title as could not, individually or in the
aggregate, reasonably be expected to result in a Material Adverse Change, and (ii)&nbsp;it has no deposit accounts maintained at a bank
or other depository or financial institution which are not Excluded Accounts other than the deposit accounts described in the Perfection
Certificate delivered to the Collateral Agent in connection herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>A
true, correct and complete list of each pending, registered or issued Patent (including any Patents that are or are intended to be listed
in the FDA&rsquo;s so-called &ldquo;Purple Book&rdquo; as covering the Product), Copyright and Trademark that relates to any aspect of
the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling,
promotion, advertising, offer for sale, distribution or sale of the Product in the Territory that is owned or co-owned by, or exclusively
licensed to, any Credit Party or any of its Subsidiaries (collectively, the &ldquo;<B>Covered Company IP</B>&rdquo;), including its name/title,
current owner or co-owners (including ownership interest), registration, patent or application number, and registration or application
date, in each jurisdiction where issued or filed in the Territory, is set forth on <U>Schedule 4.6(c)</U>&nbsp;of the Disclosure Letter.
Except as set forth on <U>Schedule 4.6(c)</U>&nbsp;of the Disclosure Letter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;(x)&nbsp;to
each Credit Party&rsquo;s Knowledge, each item of Covered Company IP owned or co-owned by a Credit Party or any of its Subsidiaries is
valid, subsisting and enforceable, (y)&nbsp;no such item of Covered Company IP has in any respect lapsed, expired, been cancelled, held
unpatentable, held unenforceable or held invalidated or become abandoned or unenforceable, in each case, except in accordance with its
statutory term or in the exercise of normal prosecution practices and reasonable business judgment, and (z)&nbsp;to each Credit Party&rsquo;s
Knowledge, no circumstance or grounds exist that would invalidate or reduce, in whole or in part, the validity, enforceability, subsistence
or scope of any such Covered Company IP, or reduce the ownership or use of such Covered Company IP, by any Credit Party or any of its
Subsidiaries, and (B)&nbsp;no written notice has been received by any Credit Party or any of its Subsidiaries challenging the validity,
patentability, enforceability, inventorship or ownership (other than from patent and trademark and other intellectual property offices
through the normal prosecution practices), or relating to any lapse, expiration, invalidation, cancellation, abandonment or unenforceability
(other than from patent and trademark and other intellectual property offices through the normal prosecution practices or relating to
the expiration of Covered Company IP in accordance with its statutory term), of any such item of Covered Company IP owned or co-owned
by a Credit Party or any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the Knowledge of any Credit Party, (A)&nbsp;each item of Covered Company IP that is exclusively in-licensed from another Person is valid,
subsisting and enforceable and no item of Covered Company IP that is exclusively in-licensed by a Credit Party or any of its Subsidiaries
has in any respect lapsed, expired, been cancelled, held unpatentable, held unenforceable or held invalidated, or become abandoned (in
each case other than in accordance with its statutory term or through the exercise of normal prosecution practices or reasonable business
judgment of the applicable licensor), and (B)&nbsp;no written notice has been received challenging the validity, patentability, enforceability,
inventorship or ownership, or relating to any lapse, expiration, invalidation, cancellation, abandonment or unenforceability, of any
item of Covered Company IP that is exclusively in-licensed by a Credit Party or any of its Subsidiaries (in each case, other than from
patent and trademark and other intellectual property offices through the applicable licensor&rsquo;s normal prosecution practices or
relating to the expiration of Covered Company IP in accordance with its statutory term);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the Knowledge of each Credit Party, all published patents, patent applications, articles and prior art references known to the Credit
Party and reasonably believed to be material to patentability of one or more claims of U.S. Covered Company IP owned or co-owned by a
Credit Party were disclosed to the U.S. Patent and Trademark Office and, to the Knowledge of each Credit Party, the Product as approved
by FDA does not infringe the claims of an issued U.S. patent or the currently pending claims of a published U.S. patent application as
of the Effective Date or applicable Closing Date if the currently pending claims were to issue and were valid, except as would not be
reasonably expected to materially adversely affect the exploitation of the Product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;each
Person who has or has had any rights in or to any owned Covered Company IP or any trade secrets owned by any Credit Party or any of its
Subsidiaries relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing,
storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of the Product in the Territory,
including each inventor named on the Patents within such owned Covered Company IP, has executed an agreement assigning his, her or its
entire right, title and interest in and to such owned Covered Company IP and such trade secrets, and the inventions, ideas, discoveries,
writings, works of authorship, information and other intellectual property embodied, described or claimed therein, to the stated owner
thereof, and (B)&nbsp;to the Knowledge of each Credit Party, no such Person has any contractual or other obligation that would preclude
or conflict with such assignment or the exploitation of the Product in the Territory or entitle such Person to ongoing payments; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no
item of Covered Company IP that is non-exclusively in-licensed from another Person is material to or necessary for research, development,
manufacturing, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising,
offering for sale, distribution or selling the Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;Each
Credit Party or any of its Subsidiaries possesses valid title to the Covered Company IP for which it is listed as the owner or co-owner,
as applicable, on <U>Schedule 4.6(c)</U>&nbsp;of the Disclosure Letter; and (ii)&nbsp;there are no Liens on any Covered Company IP, other
than Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no maintenance, annuity or renewal fees that are currently overdue beyond their allotted grace period for any of the Covered Company
IP which is owned by or, to any Credit Party&rsquo;s Knowledge, exclusively licensed to any Credit Party or any of its Subsidiaries,
nor have any applications or registrations therefor lapsed or become abandoned, been cancelled or expired (other than through the lapse,
expiration or abandonment of such Covered Company IP in accordance with its statutory term or in the exercise of normal prosecution practices
or reasonable business judgment of the Credit Parties, their respective Subsidiaries or the applicable licensor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no unpaid fees, royalties or indemnification payments under any Company IP Agreement that have become due or overdue. Each Company
IP Agreement is in full force and effect and, to the Knowledge of each Credit Party, is legal, valid, binding, and enforceable in accordance
with its respective terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to
or limiting creditors&rsquo; rights generally or by equitable principles relating to enforceability. No Credit Party or any of its Subsidiaries
is in breach of or default under any Company IP Agreement to which it is a party or may otherwise be bound, and to the Knowledge of each
Credit Party, no circumstances or grounds exist that could give rise to a claim of breach or right of rescission, termination, non-renewal,
revision, or amendment of any of the Company IP Agreements, including the execution, delivery and performance of this Agreement and the
other Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
payments by any Credit Party or any of its Subsidiaries are due to any other Person in respect of the Covered Company IP, other than
pursuant to the Company IP Agreements and those fees payable to patent and other intellectual property offices in connection with the
prosecution and maintenance of the Covered Company IP and associated attorney fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;(i)&nbsp;No
Credit Party or any of its Subsidiaries has undertaken or omitted to undertake any acts, and (ii)&nbsp;to the Knowledge of such Credit
Party in the case of Covered Company IP owned or co-owned by or exclusively licensed to any Credit Party or any of its Subsidiaries,
no circumstance or grounds exist, that, in either case of (i)&nbsp;or (ii), would invalidate or reduce, in whole or in part, the enforceability
or scope of any Credit Party&rsquo;s or any of its Subsidiary&rsquo;s right or entitlement to the Covered Company IP in any manner that
could reasonably be expected to materially adversely affect any aspect of the research, development, manufacture, production, use, commercialization,
marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of the Product
in the Territory, except as set forth on <U>Schedule 4.6(h)(A)</U>&nbsp;of the Disclosure Letter; and (B)&nbsp;(i)&nbsp;no Credit Party
or any of its Subsidiaries has omitted to undertake any acts necessary to maintain, and (ii)&nbsp;to the Knowledge of such Credit Party
in the case of Covered Company IP owned or co-owned by or exclusively licensed to any Credit Party or any of its Subsidiaries, no circumstances
or grounds exist that would impair the validity or, in whole or in part, the enforceability or scope of, in either case of (i)&nbsp;or
(ii), any Credit Party&rsquo;s or any of its Subsidiary&rsquo;s right or entitlement to the Covered Company IP in any manner that could
reasonably be expected to materially adversely affect any aspect of the research, development, manufacture, production, use, commercialization,
marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of the Product
in the Territory, except as set forth on <U>Schedule 4.6(h)(B)</U>&nbsp;of the Disclosure Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as noted on <U>Schedule 4.6(i)</U>&nbsp;of the Disclosure Letter, to the Knowledge of any Credit Party, there is no product or other
technology of any third-party that infringes a Patent within the Covered Company IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the Effective Date and each applicable Closing Date, (i)&nbsp;except as noted on <U>Schedule 4.6(j)(i)</U>&nbsp;of the Disclosure
Letter, no Credit Party is a party to, nor is it bound by, any Restricted License, and (ii)&nbsp;except as noted on <U>Schedule 4.6(j)(ii)</U>&nbsp;of
the Disclosure Letter, no Credit Party nor any of its Subsidiaries is a party to, nor is it bound by, any Excluded License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
each case where an issued U.S. Patent within the Covered Company IP where such U.S. Patent is owned or co-owned by any Credit Party or
its Subsidiaries by assignment, the assignment has been duly recorded with the U.S. Patent and Trademark Office, and if applicable, the
assignment has been duly recorded or will be recorded promptly with all similar offices and agencies anywhere in the world in which foreign
counterparts are registered, filed or issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no pending or, to the Knowledge of each Credit Party, threatened (in writing) claims against Borrower or any of its Subsidiaries
alleging (i)&nbsp;that any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport,
packaging, labelling, promotion, advertising, offer for sale, distribution or sale of the Product in the Territory infringes or violates
(or in the past infringed or violated) any of the rights of any third parties in or to any Intellectual Property (&ldquo;<B>Third-Party
IP</B>&rdquo;) or constitutes a misappropriation of (or in the past constituted a misappropriation of) any Third-Party IP, or (ii)&nbsp;that
any Covered Company IP is invalid, unpatentable or unenforceable (other than from patent and trademark offices through the normal prosecution
practices).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the Knowledge of each Credit Party, the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer
for sale, distribution or sale of the Product in the Territory does not (i)&nbsp;infringe or violate (or in the past infringed or violated)
any of the rights of third parties in or to any Third-Party IP (including any issued or registered Third-Party IP), or (ii)&nbsp;constitute
(or constituted) a misappropriation of any Third-Party IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.6(n)</U>&nbsp;of the Disclosure Letter, there are no settlements, covenants not to sue, consents, judgments,
orders or similar obligations, in each case, that were undertaken in connection with the avoidance, resolution or disposition of an actual,
anticipated or potential Adverse Proceeding (or any actual or potential basis or grounds therefor) which: (i)&nbsp;restrict the rights
of any Credit Party or any of its Subsidiaries to use any Company IP relating to any aspect of the research, development, manufacture,
production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for
sale, distribution or sale of the Product in the Territory (in order to accommodate any Third-Party IP or otherwise), or (ii)&nbsp;permit
any third parties to use any Company IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.6(o)</U>&nbsp;of the Disclosure Letter, to the Knowledge of each Credit Party, (i)&nbsp;there is no, nor
has there been any, infringement or violation by any Person of any of the Company IP or the rights therein and (ii)&nbsp;there is no,
nor has there been any, misappropriation by any Person of any of the Company IP or the subject matter thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Credit Party and each of its Subsidiaries has taken commercially reasonable measures customary in the health and life sciences sector
to protect the confidentiality and value of trade secrets owned or licensed by such Credit Party or any of its Subsidiaries, or used
or held for use by such Credit Party or any of its Subsidiaries, in each case relating to any aspect of the research, development, manufacture,
production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for
sale, distribution or sale of the Product in the Territory. Any use or disclosure by a Credit Party or any of its Subsidiaries of any
such trade secrets to any third-party has been pursuant to the terms of a written agreement including appropriate confidentiality, access,
use and non-disclosure provisions with such third-party, and, to the Knowledge of the Credit Party, no Credit Party or any of its Subsidiaries
has suffered any material data breach or other incident that has resulted in any loss, unauthorized access, use, disclosure or modification
of any such trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Units
of the Product made, used or sold in the Territory under the Patents within the Covered Company IP has been marked with the proper patent
notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the Knowledge of each Credit Party, at the time of any shipment of the Product occurring prior to the Effective Date or applicable Closing
Date, the units thereof so shipped complied with their relevant specifications and were developed and manufactured in accordance with
then applicable FDA Good Manufacturing Practices, FDA Good Clinical Practices, FDA Good Laboratory Practices, and other Requirements
of Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>With
respect to the Covered Company IP consisting of Patents, except as set forth on <U>Schedule 4.6(s)</U>&nbsp;of the Disclosure Letter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the Knowledge of such Credit Party, all prior art material to such Patents was adequately disclosed, to the extent such disclosure is
required, to the relevant patent office or considered by the respective patent offices during prosecution of such Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>subsequent
to the issuance of such Patents, no Credit Party nor any Subsidiary nor any of their respective predecessors-in-interest, has filed any
disclaimer or made or permitted any other voluntary reduction in the scope of the inventions claimed in such Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the Knowledge of such Credit Party, no subject matter of such Patents that is designated allowable or allowed by the U.S. Patent and
Trademark Office is subject to any competing conception claims of subject matter of any patent applications or patents of any third-party
and have not been the subject of any interference or derivation proceeding, and such Patents are not and have not been the subject of
any re-examination, opposition or any other post-grant proceedings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
any of such Patents is terminally disclaimed to another patent or patent application, all patents and patent applications subject to
such terminal disclaimer are included in the Collateral; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>neither
any Credit Party nor any Subsidiaries has received advice from legal counsel expressing an opinion, including a preliminary or qualified
opinion, which concludes that a challenge to the validity or enforceability, subsistence or scope of any such Patents is more likely
than not to succeed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;Neither
any Credit Party nor any Subsidiary, nor, to the Knowledge of such Credit Party, any of their respective agents or representatives, have
(i)&nbsp;engaged in any conduct, the result of which would invalidate or render unpatentable or unenforceable or materially reduce, in
whole or in part, the validity, enforceability, subsistence or scope of any Patent included within Covered Company IP, or (ii)&nbsp;omitted
to perform any necessary act to maintain the validity, patentability, enforceability, subsistence or scope of any such Patent, and (B)&nbsp;to
the Knowledge of such Credit Party, no prior owner of any such Patent of any Credit Party or any of its Subsidiaries, nor any of such
prior owner&rsquo;s agents or representatives, have (i)&nbsp;engaged in any conduct, the result of which would invalidate or render unpatentable
or unenforceable or materially reduce, in whole or in part, the validity, enforceability, subsistence or scope of any such Patent, or
(ii)&nbsp;omitted to perform any necessary act to maintain the validity, patentability, enforceability, subsistence or scope of any such
Patent, in each case of (A)&nbsp;and (B), except in the exercise of normal prosecution practices or reasonable business judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Collateral Documents create in favor of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a valid and continuing
and, upon the making of the filings and the taking of the actions required under the terms of the Loan Documents, perfected Lien on and
security interest in the Collateral (in each case, solely to the extent perfection is available under Requirements of Law through the
making of such filings and taking of such actions and except to the extent expressly not required to be perfected pursuant to the terms
of the Loan Documents), securing the payment of the Obligations, and having priority over all other Liens on and security interests in
the Collateral (except Permitted Liens).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Adverse
Proceedings, Compliance with Laws</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the Effective Date and the Tranche A Closing Date, except as set forth on <U>Schedule 4.7</U> of the Disclosure Letter, (i)&nbsp;there
are no Adverse Proceedings pending or, to the Knowledge of such Credit Party, threatened in writing, at law, in equity, in arbitration
or before any Governmental Authority, by or against Borrower or any of Borrower&rsquo;s Subsidiaries; and (ii)&nbsp;neither Borrower
nor any of Borrower&rsquo;s Subsidiaries (A)&nbsp;is in material violation of any Requirements of Law, excluding any Requirement of Law
which is being contested in good faith by appropriate proceedings, or (B)&nbsp;is subject to or in default with respect to any final
judgments, orders, writs, injunctions, settlement agreements, decrees, rules&nbsp;or regulations of any court or any federal, state,
municipal or other governmental department, commission, board, bureau, agency, instrumentality, or other Governmental Authority, domestic
or foreign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of each Closing Date other than the Tranche A Closing Date, (i)&nbsp;except as set forth on <U>Schedule 4.7</U> of the Disclosure Letter,
there are no Adverse Proceedings pending or, to the Knowledge of any Credit Party, threatened in writing, at law, in equity, in arbitration
or before any Governmental Authority, by or against Borrower or any of Borrower&rsquo;s Subsidiaries, which, if adversely determined,
either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change; and (ii)&nbsp;neither Borrower
nor any of Borrower&rsquo;s Subsidiaries (A)&nbsp;is in violation of any Requirements of Law, excluding any Requirement of Law which
is being contested in good faith by appropriate proceedings, where such violation could reasonably be expected to result in uninsured
damages, penalties or costs to Borrower or any of Borrower&rsquo;s Subsidiaries in an amount in excess of the materiality thresholds
applied by Borrower in accordance with the Exchange Act and related regulations and standards for purposes of its Exchange Act reporting
or (B)&nbsp;is subject to or in default with respect to any final judgment, order, writ, injunction, settlement agreement, decree, rule&nbsp;or
regulation of any court or any federal, state, municipal or other governmental department, commission, board, bureau, agency, instrumentality,
or other Governmental Authority, domestic or foreign that could reasonably be expected to result in uninsured damages, penalties or costs
to Borrower or any of its Subsidiaries in an amount in excess of the materiality thresholds applied by Borrower in accordance with the
Exchange Act and related regulations and standards for purposes of its Exchange Act reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
of Borrower and its Subsidiaries, to the Knowledge of each such Credit Party, is in compliance in all material respects with the terms
of all settlement agreements relating to any Adverse Proceeding to which Borrower or any Subsidiary is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Exchange
Act Documents; Financial Statements; Financial Condition; No Material Adverse Change; Books and Records</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Exchange Act Documents filed by Borrower with the SEC since December&nbsp;31, 2024, when they were filed with the SEC, conformed in all
material respects to the requirements of the Exchange Act, and as of the time they were filed with the SEC, none of such documents contained
any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein (excluding any projections
and forward-looking statements, estimates, budgets and general economic or industry data of a general nature), in the light of the circumstances
under which they were made, not misleading; <U>provided</U>, <U>that</U>, with respect to projected financial information, Borrower represents
only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it being understood
that such projections are not a guarantee of financial performance and are subject to uncertainties and contingencies, many of which
are beyond the control of Borrower or any Subsidiary, and neither Borrower nor any Subsidiary can give any assurance that such projections
will be attained, that actual results may differ in a material manner from such projections and any failure to meet such projections
shall not be deemed to be a breach of any representation or covenant herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower&rsquo;s
audited annual financial statements as of December&nbsp;31, 2024 and unaudited quarterly financial statements as of March&nbsp;31, 2025
and June&nbsp;30, 2025 (in each case, including the related notes thereto) of Borrower and its Subsidiaries included in the Exchange
Act Documents present fairly in all material respects the consolidated financial condition of Borrower and such Subsidiaries and their
consolidated results of operations as of the dates indicated and the results of their operations and the changes in their cash flows
for the periods specified. Such financial statements have been prepared in conformity with GAAP applied on a consistent basis throughout
the periods covered thereby, except as otherwise disclosed therein and, in the case of unaudited, interim financial statements, subject
to normal year-end audit adjustments and the exclusion of certain footnotes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
acknowledges that its management is responsible for the preparation and fair presentation of the financial statements of Borrower and
each of its Subsidiaries delivered to the Collateral Agent pursuant to <U>Section&nbsp;5.2(a)</U>, in each case, in conformance, in all
material respects, with GAAP. Borrower has, suitable for a company of its size and stage of development, designed, implemented and maintained
internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatement,
whether due to fraud or error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Since
December&nbsp;31, 2024, there has not occurred any change or event that has had or could reasonably be expected to have, either alone
or in conjunction with any other change(s), event(s)&nbsp;or failure(s), a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Since
December&nbsp;31, 2024, there has not occurred any Transfer by Borrower or any Subsidiary, voluntary or involuntary, of any material
part of the business, assets or property of Borrower or any Subsidiary, and no purchase or other acquisition by any of them of any business,
assets or property (including any Equity Interests of any other Person) material to Borrower or any Subsidiary, in each case, which is
not reflected in the financial statements of Borrower and its Subsidiaries included in the Exchange Act Documents (or in the notes thereto)
and has not otherwise been disclosed in writing to the Collateral Agent or Lenders on or prior to the applicable Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Books of Borrower and each of its Subsidiaries in existence immediately prior to the Effective Date and each applicable Closing Date
contain full, true and correct entries of all dealings and transactions in relation to its business and activities in conformity with
GAAP and Requirements of Law in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Solvency</B>.
The Credit Parties and their Subsidiaries, on a consolidated basis, are Solvent. Without limiting the generality of the foregoing, there
has been no proposal made or resolution adopted by any competent corporate body for the dissolution or liquidation of any Credit Party,
nor do any circumstances exist which may result in the dissolution or liquidation of any Credit Party (other than in respect of a dissolution
or liquidation expressly permitted under <U>Section&nbsp;6.3(a)(iii)</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
of Taxes</B>. All U.S. federal, state, local and non-U.S. income and other Tax returns and reports (or extensions thereof) of each Credit
Party and each of its Subsidiaries required to be filed by any of them have been timely filed and are correct in all material respects,
and all other Taxes which are due and payable by any Credit Party or any of its Subsidiaries and all assessments, fees and other governmental
charges upon any Credit Party or any of its Subsidiaries and upon their respective properties, assets, income, businesses and franchises
which are due and payable in each case have been paid when due and payable, unless and only to the extent that (i)&nbsp;the validity
or amount thereof is being contested in good faith by appropriate proceedings and the applicable Credit Party has set aside on its books
adequate reserves therefor in conformity with GAAP or (ii)&nbsp;the failure to pay such Taxes, individually or in the aggregate, does
not result or could not reasonably be expected to result in a Material Adverse Change. There is no proposed Tax assessment against any
Credit Party or any of its Subsidiaries that could reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Environmental
Matters</B>. Neither Borrower nor any of its Subsidiaries nor any of their respective Facilities or operations is subject to any outstanding
written order, consent decree or settlement agreement with any Person relating to any Environmental Law, any Environmental Claim, or
any Hazardous Materials Activity that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse
Change. There are and, to the Knowledge of such Credit Party, have been, no conditions, occurrences, or Hazardous Materials Activities
that could reasonably be expected to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries that, individually
or in the aggregate, could reasonably be expected to result in a Material Adverse Change. To the Knowledge of such Credit Party, no predecessor
of Borrower or any of its Subsidiaries has filed any notice under any Environmental Law indicating past or present treatment of Hazardous
Materials at any Facility, which could reasonably be expected to form the basis of an Environmental Claim against Borrower or any of
its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change (but, for
the avoidance of doubt, neither Borrower nor any of its Subsidiaries has, directly or indirectly, undertaken any investigation of or
made any inquiries to, or relating to, any of its or its Subsidiaries&rsquo; predecessors), and neither Borrower&rsquo;s nor any of its
Subsidiaries&rsquo; operations involves the generation, transportation, treatment, storage or disposal of hazardous waste, as defined
under 40 C.F.R. Parts 260&ndash;270 or any foreign or United States state equivalents, which could reasonably be expected to form the
basis of an Environmental Claim against Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably
be expected to result in a Material Adverse Change. No event or condition has occurred or is occurring with respect to any Credit Party
relating to any Environmental Law, any Release of Hazardous Materials, or any Hazardous Materials Activity that, individually or in the
aggregate, has resulted in, or could reasonably be expected to result in, a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Material
Contracts</B>. As of the Effective Date and each applicable Closing Date after giving effect to the consummation of the transactions
contemplated by this Agreement, except as described on <U>Schedule 4.12</U> of the Disclosure Letter, each Material Contract is a valid
and binding obligation of the applicable Credit Party and, to the Knowledge of such Credit Party, each other party thereto, and is in
full force and effect, and neither the applicable Credit Party nor, to the Knowledge of such Credit Party, any other party thereto is
in material breach thereof or default thereunder, except where such breach or default (which default has not been cured or waived) could
not reasonably be expected to give rise to any cancellation, termination or acceleration right of the applicable counterparty thereto.
As of the Effective Date and each applicable Closing Date, except as described on <U>Schedule 4.12</U> of the Disclosure Letter, no Credit
Party or any of its Subsidiaries has received any written notice from any party to any Material Contract asserting or to the Knowledge
of such Credit Party, threatening in writing to assert, circumstances that could reasonably be expected to result in the cancellation,
termination or invalidation of any Material Contract (or any provision thereof) or the acceleration of such Credit Party&rsquo;s or Subsidiary&rsquo;s
obligations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Regulatory
Compliance</B>. No Credit Party is or is required to be registered as, or is a company &ldquo;controlled&rdquo; by, an &ldquo;investment
company&rdquo; as defined in, or is subject to regulation under, the Investment Company Act of 1940, as amended. Except as could not
reasonably be expected to result in a Material Adverse Change, each Credit Party has complied with the Federal Fair Labor Standards Act
(and any foreign or United States state equivalent, as applicable). Except as could not, either individually or in the aggregate, reasonably
be expected to result in a Material Adverse Change, each Plan is in compliance with the applicable provisions of ERISA, the IRC and other
U.S. federal or state or foreign Requirements of Law, respectively. (i)&nbsp;No ERISA Event has occurred or is reasonably expected to
occur; (ii)&nbsp;neither any Credit Party nor any ERISA Affiliate has incurred, or reasonably expects to incur, any liability (and no
event has occurred which, with the giving of notice under Section&nbsp;4219 of ERISA, would result in such liability) under Section&nbsp;4201
<I>et seq</I>. of ERISA with respect to a Multiemployer Plan; and (iii)&nbsp;neither any Credit Party (to the extent applicable) nor
any ERISA Affiliate has engaged in a transaction that would be subject to Section&nbsp;4069 or 4212(c)&nbsp;of ERISA, except, with respect
to each of <U>clauses (i)</U>, <U>(ii)</U>&nbsp;and <U>(iii)</U>&nbsp;above, as could not reasonably be expected, individually or in
the aggregate, to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Margin
Stock</B>. No Credit Party is engaged principally, or as one of its important activities, in extending credit for the purpose of, whether
immediate or ultimate, purchasing or carrying Margin Stock. No Credit Party owns any Margin Stock. No Credit Party or any of its Subsidiaries
has taken or permitted to be taken any action that might cause any Loan Document to violate Regulation T, U or X of the Federal Reserve
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subsidiaries;
Capitalization</B>. <U>Schedule 4.15</U> of the Disclosure Letter includes a complete and accurate list, as of the Effective Date or
each applicable Closing Date, of Borrower and each of its Subsidiaries, setting forth (a)&nbsp;its name and jurisdiction of incorporation,
organization or formation, (b)&nbsp;in the case of each Credit Party (other than Borrower), the number of authorized and issued shares
(or equivalent) of each class (where applicable) of its Equity Interests outstanding, and (c)&nbsp;the percentage of its outstanding
shares of each class owned (directly or indirectly) by Borrower or any of its Subsidiaries and the certificate numbers(s)&nbsp;for the
same (if any), and (d)&nbsp;the number and effect, if exercised, of all of its outstanding options, warrants, rights of conversion or
purchase and all other similar rights with respect thereto. Except as set forth on <U>Schedule 4.15</U> of the Disclosure Letter, each
Credit Party is a Registered Organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Employee
Matters</B>. Neither Borrower nor any of its Subsidiaries is engaged in any unfair labor practice that could reasonably be expected to
result in a Material Adverse Change. There is (a)&nbsp;no unfair labor practice complaint pending against Borrower or any of its Subsidiaries
or, to the Knowledge of such Credit Party, threatened in writing against any of them in each case before the National Labor Relations
Board, and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement that is pending against
Borrower or any of its Subsidiaries or, to the Knowledge of such Credit Party, threatened in writing against any of them, (b)&nbsp;no
strike or work stoppage&nbsp;in existence or, to the Knowledge of such Credit Party, threatened in writing involving Borrower or any
of its Subsidiaries, and (c)&nbsp;to the Knowledge of such Credit Party, no union representation question existing with respect to the
employees of Borrower or any of its Subsidiaries and, to the Knowledge of such Credit Party, no union organization activity that is taking
place that in each case specified in any of <U>clauses (a)</U>, <U>(b)</U>&nbsp;and <U>(c)</U>&nbsp;above, individually or taken together
with any other matter specified in <U>clause (a)</U>, <U>(b)</U>&nbsp;or <U>(c)</U>&nbsp;above, could reasonably be expected to result
in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Full
Disclosure</B>. None of the documents, certificates or written statements (excluding any projections and forward-looking statements,
estimates, budgets and general economic or industry data of a general nature) furnished or otherwise made available to the Collateral
Agent or any Lender by or on behalf of any Credit Party for use in connection with the transactions contemplated hereby (in each case,
taken as a whole and as modified or supplemented by other information so furnished promptly after the same becomes available) contains
any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein
or therein, as of the time when made or delivered, not misleading in light of the circumstances in which the same were made; <U>provided</U>,
<U>that</U>, with respect to projected financial information, Borrower represents only that such information was prepared in good faith
based upon assumptions believed to be reasonable at the time (it being understood that such projections are not a guarantee of financial
performance and are subject to uncertainties and contingencies, many of which are beyond the control of Borrower or any Subsidiary, and
neither Borrower nor any Subsidiary can give any assurance that such projections will be attained, that actual results may differ in
a material manner from such projections and any failure to meet such projections shall not be deemed to be a breach of any representation
or covenant herein). To the Knowledge of such Credit Party, there are no facts (other than matters of a general economic or industry
nature) that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change and that have not
been disclosed herein or in such other documents, certificates and written statements furnished or made available to the Collateral Agent
or any Lender for use in connection with the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Anti-Corruption
Laws; Anti-Money Laundering Laws; Sanctions; Export and Import Laws</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>None
of Borrower or any of its Subsidiaries, or any of their respective directors, officers, or, to the Knowledge of such Credit Party, any
employee, any affiliate or any agent of Borrower or any of its Subsidiaries, has (i)&nbsp;used any corporate funds of Borrower or any
of its Subsidiaries for any unlawful or improper contribution, gift, entertainment or other unlawful or improper expense relating to
political activity, (ii)&nbsp;made any direct or, to the Knowledge of such Credit Party, indirect unlawful or improper payment to any
foreign or domestic government official or employee or any Person from corporate funds of Borrower or any of its Subsidiaries, (iii)&nbsp;violated
or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;<B>FCPA</B>&rdquo;), the
U.K. Bribery Act of 2010, or any other applicable anti-corruption laws (collectively, &ldquo;<B>Anti-Corruption Laws</B>&rdquo;) or (iv)&nbsp;made
any bribe, improper rebate, payoff, influence payment, kickback or other unlawful or improper payment, and no part of the proceeds of
any Credit Extension will be used, directly or, to the Knowledge of such Credit Party, indirectly, for any payments to any governmental
official or employee, political party, official of a political party, candidate for political office or anyone else acting in an official
capacity, in order to obtain, retain or direct business, or to obtain any improper advantage, in violation of Anti-Corruption Laws. No
action, suit or proceeding by or before any Governmental Authority or any arbitrator involving Borrower or any of its Subsidiaries, with
respect to Anti-Corruption Laws is pending or to the Knowledge of such Credit Party, is or has been threatened in writing nor is there
a basis for such action, suit, or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;The
operations of Borrower and each of its Subsidiaries are and have been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements of the Bank Secrecy Act of 1970 (as amended by Title III of the Uniting and Strengthening America
by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT) Act of 2001) and the anti-money laundering
laws and counterterrorist financing, rules&nbsp;and regulations of each jurisdiction (foreign or domestic) in which Borrower and its
Subsidiaries, is subject to such jurisdiction&rsquo;s Requirements of Law (collectively, &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;)
and (ii)&nbsp;no action, suit or proceeding by or before any Governmental Authority or any arbitrator involving Borrower or its Subsidiaries,
with respect to the Anti-Money Laundering Laws is pending or to the Knowledge of such Credit Party, threatened in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>None
of Borrower or any of its Subsidiaries, or any of their respective directors, officers, or, to the Knowledge of such Credit Party, any
employee, affiliate or agent of Borrower or any of its Subsidiaries, is, or is 50% or more owned or otherwise controlled by individuals
or entities that are, the target or subject of any economic, trade or financial sanctions or restrictive measures administered and enforced
by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;), the U.S. Department of State,
the United Nations Security Council, the European Union and each of its member states or His Majesty&rsquo;s Treasury of the United Kingdom,
or other relevant Governmental Authority (collectively &ldquo;<B>Sanctions</B>&rdquo;). Neither Borrower nor its Subsidiaries: (i)&nbsp;has
assets located in, or otherwise directly or indirectly derives revenues from or engages in, investments, dealings, activities, or transactions
in or with, any Sanctioned Country; or (ii)&nbsp;directly or indirectly derives revenues from, conducts any business or engages in investments,
dealings, activities, or transactions with, any Blocked Person, including the making or receiving of any contribution of funds, goods
or services to or for the benefit of any Blocked Person. Borrower and its Subsidiaries will not, directly or indirectly (including through
an agent or any other Person), use the proceeds of any Credit Extension, or lend, contribute or otherwise make available such proceeds
to any Subsidiary, joint venture partner or other Person, for (x)&nbsp;the purpose of financing the activities of any Person that is
the target or subject of Sanctions or in any Sanctioned Country, (y)&nbsp;use in any Sanctioned Country, or (z)&nbsp;any purpose that
could cause any Person to be in violation of Sanctions. No action, suit or proceeding by or before any Governmental Authority or any
arbitrator involving Borrower or any of its Subsidiaries, with respect to Sanctions is pending or to the Knowledge of such Credit Party,
threatened in writing, nor is there a basis for such action, suit or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
will not, directly or indirectly (including through an agent or any other Person), use the proceeds of any Credit Extension, or lend,
contribute or otherwise make available the proceeds of any Credit Extension to any Subsidiary, joint venture partner or other Person,
(i)&nbsp;for any payments to any government official or employee, political party, official of a political party, candidate for political
office or other Person, in order to obtain, retain or direct business, or to obtain any improper advantage in violation of Anti-Corruption
Laws, (ii)&nbsp;in violation of any Anti-Money Laundering Laws, or (iii)&nbsp;in violation of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
and each of its Subsidiaries, and their respective officers, directors, employees and, to the Knowledge of such Credit Party, any agent
or Borrower or any of its Subsidiaries, are and have been in compliance in all respects with Sanctions. Borrower and each of its Subsidiaries
have instituted and maintain policies and procedures reasonably designed to ensure compliance with Sanctions, Anti-Money Laundering Laws,
Export and Import Laws, and Anti-Corruption Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
and each of its Subsidiaries are and have been in compliance in all material respects with Export and Import Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Health
Care Matters</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Compliance
with Health Care Laws</U></I>. Except as set forth on <U>Schedule 4.19(a)</U>&nbsp;of the Disclosure Letter, each Credit Party and, to
the Knowledge of such Credit Party, each of its Subsidiaries and each officer, Affiliate, and employee acting on behalf of such Credit
Party or any of its Subsidiaries, is in compliance in all material respects with all applicable Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Compliance
with Regulatory Requirements</U></I>. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries that are
subject thereto, is in compliance in all material respects with applicable FDA Laws; and any and all laws relating to designations (including
any Orphan Drug, Fast Track, Breakthrough Therapy, Priority Review and Rare Pediatric Disease designations), Accelerated Approval, research,
development, testing, approval, licensure, clearance, authorization, exclusivity, post-approval (or post-licensure, post-authorization,
or post-clearance, as applicable) monitoring and requirements, reporting, manufacture, production, packaging, labeling, use, commercialization,
marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution or sale of the Product in the
Territory. Any units of the Product distributed, including for investigational use, or sold in the Territory at all times during the
past five (5)&nbsp;years has been (i)&nbsp;manufactured and developed in all material respects in accordance with current FDA Good Manufacturing
Practices, FDA Good Clinical Practices and FDA Good Laboratory Practices (as applicable), and (ii)&nbsp;if and to the extent the Product
is required to be approved, licensed, or cleared by the relevant Governmental Authority pursuant to FDA Laws in order to be legally marketed
in the Territory for the Product&rsquo;s intended uses, the Product has been approved, licensed, or cleared for such intended uses, meets
in all material respects any additional conditions of approval, clearance, authorization, or licensure by the competent Governmental
Authority, and except as has been set forth in <U>Schedule 4.19(b)</U>, no inquiries regarding material issues have been initiated by
any competent Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Applicability
of Controlled Substances Act</U></I>. The Product does not contain a controlled substance (as that term is defined under the Controlled
Substances Act (21 U.S.C. &sect; 801 et seq.)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Material
Statements</U></I>. Within the past five (5)&nbsp;years, neither any Credit Party, nor, to the Knowledge of such Credit Party, any Subsidiary
or any officer or employee or Affiliate of any Credit Party or Subsidiary in its capacity as a Subsidiary or as an officer, employee
or Affiliate of a Credit Party or Subsidiary (as applicable), nor, to the Knowledge of such Credit Party, any agent of any Credit Party
or Subsidiary, (i)&nbsp;has made an untrue statement of a material fact or a fraudulent statement to any Governmental Authority under
any Health Care Law, (ii)&nbsp;has failed to disclose a material fact to any Governmental Authority under any Health Care Law, or (iii)&nbsp;has
otherwise committed an act, made a statement or failed to make a statement that, at the time such statement or disclosure was made (or,
in the case of such failure, should have been made) or such act was committed, could reasonably be expected to constitute a material
violation of any Health Care Law. Each Credit Party and each of its Subsidiaries has implemented reasonable and appropriate policies
and procedures designed to ensure compliance with all Health Care Laws concerning the types of statements, disclosures, acts, and omissions
described in <U>sub-clauses (i)</U>, <U>(ii)</U>&nbsp;or <U>(iii)</U>&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Proceedings;
Audits</U></I>. Except as has been set forth on <U>Schedule 4.19(e)</U>&nbsp;of the Disclosure Letter: (i)&nbsp;there is no Adverse Proceeding
pending or, to the Knowledge of such Credit Party, threatened in writing, against any Credit Party or any of its Subsidiaries relating
to any allegations of non-compliance with any Health Care Laws, Data Protection Laws or FDA Laws; and (ii)&nbsp;to the Knowledge of such
Credit Party, there are no facts, circumstances or conditions that, individually or in the aggregate, could reasonably be expected to
form the basis for any such Adverse Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Recalls,
Safety Notices, Etc</U></I>. Except as has been set forth on <U>Schedule 4.19(f)</U>&nbsp;of the Disclosure Letter, neither any Credit
Party nor any of its Subsidiaries has initiated or otherwise engaged in any recalls, field notifications, safety warnings, &ldquo;dear
doctor&rdquo; letters, investigator notices, safety alerts or other notices of action, including as a result of any Risk Evaluation and
Mitigation Strategy (or foreign equivalent) proposed or enforced by the FDA, or any other equivalent foreign Governmental Authority relating
to an alleged lack of safety or regulatory compliance of the Product. Except as set forth on <U>Schedule 4.19(e)</U>, neither any Credit
Party nor any of its Subsidiaries has a reasonable expectation that there are grounds for imposition of a clinical hold or a withdrawal
of applicable designations of the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Preclinical
Studies / Clinical Trials</U>. </I>All pre-clinical and clinical studies (including trials) relating to the Product conducted by or on
behalf of any Credit Party or any of its Subsidiaries have been, or are being, conducted in compliance with all applicable Requirements
of Law, including the applicable requirements of FDA Laws, FDA Good Laboratory Practices, FDA Good Clinical Practices, applicable human
subject protections (including 21 C.F.R. parts 50 and 56), and the Animal Welfare Act and applicable experimental protocols, procedures
and controls, United States state equivalents and equivalent foreign laws and applicable regulations. No research involving human subjects
(including clinical trials) relating to the Product conducted by or sponsored by any Credit Party or any of its Subsidiaries has been
conducted by or supported by any U.S. federal department or agency, and none are subject to regulation under 45 C.F.R. Part&nbsp;46.
Except as set forth on <U>Schedule 4.19(g)</U>&nbsp;of the Disclosure Letter, during the past five (5)&nbsp;years, no clinical study
involving the Product conducted by or on behalf of any Credit Party or any of its Subsidiaries has been terminated or suspended by any
Regulatory Agency and neither any Credit Party nor any of its Subsidiaries has received any notice that the FDA (or foreign equivalent),
any other Governmental Authority or any institutional review board, ethics committee or safety monitoring committee (or foreign equivalent)
has recommended, initiated or, to the Knowledge of such Credit Party threatened to initiate any action to suspend or terminate any clinical
trial conducted by or on behalf of any Credit Party or any of its Subsidiaries or to otherwise restrict the preclinical research on or
clinical study of the Product. None of the safety or efficacy issues raised by a Governmental Authority in the context of a clinical
hold (or foreign equivalent) placed on products under development by any Credit Party or any of its Subsidiaries could reasonably be
expected to adversely impact the research, development, testing, manufacture, approval, clearance, authorization, exclusivity, licensure,
designation, post-approval (or post-licensure, post-authorization or post-clearance, as applicable) monitoring and commitments, reporting,
production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport,
offer for sale, distribution or sale of the Product in the Territory. Any clinical hold (or foreign equivalent) that has been placed
as of the date hereof on products under development by any Credit Party or any of its Subsidiaries, or any termination of a clinical
trial that has occurred as of the date hereof by any Credit Party or any of its Subsidiaries could not reasonably be expected to adversely
impact the financial condition of any Credit Party and its Subsidiaries (taken as a whole), or the ability of any Credit Party and its
Subsidiaries (taken as a whole) to fulfill the payment obligations under the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Advertising
/ Promotion</U></I>. For the past five (5)&nbsp;years, each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries,
officers, employees and agents has advertised, promoted, marketed and distributed (including for investigational use) the Product in
the Territory in compliance in all material respects with the applicable requirements of FDA Laws, and other Requirements of Law. Except
as set forth on <U>Schedule 4.19(h)</U>&nbsp;of the Disclosure Letter, for the past five (5)&nbsp;years, neither any Credit Party nor,
to the Knowledge of such Credit Party, any of its Subsidiaries, officers, employees or agents has received any written notice of or is
subject to any civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning
letter, untitled letter, proceeding or request for information from FDA (or foreign equivalents) or any other Governmental Authority
concerning noncompliance with any applicable FDA Laws, or other Requirements of Law with regard to advertising, promoting, marketing
or distributing the Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Recordkeeping
/ Reporting</U></I>. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, has maintained records relating
to the research, development, testing, manufacture, recall, production, handling, labeling, packaging, storage, supply, promotion, distribution,
marketing, commercialization, import, export and sale of the Product in the Territory in compliance in all material respects with FDA
Laws, Health Care Laws, and other applicable Requirements of Law, and each Credit Party and, to the Knowledge of such Credit Party, each
of its Subsidiaries, has submitted to the FDA (or foreign equivalents) and other Governmental Authorities (including Regulatory Agencies)
in a timely manner all material notices and annual or other reports required to be made, including adverse experience reports, annual
reports specific to holders of Orphan Drug designations and safety reports for the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Prohibited
Transactions; No Whistleblowers</U></I>. Except as set forth on <U>Schedule 4.19(j)</U>&nbsp;of the Disclosure Letter, within the past
five (5)&nbsp;years, to the Knowledge of such Credit Party, neither any Credit Party, any Subsidiary, any officer, Affiliate or employee
of a Credit Party or Subsidiary, nor any other Person acting on behalf of any Credit Party or any Subsidiary, directly or indirectly:
(i)&nbsp;has offered or paid any remuneration, in cash or in kind, to, or made any financial arrangements with, any past, present or
potential patient, supplier, physician or contractor, in order to illegally obtain business or payments from such Person in material
violation of any Health Care Law; (ii)&nbsp;has given or made, or is party to any illegal agreement to give or make, any illegal gift
or gratuitous payment of any kind, nature or description (whether in money, property or services) to any past, present or potential patient,
supplier, physician or contractor, or any other Person in material violation of any Health Care Law; (iii)&nbsp;has presented, or caused
to be presented, a claim for any designated health service pursuant to a referral to an entity from a physician who has (or whose immediate
family member has) a financial relationship with that entity, in material violation of any Health Care Law; (iv)&nbsp;has given or made,
or is party to any agreement to give or make on behalf of any Credit Party or any of its Subsidiaries, any contribution, payment or gift
of funds or property to, or for the private use of, any governmental official, employee or agent where either the contribution, payment
or gift or the purpose of such contribution, payment or gift is or was a material violation of the laws of any Governmental Authority
having jurisdiction over such payment, contribution or gift; (v)&nbsp;has established or maintained any unrecorded fund or asset for
any purpose or made any materially misleading, false or artificial entries on any of its books or records for any reason; or (vi)&nbsp;has
made, or is party to any agreement to make, any payment to any Person with the intention or understanding that any part of such payment
would be in material violation of any Health Care Law. Except as set forth on <U>Schedule 4.19(j)</U>&nbsp;of the Disclosure Letter,
to the Knowledge of such Credit Party, there are no actions pending or threatened (in writing) against any Credit Party or any of its
Subsidiaries or any of their respective Affiliates under any foreign, federal or United States state healthcare whistleblower statute,
including under the False Claims Act of 1863 (31 U.S.C. &sect; 3729 et seq.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Exclusion</U></I>.
Except as set forth on <U>Schedule 4.19(k)</U>&nbsp;of the Disclosure Letter, neither any Credit Party nor, to the Knowledge of such
Credit Party, any Subsidiary or any officer, employee or Affiliate of a Credit Party or Subsidiary having authority to act on behalf
of any Credit Party or any Subsidiary, is or, to the Knowledge of such Credit Party, has been threatened in writing to be: (i)&nbsp;excluded
from any Governmental Payor Program pursuant to 42 U.S.C. &sect; 1320a-7b and related regulations; (ii)&nbsp;&ldquo;suspended&rdquo;
or &ldquo;debarred&rdquo; from selling any products to the U.S. government or its agencies pursuant to the Federal Acquisition Regulation
relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4), or other U.S. Requirements
of Law; (iii)&nbsp;debarred, disqualified, suspended or excluded from participation in Medicare, Medicaid or any other Governmental Payor
Program or is listed on the General Services Administration list of excluded parties; (iv)&nbsp;debarred by FDA (or foreign equivalent)
or (v)&nbsp;a party to any other action or proceeding by any Governmental Authority that would prohibit the applicable Credit Party or
Subsidiary from distributing or selling the Product in the Territory or providing any services to any governmental or other purchaser
pursuant to any Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Health
Information</U></I>. Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, to the extent applicable,
is in material compliance with all applicable foreign, federal, state, and local laws and regulations regarding the privacy, data protection,
access, exchange, use, security, and notification of breaches of health information and regarding standards, implementation specifications,
and requirements for electronic transactions. Each Credit Party and each of its Subsidiaries, to the extent applicable, has implemented
all written policies and procedures as well as provided such training for its personnel as are reasonable and customary in the pharmaceutical
industry, satisfies in all material respects all applicable Requirements of Law, and that are otherwise designed to assure continued
compliance and to detect non-compliance with applicable Requirements of Law. Neither any Credit Party, nor any Subsidiary that is not
a Credit Party, is a &ldquo;covered entity&rdquo; or &ldquo;business associate&rdquo; as defined in HIPAA (45 C.F.R. &sect; 160.103).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I><U>Corporate
Integrity Agreement</U></I>. Neither any Credit Party or Subsidiary, nor any of their respective Affiliates, nor, to the Knowledge of
such Credit Party, any of their respective officers, directors, managing employees or agents, is, or in the reasonable business judgment
of Borrower probably (as defined in ASC 450-20-20) will become within ninety (90) days of the Effective Date or applicable Closing Date,
a party to, or has any ongoing reporting or disclosure obligations under, or is otherwise subject to, any order, individual integrity
agreement, corporate integrity agreement, monitoring agreement, deferred prosecution agreement, consent decree, corrective action plan,
settlement agreement or order or other similar agreements, or any order, in each case imposed by any Governmental Authority concerning
compliance with any laws, rules&nbsp;or regulations, issued under or in connection with a Governmental Payor Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Regulatory
Approvals or Licensures</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.20(a)(i)</U>&nbsp;of the Disclosure Letter, each Credit Party and each Subsidiary thereof involved in research,
development, testing, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring and requirements,
manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage,
transport, offer for sale, distribution or sale of the Product in the Territory has all Regulatory Approvals or Licensures material to
the conduct of its business and operations. Borrower or one of its Subsidiaries solely and exclusively owns and/or possesses valid title
to and/or right to use or exploit any and all Regulatory Submission Material owned or purported to be owned by Borrower or any of its
Subsidiaries (including without limitation the regulatory exclusivities set forth on <U>Schedule 4.20(a)(ii)</U>&nbsp;of the Disclosure
Letter, collectively the &ldquo;<B>Covered Regulatory Materials</B>&rdquo;), free and clear of all Liens other than Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;(x)&nbsp;Each
item of Covered Regulatory Materials is valid, subsisting and enforceable, (y)&nbsp;no such item of Covered Regulatory Materials has
in any respect lapsed, expired, been cancelled, held unenforceable or held invalidated or become abandoned or unenforceable, and (z)&nbsp;to
each Credit Party&rsquo;s Knowledge, no circumstance or grounds exist that would invalidate or reduce, in whole or in part, the validity,
enforceability, subsistence or scope of any such Covered Regulatory Materials, or reduce the use of such Covered Regulatory Materials,
by any Credit Party or any of its Subsidiaries, and (B)&nbsp;no written notice has been received by any Credit Party or any of its Subsidiaries
challenging the validity or enforceability, or relating to any lapse, expiration, invalidation, cancellation, abandonment or unenforceability,
of any such item of Covered Regulatory Materials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;(i)&nbsp;No
Credit Party or any of its Subsidiaries has undertaken or omitted to undertake any acts, and (ii)&nbsp;to the Knowledge of such Credit
Party in the case of Covered Regulatory Materials, no circumstance or grounds exist, that, in either case of (i)&nbsp;or (ii), would
invalidate or reduce, in whole or in part, the enforceability or scope of any Credit Party&rsquo;s or any of its Subsidiary&rsquo;s right
or entitlement to the Covered Regulatory Materials in any manner that could reasonably be expected to materially adversely affect any
aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging,
labelling, promotion, advertising, offer for sale, distribution or sale of the Product in the Territory; and (B)&nbsp;(i)&nbsp;no Credit
Party or any of its Subsidiaries has omitted to undertake any acts necessary to maintain, and (ii)&nbsp;to the Knowledge of such Credit
Party in the case of Covered Regulatory Materials, no circumstances or grounds exist that would impair the validity or, in whole or in
part, the enforceability or scope of, in either case of (i)&nbsp;or (ii), any Credit Party&rsquo;s or any of its Subsidiary&rsquo;s right
or entitlement to the Covered Regulatory Materials in any manner that could reasonably be expected to materially adversely affect any
aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging,
labelling, promotion, advertising, offer for sale, distribution or sale of the Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no pending or, to the Knowledge of each Credit Party, threatened (in writing) claims against Borrower or any of its Subsidiaries
alleging (i)&nbsp;that any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport,
packaging, labelling, promotion, advertising, offer for sale, distribution or sale of the Product in the Territory infringes or violates
(or in the past infringed or violated) any of the rights of any third parties in or to any regulatory filings, submissions, approvals,
licensures, and authorizations (&ldquo;<B>Third-Party Regulatory Materials</B>&rdquo;), or (ii)&nbsp;that any Covered Regulatory Materials
are invalid or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the Knowledge of each Credit Party, the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer
for sale, distribution or sale of the Product in the Territory does not (i)&nbsp;infringe or violate (or in the past infringed or violated)
any of the rights of third parties in or to any Third-Party Regulatory Materials, or (ii)&nbsp;constitute (or constituted) a misappropriation
of any Third-Party Regulatory Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no settlements, covenants not to sue, consents, judgments, orders or similar obligations, in each case, that were undertaken in connection
with the avoidance, resolution or disposition of an actual, anticipated or potential Adverse Proceeding (or any actual or potential basis
or grounds therefor) which: (i)&nbsp;restrict the rights of any Credit Party or any of its Subsidiaries to use any Covered Regulatory
Materials relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing,
storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of the Product in the Territory
(in order to accommodate any Third-Party Regulatory Materials or otherwise), or (ii)&nbsp;permit any third parties to use or otherwise
exploit any Covered Regulatory Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the Knowledge of each Credit Party, (i)&nbsp;there is no, nor has there been any, infringement or violation by any Person of any of the
Covered Regulatory Materials or the rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;Neither
any Credit Party nor any Subsidiary, nor, to the Knowledge of such Credit Party, any of their respective agents or representatives, have
(i)&nbsp;engaged in any conduct, the result of which would invalidate or render unenforceable or materially reduce, in whole or in part,
the validity, enforceability, subsistence or scope of any Covered Regulatory Materials, or (ii)&nbsp;omitted to perform any necessary
act to maintain the validity, enforceability, subsistence or scope of any such Covered Regulatory Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.20(b)</U>&nbsp;of the Disclosure Letter, to the Knowledge of any Credit Party, no event or circumstance
(or series of related events or circumstances) has occurred or, in the reasonable business judgment of such Credit Party, is reasonably
likely to occur, that would cause or could reasonably be expected to cause the Product to no longer meet requirements or criteria of
any applicable Regulatory Approvals or Licensures or designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Credit Party, each Subsidiary thereof and, to the Knowledge of such Credit Party, each licensee of a Credit Party or a Subsidiary thereof
of any Intellectual Property relating to the Product, is in compliance with, and at all times during the past five (5)&nbsp;years, has
complied with, all applicable foreign, federal, state and local laws, rules&nbsp;and regulations governing any aspect of the research,
development, testing, approval, licensure, clearance, authorization, post-approval (or post-licensure, post-authorization, or post-clearance,
as applicable) monitoring and requirements, reporting, manufacture, production, packaging, labeling, use, commercialization, designation,
exclusivity, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution or sale of the
Product in the Territory, including all such regulations promulgated by each applicable Regulatory Agency (including the FDA, the European
Commission, the EMA, the competent authorities of the EU Member States or any other applicable foreign equivalents), except where any
instance of failure to comply with any such laws, rules&nbsp;or regulations could not, whether individually or taken together with any
other such failures, reasonably be expected to result in a Material Adverse Change. No Credit Party or its Subsidiaries has received
any written notice from any Regulatory Agency citing action or inaction by any Credit Party or any of its Subsidiaries that would constitute
a violation of any applicable foreign, federal, state or local laws, rules, or regulations, including a Warning Letter or Untitled Letter
from FDA (or equivalent communication from any other Regulatory Agency).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Supply
and Manufacturing</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.21(a)</U>&nbsp;of the Disclosure Letter, to the Knowledge of any Credit Party, the Product at all times
has been manufactured in sufficient quantities and of a sufficient quality to satisfy demand of the Product in the Territory, without
the occurrence of any event or series of related events causing inventory of the Product to have become exhausted prior to satisfying
such demand. Except as set forth on <U>Schedule 4.21(a)</U>&nbsp;of the Disclosure Letter, to the Knowledge of such Credit Party, no
event or circumstances (or series of related events or circumstances) has occurred that has caused or could reasonably be expected to
cause (i)&nbsp;the Product to be manufactured in a quantity or of a quality insufficient to satisfy current or future demand of the Product
in the Territory or (ii)&nbsp;inventory of the Product in the Territory to have become exhausted prior to satisfying such demand of the
Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.21(b)</U>&nbsp;of the Disclosure Letter, to the Knowledge of such Credit Party, no event or circumstance
(or series of related events or circumstances) has occurred or, in the reasonable business judgment of Borrower, is reasonably likely
to occur, that would cause or could reasonably be expected to cause the Product for the Territory not to be manufactured in any calendar
year in sufficient quantities to satisfy the expected needs of patients with the disease or condition for which the Product was designated
as an Orphan Drug for such calendar year, as reasonably determined by Responsible Officers of the Borrowers in good faith (provided such
calendar year occurs during the full 7-year term of orphan drug exclusive approval granted for the Product under 21 C.F.R. &sect;&nbsp;316.34).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.21(c)</U>&nbsp;of the Disclosure Letter, to the Knowledge of any Credit Party, (i)&nbsp;no manufacturer
(including a contract manufacturer), licensing partner, or producer of the Product has been during the last five (5)&nbsp;years or is
currently subject to a material Regulatory Agency shutdown or voluntary shutdown, restriction or import or export prohibition, (ii)&nbsp;no
manufacturer (including a contract manufacturer), licensing partner, or producer of the Product has received in the last five (5)&nbsp;years
a Form&nbsp;483 or is currently subject to (1)&nbsp;a Form&nbsp;483 or (2)&nbsp;other written Regulatory Agency notice of inspectional
observations, Warning Letter, Untitled Letter or request to make changes to the Product that could impact the Product, in either case
of sub-clause (1)&nbsp;or (2)&nbsp;above with respect to any facility manufacturing or producing the Product for import, export, distribution
or sale in the Territory, and (iii)&nbsp;with respect to each such Form&nbsp;483 received (if any) or other written Regulatory Agency
notice (if any), all scientific and technical violations or other issues relating to FDA Good Manufacturing Practice requirements, or
foreign equivalents, documented therein, and any disputes regarding any such violations or issues, have been corrected or otherwise resolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as disclosed in <U>Schedule 4.21(d)&nbsp;of the Disclosure Letter</U>, no Credit Party or any of its Subsidiaries has received any written
notice or, to the Knowledge of such Credit party, other notice, from any party to any Manufacturing Agreement containing any indication
by or intent or threat of, such party to reduce or cease, in any material respect, the supply of the Product in the Territory or the
materials (including raw materials), components (including component raw materials and other component materials), equipment, technology
(including software, systems, and solutions), or any other element needed to fulfill its contractual obligations related to the Product
for the Territory in any Manufacturing Agreement through calendar year 2029 (or such earlier date in accordance with the terms and conditions
of such Manufacturing Agreement, as applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Cybersecurity
and Data Protection</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth in <U>Schedule 4.22(a)</U>&nbsp;of the Disclosure Letter, to the Knowledge of any Credit Party, the information technology
systems (including software and hardware) used in the business of each of Borrower and its Subsidiaries, including any technology systems
made available by Borrower or any of its Subsidiaries to any medical partners, physicians, patients, payors, patient assistance programs,
or other third parties in connection with the Product, (altogether, &ldquo;<B>Systems</B>&rdquo;) operate and perform in all material
respects as required to permit each of Borrower and its Subsidiaries to conduct their respective businesses as presently conducted in
the Territory. Borrower and each of its Subsidiaries has implemented and maintains reasonable and appropriate security controls and safeguards
designed to protect the confidentiality, integrity, and availability of Sensitive Information and designed to protect the Systems. To
the Knowledge of such Credit Party, no System contains any material ransomware, disabling codes or instructions, spyware, Trojan horses,
worms, viruses or other software routines that are designed or intended to delete, destroy, disable, disrupt, impair, interfere with,
perform unauthorized modifications to, or provide unauthorized access to any data, files, software, system, network or other device.
Borrower and its Subsidiaries have and maintain back-up systems, consistent with the industry in which Borrower and each of its Subsidiaries
operate and the size and condition of Borrower and each of its Subsidiaries, designed to provide continuing availability of the material
functionality provided by the Systems in the event of any malfunction of, or other event interrupting access to or the functionality
of, such Systems. Borrower and each of its Subsidiaries use commercially reasonable efforts to maintain System security, including promptly
implementing material security patches that are generally available for the Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.22(b)</U>&nbsp;of the Disclosure Letter, Borrower and each of its Subsidiaries has implemented and maintains
a commercially reasonable, enterprise-wide privacy and information security program (altogether, &ldquo;<B>Security Program</B>&rdquo;),
with plans, policies and procedures for privacy and physical and cyber security (including for disaster recovery, business continuity,
encryption, data back-up, Systems access controls, workstation use and security, incident detection, and incident response). The Security
Program includes commercially reasonable and appropriate administrative, technical and physical safeguards designed to protect the integrity
and availability of the Systems, consistent with the industry in which Borrower and each of its Subsidiaries operate and the size and
condition of Borrower and its Subsidiaries, and designed to protect against (i)&nbsp;any unauthorized, accidental, or unlawful access
to or acquisition, use, disclosure, transmission, retention, processing, loss, destruction, corruption, or modification of Personal Data
that would require notification to any affected individuals or any Governmental Authority under any applicable Data Protection Laws (each,
a &ldquo;<B>Personal Data Breach</B>&rdquo;), (ii)&nbsp;any unauthorized, accidental, or unlawful access to or acquisition, use, disclosure,
transmission, loss, destruction, corruption, or modification of Sensitive Information that is not Personal Data, and (iii)&nbsp;any security
incident that would result in unauthorized, accidental, or unlawful access to or acquisition, use, control, disruption, destruction,
or modification of any of the Systems (including cyber-attacks) that could reasonably be expected to result in a material and adverse
effect on the operation of Borrower&rsquo;s or any of its Subsidiaries&rsquo; business operations as currently conducted (<U>sub-clauses
(i)</U>&nbsp;through <U>(iii)</U>, collectively, &ldquo;<B>Security Incidents</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
and each of its Subsidiaries have conducted commercially reasonable privacy and security audits and penetration tests at reasonable intervals
on all Systems that maintain, store, access, or process Sensitive Information, in each case consistent with the industry in which Borrower
and each of its Subsidiaries operate and the size and condition of Borrower and its Subsidiaries, taken as a whole. Except as set forth
on <U>Schedule 4.22(c)</U>&nbsp;of the Disclosure Letter, Borrower and each of its Subsidiaries have taken commercially reasonable steps,
consistent with the industry in which Borrower and each of its Subsidiaries operate and the size and condition of Borrower and each of
its Subsidiaries, to address and remediate all material privacy or data security issues identified as &ldquo;critical risk&rdquo; or
 &ldquo;high risk&rdquo; in the applicable final report delivered to Borrower or any of its Subsidiaries in connection with any such audits
or penetration tests performed by a third party (including any third-party audits of the Systems).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
and each of its Subsidiaries have conducted commercially reasonable privacy and data security diligence, consistent with generally accepted
practices within the industry in which Borrower and each of its Subsidiaries operate and in material compliance with any applicable Data
Protection Laws, on all applicable service providers (including any clinical trial investigators, contract research organizations, contract
laboratories, contract manufacturers, suppliers, clinical data management organizations, back-office service providers, vendors, and
contractors) that (i)&nbsp;collect, create, receive, access, maintain, store, or otherwise process Sensitive Information for or on behalf
of Borrower or any of its Subsidiaries, or (ii)&nbsp;access or maintain the Systems. Except as set forth on <U>Schedule 4.22(d)</U>&nbsp;of
the Disclosure Letter, neither Borrower nor any of its Subsidiaries has, in the past five (5)&nbsp;years, received any written notice
from any such service provider that the service provider experienced a Security Incident.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.22(e)</U>&nbsp;of the Disclosure Letter, neither Borrower nor any of its Subsidiaries, have in the past
five (5)&nbsp;years suffered (i)&nbsp;any Personal Data Breaches, or (ii)&nbsp;any other Security Incidents which, individually or together
with any other Security Incidents, could reasonably be expected to have a material and adverse effect on Borrower&rsquo;s or any of its
Subsidiaries&rsquo; business operations, such as a material disruption of development, manufacturing, or commercialization programs relating
to the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.22(f)</U>&nbsp;of the Disclosure Letter, Borrower and each of its Subsidiaries is in material compliance
with the requirements of (i)&nbsp;their respective Security Programs, (ii)&nbsp;their respective contractual obligations regarding privacy,
security, or notification of breaches of Personal Data, (iii)&nbsp;their respective contractual non-disclosure obligations, (iv)&nbsp;their
respective publicly available privacy notices and policies, and (v)&nbsp;all applicable Data Protection Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 4.22(g)</U>&nbsp;of the Disclosure Letter, in the past five (5)&nbsp;years: (i)&nbsp;neither Borrower nor
any of its Subsidiaries has received any written third-party claims or, to the Knowledge of such Credit Party, any threat (in writing)
of a third-party claim, related to any Personal Data Breaches or other Security Incidents; and (ii)&nbsp;neither Borrower nor any of
its Subsidiaries has received any written notice of any claims or investigations (including investigations by any Governmental Authority)
relating to any Personal Data Breaches or other Security Incidents, except, in each case of <U>sub-clauses (i)</U>&nbsp;and <U>(ii)</U>&nbsp;above
as could not reasonably be expected to be material to Borrower and its Subsidiaries, taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Additional
Representations and Warranties</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the Effective Date and the Tranche A Closing Date, except as set forth on <U>Schedule 4.23(a)</U>&nbsp;of the Disclosure Letter, after
giving effect to consummation of the transactions contemplated by this Agreement, there is no Indebtedness for borrowed money owed to
Borrower or any of its Subsidiaries other than Permitted Indebtedness or Permitted Investments, or owed by Borrower or any of its Subsidiaries,
other than Permitted Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of each Closing Date other than the Tranche A Closing Date, there is no Indebtedness for borrowed money (x)&nbsp;owed to Borrower or
any of its Subsidiaries other than Permitted Indebtedness or Permitted Investments, or (y)&nbsp;owed by Borrower or any of its Subsidiaries
other than Permitted Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the Effective Date and Tranche A Closing Date, except as set forth on <U>Schedule 4.23(c)</U>&nbsp;of the Disclosure Letter, neither
Borrower nor any of its Subsidiaries are party to, or otherwise bound by, any Hedging Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of any Closing Date other than the Tranche A Closing Date, neither Borrower nor any of its Subsidiaries are party to, or otherwise bound
by, any Hedging Agreements, except for Hedging Agreements expressly permitted by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as has been disclosed in the Exchange Act Documents, as of the Effective Date and each Closing Date, there is no registration rights
agreement, investors&rsquo; rights agreement or other similar agreement relating to, governing or otherwise affecting the ownership of
any Equity Interest that is required to be pledged pursuant to the Collateral Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>AFFIRMATIVE
COVENANTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Credit Party covenants
and agrees that, from and after the Effective Date and until payment in full of all Obligations (other than inchoate indemnity obligations),
each Credit Party shall, and shall cause each of its Subsidiaries to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintenance
of Existence</B>. (a)&nbsp;Preserve, renew and maintain in full force and effect its and all its Subsidiaries&rsquo; legal existence
under the Requirements of Law in their respective jurisdictions of organization, incorporation or formation (other than as otherwise
expressly permitted under <U>Section&nbsp;6.2(a)</U>); (b)&nbsp;take all commercially reasonable action to maintain all rights, privileges
(including its good standing (to the extent the concept is applicable in such jurisdiction)), permits, licenses and franchises necessary
or desirable for it and all of its Subsidiaries in the ordinary course of its business, except in the case of <U>clause (a)</U>&nbsp;(other
than with respect to Borrower) and <U>clause (b)</U>&nbsp;above, (i)&nbsp;to the extent that failure to do so could not reasonably be
expected to result in a Material Adverse Change or (ii)&nbsp;pursuant to a transaction permitted by this Agreement; and (c)&nbsp;comply
with all Requirements of Law of any Governmental Authority to which it is subject, except where the failure to do so could not reasonably
be expected to result, individually or in the aggregate, in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Financial
Statements, Notices</B>. Deliver to the Collateral Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Financial
Statements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Annual
Financial Statements</U>. Within ninety (90) days after the end of each fiscal year of Borrower, beginning with the fiscal year ending
December&nbsp;31, 2025, a consolidated balance sheet of Borrower and its Subsidiaries, as of the end of such fiscal year, and the related
consolidated statements of income, cash flows and stockholders&rsquo; equity for such fiscal year, setting forth in each case, certified
by a Responsible Officer of Borrower, in comparative form the figures for the previous fiscal year, all prepared in accordance with GAAP,
with such consolidated financial statements to be audited and accompanied by (x)&nbsp;a report and opinion of Borrower&rsquo;s independent
certified public accounting firm of recognized national standing (which report and opinion shall be prepared in accordance with GAAP
and, from and after the commercial launch of the Product in the United States, shall not be subject to any qualification as to &ldquo;going
concern&rdquo; or &ldquo;scope of audit&rdquo;), stating that such financial statements fairly present, in all material respects, the
consolidated financial condition, results of operations and cash flows of Borrower and its Subsidiaries as of the dates and for the periods
specified in accordance with GAAP, and (y)&nbsp;if and only if Borrower is required to comply with the internal control provisions pursuant
to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 requiring an attestation report of such independent certified public accounting
firm, an attestation report of such independent certified public accounting firm as to Borrower&rsquo;s internal controls pursuant to
Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 attesting to management&rsquo;s assessment that such internal controls meet the requirements
of the Sarbanes-Oxley Act of 2002;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Quarterly
Financial Statements</U>. Within forty-five (45) days after the end of each of the first three (3)&nbsp;Fiscal Quarters of each fiscal
year of Borrower, beginning with respect to the Fiscal Quarter ending June&nbsp;30, 2025, a consolidated balance sheet of Borrower and
its Subsidiaries, as of the end of such Fiscal Quarter, and the related consolidated statements of income and cash flows and for such
Fiscal Quarter and (in respect of the second and third Fiscal Quarters of such fiscal year) for the then-elapsed portion of Borrower&rsquo;s
fiscal year, setting forth in each case in comparative form the figures for the comparable period or periods in the previous fiscal year,
all prepared in accordance with GAAP;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Quarterly
Compliance Certificate</U>. Upon delivery (or within five (5)&nbsp;Business Days following any deemed delivery) of financial statements
pursuant to <U>Section&nbsp;5.2(a)(i)</U>&nbsp;or <U>Section&nbsp;5.2(a)(ii)</U>, a duly completed Compliance Certificate signed by a
Responsible Officer of Borrower, certifying, among other things, that (A)&nbsp;such financial statements fairly present, in all material
respects, the consolidated financial condition, results of operations and cash flows of Borrower and its Subsidiaries as of the applicable
dates and for the applicable periods in accordance with GAAP consistently applied, and are not subject to any qualification or statement
as to &ldquo;going concern&rdquo; or scope of audit other than as expressly permitted under <U>Section&nbsp;5.2(a)(i)</U>&nbsp;or <U>Section&nbsp;5.2(a)(ii)</U>,
and (B)&nbsp;no Event of Default or Default has occurred or, if such an Event of Default or Default has occurred, specifying the nature
and extent thereof and any corrective action taken or proposed to be taken with respect thereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Information</U>. Within five (5)&nbsp;Business Days after the reasonable request of the Collateral Agent therefor, such additional information
regarding the operations, properties, business, liabilities or condition (financial or otherwise) of Borrower and its Subsidiaries (including
with respect to the Collateral), or compliance with the terms of this Agreement or any other Loan Documents, in each case in a form reasonably
acceptable to the Collateral Agent; <U>provided</U>, <U>that</U>, Borrower shall not be obligated to disclose any information that is
restricted by Requirements of Law or contractual agreement with a third-party (so long as such contractual restriction was not agreed
to for the specific purpose of preventing disclosure under this Agreement) or that is subject to the attorney-client privilege or constitutes
attorney work product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
of Defaults or Events of Default, ERISA Events, Withdrawal Events and Material Adverse Changes</U>. Written notice as promptly as practicable
(and in any event within five (5)&nbsp;Business Days) after a Responsible Officer of any Credit Party shall have obtained knowledge thereof,
of (i)&nbsp;the receipt by Borrower or any of its Subsidiaries of any written notice from the FDA or any other Regulatory Agency of a
pending recommendation or a final decision to withdraw marketing authorization for the Product in the U.S., or (ii)&nbsp;the occurrence
of, or the occurrence of any event which could reasonably be expected to result in, any (x)&nbsp;Default or Event of Default (including,
for the avoidance of doubt, any Withdrawal Event or Material Adverse Change) or (y)&nbsp;ERISA Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Legal
Action Notice</U>. Promptly (and in any event within five (5)&nbsp;Business Days) upon any Credit Party&rsquo;s receipt or otherwise
obtaining Knowledge thereof, written notice (which shall be deemed given to the extent timely reported in a Form&nbsp;8-K under the Exchange
Act and available on the SEC&rsquo;s EDGAR system (or any successor system adopted by the SEC), <U>provided</U>, <U>however</U>, that
such notice shall be deemed to have been so given with respect to additional information the Collateral Agent may reasonably request
only if it includes such additional information) of: (i)&nbsp;correspondence received from the SEC (or comparable agency in any applicable
foreign. jurisdiction) concerning any investigation or possible investigation or other material inquiry by such agency regarding financial
or other operational results of Borrower or any Subsidiary of Borrower; or (ii)&nbsp;any legal action, litigation, investigation or proceeding
pending or threatened in writing against Borrower or any of its Subsidiaries or any material out-licensing partners (A)&nbsp;that could
reasonably be expected to result in uninsured damages or costs to Borrower or any of its Subsidiaries in an amount in excess of the materiality
thresholds applied by Borrower in accordance with the Exchange Act and related regulations and standards for purposes of its Exchange
Act reporting or (B)&nbsp;that alleges violations of any Health Care Laws, FDA Laws, EU Laws, Data Protection Laws or any other applicable
statutes, rules, regulations, standards, guidelines, policies and orders, or applicable foreign equivalents, administered or issued by
any U.S. or foreign Governmental Authority which, individually or together with any other such allegations, could reasonably be expected
to result in a Material Adverse Change; and in each case of <U>sub-clause (i)</U>&nbsp;or <U>(ii)</U>&nbsp;above, provide such additional
information (including a description in reasonable detail regarding any material development) as the Collateral Agent may reasonably
request in relation thereto; <U>provided</U>, <U>however</U>, that neither Borrower nor any other Credit Party shall be obligated to
disclose any information that is reasonably subject to the assertion of attorney-client privilege or attorney work-product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accounting
Changes</U>. Written notice within five (5)&nbsp;Business Days after any material change in accounting policies or financial reporting
practices by Borrower or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Material
Statements and Reports</U>. Within five (5)&nbsp;Business Days after the request therefor by the Collateral Agent, copies of any material
statement or report furnished to any holder of debt securities of Borrower or any Subsidiary pursuant to the terms of any indenture,
loan or credit or similar agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Sanctions
and Anti-Money Laundering Laws Requirements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Credit
Party Information</U>. Upon request by the Collateral Agent, certain information and documentation that identifies each Credit Party
and its principals, which information includes the legal name and address of each Credit Party and its principals and such other information
that will allow the Collateral Agent and each Lender to identify such party in accordance with Sanctions and Anti-Money Laundering Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Blocked
Person Notice</U>. Notification to it and each Lender in writing promptly (but in any event within three (3)&nbsp;Business Days) upon
any Responsible Officer of any Credit Party becoming aware that any Credit Party or any Subsidiary or Affiliate of any Credit Party is
a Blocked Person or Credit Party or any Subsidiary or Affiliate of any Credit Party or any of their respective directors, officers, affiliates
or employees is (i)&nbsp;is convicted on, (ii)&nbsp;pleads nolo contendere to, (iii)&nbsp;is indicted on, or (iv)&nbsp;is arraigned and
held over on charges involving money laundering or predicate crimes to money laundering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Notwithstanding the foregoing,
any documents, materials, notices or other information, that Borrower, any Credit Party or any Subsidiary of Borrower is required to
deliver under <U>Sections 5.2(a)(i)</U>, <U>(a)(ii)</U>, <U>(b)</U>, <U>(c), (d)</U>&nbsp;and <U>(e)</U>&nbsp;above shall be deemed to
have been made if such item shall have been made available within the time period specified above on the SEC&rsquo;s EDGAR system (or
any successor system adopted by the SEC), <U>provided</U>, <U>however</U>, that in the case of any notice required to be delivered under
<U>Section&nbsp;5.2(c)</U>&nbsp;above, such notice shall be deemed to have been so made with respect to additional information the Collateral
Agent may reasonably request only if it includes such additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Taxes</B>.
Timely file all required income and other material Tax returns and reports or extensions therefor and timely pay all Taxes, assessments,
deposits and contributions imposed upon it or any of its properties or assets or in respect of any of its income, businesses or franchises
before any penalty or fine accrue thereon except to the extent that the failure to do so could not reasonably be expected to have a Material
Adverse Change; <U>provided</U>, <U>however</U>, that no such Tax or any claim for Taxes that has become due and payable and has or may
become a Lien on any Collateral shall be required to be paid if (a)&nbsp;it is being contested in good faith by appropriate proceedings
promptly instituted and diligently conducted, so long as adequate reserves therefor have been set aside on its books and maintained in
conformity with GAAP and (b)&nbsp;solely in the case of a Tax or claim that has or may become a Lien against any Collateral, such contest
proceedings conclusively operate to stay the sale or forfeiture of any portion of any Collateral to satisfy such Tax or claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Insurance</B>.
Maintain with financially sound and reputable independent insurance companies or underwriters, insurance with respect to its properties
and business against loss or damage of the kinds customarily insured against by Persons of comparable size engaged in the same or similar
business, of such types and in such amounts (after giving effect to any self-insurance reasonable and customary for similarly situated
Persons of comparable size engaged in the same or similar businesses as Borrower and its Subsidiaries) as are customarily carried under
similar circumstances by such other Persons. Subject to the timing requirements of <U>Section&nbsp;5.14</U> (solely with respect to any
such policies in effect as of the Tranche A Closing Date), any products liability or general liability insurance maintained in the United
States regarding Collateral shall name the Collateral Agent, on behalf of the Lenders and the other Secured Parties, as additional insured
or loss payee, as applicable (the additional insured clauses or endorsements for which, in form and substance reasonably satisfactory
to the Collateral Agent). So long as no Event of Default shall have occurred and be continuing, with respect to the Borrower&rsquo;s
and its Subsidiaries&rsquo; property and general liability policies, and at all times with respect to any other policies (including any
product liability policies) the Borrower and its Subsidiaries may retain all or any portion of the proceeds of any such insurance of
the Borrower and its Subsidiaries (and the Collateral Agent and each Lender shall promptly remit to Borrower any proceeds received by
it with respect to any such insurance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Operating
Accounts</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the case of any Credit Party, following the establishment of any new Collateral Account at or with any bank or other depository or financial
institution located in (i)&nbsp;the United States, subject such account to a Control Agreement or other appropriate instrument that is
reasonably acceptable to the Collateral Agent, and (ii)&nbsp;any jurisdiction other than the United States, comply with requirements
set forth in the applicable Collateral Document in relation to Collateral Accounts in such jurisdiction. For each Collateral Account
that each Credit Party at any time maintains in the United States, such Credit Party shall, within forty-five (45) days (or such longer
period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) of
establishing such Collateral Account, cause the applicable bank or other depository or financial institution located in the United States,
at or with which any Collateral Account is maintained to execute and deliver, and such Credit Party shall execute and deliver, to the
Collateral Agent, a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect the Collateral
Agent&rsquo;s Lien, for the benefit of Lenders and the other Secured Parties, in such Collateral Account in accordance with the terms
hereunder, which Control Agreement may not be terminated without the prior written consent of the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
provisions of the previous clause (a)&nbsp;shall not apply to (1)&nbsp;accounts exclusively used for payroll, payroll Taxes and other
employee wage and benefit payments to or for the benefit of any Credit Party&rsquo;s employees, (2)&nbsp;zero balance accounts, <U>provided</U>,
<U>that</U>, within two (2)&nbsp;Business Days of any deposit made into any such zero balance account, such deposit is swept in full
to an account subject to a Control Agreement, (3)&nbsp;accounts (including trust accounts) used exclusively for escrow, customs, insurance
or fiduciary purposes, (4)&nbsp;merchant accounts, (5)&nbsp;accounts used exclusively for compliance with any Requirements of Law to
the extent such Requirements of Law prohibit the granting of a Lien thereon, (6)&nbsp;accounts which constitute cash collateral in respect
of a Permitted Lien, (7)&nbsp;any other account established and maintained in the ordinary course of business or in furtherance of a
<I>bona fide</I> general corporate purpose and designated as an Excluded Account by a Responsible Officer of Borrower in writing delivered
to the Collateral Agent, the cash balance of which, individually or together with all other such accounts excluded pursuant to this <U>sub-clause
(7)</U>, does not exceed $5,000,000 at any time, <U>provided</U>, <U>that</U>, if the cash balance of such account, individually or together
with all other such accounts excluded pursuant to this <U>sub-clause (7)</U>, exceeds $5,000,000 at any time, (x)&nbsp;such account shall
no longer be deemed to be an Excluded Account hereunder as of such time, with the effect that the accounts which remain as Excluded Accounts
pursuant to <U>sub-clause (7)</U>&nbsp;are in compliance with the requirements for exclusion under <U>sub-clause (7)</U>, and (y)&nbsp;such
account shall be deemed to be a Collateral Account on such date and Borrower shall comply with the requirements of this <U>Section&nbsp;5.5</U>
with respect to such account, and (8)&nbsp;accounts not otherwise described in <U>sub-clauses (1)</U>&nbsp;through <U>(7)</U>&nbsp;above
constituting Excluded Property (all such accounts in <U>sub-clauses (1)</U>&nbsp;through <U>(8)</U>&nbsp;above, collectively, the &ldquo;<B>Excluded
Accounts</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the foregoing, the Credit Parties shall have until the date that is thirty (30) days (plus an additional thirty (30) days so long as
such Credit Party is using reasonable good faith efforts) following (i)&nbsp;the Tranche A Closing Date to comply with the provisions
of this <U>Section&nbsp;5.5</U> with regards to Collateral Accounts (other than Excluded Accounts) of the Credit Parties in existence
on the Tranche A Closing Date (or opened during such 30-day period) and (ii)&nbsp;the closing date of any Acquisition or other Investment
to comply with the provisions of this <U>Section&nbsp;5.5</U> with regards to Collateral Accounts (other than Excluded Accounts) of the
Credit Parties acquired in connection with such Acquisition or other Investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Compliance
with Laws</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Comply
in all respects with the Requirements of Law and all orders, writs, injunctions, decrees and judgments applicable to it or to its business
or its assets or properties (including Environmental Laws, ERISA, Health Care Laws, FDA Laws, Data Protection Laws, the Federal Fair
Labor Standards Act, EU Laws, and any foreign equivalents thereof), including in connection with governing any aspect of the research,
development, testing, approval, licensure, clearance, authorization, exclusivity, licensure, designation, post-approval (or post-licensure,
post-authorization, or post-clearance, as applicable) monitoring or commitments, reporting, (including post-marketing safety reports,
if any), manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting,
storage, transport, offer for sale, distribution or sale of the Product in the Territory, except, in each case, if the failure to comply
therewith individually or taken together with any other such failures, could not reasonably be expected to result in a Material Adverse
Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Implement
and maintain policies and procedures reasonably designed to ensure compliance with applicable Sanctions, Anti-Money Laundering Laws,
Export and Import Laws, Anti-Corruption Laws, Health Care Laws, and Data Protection Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Comply
with all Sanctions, Anti-Money Laundering Laws, Export and Import Laws and Anti-Corruption Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Protection
of Intellectual Property Rights</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as expressly permitted under <U>clause (b)</U>&nbsp;below, use commercially reasonable efforts to (i)&nbsp;protect, defend and maintain
the validity and enforceability of Company IP material to any aspect of the research, development, manufacture, production, use, commercialization,
marketing, import, storage, transport, offer for sale, distribution or sale of the Product in the Territory, including defending any
future or current oppositions, interference proceedings, reissue proceedings, reexamination proceedings, <I>inter partes</I> review proceedings,
derivative proceedings, post-grant review proceedings, cancellation proceedings, injunctions, lawsuits, paragraph IV patent certifications
or lawsuits under the Hatch-Waxman Act, hearings, investigations, complaints, arbitrations, mediations, demands,&nbsp;International Trade
Commission investigations, decrees, or any other disputes, disagreements, or claims, challenging the legality, validity, patentability,
enforceability, inventorship or ownership of any such Company IP; (ii)&nbsp;maintain the confidential nature of any material trade secrets
and trade secret rights used in any research, development, manufacture, production use, commercialization, marketing, importing, storage,
transport, offer for sale, distribution or sale of the Product in the Territory; (iii)&nbsp;not allow any Company IP material to any
aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer
for sale, distribution or sale of the Product in the Territory, to be abandoned, disclaimed, forfeited or dedicated to the public (other
than in accordance with its statutory term or the exercise of the Credit Parties&rsquo; normal prosecution practices and reasonable business
judgment, e.g., the abandonment of a continuation application that is no longer needed to maintain the pendency of another patent application)
or any Company IP Agreement to be terminated by any Credit Party or any of its Subsidiaries, as applicable, without the Collateral Agent&rsquo;s
prior written consent (such consent not to be unreasonably withheld, conditioned or delayed); <U>provided</U>, <U>however</U>, that with
respect to any such Company IP that is not owned by a Credit Party or any of its Subsidiaries, the obligations in sub-<U>clauses (i)</U>&nbsp;and
<U>(iii)</U>&nbsp;above shall apply only to the extent a Credit Party or any of its Subsidiaries have the right to take such actions
or to cause any licensee or other third-party to take such actions pursuant to applicable agreements or contractual rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as a Credit Party may otherwise determine in its reasonable business judgment, (i)&nbsp;use commercially reasonable efforts, either directly
or indirectly, with respect to any licensee or licensor under the terms of any Credit Party&rsquo;s (or any Subsidiary&rsquo;s) agreement
with the respective licensee or licensor, as applicable, to take any and all actions (including taking legal action to specifically enforce
the applicable terms of any license agreement) and prepare, execute, deliver and file agreements, documents or instruments which are
necessary to (A)&nbsp;prosecute and maintain the Company IP material to any aspect of the research, development, manufacture, production,
use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Product in the Territory
and (B)&nbsp;diligently defend or assert the Company IP material to any aspect of the research, development, manufacture, production,
use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Product in the Territory
against material infringement, misappropriation, violation or interference by any other Persons and, in the case of Copyrights, Trademarks
and Patents within the Company IP, against any claims of invalidity, unpatentability or unenforceability (including by bringing any legal
action for infringement, dilution, violation, derivation or defending any counterclaim of invalidity or action of a non-Affiliate third-party
for declaratory judgment of non-infringement or non-interference); (ii)&nbsp;use commercially reasonable efforts to cause any licensee
or licensor of any Company IP not to disclaim, forfeit, dedicate to the public or abandon, or fail to take any action necessary to prevent
the disclaimer, forfeiture or abandonment of Company IP necessary to any aspect of the research, development, manufacture, production,
use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Product in the Territory,
and (iii)&nbsp;use commercially reasonable efforts to cause any licensee or licensor of any Company IP not to disclaim, forfeit, dedicate
to the public or abandon, or fail to take any action necessary to prevent the disclaimer, forfeiture or abandonment of Company IP otherwise
material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage,
transport, offer for sale, distribution or sale of the Product in the Territory (other than in accordance with the applicable licensor&rsquo;s
normal prosecution practices and reasonable business judgment). Each Credit Party agrees to (1)&nbsp;notify the Collateral Agent in writing,
promptly (and in any event within ten (10)&nbsp;Business Days) after a Credit Party or any of its Subsidiaries first becomes aware of,
and thereafter (2)&nbsp;keep the Collateral Agent reasonably informed regarding, (x)&nbsp;of any infringement or violation of any of
the rights of any Credit Party or its Subsidiary in or to any Company IP, or any misappropriation by any Person of any Company IP or
any of the subject matter thereof, and (y)&nbsp;if the Product infringes or violates any Third-Party IP or constitutes a misappropriation
of any Third-Party IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Save
as contemplated by any Permitted License, use commercially reasonable efforts to protect, defend and maintain, and assert against any
biosimilar, bioequivalent or interchangeable version of the Product in the Territory, market, data and any other applicable regulatory
exclusivity provided under Requirements of Law for the manufacture, production, use, commercialization, marketing, importing, storage,
transport, offer for sale, distribution or sale of the Product in the Territory through the Term Loan Maturity Date. Borrower agrees
to (i)&nbsp;promptly notify the Collateral Agent in writing of (provided that no Credit Party or third-party confidential information
will be shared that violates trade secret protection or a court order) and (ii)&nbsp;keep the Collateral Agent reasonably informed, and
(iii)&nbsp;at the reasonable request of the Collateral Agent in writing, consult with and consider in good faith any reasonable comments
of the Collateral Agent, regarding the commencement of any filings or submissions in any opposition, interference proceeding, reissue
proceeding, reexamination proceeding, <I>inter partes</I> review proceeding, post-grant review proceeding, derivation proceeding, cancellation
proceeding, injunction, lawsuit, hearing, investigation, complaint, arbitration, mediation, demand,&nbsp;International Trade Commission
investigation, decree, or any other dispute, disagreement, or claim, in each case challenging the legality, validity, patentability,
enforceability, inventorship ownership of any material Company IP (including any claim in any Patent within the Company IP that is material
to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport,
packaging, labelling, promotion, advertising, offer for sale, distribution or sale of the Product in the Territory).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Books
and Records</B>. Maintain proper Books, in which entries that are full, true and correct in all material respects and are in conformity
with GAAP consistently applied shall be made of all material financial transactions and matters involving the assets, properties and
business of such Credit Party (or such Subsidiary).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Access
to Collateral; Audits</B>. Allow the Collateral Agent, or its agents or representatives, at any time after the occurrence and during
the continuance of an Event of Default, during normal business hours and upon reasonable advance notice, to visit and inspect any of
the Collateral or to inspect and copy and (at the sole discretion of the Collateral Agent) audit any Credit Party&rsquo;s Books. The
foregoing inspections and audits, if any, shall be at the relevant Credit Party&rsquo;s expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Use
of Proceeds</B>. (a)&nbsp;Use the proceeds of the Term Loans solely to fund its general corporate and working capital requirements; and
(b)&nbsp;not use the proceeds of the Term Loans or any other Credit Extensions, directly or indirectly, for the purpose of purchasing
or carrying any Margin Stock, for the purpose of reducing or retiring any Indebtedness that was originally incurred to purchase or carry
any Margin Stock, for the purpose of extending credit to any other Person for the purpose of purchasing or carrying any Margin Stock
or for any other purpose that might cause any Term Loan or other Credit Extension to be considered a &ldquo;purpose credit&rdquo; within
the meaning of Regulation T, U or X of the Federal Reserve Board. If requested by the Collateral Agent, Borrower shall complete and sign
Part&nbsp;I of a copy of Federal Reserve Form&nbsp;G-3 referred to in Regulation U and deliver such copy to the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Further
Assurances</B>. Promptly upon the reasonable written request of the Collateral Agent, execute, acknowledge and deliver such further documents
and do such other acts and things in order to effectuate or carry out more effectively the purposes of this Agreement and the other Loan
Documents at its expense, including after the Effective Date taking such steps as are reasonably deemed necessary or desirable by the
Collateral Agent to maintain, protect and enforce its Lien, for the benefit of Lenders and the other Secured Parties, on Collateral securing
the Obligations created under the Collateral Documents and the other Loan Documents in accordance with the terms of the Collateral Documents
and the other Loan Documents, subject to Permitted Liens. Notwithstanding the foregoing, no perfection steps shall be required outside
of the United States or the jurisdiction of organization of a Credit Party (and, if different, the jurisdiction of the principal place
of business of such Credit Party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Additional
Collateral; Guarantors</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Credit Party (other than Borrower) shall, and Borrower and each other Credit Party shall cause each of its Subsidiaries (other than Excluded
Subsidiaries) to: (i)&nbsp;guarantee the Obligations; (ii)&nbsp;grant to the Collateral Agent, for the benefit of Lenders and the other
Secured Parties, a first priority security interest in and Lien upon (subject to Permitted Liens, the limitations expressly set forth
herein and the limitations expressly set forth in the other Loan Documents), and pledge to the Collateral Agent for the benefit of Lenders
and the other Secured Parties, all of such Credit Party&rsquo;s or Subsidiary&rsquo;s properties and assets constituting Collateral (including
the certificated and uncertificated Equity Interests (other than Excluded Equity Interests) in such Subsidiary), whether now existing
or hereafter acquired or existing (including in connection with an Asset Acquisition), to secure such guaranty; and (iii)&nbsp;subject
to the timing requirements of <U>Sections 5.13</U> and <U>5.14</U> if and only to the extent applicable, execute and deliver to the Collateral
Agent, a joinder or pledge amendment to the Security Agreement (in the form(s)&nbsp;attached thereto), and such other Collateral Documents
or other documents required under the terms of the Loan Documents or as the Collateral Agent may reasonably request, including (x)&nbsp;in
connection with each pledge of certificated Equity Interests, such certificate(s)&nbsp;together with stock powers, stock transfer forms
or assignments, as applicable, properly endorsed for transfer to the Collateral Agent or duly executed in blank, in each case reasonably
satisfactory to the Collateral Agent, and (y)&nbsp;in connection with each pledge of uncertificated Equity Interests of a Person organized
in the U.S., an executed uncertificated stock control agreement among the issuer, the registered owner and the Collateral Agent, substantially
in the form attached to the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
and each other Credit Party shall, and shall cause each of its Subsidiaries (other than Excluded Subsidiaries) to: (i)&nbsp;grant to
the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a first priority security interest in and Lien upon (subject
to Permitted Liens, the limitations set forth herein and the limitations set forth in the other Loan Documents), and pledge to the Collateral
Agent for the benefit of Lenders and the other Secured Parties, all of such Credit Party&rsquo;s or Subsidiary&rsquo;s properties and
assets constituting Collateral (including the certificated and uncertificated Equity Interests (other than Excluded Equity Interests)
in such Subsidiary), whether now existing or hereafter acquired or existing (including in connection with an Asset Acquisition), to secure
the payment and performance in full of all of the Obligations; and (ii)&nbsp;subject to the timing requirements of <U>Sections 5.13 </U>and
<U>5.14</U> if and only to the extent applicable, execute and deliver to the Collateral Agent a joinder or pledge amendment to the Security
Agreement (in the form(s)&nbsp;attached thereto), and such other Collateral Documents or other documents required under the terms of
the Loan Documents or as the Collateral Agent may reasonably request, including (x)&nbsp;in connection with each pledge of certificated
Equity Interests, such certificate(s)&nbsp;together with stock powers, stock transfer forms or assignments, as applicable, properly endorsed
for transfer to the Collateral Agent or duly executed in blank, in each case reasonably satisfactory to the Collateral Agent, and (y)&nbsp;in
connection with each pledge of uncertificated Equity Interests of a Person organized in the U.S. that is a Credit Party, an executed
uncertificated stock control agreement among the issuer, the registered owner and the Collateral Agent, substantially in the form attached
to the Security Agreement, to the extent control is not achieved by the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the foregoing, each Credit Party&rsquo;s obligations to take the actions set forth in <U>clause (a)</U>&nbsp;and <U>clause (b)</U>&nbsp;above
with respect to any assets acquired as part of an Asset Acquisition or in connection with the Stock Acquisition of a Subsidiary after
the Tranche A Closing Date or any Subsidiary incorporated, organized, formed or acquired (including by a Stock Acquisition) after the
Tranche A Closing Date, shall in each case be subject to the timing requirements of <U>Section&nbsp;5.13</U>. Any document, agreement
or instrument executed or issued pursuant to this <U>Section&nbsp;5.12</U> shall be a Loan Document for all purposes under this Agreement
and the other Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the event after the Effective Date any Credit Party acquires any fee title to real estate in the U.S. with a fair market value (reasonably
determined in good faith by a Responsible Officer of such Credit Party) in excess of $5,000,000, unless otherwise agreed by the Collateral
Agent, such Person shall execute or deliver, or cause to be executed or delivered, to the Collateral Agent, (i)&nbsp;within sixty (60)
days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good
faith efforts) after such acquisition, an appraisal complying with the Financial Institutions Reform, Recovery and Enforcement Act of
1989, (ii)&nbsp;within forty-five (45) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion,
taking into account reasonable good faith efforts) after receipt of notice from the Collateral Agent that such real estate is located
in a Special Flood Hazard Area, Federal Flood Insurance, (iii)&nbsp;within sixty (60) days (or such longer period as the Collateral Agent
may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after such acquisition, a fully executed
Mortgage, in form and substance reasonably satisfactory to the Collateral Agent, together with an A.L.T.A. lender&rsquo;s title insurance
policy issued by a title insurer reasonably satisfactory to the Collateral Agent, in form and substance (including any endorsements)
and in an amount reasonably satisfactory to the Collateral Agent insuring that the Mortgage is a valid and enforceable first priority
Lien on the respective property, free and clear of all defects, encumbrances and Liens (other than Permitted Liens), (iv)&nbsp;simultaneously
with such acquisition, then-current A.L.T.A. surveys, certified to the Collateral Agent by a licensed surveyor sufficient to allow the
issuer of the lender&rsquo;s title insurance policy to issue such policy without a survey exception and (v)&nbsp;within sixty (60) days
(or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith
efforts) after such acquisition, an environmental site assessment prepared by a qualified firm reasonably acceptable to the Collateral
Agent, in form and substance reasonably satisfactory to the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Formation
or Acquisition of Subsidiaries; Designated Guarantors</B>. If (a)&nbsp;any Credit Party or any of its Subsidiaries at any time after
the Effective Date incorporates, organizes, forms or acquires (including by a Stock Acquisition or an Asset Acquisition) a Subsidiary
(including by division), other than an Excluded Subsidiary (a &ldquo;<B>New Subsidiary</B>&rdquo;) or (b)&nbsp;Borrower elects, in its
sole discretion, to designate an Excluded Subsidiary as a Credit Party (such designated Subsidiary, a &ldquo;<B>Designated Guarantor</B>&rdquo;),
then in each such case such Credit Party shall (i)&nbsp;(x)&nbsp;notify the Collateral Agent in writing promptly, and in no event later
than five (5)&nbsp;Business Days after such incorporation, organization, formation or acquisition, or designation, as applicable, and
(y)&nbsp;within thirty (30) days after such incorporation, organization, formation or acquisition, or designation, as applicable (or
such longer period as the Collateral Agent may agree in writing (such agreement, with respect to any Designated Guarantor that is a Foreign
Subsidiary, not to be unreasonably withheld, conditioned or delayed so long as such Credit Party is using reasonable good faith efforts)):
(1)&nbsp;without limiting the generality of <U>sub-clause (iii)</U>&nbsp;below, cause such New Subsidiary or Designated Guarantor, as
applicable, to the extent required or applicable, to execute and deliver to the Collateral Agent a joinder to the Security Agreement
(in the form attached thereto), any relevant IP Agreement or other Collateral Documents, and such other Collateral Documents or other
documents as the Collateral Agent may reasonably request; (2)&nbsp;cause such New Subsidiary or Designated Guarantor, as applicable,
to deliver (or cause to be delivered) to the Collateral Agent (A)&nbsp;true, correct and complete copies of the Operating Documents of
such New Subsidiary or Designated Guarantor, as applicable, (B)&nbsp;a Secretary&rsquo;s Certificate, certifying that the copies of the
Operating Documents of such New Subsidiary or Designated Guarantor, as applicable, are true, correct and complete (such Secretary&rsquo;s
Certificate to be in form and substance reasonably satisfactory to the Collateral Agent) and (C)&nbsp;a good standing certificate for
such New Subsidiary or Designated Guarantor, as applicable, certified by the Secretary of State (or the equivalent thereof) of its jurisdiction
of organization, incorporation or formation (where applicable in the subject jurisdiction); and (iii)&nbsp;cause such New Subsidiary
or Designated Guarantor, as applicable, to satisfy all collateral requirements contained in this Agreement (including <U>Section&nbsp;5.12</U>)
and each other Loan Document if and to the extent applicable to such New Subsidiary or Designated Guarantor. The parties hereto agree
that any New Subsidiary or Designated Guarantor, as applicable, shall constitute a Credit Party for all purposes hereunder as of the
date of the execution and delivery of any joinder contemplated by <U>clause (a)</U>&nbsp;above or the date such New Subsidiary or Designated
Guarantor, as applicable, provides any guarantee of the Obligations as contemplated by <U>Section&nbsp;5.12</U>. Any document, agreement
or instrument executed or issued pursuant to this <U>Section&nbsp;5.13</U> shall be a Loan Document for all purposes under this Agreement
and the other Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Post-Closing
Requirements</B>. Borrower will, and will cause each of its Subsidiaries, as applicable, to take each of the actions set forth on <U>Schedule
5.14</U> of the Disclosure Letter within the time period prescribed therefor on such schedule, which shall include, among other things,
that, notwithstanding anything to the contrary in <U>Section&nbsp;3.1(g)</U>&nbsp;or <U>Section&nbsp;5.4</U>, the Credit Parties shall
have until the date that is thirty (30) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion,
taking into account reasonable good faith efforts) following the Tranche A Closing Date to comply with the provisions of <U>Section&nbsp;5.4</U>
with regards to naming the Collateral Agent, on behalf of the Lenders and the other Secured Parties, as additional insured or loss payee,
on any products liability or general liability insurance policies maintained in the United States regarding any Collateral in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All representations and warranties
and covenants contained in this Agreement and the other Loan Documents shall be deemed modified to the extent necessary to take the actions
set forth on <U>Schedule 5.14</U> of the Disclosure Letter within the time periods set forth therein, rather than elsewhere provided
in the Loan Documents, such that to the extent any such action set forth in <U>Schedule 5.14</U> of the Disclosure Letter is not overdue,
the applicable Credit Party shall not be in breach of any representation or warranty or covenant contained in this Agreement or any other
Loan Document applicable to such action for the period from the Tranche A Closing Date until the date on which such action is required
to be fulfilled as set forth on <U>Schedule 5.14</U> of the Disclosure Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Environmental</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Deliver
to the Collateral Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
soon as practicable following receipt thereof, copies of all environmental audits, investigations, analyses and reports of any kind or
character, whether prepared by personnel of Borrower or any of its Subsidiaries or by independent consultants, governmental authorities
or any other Persons, with respect to any significant environmental matter at any Facility or with respect to any Environmental Claim
that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>promptly
upon a Responsible Officer of any Credit Party or any of its Subsidiaries obtaining knowledge of the occurrence thereof, written notice
describing in reasonable detail (A)&nbsp;any Release required to be reported to any federal, state, local or foreign governmental or
regulatory agency under any applicable Environmental Laws, (B)&nbsp;any remedial action taken by (or on behalf of) any Credit Party or
any other Person in response to (x)&nbsp;any Hazardous Materials Activities, the existence of which, individually or in the aggregate,
could reasonably be expected to result in one or more Environmental Claims resulting in a Material Adverse Change, or (y)&nbsp;any Environmental
Claims that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, and (C)&nbsp;any
Credit Party&rsquo;s discovery of any occurrence or condition on any real property adjoining or in the vicinity of any Facility that
could cause such Facility or any part thereof to be subject to any material restrictions on the ownership, occupancy, transferability
or use thereof under any Environmental Laws, <U>provided</U>, <U>that</U>, with respect to real property adjoining or in the vicinity
of any Facility, Borrower shall have no duty to affirmatively investigate or make any efforts to become or stay informed regarding any
such adjoining or nearby properties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
soon as practicable following the sending or receipt thereof by any Credit Party, a copy of any and all written communications with respect
to (A)&nbsp;any Environmental Claims that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse
Change, (B)&nbsp;any Release required to be reported to any federal, state, local or foreign governmental or regulatory agency, and (C)&nbsp;any
request for information from any Governmental Authority that suggests such Governmental Authority is investigating whether any Credit
Party or any of its Subsidiaries may be potentially responsible for any Hazardous Materials Activity that, individually or in the aggregate,
could reasonably be expected to result in a Material Adverse Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prompt
written notice describing in reasonable detail of (A)&nbsp;any proposed acquisition of stock, assets, or property by Borrower or any
of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to (x)&nbsp;expose Borrower or any of its Subsidiaries
to, or result in, Environmental Claims which could reasonably be expected to result in a Material Adverse Change or (y)&nbsp;affect the
ability of Borrower or any of its Subsidiaries to maintain in full force and effect all material Governmental Approvals required under
any Environmental Laws for their respective operations, and (B)&nbsp;any proposed action to be taken by Borrower or any of its Subsidiaries
to modify current operations, in each case of <U>sub-clause (A)</U>&nbsp;and <U>(B)</U>&nbsp;above, that, individually or taken together
with any other such proposed acquisitions or actions, could reasonably be expected to result in a Material Adverse Change; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>with
reasonable promptness, such other documents and information as from time to time may be reasonably requested by the Collateral Agent
in relation to any matters disclosed pursuant to this <U>Section&nbsp;5.15(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Credit Party shall, and shall cause each of its Subsidiaries to, promptly take any and all actions reasonably necessary to (i)&nbsp;cure
any violation of applicable Environmental Laws by Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably
be expected to result in a Material Adverse Change, and (ii)&nbsp;make an appropriate response to any Environmental Claim against Borrower
or any of its Subsidiaries and discharge any obligations it may have to any Person thereunder where failure to do so, individually or
in the aggregate, could reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Inventory;
Returns; Maintenance of Properties</B>. Keep all Inventory which constitutes the Product in good and marketable condition, free from
material defects and otherwise keep all Inventory which constitutes the Product in compliance with all applicable FDA Laws, EU Laws,
and all other foreign equivalents, as applicable, except where the failure to do so could not reasonably be expected to result in a Material
Adverse Change. Returns and allowances between a Credit Party and its Account Debtors shall follow such Credit Party&rsquo;s customary
practices. Each Credit Party will, and will cause each of its Subsidiaries to, maintain or cause to be maintained in good repair, working
order and condition, ordinary wear and tear, casualty and condemnation excepted, all material tangible properties used or useful in its
respective business, and from time to time will make or cause to be made all commercially reasonable repairs, renewals and replacements
thereof except where failure to do so could not reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Regulatory
Obligations; Maintenance of Regulatory Approval or Licensure; Licensure and Designation; Manufacturing, Marketing and Distribution</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;Comply
in all material respects with Governmental Authority research, development, testing, post-marketing approval, authorization, clearance,
or licensure requirements for the Product in the Territory, as applicable, (ii)&nbsp;maintain all Regulatory Approvals or Licensures
required or otherwise material to manufacture, market, and distribute the Product in the Territory (including meeting the supplier standards
of Medicare, Medicaid, and other federal healthcare programs), and (iii)&nbsp;with respect to each calendar year commencing with calendar
year 2025, maintain manufacturing capacity to sell the Product which has been designated as an Orphan Drug in the Territory in sufficient
quantities to satisfy or exceed the expected needs of patients with the disease or condition for which the Product was designated as
an Orphan Drug for such calendar year, as reasonably determined by Responsible Officers of the Credit Parties in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Deliver
to the Collateral Agent, as promptly as practicable after a Responsible Officer of Borrower shall have obtained Knowledge thereof, written
notice describing in reasonable detail any instance where any Credit Party or any of its Subsidiaries or licensing partners: (i)&nbsp;has
a reasonable expectation that there are grounds for imposition of a clinical hold, as described in 21 C.F.R. &sect; 312.42 or foreign
equivalent, withdrawal of an Investigational New Drug Application, as defined in 21 C.F.R. &sect; 312.38 or foreign equivalent, withdrawal
or suspension of a Product approval or licensure, as described in 21 C.F.R. Part&nbsp;314 or foreign equivalent, or a recall, as defined
in 21 C.F.R. &sect; 7.3 or foreign equivalent, in each case with respect to the Product; (ii)&nbsp;has been issued a Warning Letter or
Untitled Letter or Form&nbsp;FDA-483 from FDA (or equivalent communication from any other Regulatory Agency) with respect to the Product;
(iii)&nbsp;has received notice from a Regulatory Agency (including the European Medicines Authority) that an application for the Product
will not be approved in its present form; or (iv)&nbsp;has a reasonable expectation that the Product will lose exclusivity under 21 C.F.R.
Part&nbsp;316 or foreign equivalent or face a supply shortage materially impacting the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Material
Contracts; Collateral Documents</B>. Comply with all of its covenants, agreements, undertakings and obligations arising under, and fulfill
all of its obligations under, (a)&nbsp;subject to <U>clause (b)</U>&nbsp;below, each Material Contract to which it is a party, except
as could not reasonably be expected to have a Material Adverse Change, or (b)&nbsp;each Collateral Document to which it is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Protection
of Regulatory Materials</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as expressly permitted under <U>clause (b)</U>&nbsp;below, use commercially reasonable efforts to (i)&nbsp;protect, defend and maintain
the validity and enforceability of Covered Regulatory Materials material to any aspect of the research, development, manufacture, production,
use, commercialization, marketing, import, storage, transport, offer for sale, distribution or sale of the Product in the Territory,
including defending any future or current cancellation proceedings, injunctions, lawsuits, hearings, investigations, complaints, arbitrations,
mediations, demands, decrees, or any other disputes, disagreements, or claims, challenging the legality, validity, enforceability or
ownership of any such Covered Regulatory Materials; and (ii)&nbsp;not allow any Covered Regulatory Materials material to any aspect of
the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale,
distribution or sale of the Product in the Territory, to be abandoned, disclaimed, forfeited or dedicated to the public (other than in
accordance with its statutory term or the exercise of the Credit Parties&rsquo; reasonable business judgment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as a Credit Party may otherwise determine in its reasonable business judgment, (i)&nbsp;use commercially reasonable efforts to cause
any licensee or licensor of any Covered Regulatory Materials not to disclaim, forfeit, dedicate to the public or abandon, or fail to
take any action necessary to prevent the disclaimer, forfeiture or abandonment of Covered Regulatory Materials necessary to any aspect
of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale,
distribution or sale of the Product in the Territory, and (ii)&nbsp;use commercially reasonable efforts to cause any licensee or licensor
of any Covered Regulatory Materials not to disclaim, forfeit, dedicate to the public or abandon, or fail to take any action necessary
to prevent the disclaimer, forfeiture or abandonment of Covered Regulatory Materials otherwise material to any aspect of the research,
development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution
or sale of the Product in the Territory (other than in accordance with the applicable licensor&rsquo;s reasonable business judgment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>NEGATIVE
COVENANTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Credit Party covenants
and agrees that, from and after the Effective Date and until payment in full of all Obligations (other than inchoate indemnity obligations),
such Credit Party shall not, and shall cause each of its Subsidiaries not to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Dispositions</B>.
Convey, sell, lease, transfer, exchange, assign, covenant not to sue, enter into a coexistence agreement, exclusively or nonexclusively
license out, or otherwise dispose of (including any sale-leaseback or any transfer of assets pursuant to a plan of division), directly
or indirectly and whether in one or a series of transactions (collectively, &ldquo;<B>Transfer</B>&rdquo;), all or any part of its properties
or assets constituting Collateral (including, for the avoidance of doubt, any Equity Interests constituting Collateral issued by any
Subsidiary which are owned or otherwise held by such Credit Party) or any Covered Company IP that does not constitute Collateral under
the Loan Documents but is related to any aspect of the research, development, manufacture, production, use, commercialization, marketing,
importing, storage, transport, offer for sale, distribution or sale of Product in the Territory; except, in each case of this <U>Section&nbsp;6.1</U>,
for Permitted Transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Fundamental
Changes; Location of Collateral</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
at least ten (10)&nbsp;days prior written notice to the Collateral Agent, solely in the case of a Credit Party: (i)&nbsp;change its jurisdiction
of organization, incorporation or formation, (ii)&nbsp;change its organizational structure or type, (iii)&nbsp;change its legal name,
or (iv)&nbsp;change any organizational number (if any) assigned by its jurisdiction of organization, incorporation or formation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Maintain
its primary Books at or deliver any Collateral with a fair market value or, if less, replacement cost (in each case, as reasonably determined
in good faith by a Responsible Officer of Borrower), individually or together with any other Collateral, in excess of $5,000,000 to,
one or more mortgaged or leased locations or one or more warehouses, processors or bailees, as applicable, unless, subject to the timing
requirements of <U>Section&nbsp;5.12</U>, <U>5.13</U> or <U>5.14</U> if and only to the extent applicable (solely with respect to such
locations, warehouses, processors or bailees where such Books or Collateral is located on the Effective Date or applicable Closing Date
(or during the 30-day period following the applicable Closing Date), such Credit Party uses commercially reasonable efforts to obtain,
within thirty (30) days after such Books or Collateral are maintained (or such longer period as the Collateral Agent may agree in writing
in its sole discretion, taking into account reasonable good faith efforts) a Collateral Access Agreement for such mortgaged or leased
location or such warehouse, processor or bailee governing such Books or such Collateral (as applicable), in form and substance reasonably
satisfactory to the Collateral Agent, to the extent such Collateral is located in the United States or the jurisdiction of organization
of such Credit Party (or, if different, the jurisdiction of the principal place of business of such Credit Party). Notwithstanding anything
to the contrary herein, such obligation to deliver Collateral Access Agreements will not apply to any inventory or assets while in transit
(including such assets stored at any temporary location pending transit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Establish
or maintain any bank account of any Credit Party other than the bank accounts set forth on <U>Schedule 6.2(c)</U>&nbsp;of the Disclosure
Letter (which bank accounts constitute all of the deposit accounts, securities accounts or other similar accounts maintained by any Credit
Party on the Effective Date or applicable Closing Date), unless, in the case of any bank account that is not an Excluded Account, (i)&nbsp;the
Collateral Agent is provided at least ten (10)&nbsp;Business Days&rsquo; written notice from such Credit Party prior to the establishment
or maintenance of such account and (ii)&nbsp;such account is or is made subject to a Control Agreement or an applicable Collateral Document
to the extent required by <U>Section&nbsp;5.5</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Maintain
cash in any bank account located in other than the United States, the United Kingdom, the Netherlands or the jurisdiction of organization
of such Credit Party (or, if different, the jurisdiction of the principal place of business of such Credit Party) that would be in excess
of the amount of cash that would be appropriate for (i)&nbsp;the continued operations in the ordinary course of business of such Credit
Party or Subsidiary and (ii)&nbsp;such other business needs of such Person, as reasonably determined by a Responsible Officer of Borrower
in good faith, consistent with prudent cash management practices and not with an intent to hinder the security interests available under
the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Take
any action or engage in any transaction (or series of actions or transactions), whether by reorganization, sale of assets, merger, dissolution,
amendment of Operating Documents or otherwise, the primary purpose of which is to evade, avoid or seek to avoid the performance or observance
of any of the covenants, agreements or obligations of any Credit Party under the Loan Documents (including under the Collateral Documents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Mergers,
Acquisitions, Liquidations or Dissolutions</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Merge,
divide itself into two (2)&nbsp;or more entities, consolidate, liquidate or dissolve, or permit any of its Subsidiaries to merge, divide
itself into two (2)&nbsp;or more entities, consolidate, liquidate or dissolve with or into any other Person, except that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(x)&nbsp;any
Subsidiary of Borrower may merge or consolidate with or into a Credit Party, <U>provided</U>, <U>that</U>, the Credit Party is the surviving
entity and (y)&nbsp;any Subsidiary of Borrower may liquidate or dissolve, <U>provided</U>, <U>that</U>, prior to or concurrent with such
liquidation or dissolution, the remaining assets of such Subsidiary shall be distributed to another Subsidiary, <U>provided</U>, <U>further</U>,
that if the liquidating or dissolving Subsidiary is a Credit Party, all of the assets and business of such Subsidiary shall be distributed
to an existing or newly-formed Credit Party, and if the liquidating or dissolving Subsidiary is not a Credit Party, all of the assets
and business of such Subsidiary are transferred to a Credit Party or another Subsidiary; <U>provided</U>, <U>finally</U>, that neither
such dissolution or liquidation nor such transfer could reasonably be expected to result in a Material Adverse Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
Subsidiary of Borrower may merge or consolidate with any other Subsidiary of Borrower, <U>provided</U>, <U>that</U>, if any party to
such merger or consolidation is a Credit Party then either (x)&nbsp;such Credit Party is the surviving entity or (y)&nbsp;the surviving
or resulting entity executes and delivers to the Collateral Agent a joinder to the Security Agreement in the form attached thereto, a
joinder to any relevant IP Agreement, and such other Collateral Documents or other documents required under the terms of the Loan Documents
or as the Collateral Agent may reasonably request, as applicable, and otherwise satisfies the requirements of <U>Section&nbsp;5.13</U>
as promptly as practicable but in no event later than thirty (30) days (or such longer period as the Collateral Agent may agree in writing
and in its sole discretion, taking into account reasonable good faith efforts) following the completion of such merger or consolidation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
Subsidiary of Borrower may divide itself into two (2)&nbsp;or more entities or be dissolved or liquidated, <U>provided</U>, <U>that</U>,
if such Subsidiary is a Credit Party, the properties and assets of such Subsidiary are allocated or distributed to an existing or newly
formed or newly joined Credit Party; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
Permitted Acquisition, Permitted Transfer of Equity Interests or Permitted Investment may be structured as a merger or consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Make,
or permit any of its Subsidiaries to make, Acquisitions outside the ordinary course of business, including any purchase of all or substantially
all of the assets of, or any division or line of business of, any other Person, other than Permitted Acquisitions or Permitted Investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the avoidance of doubt, nothing in this <U>Section&nbsp;6.3</U>
shall prohibit any Credit Party or its Subsidiaries from entering into in-licensing agreements; <U>provided</U>, <U>however</U>, that
in each case no Indebtedness that is not Permitted Indebtedness hereunder is incurred or assumed in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness</B>.
Directly or indirectly, create, incur, assume or guaranty or otherwise become or remain liable with respect to, any Indebtedness that
is not Permitted Indebtedness hereunder; <U>provided</U>, <U>however</U>, that the accrual of interest, the accretion of accreted value
and the payment of interest in the form of additional Indebtedness shall not be deemed to be an incurrence of Indebtedness for purposes
of this <U>Section&nbsp;6.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Encumbrances</B>.
Except for Permitted Liens, (i)&nbsp;create, incur, allow, or suffer to exist any Lien on any Collateral, or (ii)&nbsp;permit (other
than pursuant to the terms of the Loan Documents) any material portion of the Collateral (including, for the avoidance of doubt, any
Equity Interests constituting Collateral issued by any Subsidiary which are owned or otherwise held by such Credit Party) not to be subject
to the first priority security interest (subject to Permitted Liens, the limitations expressly set forth herein and the limitations expressly
set forth in the other Loan Documents) granted in the Loan Documents or otherwise pursuant to the Collateral Documents, in each case
of this <U>clause (ii)</U>, other than as a direct result of any action by the Collateral Agent or any Lender or failure of the Collateral
Agent or any Lender to perform an obligation thereof under the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Further Negative Pledges; Negative Pledge</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Enter
into any agreement, document or instrument directly or indirectly prohibiting (or having the effect of prohibiting) or limiting the ability
of such Credit Party or Subsidiary to create, incur, assume or suffer to exist any Lien upon any Collateral, whether now owned or hereafter
acquired, in favor of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, with respect to the Obligations
or under the Loan Documents, in each case of this <U>Section&nbsp;6.6</U>, other than Permitted Negative Pledges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
<U>Sections 6.1</U> and <U>6.5</U>, no Credit Party will Transfer, or create, incur, allow or suffer to exist any Lien on, any Equity
Interests owned or otherwise held by such Credit Party that is issued by any Subsidiary that owns or otherwise holds any interest in
Covered Company IP (including any Product-Exclusive Intellectual Property) registered, issued or filed for, as applicable, in the Territory,
except for:&nbsp; (i)&nbsp;Permitted Liens; (ii)&nbsp;Permitted Transfers that would not interfere with or impede the ability of Borrower
or any Subsidiary of Borrower to conduct the research, development, manufacture, production, use, commercialization, marketing, importing,
storage, transport, offer for sale, distribution or sale of the Product in the Territory or enforce its rights with respect to any of
the foregoing within the Territory and (iii)&nbsp;sales, assignments, transfers, exchanges or other dispositions to qualify directors
if required by Requirements of Law, <U>provided</U>, <U>that</U>, such sale, assignment, transfer, exchange or other disposition shall
be for the minimum number of Equity Interests as are necessary for such qualification under Requirements of Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintenance
of Collateral Accounts</B>. Maintain any Collateral Account except in accordance with the terms of <U>Section&nbsp;5.5</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Distributions;
Investments</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Pay
any dividends or make any distribution or payment on, or redeem, retire or repurchase any of its Equity Interests (collectively, &ldquo;<B>Restricted
Payments</B>&rdquo;), except, in each case of this <U>Section&nbsp;6.8</U>, for Permitted Distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Directly
or indirectly, make any Investment other than Permitted Acquisitions and Permitted Investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the avoidance of doubt, nothing in this <U>Section&nbsp;6.8</U>
shall prohibit any Credit Party or its Subsidiaries from entering into in-licensing agreements; <U>provided</U>, <U>however</U>, that
in each case no Indebtedness that is not Permitted Indebtedness is incurred or assumed in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Restrictions on Subsidiary Distributions</B>. Enter into any agreement, document or instrument directly or indirectly prohibiting (or
having the effect of prohibiting) or limiting the ability of any Subsidiary of Borrower to (a)&nbsp;pay dividends or make any other distributions
on any of such Subsidiary&rsquo;s Equity Interests owned by Borrower or any of its other Subsidiaries, (b)&nbsp;repay or prepay any Indebtedness
owed by such Subsidiary to Borrower or any of its other Subsidiaries, (c)&nbsp;make loans or advances to Borrower or any of its other
Subsidiaries, or (d)&nbsp;transfer, lease or license any Collateral to Borrower or any of its other Subsidiaries, except, in each case
of this <U>Section&nbsp;6.9</U>, for Permitted Subsidiary Distribution Restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subordinated
Debt</B>. Notwithstanding anything to the contrary in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Make
or permit any voluntary or optional prepayment or repayment of the outstanding principal amount of any Subordinated Debt other than in
accordance with the express terms of a subordination, intercreditor or other similar agreement relating to such Subordinated Debt, if
any, that is in form and substance reasonably satisfactory to the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Make
or permit any payment of interest (including accrued and unpaid interest) in cash on or in respect of any Subordinated Debt at any time
that a Default or Event of Default shall have occurred and be continuing other than in accordance with the express terms of a subordination,
intercreditor or other similar agreement relating to such Subordinated Debt, if any, that is in form and substance reasonably satisfactory
to the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the case of any Subsidiary of Borrower, create, incur or assume or otherwise become directly liable for any Subordinated Debt, or guaranty
or otherwise become directly or indirectly liable for any Subordinated Debt of Borrower or any other Subsidiary of Borrower, unless such
Subsidiary of Borrower is a Credit Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Amend,
restate, supplement or otherwise modify any terms, conditions or other provisions of any Subordinated Debt, or any agreement, instrument
or other document relating thereto, in any manner which would contravene in any respect any of the foregoing clauses of this <U>Section&nbsp;6.10</U>
or adversely affect the payment or priority subordination thereof (as applicable) to Obligations owed to Lenders, in each case except
under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt, if any, is subject,
without the prior written consent of the Collateral Agent (in its sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Amendments
or Waivers of Organizational Documents</B>. Amend, restate, supplement or otherwise modify, or waive, any provision of its Operating
Documents in a manner that would reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Compliance</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Become
an &ldquo;investment company&rdquo; under the Investment Company Act of 1940, or undertake as one of its important activities extending
credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use
the proceeds of any Credit Extension for that purpose;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>With
respect to any ERISA Affiliate, cause or suffer to exist (i)&nbsp;any event that would result in the imposition of a Lien under ERISA
on any assets or properties of any Credit Party or a Subsidiary of a Credit Party with respect to any Plan or (ii)&nbsp;any other ERISA
Event that, in the case of <U>sub-clauses (i)</U>&nbsp;and <U>(ii)</U>&nbsp;above, could reasonably be expected to, individually or in
the aggregate, result in a Material Adverse Change; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Permit
the occurrence of any other event with respect to any present pension, profit sharing or deferred compensation plan which could reasonably
be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Compliance
with Sanctions, Export and Import Laws, Anti-Corruption Laws and Anti-Money Laundering Laws</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Permit
any of its Subsidiaries or Affiliates to, directly or indirectly, enter into any documents or contracts with any Blocked Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Permit
any of its Subsidiaries or controlled Affiliates to, directly or indirectly, (i)&nbsp;conduct any prohibited business or engage in any
prohibited investment, activity, transaction or dealing with any Blocked Person, including the making or receiving of any contribution
of funds, goods or services to or for the benefit of any Blocked Person, (ii)&nbsp;deal in, or otherwise engage in any investment, activity,
transaction or dealing relating to, any property or interests in property blocked pursuant to Sanctions, or (iii)&nbsp;engage in or conspire
to engage in any investment, activity, transaction or dealing that evades or avoids or violates, or has the purpose of evading or avoiding,
or attempts to violate, any prohibitions under Sanctions, Export and Import Laws, Anti-Corruption Laws or Anti-Money Laundering Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Directly
or indirectly (including through an agent or any other Person), use any of the proceeds of any Credit Extension, or lend, contribute
or otherwise make available such proceeds of any Credit Extension to any Subsidiary, joint venture partner or other Person, (i)&nbsp;for
any payments to any government official or employee, political party, official of a political party, candidate for political office or
anyone else, in order to obtain, retain or direct business, or to obtain any improper advantage, in violation in any respect of Anti-Corruption
Laws, (ii)&nbsp;in violation in any respect of any Anti-Money Laundering Laws, (iii)&nbsp;in violation of Sanctions or (iv)&nbsp;in violation
of Export and Import Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Permit
any of its Subsidiaries to, directly or, to the Knowledge of Borrower, indirectly, fund all or part of any repayment of the Credit Extensions
or other payments under this Agreement out of proceeds derived from criminal activity or activity or transactions in violation in any
respect of Anti- Corruption Laws, Export and Import Laws, Anti-Money Laundering Laws or Sanctions, or that would otherwise cause any
Person (including any Person participating in the Credit Extensions, whether as agent, lender, sponsor, underwriter, advisor, investor,
or otherwise) to be in violation in any respect of Anti-Corruption Laws, Export and Import Laws, Anti-Money Laundering Laws or Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Material
Contracts</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;Waive,
amend, cancel or terminate, exercise or fail to exercise, any rights constituting or relating to any of the Material Contracts or (ii)&nbsp;breach,
default under, or take any action or fail to take any action that, with the passage of time or the giving of notice or both, would constitute
a default or event of default under any of the Material Contracts, in each case of this <U>Section&nbsp;6.14</U>, which, individually
or taken together with any other such waivers, amendments, cancellations, terminations, exercises or failures, could reasonably be expected
to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From
and after the Effective Date, enter into any Manufacturing Agreement (excluding, for the avoidance of doubt, any Manufacturing Agreement
listed on <U>Schedule 13.1</U> of the Disclosure Letter and all amendments, restatements, amendment and restatements, extensions, supplements
or other modifications thereto) relating to active pharmaceutical ingredients or finished products relating to the Product (i)&nbsp;that
cannot be collaterally assigned to secure the Obligations, (ii)&nbsp;that cannot be assigned to a purchaser in a foreclosure sale of
all or any portion of the Collateral (subject to assumption by the purchaser of all obligations under such Material Contract) in the
event of any exercise of rights or remedies under the Loan Documents, or (iii)&nbsp;that contains provisions that restrict or penalize
the granting of a security interest in or Lien on such Material Contract or the assignment of such Material Contract upon the sale or
other disposition of all or a portion of a product to which such Material Contract relates, in each case without using its commercially
reasonable efforts to ensure such Manufacturing Agreement does not contain the terms listed in <U>sub-clauses (i)</U>&nbsp;to <U>(iii)</U>&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;TTM
Net Sales</B>. From January&nbsp;1, 2027 and without violating any other term or provision of this Agreement, permit TTM Net Sales of
Borrower and its Subsidiaries, tested at the end of the first Fiscal Quarter of 2027 based on the audited financial statements delivered
pursuant to <U>Section&nbsp;5.2(a)(i)</U>&nbsp;for the Fiscal Year ended 2026, and tested at the end of each Fiscal Quarter thereafter
based on the financial statements delivered pursuant to <U>Section&nbsp;5.2(a)(i)</U>&nbsp;or <U>Section&nbsp;5.1(a)(ii)</U>, as applicable,
to be less than the amount set forth in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid">Twelve Months Ending</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Minimum TTM Sales</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: justify">December&nbsp;31, 2026</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">March&nbsp;31, 2027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">June&nbsp;30, 2027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">September&nbsp;30, 2027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">December&nbsp;31, 2027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">March&nbsp;31, 2028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">June&nbsp;30, 2028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">September&nbsp;30, 2028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">December&nbsp;31, 2028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Thereafter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">[***]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Minimum
Liquidity</B>. From and after the date on which Borrower commences the payment of any dividends or distributions in cash with respect
to Borrower&rsquo;s Series&nbsp;A Preferred Stock, after giving effect to the transactions contemplated hereunder and without violating
any other term or provision of this Agreement, permit consolidated Liquidity of Borrower and its Subsidiaries, tested daily commencing
with the first Business Day occurring immediately after such date, to be less than $20,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>EVENTS
OF DEFAULT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any one of the following
shall constitute an event of default (an &ldquo;<B>Event of Default</B>&rdquo;) under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
Default</B>. Any Credit Party fails to (a)&nbsp;make any payment of any principal of the Term Loans when and as the same shall become
due and payable, whether at the due date thereof (including pursuant to <U>Section&nbsp;2.2(c)</U>) or at a date fixed for prepayment
(whether voluntary or mandatory) thereof or by acceleration thereof or otherwise, or (b)&nbsp;within five (5)&nbsp;Business Days after
the same becomes due and payable, any payment of interest or premium pursuant to <U>Section&nbsp;2.2</U>, including any applicable Additional
Consideration, Exit Consideration, Makewhole Amount or Prepayment Premium (which such five (5)&nbsp;Business Day cure period shall not
apply to any such payments due on the Term Loan Maturity Date or an earlier date pursuant to <U>Section&nbsp;2.2(c)(i)</U>&nbsp;or <U>Section&nbsp;2.2(c)(ii)</U>&nbsp;hereof
or the date of acceleration pursuant to <U>Section&nbsp;8.1(a)</U>&nbsp;hereof). A failure to pay any such interest, premium or Obligations
pursuant to the foregoing <U>clause (b)</U>&nbsp;prior to the end of such five (5)&nbsp;Business Day-period shall not constitute an Event
of Default (unless such payment is due on the Term Loan Maturity Date or such earlier date pursuant to <U>Section&nbsp;2.2(c)(i)</U>&nbsp;or
<U>Section&nbsp;2.2(c)(ii)</U>&nbsp;hereof or the date of acceleration pursuant to <U>Section&nbsp;8.1(a)</U>&nbsp;hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Covenant
Default</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Credit Parties: (i)&nbsp;fail or neglect to perform any obligation in <U>Sections 5.5</U>, <U>5.6</U>, <U>5.7</U>, <U>5.10</U>, <U>5.12</U>,
<U>5.13</U> or <U>5.14</U> or (ii)&nbsp;violate or breach any covenant or agreement in <U>Section&nbsp;6</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Credit Parties fail or neglect to perform any obligation in <U>Section&nbsp;5.2</U> or <U>5.17</U> and, in the case where such failure
or neglect is capable of being cured such failure or neglect continues for ten (10)&nbsp;days after the earlier of the date on which
(i)&nbsp;a Responsible Officer of any Credit Party becomes aware of such failure or neglect and (ii)&nbsp;written notice thereof shall
have been delivered to Borrower by the Collateral Agent or any Lender. Cure periods provided under this <U>Section&nbsp;7.2(b)</U>&nbsp;shall
not apply, among other things, to any of the covenants referenced in <U>clause (a)</U>&nbsp;above; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Credit Parties fail or neglect to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in
this Agreement or any Loan Documents on its part to be performed, kept or observed and, where such failure or neglect is capable of being
cured such failure or neglect continues for twenty (20) days after the earlier of the date on which (i)&nbsp;a Responsible Officer of
any Credit Party becomes aware of such failure or neglect and (ii)&nbsp;written notice thereof shall have been delivered to Borrower
by the Collateral Agent or any Lender. Cure periods provided under this <U>Section&nbsp;7.2(c)</U>&nbsp;shall not apply, among other
things, to any of the covenants referenced in <U>clauses (a)</U>&nbsp;or <U>(b)</U>&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Withdrawal
Event; Material Adverse Change</B>. A Withdrawal Event occurs with respect to Product, or a Material Adverse Change occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Attachment;
Levy; Restraint on Business</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;The
service of process seeking to attach, by trustee or similar process, any funds of any Credit Party or of any entity under the control
of any Credit Party (including a Subsidiary) in excess of $10,000,000 on deposit or otherwise maintained with the Collateral Agent, or
(ii)&nbsp;a notice of Lien or levy is filed against any material portion of Collateral by any Governmental Authority, and the same under
<U>sub-clauses (i)</U>&nbsp;or <U>(ii)</U>&nbsp;hereof are not, within thirty (30) days after the occurrence thereof, discharged or stayed
(whether through the posting of a bond or otherwise); <U>provided</U>, <U>however</U>, that no Credit Extensions shall be made during
any thirty (30) day cure period; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;Any
material portion of Collateral is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii)&nbsp;any court
order enjoins, restrains, or prevents Borrower and its Subsidiaries from conducting any material part of their business, taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Insolvency</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>An
involuntary proceeding shall be commenced or an involuntary petition shall be filed in a court of competent jurisdiction seeking: (i)&nbsp;relief
in respect of any Credit Party, or of a substantial part of the property of any Credit Party, under Title 11 of the United States Code,
as now constituted or hereafter amended, or any other federal, state or foreign bankruptcy, insolvency, receivership or other similar
law; (ii)&nbsp;the voluntary or involuntary appointment of a receiver, interim receiver, receiver and manager, administrative receiver,
administrator, trustee, custodian, sequestrator, conservator or other similar official for or in respect of any Credit Party or for all
or a substantial part of the property or assets or undertakings of any Credit Party; (iii)&nbsp;issuance of a warrant of attachment,
execution, distraint or similar process against all or a substantial part of the property or assets or undertakings of any Credit Party;
or (iv)&nbsp;the winding-up or liquidation of any Credit Party; and in each case of <U>sub-clause (i)</U>&nbsp;through <U>(iv)</U>&nbsp;above,
such proceeding or petition shall continue undismissed or unstayed for sixty (60) days or an order or decree approving or ordering any
of the foregoing shall be entered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
Credit Party shall: (i)&nbsp;voluntarily commence any proceeding or file any petition seeking relief under Title 11 of the United States
Code, as now constituted or hereafter amended, or any other existing or future federal, state or foreign bankruptcy, insolvency, receivership,
relief of debtors or similar law; (ii)&nbsp;consent to the institution of, or fail to contest in a timely and appropriate manner, any
proceeding or the filing of any petition described in <U>clause (a)</U>&nbsp;above; (iii)&nbsp;apply for or consent to the appointment
of a receiver, interim receiver, receiver and manager, administrative receiver, administrator, trustee, custodian, sequestrator, conservator
or other similar official for or in respect of any Credit Party or for any substantial portion of the property or assets or undertakings
of any Credit Party; (iv)&nbsp;file an answer admitting the material allegations of a petition filed against it in any such proceeding;
(v)&nbsp;make a general assignment for the benefit of creditors, or enter into a composition, compromise, assignment or arrangement with
any of its creditors (whether by way of a voluntary arrangement, schedule of arrangement, deed of compromise or otherwise); (vi)&nbsp;become
unable to, admit in writing its inability to or fail to, generally pay its debts as they become due; (vii)&nbsp;take any corporate action
for the purpose of effecting any of the foregoing; or (viii)&nbsp;wind up or liquidate (except as otherwise expressly permitted hereunder);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[Reserved];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>An
affirmative vote by the applicable Board of Directors to commence any case, proceeding or other action described in <U>clause (a)</U>&nbsp;above
or any other action by any Credit Party to otherwise cause, consent to, approve or acquiesce in any of the acts described in <U>clauses
(a)</U>&nbsp;or <U>(b)</U>&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other
Agreements</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
Credit Party or any of its Subsidiaries fails to pay any Indebtedness (other than the Indebtedness represented by this Agreement and
the other Loan Documents) within any applicable grace period after such payment is due and payable (including at final maturity) or after
the acceleration of any such Indebtedness by the holder(s)&nbsp;thereof because of a default, in each case, if the total amount of such
Indebtedness unpaid or accelerated exceeds $10,000,000; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
limiting the generality of <U>clause (a)</U>&nbsp;above, an event of default occurs under any Hedging Agreement as to which any Credit
Party or any of its Subsidiaries is the defaulting party or any termination event occurs under any Hedging Agreement as to which any
Credit Party or any of its Subsidiaries is a party, in either case if, in respect of such Hedging Agreement and as a result of such occurrence,
the Hedge Termination Value owed by any such Credit Party or Subsidiary is greater than $5,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Judgments</B>.
One or more final, non-appealable judgments, orders, or decrees for the payment of money in an amount in excess of $5,000,000 (but excluding
any final judgments, orders, or decrees for the payment of money, in each case that is covered by a policy from an independent third-party
insurance carrier as to which such insurance carrier has not excluded or denied liability or by an indemnification claim against a solvent
and unaffiliated Person that is not a Credit Party or a Subsidiary of a Credit Party as to which such Person has not denied liability
for such claim), shall be rendered against one or more Credit Parties and the same are not, within thirty (30) days after the entry thereof,
discharged or execution thereof stayed or bonded pending appeal, or such judgments are not discharged prior to the expiration of any
such stay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Misrepresentations</B>.
Any Credit Party or any Person acting for any Credit Party makes or is deemed to make any representation, warranty, or other statement
now or later in this Agreement, any other Loan Document or in any writing delivered to the Collateral Agent or any Lender or to induce
the Collateral Agent or any Lender to enter this Agreement or any other Loan Document, and such representation, warranty, or other statement
is incorrect in any material respect (or, to the extent any such representation, warranty or other statement is qualified by materiality
or Material Adverse Change, in any respect) when made or deemed to be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Loan
Documents; Collateral</B>. Any material provision of any Loan Document shall for any reason cease to be valid and binding on or enforceable
against any Credit Party, or any Credit Party shall so state in writing or bring an action to limit its obligations or liabilities thereunder;
or any Collateral Document shall for any reason (other than pursuant to or as expressly permitted by the terms thereof) cease to create
a valid security interest in any material portion of the Collateral purported to be covered thereby or such security interest shall for
any reason (other than pursuant to or as expressly permitted by the terms of the Loan Documents) cease to be a perfected and first priority
security interest in any material portion of the Collateral subject thereto, subject only to Permitted Liens, in each case, other than
as a direct result of any action by the Collateral Agent or any Lender or failure of the Collateral Agent or any Lender to perform an
obligation thereof under the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ERISA
Event</B>. An ERISA Event occurs that, individually or taken together with any other ERISA Events, results or could reasonably be expected
to result in a Material Adverse Change or the imposition of a Lien under Section&nbsp;303(k)&nbsp;of ERISA on any Collateral that, individually
or taken together with any other such Liens, could reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Intercreditor
Agreements</B>. (i)&nbsp;A default or breach on the part of a Credit Party occurs under any other subordination, intercreditor or other
similar agreement with respect to any Permitted Indebtedness that constitutes Subordinated Debt or (ii)&nbsp;any creditor party to such
an agreement with the Collateral Agent (or Lenders) and any Credit Party breaches any of the terms of such agreement, in each case of
<U>clauses (i)</U>&nbsp;and <U>(ii)</U>&nbsp;to the extent such breach or default results or could reasonably be expected to result in
a Material Adverse Change. For the avoidance of doubt, default or breaches by any Secured Party shall not constitute an Event of Default
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>RIGHTS
AND REMEDIES UPON AN EVENT OF DEFAULT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Rights
and Remedies</B>. While an Event of Default occurs and continues, the Collateral Agent may, or at the request of the Required Lenders,
will, without notice or demand:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>declare
all Obligations (including, for the avoidance of doubt, any and all amounts payable pursuant to <U>Section&nbsp;2.2(e)</U>, <U>Section&nbsp;2.2(f)</U>&nbsp;and
<U>Section&nbsp;2.7(b)</U>, as applicable) immediately due and payable (but if an Event of Default described in <U>Section&nbsp;7.5</U>
occurs, all Obligations, including any and all amounts payable pursuant to <U>Section&nbsp;2.2(e)</U>, <U>Section&nbsp;2.2(f)</U>&nbsp;and
<U>Section&nbsp;2.7(b)</U>, as applicable, are automatically and immediately due and payable without any notice, demand or other action
by the Collateral Agent or any Lender), whereupon all Obligations for principal, interest, premium or otherwise (including, for the avoidance
of doubt, any and all amounts payable pursuant to <U>Section&nbsp;2.2(e)</U>, <U>Section&nbsp;2.2(f)</U>&nbsp;and <U>Section&nbsp;2.7(b)</U>,
as applicable) shall become due and payable by Borrower without presentment for payment, demand, notice of protest or other demand or
notice of any kind, which are all expressly waived by the Credit Parties hereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>stop
advancing money or extending credit for Borrower&rsquo;s benefit under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>settle
or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that the Collateral Agent considers
advisable, notify any Person owing Borrower money of the Collateral Agent&rsquo;s security interest, for the benefit of the Lenders and
the other Secured Parties, in such funds, and verify the amount of the Collateral Accounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>make
any payments and do any acts it considers necessary or reasonable to protect the Collateral or the Collateral Agent&rsquo;s security
interest, for the benefit of Lenders and the other Secured Parties, in the Collateral. Borrower shall assemble the Collateral if the
Collateral Agent or the Required Lenders requests and make it available as the Collateral Agent designates or the Required Lenders designate.
The Collateral Agent or its agents or representatives may enter premises where the Collateral is located, take and maintain possession
of any part of the Collateral, and pay, purchase, contest, or compromise any Lien that appears to be prior or superior to its security
interest, for the benefit of Lenders and the other Secured Parties, and pay all expenses incurred. Effective solely while an Event of
Default occurs and continues, Borrower grants the Collateral Agent an irrevocable, royalty-free license or other right to enter, use,
operate and occupy (and for its agents or representatives to enter, use, operate and occupy), without charge, any such premises to exercise
any of the Collateral Agent&rsquo;s or any Lender&rsquo;s rights or remedies under this <U>Section&nbsp;8.1</U> (including in order to
take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, advertise for sale, sell, assign, license
out, convey, transfer or grant options to purchase any Collateral);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>apply
to the Obligations (i)&nbsp;any balances and deposits of Borrower it holds, (ii)&nbsp;any amount held by the Collateral Agent owing to
or for the credit or the account of Borrower or (iii)&nbsp;any balance from any Collateral Account of any Credit Party or instruct the
bank at which any such Collateral Account is maintained to pay the balance of any such Collateral Account to the Collateral Agent, for
the benefit of Lenders and the other Secured Parties, or to any Lender on behalf of itself and the other Secured Parties, as the Collateral
Agent shall direct;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>ship,
reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral; and in connection therewith,
while an Event of Default occurs and continues, with respect to any and all Intellectual Property owned or held by any Credit Party and
included in Collateral, each Credit Party hereby grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties,
to the maximum extent permitted: an irrevocable, non-exclusive, assignable, royalty-free license or other right to use (and for its agents
or representatives to use), without charge, including the right to sublicense, use and practice, any and all of such Credit Party&rsquo;s
rights to such Intellectual Property in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize
upon, advertise for sale, sell, assign, license out, convey, transfer or grant options to purchase any Collateral, and access to all
media in which any of the licensed items may be recorded or stored and to all Software and programs used for the compilation or printout
thereof; and in connection with the Collateral Agent&rsquo;s exercise of its rights or remedies under this <U>Section&nbsp;8.1</U> (including
in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, license out, convey,
transfer or grant options to purchase any Collateral), each Credit Party&rsquo;s rights under all licenses for rights to any Intellectual
Property included in the Collateral will (to the maximum extent permitted) be exercisable and enforceable directly by the Collateral
Agent for the benefit of all Secured Parties as if the Collateral Agent were a third-party beneficiary for such purpose under such licenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>place
a &ldquo;hold&rdquo; on any account maintained with the Collateral Agent or deliver a notice of exclusive control, any entitlement order,
or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>demand
and receive possession of the Books of any Credit Party regarding Collateral; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>exercise
all rights and remedies available to the Collateral Agent or any Lender under the Collateral Documents or any other Loan Documents or
at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the Collateral Agent
and Lender agrees that in connection with any foreclosure or other exercise of rights under this Agreement or any other Loan Document
with respect to any Intellectual Property included in the Collateral, the rights of the licensees under any license of such Intellectual
Property will not be terminated, limited or otherwise adversely affected so long as no default exists thereunder in a way that would
permit the licensor to terminate such license (commonly termed a non-disturbance). Without limitation to any other provision herein or
in any other Loan Document, while an Event of Default occurs and continues, at the Collateral Agent&rsquo;s or the Required Lenders&rsquo;
request, representatives from Borrower and the Collateral Agent shall promptly meet (in person or telephonically) to discuss in good
faith how to collect, receive, appropriate and realize upon Borrower&rsquo;s rights and interests in, to and under any Company IP Agreement,
including in connection with any foreclosure or other exercise of the Collateral Agent&rsquo;s or any Lender&rsquo;s rights with respect
thereto. If Borrower and the Collateral Agent do not mutually agree with respect thereto within ten (10)&nbsp;Business Days after such
request by the Collateral Agent, then the Collateral Agent may request Borrower to, and Borrower (promptly following the receipt of such
request) shall, use reasonable best efforts to obtain the written consent of any counterparty to the exercise by the Collateral Agent
or any Lender of any and all rights and remedies under this Agreement or any other Loan Document with respect to any Company IP Agreement,
in form and substance reasonably satisfactory to the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Power
of Attorney</B>. Borrower hereby irrevocably appoints the Collateral Agent and any Related Party thereof as its lawful attorney-in-fact,
exercisable solely upon the occurrence and during the continuance of an Event of Default, to: (a)&nbsp;endorse Borrower&rsquo;s name
on any checks or other forms of payment or security; (b)&nbsp;sign Borrower&rsquo;s name on any invoice or bill of lading for any Account
or drafts against Account Debtors; (c)&nbsp;settle and adjust disputes and claims about the Collateral Accounts directly with depository
banks where the Collateral Accounts are maintained, for amounts and on terms the Collateral Agent determines reasonable; (d)&nbsp;make,
settle, and adjust all claims under Borrower&rsquo;s products liability or general liability insurance policies maintained in any jurisdiction
regarding Collateral; (e)&nbsp;pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the
Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f)&nbsp;transfer the
Collateral into the name of the Collateral Agent or a third-party as the Code permits. Borrower hereby appoints the Collateral Agent
and any Related Party thereof as its lawful attorney-in-fact solely to file or record any documents necessary to perfect or continue
the perfection of the Collateral Agent&rsquo;s security interest, for the benefit of Lenders and the other Secured Parties, in the Collateral
regardless of whether an Event of Default has occurred until all Obligations (other than contingent indemnification obligations to the
extent no claim giving rise thereto has been asserted) have been satisfied in full and no Lender is under any further obligation to make
Credit Extensions hereunder. The foregoing appointment of the Collateral Agent and any Related Party thereof as Borrower&rsquo;s attorney
in fact, and all of the Collateral Agent&rsquo;s (or such Related Party&rsquo;s) rights and powers, coupled with an interest, are irrevocable
until all Obligations (other than contingent indemnification obligations to the extent no claim giving rise thereto has been asserted)
have been fully repaid and performed and each Lender&rsquo;s obligation to provide Credit Extensions terminates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Application
of Payments and Proceeds Upon Default</B>. If an Event of Default has occurred and is continuing, the Collateral Agent shall apply any
funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result of any collection of Collateral
Accounts or disposition of any other Collateral, or otherwise, to the Obligations in such order as the Collateral Agent shall determine
in its sole discretion. Any surplus shall be paid to Borrower or other Persons legally entitled thereto; Borrower shall remain liable
to Lenders for any deficiency. If the Collateral Agent or any Lender directly or indirectly enters into a deferred payment or other credit
transaction with any purchaser at any sale of Collateral, the Collateral Agent or such Lender, as applicable, shall have the option,
exercisable at any time, of either reducing the Obligations by the principal amount of the purchase price or deferring the reduction
of the Obligations until the actual receipt by the applicable Lender(s)&nbsp;of cash therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Collateral
Agent&rsquo;s Liability for Collateral</B>. So long as the Collateral Agent complies with Requirements of Law regarding the safekeeping
of the Collateral in the possession or under the control of the Collateral Agent and absent bad faith, gross negligence or willful misconduct
of the Collateral Agent (as determined by a court of competent jurisdiction by final and nonappealable judgment), the Collateral Agent
shall not be liable or responsible for: (a)&nbsp;the safekeeping of the Collateral; (b)&nbsp;any loss or damage to the Collateral; or
(c)&nbsp;any act or default of any other Person. In no event shall the Collateral Agent or any Lender have any liability for any diminution
in the value of the Collateral for any reason except as a result of the Collateral Agent&rsquo;s bad faith, gross negligence or willful
misconduct (as determined by a court of competent jurisdiction by final and nonappealable judgment). Subject to the forgoing, Borrower
bears all risk of loss, damage or destruction of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Waiver; Remedies Cumulative</B>. The Collateral Agent&rsquo;s or any Lender&rsquo;s failure, at any time or times, to require strict
performance by Borrower or any other Person of any provision of this Agreement or any other Loan Document shall not waive, affect, or
diminish any right of the Collateral Agent or any Lender thereafter to demand strict performance and compliance herewith or therewith.
No waiver hereunder shall be effective unless signed by the party granting the waiver and then is only effective for the specific instance
and purpose for which it is given. Each of the Collateral Agent&rsquo;s and Lender&rsquo;s rights and remedies under this Agreement and
the other Loan Documents are cumulative. Each of the Collateral Agent and Lenders has all rights and remedies provided under the Code,
by law, or in equity. The exercise by the Collateral Agent or any Lender of one right or remedy is not an election and shall not preclude
the Collateral Agent or any Lender from exercising any other remedy under this Agreement or other remedy available at law or in equity,
and the waiver by the Collateral Agent or any Lender of any Event of Default is not a continuing waiver. The Collateral Agent&rsquo;s
or any Lender&rsquo;s delay in exercising any remedy is not a waiver, election, or acquiescence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Demand
Waiver; Makewhole Amount; Prepayment Premium; Exit Consideration</B>. Borrower waives demand, notice of default or dishonor, notice of
payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts,
documents, instruments, chattel paper, and guarantees held by the Collateral Agent on which Borrower is liable. Borrower acknowledges
and agrees that if the Obligations shall be or are prepaid pursuant to <U>Section&nbsp;2.2(c)</U>&nbsp;or the maturity of all Obligations
shall be accelerated pursuant to <U>Section&nbsp;8.1(a)</U>&nbsp;by reason of the occurrence of an Event of Default, the applicable Makewhole
Amount, Prepayment Premium and Exit Consideration that is payable pursuant to <U>Section&nbsp;2.2(e)</U>, <U>Section&nbsp;2.2(f)</U>&nbsp;and
<U>Section&nbsp;2.7(b)</U>&nbsp;(as applicable), as well as any other accrued Additional Consideration that is payable pursuant to <U>Section&nbsp;2.7</U>,
shall become due and payable by Borrower upon such prepayment, whether such prepayment is voluntary or mandatory, as provided in <U>Section&nbsp;2.2(c)</U>&nbsp;or
acceleration, whether in the case of acceleration such acceleration is automatic or is effected by the Collateral Agent&rsquo;s or any
Lender&rsquo;s declaration thereof, as provided in <U>Section&nbsp;8.1(a)</U>, and shall also become due and payable in the event the
Obligations are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any
other similar means, and Borrower shall pay the applicable Makewhole Amount, Prepayment Premium and Exit Consideration that is payable
pursuant to <U>Section&nbsp;2.2(e)</U>, <U>Section&nbsp;2.2(f)</U>&nbsp;and <U>Section&nbsp;2.7(b)</U>&nbsp;(as applicable), as well
as any other accrued Additional Consideration that is payable pursuant to <U>Section&nbsp;2.7</U>, as compensation to Lenders for the
loss of its investment opportunity and not as a penalty, and Borrower waives any right to object thereto in any voluntary or involuntary
bankruptcy, insolvency or similar proceeding or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>NOTICES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices, consents, requests,
approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be in writing and shall be
deemed to have been validly served, given, or delivered: (a)&nbsp;upon the earlier of actual receipt and three (3)&nbsp;Business Days
after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b)&nbsp;upon
transmission, when sent by electronic mail; (c)&nbsp;one (1)&nbsp;Business Day after deposit with a reputable overnight courier with
all charges prepaid; or (d)&nbsp;when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified
and sent to the address, or email address (if any) indicated below. Any party to this Agreement may change its mailing or electronic
mail address by giving all other parties hereto written notice thereof in accordance with the terms of this <U>Section&nbsp;9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If to Borrower
or any other Credit Party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Precigen,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">20374 Seneca Meadows Parkway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Germantown, Maryland 20876</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2.5in">&nbsp;</TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">Attn:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Legal Officer</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">Email:</TD><TD STYLE="text-align: justify">dlehr@precigen.com</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 1.5in"><FONT STYLE="font-size: 10pt">If to Collateral Agent:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">BioPharma Credit PLC</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2in">51 Lime Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">19<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">London, United Kingdom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">EC3M 7DQ</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">Attn: Company Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">with a copy to
(which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">BioPharma Credit
PLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2in">c/o Pharmakon Advisors,
LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2in">110 East 59th Street,
# 2800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2in">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2in">Attn: Pedro Gonzalez
de Cosio</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2in">Phone: +1 (212) 883-2296</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">Fax: +1 (917) 210-4048</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2in">Email: pharmakon@pharmakonadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">New York, NY 10036-6745</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Attn: Geoffrey E. Secol</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Phone: +1 (212) 872-8081</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Email: gsecol@akingump.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="width: 1.5in">If to any Lender:</TD>
  <TD>To the address of such Lender set forth on <U>Exhibit&nbsp;D</U> attached hereto</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">with a copy to
(which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">Pharmakon Advisors,
LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">110 East 59th Street,
#2800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">Attn: Pedro Gonzalez
de Cosio</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">Phone: +1 (212) 883-2296</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in">Fax: +1 (917) 210-4048</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Email: pharmakon@pharmakonadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">New York, NY 10036-6745</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Attn: Geoffrey E. Secol</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Phone: +1 (212) 872-8081</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Email: gsecol@akingump.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>CHOICE
OF LAW, VENUE, AND JURY TRIAL WAIVER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT AND THE OTHER
LOAN DOCUMENTS (EXCLUDING THOSE LOAN DOCUMENTS THAT BY THEIR OWN TERMS ARE EXPRESSLY GOVERNED BY THE LAWS OF ANOTHER JURISDICTION) SHALL
BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLES
OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY
JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD
TO PROCEDURAL MATTERS AFFECTING THE ENFORCEMENT OF ANY LIENS IN COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT
EXTENT. Each party hereto submits to the exclusive jurisdiction of the courts of the State of New York sitting in New York County, and
of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and agrees that all
claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest
extent permitted by Requirements of Law, in such Federal court; <U>provided</U>, <U>however</U>, that nothing in this Agreement shall
be deemed to operate to preclude the Collateral Agent or any Lender from bringing suit or taking other legal action in any other jurisdiction
to realize on the Collateral or any other security for the Obligations, or to enforce a judgment or other court order in favor of the
Collateral Agent or any Lender. Each Credit Party expressly submits and consents in advance to such jurisdiction in any action or suit
commenced in any such court, and each Credit Party hereby waives any objection that it may have based upon lack of personal jurisdiction,
improper venue, or <I>forum non conveniens</I> and hereby consents to the granting of such legal or equitable relief as is deemed appropriate
by such court. Each Credit Party hereby waives personal service of the summons, complaints, and other process issued in such action or
suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to
such party at the address set forth in (or otherwise provided in accordance with the terms of) <U>Section&nbsp;9</U> of this Agreement
and that service so made shall be deemed completed upon the earlier to occur of such party&rsquo;s actual receipt thereof or three (3)&nbsp;days
after deposit in the U.S. mails, proper postage prepaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>TO THE FULLEST EXTENT
PERMITTED BY REQUIREMENTS OF LAW, EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ITS RIGHT TO A JURY TRIAL IN ANY CLAIM, SUIT, ACTION OR
PROCEEDING WITH RESPECT TO, OR DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH, THIS AGREEMENT, ANY OTHER LOAN DOCUMENT
OR THE TRANSACTIONS CONTEMPLATED HEREIN AND THEREIN OR RELATED HERETO OR THERETO (WHETHER FOUNDED IN CONTRACT, TORT OR ANY OTHER THEORY).
EACH PARTY HERETO (A)&nbsp;CERTIFIES THAT NO OTHER PARTY AND NO RELATED PARTY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT,&nbsp;IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;ACKNOWLEDGES THAT IT
AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION&nbsp;10</U>
AND (C)&nbsp;HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>GENERAL
PROVISIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Successors
and Assigns</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement binds and is for the benefit of the parties hereto and their respective successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
Credit Party may transfer, pledge or assign this Agreement or any other Loan Document or any rights or obligations hereunder or thereunder
without the prior written consent of each Lender. Subject to <U>Section&nbsp;11.1(d)</U>, any Lender may at any time sell, transfer,
assign or pledge this Agreement or any other Loan Document or any of its rights or obligations hereunder or thereunder, or grant a participation
in all or any part of, or any interest in, such Lender&rsquo;s obligations, rights or benefits under this Agreement and the other Loan
Documents, including with respect to any Term Loan (or any portion thereof), to any other Lender, any Affiliate of any Lender or any
third Person without Borrower&rsquo;s consent (any such sale, transfer, assignment, pledge or grant of a participation, a &ldquo;<B>Lender
Transfer</B>&rdquo;), including, for the avoidance of doubt, in furtherance of, as contemplated under or otherwise in connection with
any Lender&rsquo;s credit facility (including any exercise of rights or remedies thereunder or any actions as a result of any such exercise);
<U>provided</U>, <U>however</U>, that no Lender may make a Lender Transfer to a Disqualified Assignee without Borrower&rsquo;s prior
written consent except after the occurrence and during the continuance of an Event of Default (in which case such consent is not required).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the case of a Lender Transfer in the form of a participation granted by any Lender to any third Person, (i)&nbsp;such Lender&rsquo;s
obligations under this Agreement shall remain unchanged, (ii)&nbsp;such Lender shall remain solely responsible to the other parties hereto
for the performance of its obligations hereunder, (iii)&nbsp;Borrower shall continue to deal solely and directly with such Lender in
connection with such Lender&rsquo;s rights and obligations under this Agreement and (iv)&nbsp;any agreement or instrument pursuant to
which such Lender sells such participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to
approve any amendment, restatement, amendment and restatement, supplement or other modification hereto, in each case subject to the terms
and conditions of this Agreement. Borrower agrees that each participant shall be entitled to the benefits of <U>Sections 2.5</U> and
<U>2.6</U> (subject to the requirements and limitations therein, including the requirements under <U>Section&nbsp;2.6(d)</U>&nbsp;(it
being understood that the documentation required under <U>Section&nbsp;2.6(d)</U>&nbsp;shall be delivered to the applicable Lender))
to the same extent as if it were a Person that had acquired its interest by assignment pursuant to <U>clause (b)</U>&nbsp;above; <U>provided</U>
that, with respect to any participation, such participant shall not be entitled to receive any greater payment under <U>Sections 2.5</U>
or <U>2.6</U> than the applicable Lender (i.e., the party that participated the interest) would have been entitled to receive, except
to the extent of any entitlement to receive a greater payment resulting from a Change in Law that occurs after such participant acquired
the applicable participation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
shall record any Lender Transfer in the Note Register. Each Lender shall provide Borrower and the Collateral Agent with written notice
of a Lender Transfer delivered no later than five (5)&nbsp;Business Days (or immediately if known fewer than five (5)&nbsp;Business Days)
prior to the date on which such Lender Transfer is proposed to be consummated. If any Lender sells a participation, such Lender shall,
acting solely for this purpose as a non-fiduciary agent of Borrower, maintain a register on which it enters the name and address of each
participant and principal amounts (and stated interest) of each participant&rsquo;s interest in the Term Loans or other obligations under
the Loan Documents (the &ldquo;<B>Participant Register</B>&rdquo;); <U>provided</U>, <U>however</U>, that such Lender shall have no obligation
to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to
a participant&rsquo;s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the
extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in &ldquo;registered
form&rdquo; within the meaning of Section&nbsp;5f.103-1(c)&nbsp;of the United States Treasury regulations (or any amended or successor
version) or Section&nbsp;163(f), 871(h)(2)&nbsp;and 881(c)(2)&nbsp;of the IRC and any related regulations (and any other relevant or
successor provisions of the IRC or such regulations). The entries in the Participant Register shall be conclusive absent manifest error,
and the Collateral Agent and each Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such
participation for all purposes of this Agreement notwithstanding any notice to the contrary. For avoidance of doubt, no Lender Transfer
shall be made to a Blocked Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
attempted transfer, pledge or assignment of this Agreement or any other Loan Document or any rights or obligations hereunder or thereunder
in violation of this <U>Section&nbsp;11.1</U> shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnification</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
agrees to indemnify and hold harmless each of the Collateral Agent, Lenders and its and their respective Affiliates (and its or their
respective successors and assigns) and each manager, member, partner, controlling Person, director, officer, employee, agent or sub-agent,
advisor and affiliate thereof (each such Person, an &ldquo;<B>Indemnified Person</B>&rdquo;) from and against any and all Indemnified
Liabilities; <U>provided</U>, <U>however</U>, that Borrower shall have no obligation to any Indemnified Person hereunder with respect
to any Indemnified Liabilities to the extent such Indemnified Liabilities (i)&nbsp;are determined by a court of competent jurisdiction
by final and nonappealable judgment to have resulted from the bad faith, gross negligence or willful misconduct of such Indemnified Person
(or the bad faith, gross negligence or willful misconduct of such Indemnified Person&rsquo;s affiliates or controlling Persons or any
of their respective managers, members, partners, controlling Persons, directors, officers, employees, agents or sub-agents, advisors
or affiliates), (ii)&nbsp;result from a claim brought by Borrower against an Indemnified Person for material breach in bad faith of any
of such Indemnified Person&rsquo;s obligations hereunder or under any other Loan Document, if Borrower has obtained a final and nonappealable
judgment in its favor on such claim as determined by a court of competent jurisdiction, or (iii)&nbsp;result from a claim not involving
an act or omission of Borrower or any of its Subsidiaries that is brought by an Indemnified Person against another Indemnified Person
(other than against the Collateral Agent in its capacity as such). This <U>Section&nbsp;11.2(a)</U>&nbsp;shall not apply with respect
to Taxes other than any Taxes that represent liabilities, obligations, losses, damages, penalties, claims, costs, expenses and disbursements
arising from any non-Tax claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the extent permitted by Requirements of Law, no party to this Agreement shall assert, and each party to this Agreement hereby waives,
any claim against any other party hereto (and its or their successors and assigns), and each manager, member, partner, controlling Person,
director, officer, employee, agent or sub-agent, advisor and affiliate thereof, on any theory of liability, for special, indirect, consequential
or punitive damages (as opposed to direct or actual damages) (whether or not the claim therefor is based on contract, tort or duty imposed
by any applicable legal requirement) arising out of, in connection with, arising out of, as a result of, or in any way related to, this
Agreement or any Loan Document or any agreement or instrument contemplated hereby or thereby or referred to herein or therein, the transactions
contemplated hereby or thereby, any Credit Extension or the use of the proceeds thereof or any act or omission or event occurring in
connection therewith, and each party to this Agreement hereby waives, releases and agrees not to sue upon any such claim or any such
damages, whether or not accrued and whether or not known or suspected to exist in its favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
action taken by any Credit Party under or with respect to any Loan Document, even if required under any Loan Document, or at the request
of the Collateral Agent or any Lender, shall be at the expense of such Credit Party, and neither the Collateral Agent nor any Secured
Party shall be required under any Loan Document to reimburse any Credit Party or any Subsidiary of any Credit Party therefor except as
expressly provided therein. In addition, and without limiting the generality of <U>Section&nbsp;2.4</U>, Borrower agrees to pay or reimburse
promptly upon demand each of the Collateral Agent and Lenders (and their respective successors and assigns) and each of their respective
Related Parties, if applicable, for any and all fees, expenses and disbursements of the kind or nature described in <U>clause (b)</U>&nbsp;of
the definition of &ldquo;Lender Expenses&rdquo; or described in the definition of &ldquo;Indemnified Liabilities&rdquo; incurred by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severability
of Provisions</B>. In case any provision in or obligation hereunder or under any other Loan Document shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation
in any other jurisdiction, shall not in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Correction
of Loan Documents</B>. The Collateral Agent or Required Lenders may correct patent errors and fill in any blanks in the Loan Documents
consistent with the agreement of the parties hereto so long as the Collateral Agent or Required Lenders, as applicable, provides the
Credit Parties and the other parties hereto with written notice of such correction and allows the Credit Parties at least ten (10)&nbsp;days
to object to such correction in writing delivered to the Collateral Agent and each Lender. In the event of such objection, such correction
shall not be made except by an amendment to this Agreement in accordance with <U>Section&nbsp;11.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Amendments
in Writing; Integration</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
amendment, restatement, amendment and restatement or other modification of or supplement to any provision of this Agreement or any other
Loan Document, or waiver, discharge or termination of any obligation hereunder or thereunder, no approval or consent hereunder or thereunder
(including any consent to any departure by Borrower or any other Credit Party herefrom or therefrom), shall in any event be effective
unless the same shall be in writing and signed by Borrower (on its own behalf and on behalf of each other Credit Party) and the Required
Lenders; <U>provided</U>, <U>however</U>, that no such amendment, restatement, amendment and restatement, modification, supplement, waiver,
discharge, termination, approval or consent shall, unless in writing and signed by the Collateral Agent and the Required Lenders, affect
the rights or duties of, or any amounts payable to, the Collateral Agent under this Agreement or any other Loan Document. Any such waiver,
approval or consent granted shall be limited to the specific circumstance expressly described in it, and shall not apply to any subsequent
or other circumstance, whether similar or dissimilar, or give rise to, or evidence, any obligation or commitment to grant any further
waiver, approval or consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.
All prior agreements, understandings, representations, warranties, and negotiations among the parties hereto about the subject matter
of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Counterparts</B>.
This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed
and delivered, is an original, and all taken together, constitute one Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Survival;
Termination</B>. All covenants, representations and warranties made in this Agreement continue in full force until this Agreement has
terminated pursuant to this <U>Section&nbsp;11.7</U> and all Obligations (other than contingent indemnification obligations to the extent
no claim giving rise thereto has been asserted and any other obligations which, by their terms, are to survive the termination of this
Agreement) have been paid in full and satisfied in accordance with the terms of this Agreement. The obligation of Borrower or any other
the Credit Parties in <U>Section&nbsp;11.2</U> to indemnify Indemnified Persons shall survive until the statute of limitations with respect
to such claim or cause of action shall have run. So long as all Obligations (other than contingent indemnification obligations to the
extent no claim giving rise thereto has been asserted and any other obligations which, by their terms, are to survive the termination
of this Agreement and for which no claim has been made) have been paid in full and satisfied in accordance with the terms of this Agreement,
this Agreement and the other Loan Documents shall be terminated automatically upon payment in full of all Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Confidentiality</B>.
Any information regarding the Credit Parties and their Subsidiaries and their businesses provided to the Collateral Agent or any Lender
by or on behalf of any Credit Party pursuant to the Loan Documents shall be deemed &ldquo;Confidential Information&rdquo;; provided,
however, that Confidential Information does not include information that is either: (i)&nbsp;in the public domain or in the possession
of the Collateral Agent, any Lender or any of their respective Affiliates or when disclosed to the Collateral Agent, any Lender or any
of their respective Affiliates, or becomes part of the public domain after disclosure to the Collateral Agent, any Lender or any of their
respective Affiliates, in each case, other than as a result of a breach by the Collateral Agent, any Lender or any of their respective
Affiliates of the obligations under this <U>Section&nbsp;11.8</U>; or (ii)&nbsp;disclosed to the Collateral Agent, any Lender or any
of their respective Affiliates by a third-party if the Collateral Agent, such Lender or such Affiliate, as applicable, does not know
(following reasonable inquiry) that the third-party is prohibited from disclosing the information. Neither the Collateral Agent nor any
Lender shall disclose any Confidential Information to a third-party or use Confidential Information for any purpose other than the administration
of the Loan Documents, the exercise of its rights or remedies under the Loan Documents or the performance of its duties or obligations
under the Loan Documents. The foregoing in this <U>Section&nbsp;11.8</U> notwithstanding, the Collateral Agent and each Lender may disclose
Confidential Information: (a)&nbsp;to any of its Subsidiaries or Affiliates; (b)&nbsp;to prospective transferees, purchasers or participants
of any interest in the Term Loans (including, for the avoidance of doubt, in connection with any proposed Lender Transfer), <U>provided</U>,
<U>that</U>, no such disclosure to any Disqualified Assignees shall be permitted hereunder without Borrower&rsquo;s prior written consent
(which consent shall not be required after the occurrence and during the continuance of an Event of Default); (c)&nbsp;as required by
law, regulation, subpoena, or other order, <U>provided</U>, <U>that</U>, (x)&nbsp;prior to any disclosure under this <U>clause (c)</U>,
the Collateral Agent or such Lender, as applicable, agrees to endeavor to provide Borrower with prior written notice thereof, and with
respect to any law, regulation, subpoena or other order, to the extent that the Collateral Agent or such Lender is permitted to provide
such prior notice to Borrower pursuant to the terms hereof, and (y)&nbsp;any disclosure under this <U>clause (c)</U>&nbsp;shall be limited
solely to that portion of the Confidential Information as may be specifically compelled by such law, regulation, subpoena or other order;
(d)&nbsp;as the Collateral Agent or any Lender otherwise deems necessary or prudent under Sanctions, Anti-Money Laundering Laws, the
Anti-Corruption Laws, or Export and Import Laws; (e)&nbsp; to the extent requested by regulators having jurisdiction over the Collateral
Agent or such Lender or as otherwise required in connection with the Collateral Agent&rsquo;s or such Lender&rsquo;s examination or audit
by such regulators (including any self-regulatory authority, such as the National Association of Insurance Commissioners); (f), as the
Collateral Agent or such Lender considers reasonably necessary in exercising any rights or remedies under the Loan Documents or in connection
with any proceeding relating to the Agreement or any other Loan Documents; (g)&nbsp;to any party hereto; (h)&nbsp;to third-party service
providers of the Collateral Agent or such Lender; and (i)&nbsp;to any of the Collateral Agent&rsquo;s or such Lender&rsquo;s Related
Parties; <U>provided</U>, <U>however</U>, that the third parties to which Confidential Information is disclosed pursuant to <U>clauses
(a)</U>, <U>(b)</U>, (<U>h</U>)&nbsp;and <U>(i)</U>&nbsp;above are bound by obligations of confidentiality and non-use that are no less
restrictive than those contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of this <U>Section&nbsp;11.8</U>
shall survive the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Attorneys&rsquo;
Fees, Costs and Expenses</B>. In any action or proceeding between, on the one hand, any Credit Party and, on the other hand, the Collateral
Agent or any Lender, arising out of or relating to the Loan Documents other than in connection with the enforcement against any Credit
Party of this Agreement or any other Loan Document, the prevailing party shall be entitled to recover its reasonable attorneys&rsquo;
fees and other costs and expenses incurred, in addition to any other relief to which it may be entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Right
of Set-Off</B>. In addition to any rights now or hereafter granted under Requirements of Law and not by way of limitation of any such
rights, upon the occurrence of an Event of Default and at any time thereafter during the continuance of any Event of Default, each Lender
is hereby authorized by each Credit Party at any time or from time to time, without prior notice to any Credit Party, any such notice
being hereby expressly waived by Borrower (on its own behalf and on behalf of each other Credit Party), to set off and to appropriate
and to apply any and all deposits (general or special, including Indebtedness evidenced by certificates of deposit, whether matured or
unmatured, but not including trust accounts) and any other Indebtedness at any time held or owing by such Lender to or for the credit
or the account of any Credit Party against and on account of the obligations and liabilities of any Credit Party to such Lender hereunder
and under the other Loan Documents, including all claims of any nature or description arising out of or connected hereto or with any
other Loan Document, irrespective of whether or not (a)&nbsp;the Collateral Agent or such Lender shall have made any demand hereunder
or (b)&nbsp;the principal of or the interest on the Term Loans or any other amounts due hereunder shall have become due and payable pursuant
to <U>Section&nbsp;2</U> and although such obligations and liabilities, or any of them, may be contingent or unmatured. Each Lender agrees
promptly to notify Borrower and the Collateral Agent after any such set off and application made by such Lender; <U>provided</U>, <U>that</U>,
the failure to give such notice shall not affect the validity of such set off and application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Marshalling;
Payments Set Aside</B>. Neither the Collateral Agent nor any Lender shall be under any obligation to marshal any assets in favor of any
Credit Party or any other Person or against or in payment of any or all of the Obligations. To the extent that any Credit Party makes
a payment or payments to any Lender, or the Collateral Agent or any Lender enforces any Liens or exercises its rights of setoff, and
such payment or payments or the proceeds of such enforcement or setoff or any part thereof are subsequently invalidated, declared to
be fraudulent or preferential, set aside or required to be repaid to a trustee, receiver or any other party under any bankruptcy law,
any other state or federal law, common law or any equitable cause, then, to the extent of such recovery, the obligation or part thereof
originally intended to be satisfied, and all Liens, rights and remedies therefor or related thereto, shall be revived and continued in
full force and effect as if such payment or payments had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Electronic
Execution of Documents</B>. The words &ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature,&rdquo; and words of like import
in this Agreement and the other Loan Documents shall be deemed to include electronic signatures or electronic records, each of which
shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping
system, as the case may be, to the extent and as provided for in any Requirements of Law, including the Federal Electronic Signatures
in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based
on the Uniform&nbsp;Electronic Transactions Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Captions</B>.
Section&nbsp;headings herein are included herein for convenience of reference only and shall not constitute a part hereof for any other
purpose or be given any substantive effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Construction
of Agreement</B>. The parties hereto mutually acknowledge that they and their respective attorneys have participated in the preparation
and negotiation of this Agreement. In cases of uncertainty, this Agreement shall be construed without regard to which of the parties
hereto caused the uncertainty to exist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Third
Parties</B>. Nothing in this Agreement, whether express or implied, is intended to: (a)&nbsp;except as expressly provided in <U>Section&nbsp;11.2(a)</U>,
confer any benefits, rights or remedies under or by reason of this Agreement on any Persons other than the express parties to it and
their respective successors and permitted assigns; (b)&nbsp;relieve or discharge the obligation or liability of any Person not an express
party to this Agreement; or (c)&nbsp;give any Person not an express party to this Agreement any right of subrogation or action against
any party to this Agreement. Unless expressly provided to the contrary in this Agreement, a Person who is not a party to this Agreement
has no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce or enjoy the benefit of any term of this Agreement. Notwithstanding
any term of any Loan Document, the consent of any Person who is not a party to this Agreement is not required to rescind or vary this
Agreement at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Advisory or Fiduciary Duty</B>. The Collateral Agent and each Lender may have economic interests that conflict with those of the Credit
Parties. Each Credit Party agrees that nothing in the Loan Documents or otherwise will be deemed to create an advisory, fiduciary or
agency relationship or fiduciary or other implied duty between any Lender or the Collateral Agent, on the one hand, and such Credit Party,
its Subsidiaries, and any of their respective stockholders or affiliates, on the other hand. Each Credit Party acknowledges and agrees
that (i)&nbsp;the transactions contemplated by the Loan Documents are arm&rsquo;s-length commercial transactions between each Lender
and the Collateral Agent, on the one hand, and such Credit Party, its Subsidiaries and their respective affiliates, on the other hand,
(ii)&nbsp;in connection therewith and with the process leading to such transaction, the Collateral Agent and each Lender is acting solely
as a principal and not the advisor, agent or fiduciary of such Credit Party, its Subsidiaries or their respective affiliates, management,
stockholders, creditors or any other Person, (iii)&nbsp;neither the Collateral Agent nor any Lender has assumed an advisory or fiduciary
responsibility in favor of any Credit Party, its Subsidiaries or their respective affiliates with respect to the transactions contemplated
hereby or the process leading thereto (irrespective of whether the Collateral Agent or any Lender or any of their respective affiliates
has advised or is currently advising such Credit Party, its Subsidiaries or their respective affiliates on other matters) or any other
obligation to such Credit Party, its Subsidiaries or their respective affiliates except the obligations expressly set forth in the Loan
Documents, and (iv)&nbsp;each Credit Party, its Subsidiaries and their respective affiliates have consulted their own legal and financial
advisors to the extent each deemed appropriate. Each Credit Party further acknowledges and agrees that it is responsible for making its
own independent judgment with respect to such transactions and the process leading thereto. Each Credit Party agrees that it will not
claim that the Collateral Agent or any Lender has rendered advisory services of any nature or respect or owes a fiduciary or similar
duty to such Credit Party, its Subsidiaries or their respective affiliates in connection with such transaction or the process leading
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Credit
Parties&rsquo; Agent</B>. Each of the Credit Parties hereby irrevocably appoints Borrower, as its agent, attorney-in-fact and legal representative
for all purposes, including requesting disbursement of the Term Loans and receiving account statements and other notices and communications
to Credit Parties (or any of them) from the Collateral Agent or the Lenders, executing amendments, waivers or other modifications of
or supplements to Loan Documents and executing or designating new Loan Documents. The Collateral Agent or the Lenders may rely, and shall
be fully protected in relying, on any request for the Term Loans, disbursement instruction, report, information or any other notice or
communication made or given by Borrower and any amendment, restatement, amendment and restatement, waiver or other modification of or
supplement to a Loan Document or the execution or designation of new Loan Documents executed or made by Borrower, whether in its own
name or on behalf of one or more of the other Credit Parties, and the Collateral Agent or the Lenders shall not have any obligation to
make any inquiry or request any confirmation from or on behalf of any other Credit Party as to the binding effect on it of any such request,
instruction, report, information, other notice, communication, amendment, restatement, amendment and restatement, supplement, waiver,
other modification, execution or designation, nor shall the joint and several character of the Credit Parties&rsquo; obligations hereunder
be affected thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>COLLATERAL
AGENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Appointment
and Authority</B>. Each of the Lenders hereby irrevocably appoints BioPharma Credit PLC to act on its behalf as the Collateral Agent
hereunder and under the other Loan Documents and authorizes the Collateral Agent to take such actions on its behalf and to exercise such
powers as are delegated to the Collateral Agent by the terms hereof or thereof, together with such actions and powers as are reasonably
incidental thereto. Except for the first two (2)&nbsp;sentences of <U>Section&nbsp;12.6</U> and <U>Section&nbsp;12.8</U>, the provisions
of this <U>Section&nbsp;12</U> are solely for the benefit of the Collateral Agent and Lenders, and neither Borrower nor any other Credit
Party shall have rights as a third-party beneficiary of any of such provisions. Subject to <U>Section&nbsp;12.8</U> and <U>Section&nbsp;11.5</U>,
any action required or permitted to be taken by the Collateral Agent hereunder shall be taken with the prior approval of the Required
Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Rights
as a Lender</B>. The Person serving as the Collateral Agent hereunder shall have the same rights and powers in its capacity as a Lender
as any other Lender and may exercise the same as though it were not the Collateral Agent and the term &ldquo;Lender&rdquo; or &ldquo;Lenders&rdquo;
shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Collateral Agent
hereunder in its individual capacity. Such Person and its Affiliates may lend money to, own securities of, act as the financial advisor
or in any other advisory capacity for and generally engage in any kind of business with Borrower or any Subsidiary or other Affiliate
thereof as if such Person were not the Collateral Agent hereunder and without any duty to account therefor to any Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Exculpatory
Provisions</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Collateral Agent shall not have any duties or obligations to the Lenders except those expressly set forth herein and in the other Loan
Documents to which it is a party. Without limiting the generality of the foregoing, with respect to the Lenders, the Collateral Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>shall
not be subject to any fiduciary or other implied duties, regardless of whether a Default or Event of Default has occurred and is continuing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>shall
not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly
contemplated hereby or by the other Loan Documents to which it is a party that the Collateral Agent is required to exercise as directed
in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in
such other Loan Documents), <U>provided</U> that the Collateral Agent shall not be required to take any action that, in its opinion or
the opinion of its counsel, may expose the Collateral Agent to liability or that is contrary to any Loan Document or Requirements of
Law; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>shall
not, except as expressly set forth herein and in the other Loan Documents to which it is a party, have any duty to disclose, and shall
not be liable for the failure to disclose, any information relating to any Credit Party or any of its Affiliates that is communicated
to or obtained by the Person serving as the Collateral Agent or any of its Affiliates in any capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Collateral Agent shall not be liable for any action taken or not taken by it (i)&#8239;with the consent or at the request of the Required
Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Collateral Agent shall believe in good faith
shall be necessary, under the circumstances as provided in <U>Section&#8239;11.5</U>) or (ii)&#8239;in the absence of its own gross negligence
or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Collateral Agent shall
be deemed not to have knowledge of any Default or Event of Default unless and until notice describing such Default or Event of Default
is given to the Collateral Agent in writing by Borrower or a Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Collateral Agent shall not be responsible for or have any duty to ascertain or inquire into (i)&#8239;any statement, warranty or representation
made in or in connection with this Agreement or any other Loan Document, (ii)&#8239;the contents of any certificate, report or other document
delivered hereunder or thereunder or in connection herewith or therewith, (iii)&#8239;the performance or observance of any of the covenants,
agreements or other terms or conditions set forth herein or therein or the occurrence of any Default or Event of Default, (iv)&#8239;the
validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument
or document or (v)&#8239;the satisfaction of any condition set forth in <U>Section&#8239;3</U> or elsewhere herein, other than to confirm
receipt of items expressly required to be delivered to the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Reliance
by Collateral Agent</B>. The Collateral Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any
notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, internet or
intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated
by the proper Person. The Collateral Agent also may rely upon any statement made to it orally or by telephone and believed by it to have
been made by the proper Person and shall not incur any liability for relying thereon. The Collateral Agent may consult with legal counsel
(who may be counsel for Borrower), independent accountants, manufacturing consultants and other experts selected by it, and shall not
be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants, consultants or experts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Delegation
of Duties</B>. The Collateral Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other
Loan Document by or through any one or more sub-agents appointed by the Collateral Agent. The Collateral Agent and any such sub-agent
may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory
provisions of this <U>Section&#8239;12</U> shall apply to any such sub-agent and to the Related Parties of the Collateral Agent and any
such sub-agent. The Collateral Agent shall not be responsible for the negligence or misconduct of any sub-agent except to the extent
that a court of competent jurisdiction determines in a final and nonappealable judgment that the Collateral Agent acted with gross negligence
or willful misconduct in the selection of such sub-agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Resignation
of Collateral Agent</B>. The Collateral Agent may at any time give notice of its resignation to the Lenders and Borrower. Upon the receipt
of any such notice of resignation, the Required Lenders shall have the right, in consultation with Borrower so long as no Default or
Event of Default has occurred and is continuing, to appoint a successor (which shall not be a Disqualified Assignee except after the
occurrence and during the continuation of an Event of Default). If no successor shall have been so appointed by the Required Lenders
and shall have accepted such appointment within thirty (30) days after the retiring Collateral Agent gives notice of its resignation,
then the retiring Collateral Agent may, on behalf of the Lenders, appoint a successor Collateral Agent that is a Related Party of the
Collateral Agent or any Lender; <U>provided</U> that, whether or not a successor has been appointed or has accepted such appointment,
such resignation shall become effective upon delivery of the notice thereof. Upon the acceptance of a successor&rsquo;s appointment as
Collateral Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of
the retiring (or retired) Collateral Agent, and the retiring Collateral Agent shall be discharged from all of its duties and obligations
under the Loan Documents (if not already discharged therefrom as provided above in this <U>Section&#8239;12.6</U>). After the retiring
Collateral Agent&rsquo;s resignation, the provisions of <U>Section&#8239;12</U> and <U>Section&#8239;10</U> shall continue in effect for
the benefit of such retiring Collateral Agent, its sub-agents and their respective Related Parties in respect of any actions taken or
omitted to be taken by any of them while the retiring Collateral Agent was acting as Collateral Agent. Upon any resignation by the Collateral
Agent, all payments, communications and determinations provided to be made by, to or through the Collateral Agent shall instead be made
by, to or through each Lender directly, until such time as a Person accepts an appointment as Collateral Agent in accordance with this
<U>Section&#8239;12.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Options: NewSection; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Non-Reliance
on Collateral Agent and Other Lenders</B>. Each Lender acknowledges that it has, independently and without reliance upon the Collateral
Agent or any other Lender or any of their respective Related Parties and based on such documents and information as it has deemed appropriate,
made its own credit analysis and decision to enter into this Agreement and make Credit Extensions hereunder. Each Lender also acknowledges
that it will, independently and without reliance upon the Collateral Agent or any other Lender or any of their respective Related Parties
and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking
or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder
or thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Collateral
and Guaranty Matters</B>. Each Lender agrees that any action taken by the Collateral Agent or the Required Lenders in accordance with
the provisions of this Agreement or of the other Loan Documents, and the exercise by the Collateral Agent or Required Lenders of the
powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding
upon all of the Lenders. Without limiting the generality of the foregoing, the Lenders irrevocably authorize and instruct the Collateral
Agent, and the Collateral Agent agrees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
release any Lien on any property granted to or held by the Collateral Agent under any Collateral Document (i)&#8239;upon payment and satisfaction
in full of the Obligations (other than inchoate indemnity obligations), (ii)&#8239;that is sold, transferred, disposed or to be sold,
transferred, disposed as part of or in connection with any sale, transfer or other disposition (other than any sale to a Credit Party)
permitted hereunder, (iii)&#8239;subject to <U>Section&#8239;11.5</U>, if approved, authorized or ratified in writing by the Required Lenders,
or (iv)&#8239;to the extent such property is owned by a Guarantor upon the release of such Guarantor from its obligations under the Loan
Documents pursuant to <U>clause (c)</U>&#8239;below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
subordinate any Lien on any property granted to or held by the Collateral Agent under any Loan Document to the holder of any Lien on
such property that is permitted by <U>clauses (d)</U>, <U>(i)</U>, <U>(j), (m)</U>, <U>(n)</U>&#8239;and <U>(r)</U>&#8239;of the definition
of &ldquo;Permitted Liens&rdquo; (solely with respect to modifications, replacements, extensions or renewals of Liens permitted under
<U>clauses (d)</U>, <U>(i)</U>, <U>(j), (m)</U>&#8239;and <U>(n)</U>&#8239;of the definition of &ldquo;Permitted Liens&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
release any Guarantor from its obligations under the Security Agreement (and other applicable Collateral Documents) if such Person ceases
to be a Subsidiary (or becomes an Excluded Subsidiary (to the extent not designated by Borrower to be a Designated Guarantor)) as a result
of a transaction permitted hereunder or upon payment and satisfaction in full of the Obligations (other than inchoate indemnity obligations);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
enter into non-disturbance and similar agreements in connection with the licensing of Intellectual Property permitted pursuant to the
terms of this Agreement, including any agreement that makes the Lien of the Collateral Agent expressly subject to all rights of any such
licensee under any such license; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
enter into a subordination, intercreditor, or other similar agreement with respect to any Indebtedness that constitutes Subordinated
Debt that in each case is permitted under the definition of Permitted Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon request by the Collateral Agent at any time
the Required Lenders will confirm in writing the Collateral Agent&rsquo;s authority to release or subordinate its interest in particular
types or items of property, or to release any Guarantor from its obligations under the Security Agreement (and other applicable Collateral
Documents) pursuant to this <U>Section&#8239;12.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In each case as
specified in this <U>Section&#8239;12.8</U>, the Collateral Agent will (and each Lender irrevocably authorizes and instructs the Collateral
Agent to), at Borrower&rsquo;s expense, </FONT>(A)&#8239;deliver to Borrower any Collateral that is in the Collateral Agent&rsquo;s possession
(if any) in connection with the release of the Collateral Agent&rsquo;s Lien thereon, and (B)&#8239;execute and deliver to the applicable
Credit Party such documents as such Credit Party may reasonably request (i)&#8239;to evidence the release or subordination of such item
of Collateral from the Liens and security interests granted under the Collateral Documents, (ii)&#8239;to enter into non-disturbance or
similar agreements in connection with the licensing of Intellectual Property, including any agreement that makes the Lien of the Collateral
Agent expressly subject to all rights of any such licensee under any such license, (iii)&#8239;to enter into a subordination, intercreditor,
or other similar agreement with respect to any Indebtedness that constitutes Subordinated Debt to the extent such Subordinated Debt is
permitted under the definition of Permitted Indebtedness or (iv)&#8239;to evidence the release of any Guarantor from its obligations under
the Security Agreement (and other applicable Collateral Documents), in each case in accordance with the terms of the Loan Documents and
this <U>Section&#8239;12.8</U> and in form and substance reasonably acceptable to the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without limiting the generality of <U>Section&#8239;12.10</U>
below, the Collateral Agent shall deliver to the Lenders notice of any action taken by it under this <U>Section&#8239;12.8</U> promptly
after the taking thereof; <U>provided, that</U>, delivery of or failure to deliver any such notice shall not affect the Collateral Agent&rsquo;s
rights, powers, privileges and protections under this <U>Section&#8239;12</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Reimbursement
by Lenders</B></FONT>. To the extent that Borrower for any reason fails to indefeasibly pay any amount required under <U>Section&#8239;2.4</U>
to be paid by it to the Collateral Agent (or any sub-agent thereof) or any Related Party of any of the foregoing, each Lender severally
agrees to pay to the Collateral Agent (or any such sub-agent) or such Related Party, as the case may be, such Lender&rsquo;s <I>pro rata</I>
share (based upon the percentages as used in determining the Required Lenders as of the time that the applicable unreimbursed expense
or indemnity payment is sought) of such unpaid amount; <U>provided</U> that the unreimbursed expense or indemnified loss, damage, liability
or related expense, as the case may be, was incurred by or asserted against the Collateral Agent (or any such sub-agent) in its capacity
as such or against any Related Party of any of the foregoing acting for the Collateral Agent (or any sub-agent) in connection with such
capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notices
and Items to Lenders</B>. The Collateral Agent shall deliver to the Lenders each notice, report, statement, approval, direction, consent,
exemption, authorization, waiver, certificate, filing or other item received by it pursuant to this Agreement or any other Loan Document
(including any item received by it pursuant to <U>Section&#8239;3</U> or set forth on <U>Schedule 5.14</U> of the Disclosure Letter);
<U>provided</U>, <U>that</U>, any delivery of or failure to deliver any such notice, report, statement, approval, direction, consent,
exemption, authorization, waiver, certificate, filing or item shall not otherwise alter or effect the rights of the Lenders or the Collateral
Agent under this Agreement or any other Loan Document or the validity of such item. In addition, to the extent the Collateral Agent or
the Required Lenders deliver any notices, approvals, authorizations, directions, consents or waivers to Borrower pursuant to this Agreement
or any other Loan Document, the Collateral Agent or the Required Lenders, as applicable, will also deliver such notice, approval, authorization,
direction, consent or waiver to the other Lenders on or about the same time such notice, approval, authorization, direction, consent
or waiver is provided to Borrower; <U>provided</U>, <U>that</U>, the delivery of or failure to deliver such notice, approval, authorization,
direction, consent or waiver to the other Lenders shall not in any way effect the obligations of Borrower, or the rights of the Collateral
Agent or the Required Lenders, in respect of such notice, approval, authorization, direction, consent or waiver or the validity thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #010000"><B>13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><U>DEFINITIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Definitions</B>.
For the purposes of and as used in the Loan Documents: (a)&#8239;references to any Person include its successors and assigns and, in the
case of any Governmental Authority, any Person succeeding to its functions and capacities; (b)&#8239;except as the context otherwise requires
(including to the extent otherwise expressly provided in any Loan Document), (i)&#8239;references to any law, statute, treaty, order,
policy, rule&#8239;or regulation include any amendments, supplements and successors thereto and (ii)&#8239;references to any contract,
agreement, consent, waiver, instrument or other document include any amendments, restatements, amendments and restatements, supplements
or other modifications thereto or thereof from time to time to the extent permitted by the provisions thereof and to the extent permitted
by or otherwise not in contravention of this Agreement or any other Loan Documents; (c)&#8239;the words &ldquo;shall&rdquo; and &ldquo;will&rdquo;
are interchangeable and will be understood to be imperative or mandatory in nature; (d)&#8239;the word &ldquo;may&rdquo; is permissive;
(e)&#8239;the word &ldquo;or&rdquo; has the inclusive meaning represented by the phrase &ldquo;and/or&rdquo;; (f)&#8239;the words &ldquo;include&rdquo;,
 &ldquo;includes&rdquo; and &ldquo;including&rdquo; are not limiting; (g)&#8239;the singular includes the plural and the plural includes
the singular; (h)&#8239;numbers denoting amounts that are set off in parentheses are negative unless the context dictates otherwise; (i)&#8239;each
authorization herein shall be deemed irrevocable and coupled with an interest; (j)&#8239;all accounting terms shall be interpreted, and
all determinations relating thereto shall be made, in accordance with GAAP; (k)&#8239;references to any time of day shall be to New York
time; (l)&#8239;the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo;, &ldquo;hereby&rdquo;, &ldquo;hereto&rdquo; and &ldquo;hereunder&rdquo;
refer to this Agreement as a whole; and (m)&#8239;unless otherwise expressly provided, references to specific sections, articles, clauses,
sub-clauses, annexes and exhibits are to this Agreement and references to specific schedules are to the Disclosure Letter. The provisions
of this <U>Section&#8239;13.1</U> shall survive the termination of this Agreement. As used in this Agreement, the following capitalized
terms have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Account</B>&rdquo;
means any &ldquo;account&rdquo; as defined in the Code with such additions to such term as may hereafter be made, and includes all accounts
receivable, book debts, and other sums owing to Credit Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Account Debtor</B>&rdquo;
means any &ldquo;account debtor&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Acquisition</B>&rdquo;
means (a)&#8239;any Stock Acquisition, or (b)&#8239;any Asset Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Additional
Consideration</B>&rdquo; means, individually or collectively, as the context dictates, t</FONT>he Tranche A Additional Consideration
and the Tranche B Additional Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Advance Request
Form</B>&rdquo; means a Loan Advance Request Form&#8239;in substantially the form attached hereto as <U>Exhibit&#8239;A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Adverse Proceeding</B>&rdquo;
means any action, suit, proceeding, hearing (whether administrative, judicial or otherwise), governmental investigation or arbitration
(whether or not purportedly on behalf of any Credit Party or any of its Subsidiaries) at law or in equity, or before or by any Governmental
Authority, domestic or foreign (including any Environmental Claims), whether pending or, to the Knowledge of such Credit Party, threatened
against or adversely affecting any Credit Party or any of its Subsidiaries or any property of Borrower or any of its Subsidiaries. For
the avoidance of doubt, an action, suit, proceeding, hearing, or arbitration that follows or precedes an investigation shall be treated
as a new and separate Adverse Proceeding from the investigation, whether or not such action, suit, proceeding, hearing, or arbitration
is brought by any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any Person, each other Person that owns or controls, directly or indirectly, such Person, any other Person that
controls or is controlled by or is under common control with such Person, and each of that Person&rsquo;s senior executive officers,
directors, partners and, for any Person that is a limited liability company or limited liability partnership, that Person&rsquo;s managers
and members. As used in this definition, &ldquo;control&rdquo; means (a)&#8239;direct or indirect beneficial ownership of at least fifty
percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction)
of the voting share capital or other equity interest in a Person or (b)&#8239;the power to direct or cause the direction of the management
of such Person by contract or otherwise. In no event shall the Collateral Agent or any Lender be deemed to be an Affiliate of Borrower
or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Anti-Corruption
Laws</B>&rdquo; is defined in Section&#8239;<U>4.18(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Anti-Money Laundering
Laws</B>&rdquo; is defined in <U>Section&#8239;4.18(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Applicable Margin</B>&rdquo;
means, for any day, as to any Term Loan, a rate <I>per annum</I> equal to six and one-half percent (6.50%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Applicable Percentage</B>&rdquo;
means at any time: (a)&#8239;with respect to the Tranche A Loan or the Tranche A Loan Amount, the percentage equal to a fraction, the
numerator of which is (i)&#8239;on or prior to the Tranche A Closing Date, the amount of such Lender&rsquo;s Tranche A Commitment at such
time and the denominator of which is the Tranche A Loan Amount at such time or (ii)&#8239;thereafter, the outstanding principal amount
of such Lender&rsquo;s portion of the Tranche A Loan at such time, and the denominator of which is the aggregate outstanding principal
amount of the Tranche A Loan at such time; (b)&#8239;with respect to the Tranche B Loan or the Tranche B Loan Amount, the percentage equal
to a fraction, the numerator of which is (i)&#8239;on or prior to the Tranche B Closing Date, the amount of such Lender&rsquo;s Tranche
B Commitment at such time and the denominator of which is the Tranche B Loan Amount at such time or (ii)&#8239;thereafter, the outstanding
principal amount of such Lender&rsquo;s portion of the Tranche B Loan at such time, and the denominator of which is the aggregate outstanding
principal amount of the Tranche B Loan at such time; and (c)&#8239;with respect to the Term Loans and the Term Loan Commitments, the percentage
equal to a fraction, the numerator of which is, the sum of the amount of such Lender&rsquo;s outstanding Term Loan Commitments and the
amount of such Lender&rsquo;s portion of the outstanding principal amount of the Term Loans at such time, and the denominator of which
is the sum of the amount of all outstanding Term Loan Commitments and the aggregate outstanding principal amount of the Term Loans at
such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ASC</B>&rdquo;
is defined in <U>Section&#8239;1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Asset Acquisition</B>&rdquo;
means, with respect to Borrower or any of its Subsidiaries, any purchase, in-license or other acquisition of properties or assets (other
than properties or assets from third parties used in the ordinary course of business, including inventory, raw materials, vehicles, equipment,
office supplies, software and other similar assets) of any other Person (including any purchase or other acquisition of any entire business
unit, line of business or division of such Person). For the avoidance of doubt, &ldquo;Asset Acquisition&rdquo; includes any co-promotion
or co-marketing arrangement pursuant to which Borrower or any Subsidiary acquires rights to promote or market the products of another
Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;</FONT><B>Available
Tenor</B>&rdquo; means, as of any date of determination and with respect to the then-current Benchmark, as applicable, (a)&#8239;if the
then-current Benchmark is a term rate, any tenor for such Benchmark or that is or may be used for determining the length of an Interest
Period or (b)&#8239;otherwise, any payment period for interest calculated with reference to such Benchmark, as applicable, pursuant to
this Agreement as of such date. means, as of any date of determination and with respect to the then-current Benchmark, as applicable,
(a)&#8239;if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining
the length of an interest period pursuant to this Agreement or (b)&#8239;otherwise, any payment period for interest calculated with reference
to such Benchmark (or component thereof) that is or may be used for determining any frequency of making payments of interest calculated
with reference to such Benchmark pursuant to this Agreement, in each case, as of such date and not including, for the avoidance of doubt,
any tenor for such Benchmark that is then-removed from the definition of &ldquo;Interest Period&rdquo; pursuant to <U>Section&#8239;2.3(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Bankruptcy Code</B>&rdquo;
means Title 11 of the United States Code entitled &ldquo;Bankruptcy,&rdquo; as now and hereafter in effect, or any successor statute
(and any foreign equivalent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benchmark</B>&rdquo;
means, initially, the Term SOFR Reference Rate; <U>provided</U> that if a Benchmark Transition Event has occurred with respect to the
Term SOFR Reference Rate or the then-current Benchmark, then &ldquo;Benchmark&rdquo; means the applicable Benchmark Replacement to the
extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to <U>Section&#8239;2.3(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benchmark Replacement</B>&rdquo;
means, with respect to any Benchmark Transition Event, the first alternative set forth in the order below that can be determined by the
Collateral Agent for the applicable Benchmark Replacement Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Daily
Simple SOFR; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
sum of: (i)&#8239;the alternate benchmark rate that has been selected by the Collateral Agent and Borrower giving due consideration to
(A)&#8239;any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant
Governmental Body or (B)&#8239;any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to
the then-current Benchmark for Dollar-denominated syndicated credit facilities and (ii)&#8239;the related Benchmark Replacement Adjustment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>provided</U></FONT>
that, if the Benchmark Replacement as determined pursuant to <U>clause (a)</U>&#8239;or <U>(b)</U>&#8239;above would be less than the Floor,
the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benchmark Replacement
Adjustment</B>&rdquo; means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement (other
than Daily Simple SOFR), the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive
or negative value or zero) that has been selected by the Collateral Agent and Borrower giving due consideration to (a)&#8239;any selection
or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such
Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b)&#8239;any evolving or then-prevailing
market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement
of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benchmark Replacement
Date</B>&rdquo; means a date and time determined by the Collateral Agent in its reasonable discretion, which date shall be no later than
the earliest to occur of the following events with respect to the then-current Benchmark:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
the case of <U>clause (a)</U>&#8239;or <U>(b)</U>&#8239;of the definition of &ldquo;Benchmark Transition Event,&rdquo; the later of (i)&#8239;the
date of the public statement or publication of information referenced therein and (ii)&#8239;the date on which the administrator of such
Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors
of such Benchmark (or such component thereof); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
the case of <U>clause (c)</U>&#8239;of the definition of &ldquo;Benchmark Transition Event,&rdquo; the first date on which such Benchmark
(or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator
of such Benchmark (or such component thereof) to be non-representative; <U>provided</U> that such non-representativeness will be determined
by reference to the most recent statement or publication referenced in such clause (c)&#8239;and even if any Available Tenor of such Benchmark
(or such component thereof) continues to be provided on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
the &ldquo;Benchmark Replacement Date&rdquo; will be deemed to have occurred in the case of <U>clause (a)</U>&#8239;or <U>(b)</U>&#8239;above
with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current
Available Tenors of such Benchmark (or the published component used in the calculation thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benchmark Transition
Event</B>&rdquo; means the occurrence of one or more of the following events with respect to the then-current Benchmark:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used
in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark
(or such component thereof), permanently or indefinitely; <U>provided</U>, <U>that</U>, at the time of such statement or publication,
there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published
component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with
jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator
for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator
for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will
cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; <U>provided</U>, <U>that</U>,
at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of
such Benchmark (or such component thereof); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published
component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not,
or as of a specified future date will not be, representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
a &ldquo;Benchmark Transition Event&rdquo; will be deemed to have occurred with respect to any Benchmark if a public statement or publication
of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component
used in the calculation thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benchmark Unavailability
Period</B>&rdquo; means, the period (if any) (a)&#8239;beginning at the time that a Benchmark Replacement Date has occurred if, at such
time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance
with <U>Section&#8239;2.3(f)</U>&#8239;and (b)&#8239;ending at the time that a Benchmark Replacement has replaced the then-current Benchmark
for all purposes hereunder and under any Loan Document in accordance with <U>Section&#8239;2.3(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;</FONT><B>BLA</B>&rdquo;
means a Biologics License Application, including both an original BLA and 351(k)&#8239;BLA under the Biologics Price Competition and Innovation
Act (&ldquo;<B>BPCIA</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Blocked
Person</B>&rdquo; </FONT>means an individual or entity that is, or is 50% or more owned or controlled by individuals or entities that
are: (i)&#8239;identified on the list of Specially Designated Nationals and Blocked Persons maintained by OFAC, the Consolidated List
of Financial Sanctions Targets in the UK maintained by His Majesty&rsquo;s Treasury, the Consolidated List of Persons, Groups, and Entities
Subject to EU Financial Sanctions, or any other Person listed on any Sanctions-related list administered or maintained by the United
States, the United Kingdom, the European Union or any other Sanctions authority; (ii)&#8239;the subject or target of blocking or asset-freezing
Sanctions; or (iii)&#8239;located, organized or resident in a Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Board of Directors</B>&rdquo;
means, with respect to any Person, (i)&#8239;in the case of any corporation, the board of directors of such Person, (ii)&#8239;in the case
of any limited liability company, the board of managers of such Person, or if there is none, the Board of Directors of the managing member
of such Person, (iii)&#8239;in the case of any partnership, the Board of Directors of the general partner of such Person and (iv)&#8239;in
any other case, the functional equivalent of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Board of Governors</B>&rdquo;
means the Board of Governors of the United States Federal Reserve System, or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Books</B>&rdquo;
means all books and records including ledgers, records regarding a Credit Party&rsquo;s assets or liabilities, the Collateral, business
operations or financial condition, and all computer programs or storage or any equipment containing such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Borrower</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Borrowing Resolutions</B>&rdquo;
means, with respect to any Person, those resolutions adopted by such Person&rsquo;s Board of Directors or other competent corporate body,
as required pursuant to Requirements of Law and delivered by such Person to the Collateral Agent pursuant to <U>Section&#8239;3.1</U>
approving the Loan Documents to which such Person is a party and the transactions contemplated thereby (including the Term Loan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means any day that is not a Saturday or a Sunday or a day on which banks are authorized or required to be closed in New York, New York
or London, England.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Capital Lease</B>&rdquo;
means, as applied to any Person, any lease of, or other arrangement conveying the right to use, any property by that Person as lessee
which, in accordance with GAAP, is required to be accounted for as a finance lease (and not an operating lease) on a balance sheet of
that Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Capital Lease Obligations</B>&rdquo;
means, at any time, with respect to any Capital Lease, any lease entered into as part of any sale leaseback transaction of any Person
or any synthetic lease, the amount of all obligations of such Person that is (or that would be, if such synthetic lease or other lease
were accounted for as a Capital Lease) capitalized on a balance sheet of such Person prepared in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Cash Equivalents</B>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>securities
issued or directly and fully guaranteed or insured by the United States government or any agency or instrumentality of the United States
government or by the government of any other member country of the Organisation for Economic Co-operation and Development <FONT STYLE="font-size: 10pt">(</FONT>&ldquo;<B>OECD</B>&rdquo;)
(provided that the full faith and credit of the United States or such other member country of OECD, as applicable, is pledged in support
of those securities) or any agency or instrumentality of the OECD, in each case, having maturities of not more than two (2)&#8239;years
from the date of acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>certificates
of deposit, time deposits with maturities of one year or less from the date of acquisition, bankers&rsquo; acceptances with maturities
not exceeding one year and overnight bank deposits and demand deposits, in each case, with any commercial bank having (i)&#8239;capital
and surplus in excess of $500,000,000 in the case of U.S. banks or (ii)&#8239;capital and surplus in excess of $100,000,000 (or the U.S.
dollar equivalent as of the date of determination) in the case of non-U.S. banks or a rating for its long-term unsecured and noncredit
enhanced debt obligations of &ldquo;A&rdquo; or higher by Standard&#8239;&amp; Poor&rsquo;s Rating Services or Fitch Ratings Ltd or &ldquo;A2&rdquo;
or higher by Moody&rsquo;s Investors Service Limited;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>commercial
paper or marketable short-term money market or readily marketable direct obligations and similar securities having a credit rating of
either A-1 or higher by Standard&#8239;&amp; Poor&rsquo;s Rating Service or F1 or higher by Fitch Ratings Ltd or P-1 or higher Moody&rsquo;s
Investors Service Limited, and, in each case, maturing within two (2)&#8239;years after the date of acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>repurchase
obligations with a term of not more than seven (7)&#8239;days for underlying securities of the types described in <U>clauses (a)</U>&#8239;and
<U>(c)</U>&#8239;above entered into with any financial institution meeting the qualifications specified in <U>clause (b)</U>&#8239;above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>investment
funds investing ninety-five percent (95.0%) of their assets in securities of the types described in <U>clauses (a)</U>&#8239;through <U>(d)</U>&#8239;above
and <U>clause (f)</U>&#8239;below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>investments
in money market funds which have a credit rating of either A-1 or higher by Standard&#8239;&amp; Poor&rsquo;s Rating Service or F1 or
higher by Fitch Ratings Ltd or P-1 or higher by Moody&rsquo;s Investors Service Limited (or, if at any time none of Fitch Ratings Ltd,
Moody&rsquo;s Investors Service Limited or Standard&#8239;&amp; Poor&rsquo;s Rating Service shall be rating such obligations, an equivalent
rating from another rating agency) and that have portfolio assets of at least $1,000,000,000; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
investments in accordance with Borrower&rsquo;s investment policy as of the Effective Date or otherwise approved in writing by the Collateral
Agent (such approval not to be unreasonably withheld, conditioned or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Change in Control</B>&rdquo;
means: (a)&#8239;a transaction or series of transactions (including any merger or consolidation involving Borrower) whereby any &ldquo;person&rdquo;
or &ldquo;group&rdquo; (within the meaning of <U>Section&#8239;13(d)</U>&#8239;or <U>14(d)</U>&#8239;of the Exchange Act, but excluding
any employee benefit plan of such Person or its Subsidiaries, and any Person acting in its capacity as trustee, agent or other fiduciary
or administrator of any such plan), other than one or more Permitted Holders (i)&#8239;is or becomes the &ldquo;beneficial owner&rdquo;
(as defined in Rule&#8239;13d-3 under the Exchange Act), directly or indirectly, of more than fifty percent (50.0%) of the voting power
of outstanding Equity Interests of Borrower ordinarily entitled to vote in the election of directors (or compatible voting Equity Interests),
or (ii)&#8239;obtains the power (whether or not exercised) to elect a majority of directors of Borrower; (b)&#8239;a sale, directly or
indirectly, of all or substantially all of the consolidated assets of Borrower and its Subsidiaries in one transaction or a series of
transactions (whether by way of merger, stock purchase, asset purchase or otherwise); or (c)&#8239;a merger or consolidation involving
Borrower in which Borrower is not the surviving Person or in which Persons holding more than fifty percent (50.0%) of the power to elect
a majority of directors of Borrower immediately prior to such merger or consolidation do not continue to hold at least fifty percent
(50.0%) of such power immediately after such merger or consolidation, unless the Permitted Holders will hold at least fifty percent (50.0%)
of such power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Change in Control
Notice</B>&rdquo; is defined in <U>Section&#8239;2.2(c)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Change in Law</B>&rdquo;
means the occurrence, after the date of this Agreement, of any of the following: (a)&#8239;the adoption or taking into effect of any law,
treaty, order, policy, rule&#8239;or regulation, (b)&#8239;any change in any law, treaty, order, policy, rule&#8239;or regulation or in
the administration, interpretation or application thereof by any Governmental Authority or (c)&#8239;the making or issuance of any request,
guideline or directive (whether or not having the force of law) by any Governmental Authority; <U>provided</U> that notwithstanding anything
herein to the contrary, (x)&#8239;the regulations promulgated under the Dodd-Frank Wall Street Reform and Consumer Protection Act and
all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y)&#8239;all requests, rules, guidelines
or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or
similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall be deemed to be
a &ldquo;Change in Law&rdquo;, regardless of the date enacted, adopted or issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Date</B>&rdquo;
means the Tranche A Closing Date or the Tranche B Closing Date, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo;
means the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; <U>provided</U>,
<U>that</U>, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently
in different Articles of the Code, the definition of such term contained in Article&#8239;9 of the Code shall govern; provided, further,
that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies
with respect to, the Collateral Agent&rsquo;s Lien, for the benefit of Lenders and the other Secured Parties, on any Collateral is governed
by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term &ldquo;Code&rdquo; shall mean the
Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to
such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral</B>&rdquo;
means, collectively, &ldquo;Collateral&rdquo;, as such term is defined in the Security Agreement and any and all other assets and properties
of whatever kind and nature subject or purported to be subject from time to time to a Lien under any Collateral Document, but in any
event excluding all Excluded Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral Access
Agreement</B>&rdquo; means an agreement, in form and substance reasonably satisfactory to the Collateral Agent and to which the Collateral
Agent is a party, pursuant to which a mortgagee or lessor of real property on which Collateral is stored or otherwise located, or a warehouseman,
processor or other bailee of Inventory or other property owned by any Credit Party, acknowledges the Liens and security interests of
the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and waives (or, if approved by the Collateral Agent in
its sole discretion, subordinates) any Liens or security interests held by such Person on any such Collateral, and, in the case of any
such agreement with a mortgagee or lessor, permits the Collateral Agent and any Lender (and its representatives and designees) reasonable
access to any Collateral stored or otherwise located thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral Account</B>&rdquo;
means any Deposit Account of a Credit Party maintained with a bank or other depository or financial institution located in the United
States, and any Securities Account of a Credit Party maintained with a securities intermediary located in the United States or any Commodity
Account of a Credit Party maintained with a commodity intermediary located in the United States, in each case, other than an Excluded
Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral Agent</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral Documents</B>&rdquo;
means the Security Agreement, the Control Agreements, the IP Agreements, any Mortgages and all other instruments, documents and agreements
delivered by any Credit Party pursuant to or incidental to this Agreement or any of the other Loan Documents, in each case, in order
to grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, or perfect a Lien on any Collateral as security
for the Obligations, and all amendments, restatements, amendments and restatements, modifications or supplements thereof or thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commodity Account</B>&rdquo;
means any &ldquo;commodity account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company IP</B>&rdquo;
means any and all of the following, as they exist in and throughout the Territory to the extent owned by or licensed to Borrower or any
of its Subsidiaries: (a)&#8239;Covered Company IP; (b)&#8239;improvements, continuations, continuations-in-part, divisions, provisionals
or any substitute applications with respect to any of the Covered Company IP, any patent issued with respect to any of the Covered Company
IP, including any patent right claiming the apparatus, system, component or composition of matter of, or the method of making or using,
the Product in the Territory, any reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary
protection certificate) of any such patent and all foreign and international counterparts of any of the foregoing, and any confirmation
patent or registration patent or patent of addition based on any such patent; (c)&#8239;trade secrets or trade secret rights, including
any rights to unpatented inventions, know-how, show-how, operating manuals, confidential or proprietary information, research in progress,
algorithms, data, databases, data collections, designs, processes, procedures, methods, protocols, materials, formulae, drawings, schematics,
blueprints, flow charts, models, strategies, prototypes, techniques, and the results of experimentation and testing, including samples,
in each case, as specifically related to any research, development, manufacture, production, use, commercialization, marketing, importing,
storage, transport, offer for sale, distribution or sale of the Product in the Territory; (d)&#8239;to the extent not described in <U>clauses
(a)</U>, <U>(b)</U>&#8239;or <U>(c)</U>&#8239;above, any and all IP Ancillary Rights specifically relating to any of the foregoing (other
than all income, royalties, proceeds and liabilities at any time due and payable or asserted under or with respect to any of the foregoing),
including, for the avoidance of doubt, all rights to sue or recover at law or in equity for any past, present or future infringement,
misappropriation, dilution, violation or other impairment thereof, and, in each case, all rights to obtain any other intellectual property
right ancillary to any Copyright, Trademark, Patent, Software, trade secrets or trade secret rights; and (e)&#8239;all data provided in
any regulatory filings, submissions and approvals related to any research, development, manufacture, production, use, commercialization,
marketing, importing, storage, transport, offer for sale, distribution or sale of Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company IP Agreement</B>&rdquo;
means each contract or agreement, pursuant to which Borrower or any of its Subsidiaries has the legal right to exploit Covered Company
IP or other Intellectual Property that is owned by another Person and is material to any aspect of the research, development, manufacture,
production, use, supply, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Product
in the Territory, including that certain Product Commercialization Agreement, dated March&#8239;19, 2025, between Borrower and EVERSANA
Life Science Services, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Competitor</B>&rdquo;
means, at any time of determination, any Person (and each other Person that owns or controls, directly or indirectly, such Person, or
that controls or is controlled by or is under common control with such Person) that is directly and primarily engaged in the same, substantially
the same, or similar line of business as Borrower and its Subsidiaries, taken as a whole, as of such time. As used in this definition,
 &ldquo;control&rdquo; means (a)&#8239;direct or indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage
which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other
equity interest in a Person or (b)&#8239;the power to direct or cause the direction of the management of such Person by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Compliance Certificate</B>&rdquo;
means that certain certificate in the form attached hereto as <U>Exhibit&#8239;E</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Conforming Changes</B>&rdquo;
means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark
Replacement, any technical, administrative or operational changes (including changes to the definition of &ldquo;Business Day,&rdquo;
the definition of &ldquo;U.S. Government Securities Business Day,&rdquo; the definition of &ldquo;Interest Period&rdquo; or any similar
or analogous definition (or the addition of a concept of &ldquo;interest period&rdquo;), timing and frequency of determining rates and
making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length
of lookback periods and other technical, administrative or operational matters) that the Collateral Agent decides (after consultation
with Borrower) may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration
thereof by the Collateral Agent in a manner substantially consistent with market practice (or, if the Collateral Agent decides that adoption
of any portion of such market practice is not administratively feasible or if the Collateral Agent determines that no market practice
for the administration of any such rate exists, in such other manner of administration as the Collateral Agent decides is reasonably
necessary in connection with the administration of this Agreement and the other Loan Documents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Connection Income
Taxes</B>&rdquo; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise
Taxes or branch profits Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Contingent Obligation</B>&rdquo;
means, for any Person, (a)&#8239;any direct or indirect liability, contingent or not, of that Person for any indebtedness, lease, dividend,
letter of credit or other obligation of another Person directly or indirectly guaranteed, endorsed, co-made, discounted or sold with
recourse by that Person, or for which that Person is directly or indirectly liable (other than by endorsements of instruments in the
course of collection) and (b)&#8239;any obligation of that Person to pay an earn-out payment, milestone payment or similar contingent
payment or contingent compensation (including purchase price adjustments but excluding license fees, royalties payable and milestones
based on net sales) to a counterparty incurred or created in connection with an Acquisition, Transfer, or Investment or otherwise in
connection with any collaboration, development or similar agreement, in each instance where such contingent payment or compensation becomes
due and payable upon the occurrence of an event or the performance of an act (and not solely with the passage of time). The amount of
a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or,
if not determinable by a Responsible Officer of such Person, the amount required to be shown as a liability on the balance sheet of such
Person in accordance with GAAP (or, if not required to be so shown, the maximum reasonably anticipated amount reasonably determined by
a Responsible Officer of such Person in good faith); but the amount may not exceed the maximum of the obligations under any guarantee
or other support arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Control Agreement</B>&rdquo;
means, with respect to any Credit Party, any control agreement entered into among such Credit Party, the Collateral Agent and, in the
case of a Deposit Account, the bank or other depository or financial institution located in the United States, at which such Credit Party
maintains such Deposit Account, or, in the case of a Securities Account or a Commodity Account, the securities intermediary or commodity
intermediary located in the United States, at which such Credit Party maintain such Securities Account or Commodities Account, in either
case, pursuant to which the Collateral Agent obtains control (within the meaning of the Code) pursuant to a &ldquo;springing&rdquo; control
agreement, or otherwise has a perfected first priority security interest (subject to any Permitted Liens), over such Collateral Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Copyrights</B>&rdquo;
means any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and
derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret (and all related
IP Ancillary Rights).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Covered Company
IP</B>&rdquo; is defined in <U>Section&#8239;4.6(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Covered Regulatory
Materials</B>&rdquo; is defined in <U>Section&#8239;4.20(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Covers</B>&rdquo;
means, with respect to the Product, a product, or the Platform (as applicable) and to any Intellectual Property, that, in the absence
of ownership of, or a license granted under, such Intellectual Property, the use, manufacture, offer for sale, sale, importation or other
commercialization of the Product, such product, or the Platform (as applicable) would infringe such Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Credit Extension</B>&rdquo;
means any Term Loan or any other extension of credit by any Lender for Borrower&rsquo;s benefit pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Credit Party</B>&rdquo;
means Borrower and each Guarantor (including any Designated Guarantor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Daily
Simple SOFR</B>&rdquo;</FONT> means, for any day, SOFR, with the conventions for this rate (which will include a lookback) being established
by the Collateral Agent in accordance with the conventions for this rate recommended by the Relevant Governmental Body for determining
 &ldquo;Daily Simple SOFR&rdquo; for bilateral business loans; <U>provided</U>, <U>that</U>, if the Collateral Agent decides that any
such convention is not administratively feasible for the Collateral Agent, then the Collateral Agent may establish another convention
in its reasonable discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Data Protection
Laws</B>&rdquo; means any and all applicable foreign or domestic (including U.S. federal, state and local), statutes, ordinances, orders,
rules, regulations, judgments, Governmental Approvals, or any other requirements of Governmental Authorities relating to privacy, security,
notification of breaches, data transfers, confidentiality of Personal Data or other Sensitive Information or to any database registration
or data localization requirements, in each case, in any manner applicable to Borrower or any of its Subsidiaries, including, to the extent
applicable, Section&#8239;5 of the FTC Act and other consumer protection laws, HIPAA, GDPR, the Belgian Data Protection Act of July&#8239;30,
2018, state comprehensive privacy laws (including the Maryland Online Data Privacy Act of 2024, Md. Com. Law &sect; 14-4701, <I>et seq.</I>
(2024)), other U.S. state health information privacy or genetic privacy laws, and state breach notification laws, and including any required
policies and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Default</B>&rdquo;
means any breach of or default under any term, provision, condition, covenant or agreement contained in this Agreement or any other Loan
Document or any other event, in each case that, with the giving of notice or the lapse of time or both, would constitute an Event of
Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Default Rate</B>&rdquo;
is defined in <U>Section&#8239;2.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Deposit Account</B>&rdquo;
means any &ldquo;deposit account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Designated Guarantor</B>&rdquo;
is defined in <U>Section&#8239;5.13</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Letter</B>&rdquo;
means the disclosure letter to this Agreement, dated the Effective Date and delivered by the Credit Parties to the Collateral Agent pursuant
to <U>Section&#8239;3.1(a)</U>&#8239;hereof, as updated on each subsequent Closing Date (if required and as expressly permitted hereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disqualified Assignee</B>&rdquo;
means (a)&#8239;any Competitor of Borrower, or (b)&#8239;any Affiliate of any Competitor of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disqualified Equity
Interest</B>&rdquo; means any Equity Interest that, by its terms (or by the terms of any security or other Equity Interests into which
it is convertible or for which it is exchangeable) or upon the happening of any event or condition: (a)&#8239;matures or is mandatorily
redeemable, pursuant to a sinking fund obligation or otherwise (except if redeemable or convertible into other Equity Interest that would
not constitute a Disqualified Equity Interest or as a result of a change of control, asset sale or similar event so long as any and all
rights of the holders thereof upon the occurrence of a change of control, asset sale or similar event shall be subject to the prior repayment
in full in cash of the Term Loans and the satisfaction in full of all other Obligations (other than inchoate indemnity obligations) in
accordance with the terms of this Agreement); (b)&#8239;is redeemable at the option of the holder thereof, in whole or in part (except
if redeemable or convertible into other Equity Interest that would not constitute a Disqualified Equity Interest or as a result of a
change of control, asset sale or similar event so long as any rights of the holders thereof upon the occurrence of a change of control,
asset sale or similar event shall be subject to the prior repayment in full in cash of the Term Loans and the satisfaction in full of
all other Obligations (other than inchoate indemnity obligations) in accordance with this Agreement); (c)&#8239;provides for the scheduled
payments of dividends or distributions in cash; or (d)&#8239;is convertible into or exchangeable for (i)&#8239;Indebtedness which is not
Permitted Indebtedness or (ii)&#8239;any other Equity Interest that would constitute a Disqualified Equity Interest; in each case described
in <U>clauses (a)</U>&#8239;through <U>(d)</U>&#8239;above, prior to the date that is 180 days after the Term Loan Maturity Date; <U>provided</U>
that, if any such Equity Interest is issued pursuant to any plan for the benefit of any employee, director, manager or consultant of
Borrower or its Subsidiaries or by any such plan to such employee, director, manager or consultant, such Equity Interest shall not constitute
a &ldquo;Disqualified Equity Interest&rdquo; solely because it may be required to be repurchased by Borrower or its Subsidiaries in order
to satisfy applicable statutory or regulatory obligations or as a result of the termination, death or disability of such employee, director,
manager or consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Dollars</B>,&rdquo;
 &ldquo;<B>dollars</B>&rdquo; or use of the sign &ldquo;<B>$</B>&rdquo; means only lawful money of the United States and not any other
currency, regardless of whether that currency uses the &ldquo;$&rdquo; sign to denote its currency or may be readily converted into lawful
money of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Domestic Subsidiary</B>&rdquo;
means, with respect to any Credit Party, a Subsidiary of such Credit Party that is incorporated or organized under the laws of the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effective Date</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Environmental Claim</B>&rdquo;
means any investigation, notice, notice of violation, claim, action, suit, proceeding, demand, abatement order or other order or directive
(conditional or otherwise), by any Governmental Authority or any other Person, arising (i)&#8239;pursuant to or in connection with any
actual or alleged violation of any Environmental Law; (ii)&#8239;in connection with any Hazardous Material or any actual or alleged Hazardous
Materials Activity; or (iii)&#8239;in connection with any actual or alleged damage, injury, threat or harm to health, safety, natural
resources or the environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Environmental Laws</B>&rdquo;
means any and all current or future, foreign or domestic, statutes, ordinances, orders, rules, regulations, judgments, Governmental Approvals,
or any other requirements of Governmental Authorities relating to (i)&#8239;environmental matters, including those relating to any Hazardous
Materials Activity; (ii)&#8239;the generation, use, storage, transportation or disposal of Hazardous Materials; or (iii)&#8239;occupational
safety and health, industrial hygiene, land use or the protection of human, plant or animal health or welfare, in each case, in any manner
applicable to any Credit Party or any of its Subsidiaries or any Facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Equity Interests</B>&rdquo;
means collectively, with respect to any Person, any and all shares, interests, participations or other equivalents (however designated)
of capital stock of a corporation, any and all equivalent ownership interests in such Person (other than a corporation), including partnership
interests and membership interests, and any and all warrants, rights or options to purchase or other arrangements or rights to acquire
(by purchase, conversion, dividend, distribution or otherwise) any of the foregoing (and all other rights, powers, privileges, interests,
claims and other property in any manner arising therefrom or relating thereto); <U>provided</U>, <U>however</U>, that any Indebtedness
convertible into Equity Interests (or into any combination of cash and Equity Interests based on the value of such Equity Interests)
shall not constitute Equity Interests unless and until (and solely to the extent) so converted into Equity Interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA</B>&rdquo;
means the Employee Retirement Income Security Act of 1974, and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA Affiliate</B>&rdquo;
means, with respect to any Person, any trade or business (whether or not incorporated) that, together with such Person, is treated as
a single employer under Section&#8239;414(b)&#8239;or (c)&#8239;of the IRC or, solely for purposes of Section&#8239;302 of ERISA or Section&#8239;412
of the IRC, Section&#8239;414(m)&#8239;or (o)&#8239;of the IRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA Event</B>&rdquo;
means (a)&#8239;any &ldquo;reportable event,&rdquo; as defined in Section&#8239;4043 of ERISA or the regulations issued thereunder, with
respect to a Plan (other than an event for which the 30-day notice period is waived by regulation); (b)&#8239;with respect to a Plan,
the failure by Borrower or its Subsidiaries or their ERISA Affiliates to satisfy the minimum funding standard of Section&#8239;412 of
the IRC and Section&#8239;302 of ERISA, whether or not waived; (c)&#8239;the failure by Borrower or its Subsidiaries or their ERISA Affiliates
to make by its due date a required installment under Section&#8239;430(j)&#8239;of the IRC with respect to any Plan or to make any required
contribution to a Multiemployer Plan; (d)&#8239;the filing pursuant to Section&#8239;412(c)&#8239;of the IRC or Section&#8239;302(c)&#8239;of
ERISA of an application for a waiver of the minimum funding standard with respect to any Plan; (e)&#8239;the incurrence by Borrower or
any of its ERISA Affiliates of any liability under Title IV of ERISA with respect to the termination of any Plan; (f)&#8239;the receipt
by Borrower or its Subsidiaries or any of their respective ERISA Affiliates from the Pension Benefit Guaranty Corporation (referred to
and defined in ERISA) or a plan administrator of any notice relating to the intention to terminate any Plan under Section&#8239;4041 or
any Multiemployer Plan under 4041A of ERISA or to appoint a trustee to administer any Plan under Section&#8239;4042 of ERISA, or the occurrence
of any event or condition which could reasonably be expected to constitute grounds under ERISA for the termination of, or the appointment
of a trustee to administer, any Plan under Section&#8239;4041 Section&#8239;or 4042 of ERISA; (g)&#8239;the incurrence by Borrower or its
Subsidiaries or any of their respective ERISA Affiliates of any liability with respect to the withdrawal from any Plan pursuant to Section&#8239;4063
of ERISA or Multiemployer Plan; (h)&#8239;the receipt by Borrower or its Subsidiaries or any of their respective ERISA Affiliates of any
notice, concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent,
within the meaning of Section&#8239;4245 of ERISA; (i)&#8239;the &ldquo;substantial cessation of operations&rdquo; by Borrower or its Subsidiaries
or their ERISA Affiliates within the meaning of Section&#8239;4062(e)&#8239;of ERISA with respect to a Plan; or (j)&#8239;the occurrence
of a nonexempt prohibited transaction (within the meaning of Section&#8239;4975 of the IRC or Section&#8239;406 of ERISA) with respect
to a Plan which could reasonably be expected to result in a material liability to Borrower or its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>EU Laws</B>&rdquo;
means all applicable statutes, rules&#8239;and regulations implemented administered or enforced by the European Commission, the European
Medicines Agency (&ldquo;<B>EMA</B>&rdquo;) or the competent authorities of the EU Member States including, but not limited to, the EU
Community Code on medicinal products (Directive 2001/83/EC), the EMA Regulation (Regulation (EC) No 726/2004), the Manufacturing Directive
(Commission Directive 2003/94/EC), the Clinical Trials Regulation (Regulation (EU) No 536/2014), and related implementing legislation
of individual EU Member States and related guidance at EU level and national level in individual EU Member States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>EU Member State</B>&rdquo;
means a country that is (a)&#8239;included in the Territory and (b)&#8239;a member state of the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>European Union</B>&rdquo;
means, collectively, the individual Member States of the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Event of Default</B>&rdquo;
is defined in <U>Section&#8239;7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange Act</B>&rdquo;
means the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange Act Documents</B>&rdquo;
means any and all documents filed by Borrower with the SEC pursuant to the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Accounts</B>&rdquo;
is defined in <U>Section&#8239;5.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Equity
Interests</B>&rdquo; means, collectively: (i)&#8239;any Equity Interests in any Subsidiary with respect to which the grant to the Collateral
Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral
Agent, for the benefit of Lenders and the other Secured Parties, of, such Equity Interests, to secure the Obligations (and any guaranty
thereof) are validly prohibited by Requirements of Law; (ii)&#8239;any Equity Interests in any Subsidiary with respect to which the grant
to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge
to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Equity Interests, to secure the Obligations
(and any guaranty thereof) require the consent, approval or waiver of any Governmental Authority or other third-party and such consent,
approval or waiver has not been obtained by Borrower following Borrower&rsquo;s commercially reasonable efforts to obtain the same; (iii)&#8239;any
Equity Interests in any Subsidiary that is a non-Wholly-Owned Subsidiary that the grant to the Collateral Agent, for the benefit of Lenders
and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders
and the other Secured Parties, of, such Equity Interests, to secure the Obligations (and any guaranty thereof) are validly prohibited
by, or would give any third-party (other than Borrower or an Affiliate of Borrower) the right to terminate its obligations under, the
Operating Documents or the joint venture agreement or shareholder agreement with respect to, or any other contract with such third-party
relating to such non-Wholly-Owned Subsidiary, including any contract evidencing Indebtedness of such non-Wholly-Owned Subsidiary (other
than customary non-assignment provisions which are ineffective under Article&#8239;9 of the Code or other Requirements of Law), but only,
in each case, to the extent, and for so long as such Operating Document, joint venture agreement, shareholder agreement or other contract
is in effect; (iv)&#8239;any Equity Interests in excess of 65% of the voting capital stock of any Subsidiary that is a Foreign Subsidiary
(other than a Credit Party) or a FSHCO, (v)&#8239;all or a portion of the Equity Interests in any Foreign Subsidiary or FSHCO, the pledge
of which would, in the reasonable determination of a Responsible Officer of Borrower in good faith, reasonably be expected to result
in a tax liability for Borrower or its Subsidiaries under Section&#8239;956 of the IRC (or a successor or similar provision) or Treasury
Regulations promulgated thereunder as a result of a change in Requirements of Law occurring after the date hereof that causes a material
adverse tax consequence to Borrower or its Subsidiaries; and (vi)&#8239;any Equity Interests in any other Subsidiary with respect to which,
Borrower and the Collateral Agent reasonably determine by mutual agreement that the cost of granting the Collateral Agent, for the benefit
of Lenders and the other Secured Parties, a security interest in and Lien upon, and pledging to the Collateral Agent, for the benefit
of Lenders and the other Secured Parties, such Equity Interests, to secure the Obligations (and any guaranty thereof) are excessive,
relative to the value to be afforded to the Secured Parties thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Foreign
Subsidiary</B>&rdquo; is defined in the definition of &ldquo;Excluded Subsidiaries&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded License</B>&rdquo;
means any license or sublicense, by a Credit Party to a Person other than Borrower or any Subsidiary of Borrower, (a)&#8239;of, except
as permitted under any of clauses (d)&#8239;&ndash; <U>(g)</U>&#8239;of the definition of &ldquo;Permitted License&rdquo;, any Product-Exclusive
Intellectual Property within the Territory, whether exclusive or non-exclusive, (b)&#8239;of Intellectual Property within the Territory
that Covers the Product and interferes with or impedes the ability of Borrower or any Subsidiary of Borrower to conduct the research,
development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution
or sale of the Product in the Territory or enforce its rights with respect to any of the foregoing within the Territory, or (c)&#8239;except
as permitted under any of <U>clauses (c)</U>&#8239;&ndash; <U>(g)</U>&#8239;of the definition of &ldquo;Permitted License&rdquo;, that
requires any Credit Party to pay to the licensee any royalties, milestones or similar payments that are based on the research, development,
manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the
Product in the Territory. For clarity, and notwithstanding anything to the contrary herein, in no event shall any Permitted Non-Product
Platform License be considered an Excluded License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Property</B>&rdquo;
has the meaning set forth for such term in the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Subsidiaries</B>&rdquo;
means, collectively: (i)&#8239;any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and
the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders
and the other Secured Parties, of, such Subsidiary&rsquo;s properties and assets subject or purported to be subject from time to time
to a Lien under any Collateral Document and the Equity Interests in such Subsidiary to secure the Obligations (and any guaranty thereof)
are validly prohibited by Requirements of Law; (ii)&#8239;any Subsidiary with respect to which the grant to the Collateral Agent, for
the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent,
for the benefit of Lenders and the other Secured Parties, of, such Subsidiary&rsquo;s properties and assets subject or purported to be
subject from time to time to a Lien under any Collateral Document and the Equity Interests in such Subsidiary to secure the Obligations
(and any guaranty thereof) require the consent, approval or waiver of any Governmental Authority or other third-party (other than Borrower
or an Affiliate of Borrower) and any such consent, approval or waiver has not been obtained, directly or indirectly, by Borrower following
Borrower&rsquo;s direct and indirect commercially reasonable efforts to obtain the same; (iii)&#8239;any Subsidiary that is a non-Wholly
Owned Subsidiary, with respect to which, the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties,
of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties,
of, the properties and assets of such non-Wholly Owned Subsidiary, to secure the Obligations (and any guaranty thereof) are validly prohibited
by, or would give any third-party (other than Borrower or an Affiliate of Borrower) the right to terminate its obligations under, such
non-Wholly Owned Subsidiary&rsquo;s Operating Documents or the joint venture agreement or shareholder agreement with respect thereto
or any other contract with such third-party relating to such non-Wholly Owned Subsidiary, including any contract evidencing Indebtedness
of such non-Wholly Owned Subsidiary (other than customary non-assignment provisions which are ineffective under Article&#8239;9 of the
Code or other Requirements of Law), but only, in each case, to the extent, and for so long as such Operating Document, joint venture
agreement, shareholder agreement or other contract is in effect; (iv)&#8239;with respect to any Foreign Subsidiary, either (A)&#8239;the
properties and assets owned by such Subsidiary have an aggregate fair market value (as reasonably determined in good faith by a Responsible
Officer of Borrower), individually and when aggregated together with all other Subsidiaries excluded under this <U>sub-clause (iv)</U>,
of less than $5,000,000 or (B)&#8239;such Foreign Subsidiary becoming a Guarantor could reasonably be expected to have material adverse
tax consequences to the Borrower and its Subsidiaries, taken as a whole; (v)&#8239;any Foreign Subsidiary or FSHCO (each, an &ldquo;<U>Excluded
Foreign Subsidiary</U>&rdquo;); (vi)&#8239;any Domestic Subsidiary that is a direct or indirect Subsidiary of a Foreign Subsidiary; and
(vii)&#8239;any other Subsidiary with respect to which, Borrower and the Collateral Agent reasonably determine by mutual agreement that
the cost of granting the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a security interest in and Lien
upon, and pledging to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, such Subsidiary&rsquo;s properties
and assets subject or purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests of such
Subsidiary to secure the Obligations (and any guaranty thereof) are excessive relative to the value to be afforded to the Secured Parties
thereby. Notwithstanding the foregoing or any other provision of this Agreement, the parties hereto agree that without the prior written
consent of the Collateral Agent or the Required Lenders, no Subsidiary existing as of the Effective Date or organized, formed or acquired,
directly or indirectly, by any Credit Party from and after the Effective Date, that at any time (A)&#8239;owns or co-owns any material
Company IP or that holds rights in or to any Covered Regulatory Materials, (B)&#8239;is party to any Company IP Agreement, (C)&#8239;enters
into any Material Contract or otherwise becomes a party thereto or bound thereby or (D)&#8239;otherwise engages in any business operations
material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage,
transport, packaging, labelling, promotion, advertising, offer or sale, distribution or sale of the Product in the Territory and owns
properties and assets with an aggregate fair market value (as reasonably determined in good faith by a Responsible Officer of Borrower)
equal to or greater than $5,000,000, individually and when aggregated together with all other Subsidiaries excluded under <U>sub-clause
(iv)</U>&#8239;above, shall, in any such case, be (or be deemed to be) an Excluded Subsidiary for any purpose under the Loan Documents
and, therefore, such Subsidiary shall constitute a Credit Party for all purposes under the Loan Documents, as of the date of such ownership,
co-ownership, maintenance, license, entry or becoming so bound or engagement, <U>and</U>, <U>additionally</U>, in each case, Borrower
shall cause such entity, within the time periods required by <U>Section&#8239;5.12</U>, <U>5.13</U>, or <U>5.14</U>, as and to the extent
applicable, to become a Guarantor in accordance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Taxes</B>&rdquo;
means any of the following Taxes imposed on or with respect to Lender or required to be withheld or deducted from a payment to Lender,
(a)&#8239;Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i)&#8239;imposed
by the United States or as a result of Lender being organized under the laws of, or having its principal office or its applicable lending
office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii)&#8239;that are Other Connection Taxes,
(b)&#8239;U.S. federal withholding Taxes imposed on amounts payable to or for the account of Lender with respect to any Obligation pursuant
to a law in effect on the date on which (i)&#8239;Lender acquires such interest in any Obligation or (ii)&#8239;Lender changes its lending
office, except in each case to the extent that, pursuant to <U>Section&#8239;2.6</U>, amounts with respect to such Taxes were payable
either to Lender&rsquo;s assignor immediately before Lender became a party hereto or to Lender immediately before it changed its lending
office, (c)&#8239;Taxes attributable to Lender&rsquo;s failure to comply with <U>Section&#8239;2.6(d)</U>, and (d)&#8239;any U.S. federal
withholding Taxes imposed under FATCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exit Consideration</B>&rdquo;
means, individually or collectively, as the context dictates, the Tranche A Exit Consideration and the Tranche B Exit Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Export and Import
Laws</B>&rdquo; means any applicable law, regulation, order or directive that applies to the import, export, re-export, transfer, disclosure
or provision of goods, software, technology or technical assistance including restrictions or controls administered pursuant to the U.S.
Export Administration Regulations, 15 C.F.R. Parts 730-774, administered by the U.S. Department of Commerce, Bureau of Industry and Security;
U.S. Customs regulations; and similar import and export laws, regulations, orders and directives of other jurisdictions to the extent
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Facility</B>&rdquo;
means, with respect to any Credit Party, any real property (including all buildings, fixtures or other improvements located thereon)
now, hereafter or heretofore owned, leased, operated or used by such Credit Party or any of its Subsidiaries or any of their respective
predecessors or Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FATCA</B>&rdquo;
means Sections 1471 through 1474 of the IRC, as of the date of this Agreement (including, for the avoidance of doubt, any agreements
between the governments of the United States and the jurisdiction in which the applicable Lender is resident implementing such provisions),
or any amended or successor version that is substantively comparable and not materially more onerous to comply with, and any current
or future regulations promulgated thereunder or official interpretations thereof, any agreements entered into pursuant to Section&#8239;1471(b)(1)&#8239;of
the IRC, any intergovernmental agreement entered into in connection with the implementation of the foregoing sections of the IRC and
any fiscal or regulatory legislation, regulations, rules&#8239;or practices adopted pursuant to, or official interpretations implementing
such Sections of the IRC or intergovernmental agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FCPA</B>&rdquo;
is defined in <U>Section&#8239;4.18(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA</B>&rdquo;
means the United States Food and Drug Administration (and any United States state and foreign equivalents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA Good Clinical
Practices</B>&rdquo; means the standards set forth in 21 C.F.R. Parts 50, 54, 56, 312, 314, 316 and 45 C.F.R. Part&#8239;46 (and any foreign
equivalents), and as interpreted through FDA&rsquo;s applicable guidance documents (and foreign equivalents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA Good Laboratory
Practices</B>&rdquo; means the standards set forth in 21 C.F.R. Part&#8239;58 (and any foreign equivalent), and as interpreted through
applicable guidance documents by FDA (and foreign equivalents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA Good Manufacturing
Practices</B>&rdquo; means the standards set forth in 21 C.F.R. Parts 4, 210, 211, 600, 610 and 829 (and any foreign equivalents), and
as interpreted through applicable guidance documents by FDA (and foreign equivalents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA Laws</B>&rdquo;
means all applicable statutes (including the Food, Drug, and Cosmetic Act (21 U.S.C. &sect; 301 et seq.) and the Public Health Service
Act (42 U.S.C. &sect; 262 through &sect; 263)), rules&#8239;and regulations implemented, administered, or enforced by the FDA and any
United States state and foreign equivalents, and as interpreted through applicable guidance documents by the FDA (and United States state
and foreign equivalents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Federal Reserve
Board</B>&rdquo; means the Board of Governors of the Federal Reserve System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Fiscal Quarter</B>&rdquo;
means a fiscal quarter of any Fiscal Year, ending March&#8239;31, June&#8239;30, September&#8239;30 or December&#8239;31, as applicable,
of each calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Fiscal Year</B>&rdquo;
means the fiscal year of Borrower and its Subsidiaries ending on December&#8239;31 of each calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Floor</B>&rdquo;
</FONT>means a rate of interest equal to three and three-quarters percent (3.75%) <I>per annum</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Foreign Lender</B>&rdquo;
means a Lender that is not a &ldquo;United States person&rdquo; as defined in Section&#8239;7701(a)(30) of the IRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Foreign Subsidiary</B>&rdquo;
means, with respect to any Credit Party, any Subsidiary of such Credit Party that is not a Domestic Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FSHCO</B>&rdquo;
means any Subsidiary that has no material assets other than equity (or debt treated for U.S. federal income tax purposes as equity) of
one or more Foreign Subsidiaries or other FSHCOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo;
means with respect to Borrower and its Subsidiaries, generally accepted accounting principles in the United States as set forth in the
opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements
and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by
a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination, consistently
applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GDPR</B>&rdquo;
means, as amended and restated from time to time, collectively, (i)&#8239;Regulation (EU) 2016/679 of the European Parliament and of the
Council of 27 April&#8239;2016 on the protection of natural persons with regard to the processing of personal data and on the free movement
of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) (the &ldquo;<B>EU GDPR</B>&rdquo;) and (ii)&#8239;the
UK Data Protection Act 2018 and the EU GDPR as it forms part of the laws of the United Kingdom by virtue of section 3 of the European
Union (Withdrawal) Act 2018 and as amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit)
Regulations 2019 (the &ldquo;<B>UK GDPR</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Approval</B>&rdquo;
means any consent, authorization, approval, licensure, clearance, order, license, franchise, permit, certificate, accreditation, registration,
filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Authority</B>&rdquo;
means any nation or government, any supranational organization, any state or other political subdivision thereof, any agency (including
Regulatory Agencies, data protection authorities, and agencies acting as supervisory governmental organizations on issues of privacy
protection), government department (including the U.S. Department of Justice), authority (including state attorneys general), instrumentality,
regulatory body, ministry, board, commission, court, central bank or other entity exercising executive, legislative, judicial, taxing,
regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Payor
Programs</B>&rdquo; means all governmental third-party payor programs in which any Credit Party or its Subsidiaries participates, including
Medicare, Medicaid, TRICARE or any other U.S. federal or state health care programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Guarantor</B>&rdquo;
means, at any time, any Person that is, pursuant to the terms of any Loan Document, a guarantor of any of the Obligations at that time,
including any Designated Guarantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Hazardous Materials</B>&rdquo;
means any chemical, material or substance, exposure to which is prohibited, limited or regulated by any Governmental Authority or which
may or could pose a hazard to the health and safety of the owners, occupants or any Persons in the vicinity of any Facility or to the
indoor or outdoor environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Hazardous Materials
Activity</B>&rdquo; means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous Materials,
including the use, manufacture, possession, storage, holding, presence, existence, location, Release, threatened Release, discharge,
placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal, disposition or
handling of any Hazardous Materials, and any corrective action or response action with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Health Care Laws</B>&rdquo;
means, collectively: (a)&#8239;applicable federal, state or local laws, rules, regulations, orders, ordinances, codes, statutes, standards,
and requirements issued under or in connection with Medicare, Medicaid or any other Governmental Payor Programs or with commercial third-party
payor programs; (b)&#8239;applicable federal and state laws and regulations governing health information, including HIPAA; (c)&#8239;applicable
federal, state and local fraud and abuse laws of any Governmental Authority, including the federal Anti-Kickback Statute (42 U.S.C. &sect;
1320a-7(b)), the Stark law (42 U.S.C. &sect; 1395nn and 1396b(s)), the civil False Claims Act (31 U.S.C. &sect; 3729 et seq.), Sections
1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes, and also any other
U.S. or foreign laws or regulations that are applicable to health care fraud, abuse, corruption, waste, bribery, inducements, false statements,
or false claims; (d)&#8239;the Medicare Prescription Drug,&#8239;Improvement, and Modernization Act of 2003 (Pub. L. No.&#8239;108-173)
and the regulations promulgated thereunder and any other federal, state or local laws or regulations (or foreign equivalents thereof)
governing the disclosure of payments or providing other items of value or remuneration or drug product samples to health care professionals,
to the extent applicable; (e)&#8239;the Physician Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h); (f)&#8239;all applicable reporting
and disclosure requirements, including any arising under the Medicaid Drug Rebate Program (e.g., Monthly and Quarterly Average Manufacturer
Price, Baseline Average Manufacturer Price, and Rebate Per Unit, as applicable), Medicare Part&#8239;B (Quarterly Average Sales Price),
Section&#8239;602 of the Veteran&rsquo;s Health Care Act (Public Health Service 340B Quarterly Ceiling Price), Section&#8239;603 of the
Veteran&rsquo;s Health Care Act (Quarterly and Annual Non-Federal Average Manufacturer Price and Federal Ceiling Price), Best Price,
Federal Supply Schedule Contract Prices and Tricare Retail Pharmacy Refunds, and Medicare Part&#8239;D; (g)&#8239;applicable federal, state
or local laws, rules, regulations, ordinances, statutes and requirements relating to (<I>i</I>)&#8239;the regulation of managed care,
third-party payors and Persons bearing the financial risk for the provision or arrangement of health care services, <I>(ii)</I>&#8239;billings
to insurance companies, health maintenance organizations and other Managed Care Plans or otherwise relating to insurance fraud and (<I>iii</I>)&#8239;any
insurance, health maintenance organization or managed care Requirements of Law; (h)&#8239;regulations for the protection of human research
subjects (including 45 C.F.R. part 46, and any foreign or United States state equivalents); (i)&#8239;requirements for licensure or permitting
of personnel who are engaged in marketing, sales, or medical activities under federal, state, or local laws (or foreign equivalents);
(j)&#8239;requirements concerning disclosure of pricing information and other company information to the public, customers, prescribers
or to state and local agencies under federal, state, or local laws (or foreign equivalents); (k)&#8239;laws and regulations requiring
the adoption of compliance codes or policies; (l)&#8239;the interoperability, information blocking, and health information technology
certification program regulations promulgated under the 21st Century Cures Act, the underlying provisions of the 21st Century Cures Act
(42 U.S.C. &sect; 300jj et seq.) and regulations implementing information blocking penalties promulgated under the 21<SUP>st</SUP> Century
Cures Act, as applicable, and (m)&#8239;any other applicable Requirements of Law (including any applicable EU laws or other foreign equivalents)
relating to research, development, testing, approval, exclusivity, licensure, clearance, authorization, designation, post-approval (or
post-licensure, post-clearance, or post-approval, as applicable) monitoring or commitments, reporting, manufacture, production, packaging,
labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, distribution, sale or
offer for sale or lease, or payment of or for the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Hedge Termination
Value</B>&rdquo; means, with respect to any Hedging Agreement, after taking into account the effect of any legally enforceable netting
agreement relating to such Hedging Agreement (if any), (a)&#8239;for any date occurring on or after the date such Hedging Agreement has
been closed out and termination value determined in accordance therewith, such termination value, and (b)&#8239;for any date occurring
prior to the date referenced in cause (a)&#8239;above, the amount determine as the mark-to-market value for such Hedging Agreement, as
determined based upon one or more mid-market or other readily available quotation(s)&#8239;provided by any recognized dealer in such Hedging
Agreement (which may include a Lender or any Affiliate of a Lender).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Hedging Agreement</B>&rdquo;
means any interest rate, currency, commodity or equity swap, collar, cap, floor or forward rate agreement, or other agreement or arrangement
designed to protect a Person against fluctuations in interest rates, currency exchange rates or commodity or equity prices or values
(including any option with respect to any of the foregoing and any combination of the foregoing agreements or arrangements), and any
confirmation execution in connection with any such agreement or arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>HIPAA</B>&rdquo;
means the Health Insurance Portability and Accountability Act of 1996, as amended and supplemented by the Health Information Technology
for Economic and Clinical Health (HITECH) Act of 2009, any and all rules&#8239;or regulations promulgated from time to time thereunder
(including the regulations codified in 45 C.F.R. Parts 160, 162, and 164), and any U.S. state or federal laws with regard to the security,
privacy, or notification of breaches of the confidentiality of health information which are not preempted pursuant to 45 C.F.R. Part&#8239;160,
Subpart B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IFRS</B>&rdquo;
means international accounting standards within the meaning of IAS Regulation 1606/2002 to the extent applicable to the relevant financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indebtedness</B>&rdquo;
means, with respect to any Person, without duplication: (a)&#8239;all indebtedness for advanced or borrowed money of, or credit extended
to, such Person; (b)&#8239;all obligations issued, undertaken or assumed by such Person as the deferred purchase price of assets, properties,
services or rights (other than (i)&#8239;accrued expenses and trade payables entered into in the ordinary course of business consistent
with past practice which are not more than one hundred and eighty (180) days past due or subject to a bona fide dispute, (ii)&#8239;obligations
to pay for services provided by employees and individual independent contractors in the ordinary course of business consistent with past
practice which are not more than one hundred twenty (120) days past due or subject to a bona fide dispute, (iii)&#8239;liabilities associated
with customer prepayments and deposits and (iv)&#8239;prepaid or deferred revenue arising in the ordinary course of business), including
(A)&#8239;any obligation or liability to pay deferred purchase price or other similar deferred consideration for such assets, properties,
services or rights where such deferred purchase price or consideration becomes due and payable solely upon the passage of time, and (B)&#8239;any
obligation described in <U>clause (b)</U>&#8239;of the definition of Contingent Obligation that becomes due and payable (or that becomes
due and payable) solely with the passage of time (and not the occurrence of an event or the performance of an act); (c)&#8239;the face
amount of all letters of credit issued for the account of such Person and, without duplication, all drafts drawn thereunder and all reimbursement
or payment obligations with respect to letters of credit, surety bonds, performance bonds and other similar instruments issued by such
Person; (d)&#8239;all obligations of such Person evidenced by notes, bonds, debentures or other debt securities or similar instruments
(including debt securities convertible into Equity Interests), including obligations so evidenced incurred in connection with the acquisition
of properties, assets or businesses; (e)&#8239;all indebtedness of such Person created or arising under any conditional sale or other
title retention agreement or incurred as financing, in either case with respect to property acquired by such Person (even though the
rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property);
(f)&#8239;all Capital Lease Obligations of such Person; (g)&#8239;the principal balance outstanding under any synthetic lease, off-balance
sheet loan or similar off balance sheet financing product by such Person; (h)&#8239;Disqualified Equity Interests; (i)&#8239;all indebtedness
referred to in <U>clauses (a)</U>&#8239;through <U>(h)</U>&#8239;above of other Persons secured by (or for which the holder of such indebtedness
has an existing right, contingent or otherwise, to be secured by) any Lien upon or in assets or properties (including accounts and contracts
rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such indebtedness of such other
Persons (limited to the fair market value of the assets subject to such Lien); and (j)&#8239;any obligation of such Person described in
<U>clause (a)</U>&#8239;of the definition of Contingent Obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indemnified Liabilities</B>&rdquo;
means, collectively, any and all liabilities, obligations, losses, damages (including natural resource damages), penalties, claims, actions,
judgments, suits, costs, reasonable and documented out-of-pocket fees, expenses and disbursements of any kind or nature whatsoever (including
the reasonable and documented fees and disbursements of one primary legal counsel for Indemnified Persons plus, as applicable, one local
legal counsel in each relevant material jurisdiction and one intellectual property legal counsel, and in the case of an actual or perceived
conflict of interest, one additional legal counsel for such affected Indemnified Persons), incurred by any Indemnified Person or asserted
against any Indemnified Person by any Person (including Borrower or any other Credit Party) relating to or arising out of or in connection
with, or as a result of, this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby (including any
Lender&rsquo;s agreement to make Credit Extensions or the use or intended use of the proceeds thereof, or any enforcement of any of the
Loan Documents (including any sale of, collection from, or other realization upon any of the Collateral or the enforcement of any guaranty
of the Obligations)), including (i)&#8239;the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument
contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the
consummation of the transactions contemplated hereby or thereby, (ii)&#8239;any Term Loan or the use or proposed use of the proceeds therefrom,
(iii)&#8239;any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by Borrower or
any of its Subsidiaries, or any liability relating to any Environmental Law, any Release of Hazardous Materials or any Hazardous Materials
Activity, (iv)&#8239;any actual or prospective claim, suit, litigation, investigation, hearing or proceeding relating to any of the foregoing,
whether based on contract, tort or any other theory, whether brought by, commenced or threatened in writing by any Person (including
Borrower or any of its affiliates), and regardless of whether any Indemnified Person is or is designated as a party or a potential party
thereto, and (v)&#8239;the enforcement of the indemnity hereunder, in each case whether direct, indirect or consequential and whether
based on any federal, state or foreign laws, statutes, rules&#8239;or regulations, on common law or equitable cause or on contract or
otherwise, that may be imposed on, incurred by, or asserted against any such Indemnified Person, in any manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indemnified Person</B>&rdquo;
is defined in <U>Section&#8239;11.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indemnified Taxes</B>&rdquo;
means (a)&#8239;Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of
any Credit Party under any Loan Document and (b)&#8239;to the extent not otherwise described in <U>clause (a)</U>&#8239;above, Other Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Initial Payment
Date</B>&rdquo; means the first Payment Date that occurs on September&#8239;29, 2028.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Insolvency Proceeding</B>&rdquo;
means, with respect to any Person, any proceeding by or against such Person under the Bankruptcy Code, or any other domestic or foreign
bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors,
or proceedings seeking reorganization, arrangement, rescue process or other relief; <U>provided</U>, <U>however</U>, that, solely with
respect to any Person incorporated, organized or formed in any jurisdiction other than the United States, &ldquo;Insolvency Proceeding&rdquo;
shall not include any winding-up petition against such Credit Party which is frivolous or vexatious and is discharged or dismissed within
thirty (30) days of the commencement thereof or any step or procedure in connection with any transaction otherwise permitted under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Intellectual Property</B>&rdquo;
means all:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Copyrights,
Trademarks, and Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>trade
secrets and trade secret rights, including any rights to unpatented inventions, know-how, show-how and operating manuals;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&#8239;all
computer programs, including source code and object code versions, (ii)&#8239;all data, databases and compilations of data, whether machine
readable or otherwise, and (iii)&#8239;all documentation, training materials and configurations related to any of the foregoing (collectively,
 &ldquo;<B>Software</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
right, title and interest arising under any contract or Requirements of Law in or relating to Internet Domain Names;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>design
rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>IP
Ancillary Rights (including all IP Ancillary Rights related to any of the foregoing); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
similar or equivalent rights to any of the foregoing anywhere in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Interest Date</B>&rdquo;
means the last day of each calendar quarter, commencing with the last Business Day occurring in the calendar quarter during which the
Tranche A Closing Date occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Interest Period</B>&rdquo;
means, as to each Term Loan: (a)(i)&#8239;with respect to the Tranche A Loan, the period commencing on (and including) the Tranche A Closing
Date and ending on (and including) the first Interest Date following the Tranche A Closing Date, (ii)&#8239;with respect to the Tranche
B Loan, the period commencing on (and including) the Tranche B Closing Date and ending on (and including) the first Interest Date following
the Tranche B Closing Date; and (b)&#8239;thereafter, with respect to each Term Loan, each period beginning on (and including) the first
day following the end of the preceding Interest Period and ending on the earlier of (and including) (x)&#8239;the next Interest Date and
(y)&#8239;the Term Loan Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Internet Domain
Name</B>&rdquo; means all right, title and interest (and all related IP Ancillary Rights) arising under any contract or Requirements
of Law in or relating to Internet domain names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Inventory</B>&rdquo;
means all &ldquo;inventory&rdquo; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter
be made, and includes all merchandise (including inventory of the Product), materials (including raw materials), parts, components (including
component materials and component raw materials), supplies, packing and shipping materials, work in process and finished products, technology
(including software, systems, and solutions), and all elements needed to fulfill obligations related to the Product under any Manufacturing
Agreements including such inventory as is temporarily out of a Credit Party&rsquo;s or Subsidiary&rsquo;s custody or possession or in
transit (prior to title having transferred) and including any returned goods and any documents of title representing any of the above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investment</B>&rdquo;
means (a)&#8239;any beneficial ownership interest in any Person (including Equity Interests), (b)&#8239;any Acquisition or (c)&#8239;the
making of any advance, loan, extension of credit or capital contribution in or to, any Person. The amount of an Investment shall be the
amount actually invested (which, in the case of any Investment by a Credit Party or any of its Subsidiaries constituting the contribution
of an asset or property, shall be based on the good faith estimate of the fair market value of such asset or property at the time such
Investment is made as reasonably determined in good faith by a Responsible Officer of such Credit Party), less the amount of cash received
or returned for such Investment, without adjustment for subsequent increases or decreases in the value of such Investment or write-ups,
write-downs or write-offs with respect thereto; <U>provided</U> that in no event shall such amount be less than zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IP Agreements</B>&rdquo;
means, collectively, (a)&#8239;those certain IP Security Agreement(s)&#8239;entered into by and between Borrower or another Credit Party,
on the one hand, and the Collateral Agent, on the other hand, dated as of the Tranche A Closing Date, and (b)&#8239;any IP Security Agreement
entered into by and between any relevant Credit Party and the Collateral Agent after the Tranche A Closing Date in accordance with the
Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IP Ancillary Rights</B>&rdquo;
means, with respect to any Copyright, Trademark, Patent, Software, trade secrets or trade secret rights, including any rights to unpatented
inventions, know-how, show-how and operating manuals, all income, royalties, proceeds and liabilities at any time due or payable or asserted
under or with respect to any of the foregoing or otherwise with respect thereto, including all rights to sue or recover at law or in
equity for any past, present or future infringement, misappropriation, dilution, violation or other impairment thereof, and, in each
case, all rights to obtain any other intellectual property right ancillary to any Copyright, Trademark, Patent, Software, trade secrets
or trade secret rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IP Security Agreement</B>&rdquo;
means &ldquo;IP Security Agreement&rdquo;, as such term is defined in the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IRC</B>&rdquo;
means the Internal Revenue Code of 1986, as amended, or any successor statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IRS</B>&rdquo;
means the United States Internal Revenue Service or any successor agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Knowledge</B>&rdquo;
means, with respect to any Person, the actual knowledge, after reasonable investigation, of the Responsible Officers of such Person;
<U>provided</U>, <U>that</U>, with respect to Borrower, reasonable investigation means that Borrower has also affirmatively sought out
information from its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lender</B>&rdquo;
means each Person signatory hereto as a &ldquo;Lender&rdquo; and its successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lender Expenses</B>&rdquo;
means, collectively (without duplication):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
reasonable and documented out-of-pocket fees and expenses of the Collateral Agent and, as applicable, each Lender (and their respective
successors and assigns) and their respective Related Parties (including the reasonable and documented out-of-pocket fees, expenses and
disbursements of any legal counsel or other professional advisors (it being agreed that such legal counsel fees, expenses and disbursements
shall be limited to one primary legal counsel, one local legal counsel in each applicable jurisdiction and one intellectual property
legal counsel (as and to the extent applicable) for the Collateral Agent, Lenders and Related Parties, taken as a whole and in the case
of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Person)), manufacturing consultants,
safety consultants or intellectual property experts (it being agreed that such consultant or expert fees, expenses and disbursements
shall be limited to one of each such consultant and one such expert for the Collateral Agent, Lenders and such Related Parties, taken
as a whole) therefor, (i)&#8239;incurred in connection with developing, preparing, negotiating, syndicating, executing and delivering,
and interpreting, investigating and administering, the Loan Documents (or any term or provision thereof), any commitment, proposal letter,
letter of intent or term sheet therefor or any other document prepared in connection therewith, (ii)&#8239;incurred in connection with
the consummation and administration of any transaction contemplated therein, (iii)&#8239;incurred in connection with the performance of
any obligation or agreement contemplated therein, (iv)&#8239;incurred in connection with any modification or amendment or restatement
of any term or provision of, or any supplement to, or the termination (in whole or in part) of, any Loan Document, (v)&#8239;incurred
in connection with internal audit reviews and Collateral audits, or (vi)&#8239;otherwise incurred with respect to the Credit Parties in
connection with the Loan Documents, including any filing or recording fees and expenses; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
reasonable and documented out-of-pocket costs and expenses incurred by the Collateral Agent and each Lender (and their respective successors
and assigns) and their respective Related Parties (including the reasonable and documented out-of-pocket fees, expenses and disbursements
of any legal counsel therefor for the Collateral Agent, Lenders and such Related Parties taken as a whole and in the case of an actual
or perceived conflict of interest, one additional legal counsel for such affected Indemnified Person) in connection with (i)&#8239;any
refinancing or restructuring of the credit arrangements provided hereunder in the nature of a &ldquo;work-out,&rdquo; (ii)&#8239;the enforcement
or protection or preservation of any right or remedy under any Loan Document, any Obligation, with respect to any of the Collateral or
any other related right or remedy, or (iii)&#8239;the commencement, defense, conduct of, intervention in, or the taking of any other action
with respect to, any proceeding (including any Insolvency Proceeding) related to any Credit Party or any Subsidiary of any Credit Party
in respect of any Loan Document or Obligation, or otherwise in connection with any Loan Document or Obligation (or the response to and
preparation for any subpoena or request for document production relating thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lender Transfer</B>&rdquo;
is defined in <U>Section&#8239;11.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lien</B>&rdquo;
means a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind or assignment for security
purposes, whether voluntarily incurred or arising by operation of law or otherwise against any property or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Liquidity</B>&rdquo;
means, at any time of determination, an amount equal to the sum of unrestricted cash and Cash Equivalents (including the proceeds of
the Term Loans) maintained by the Credit Parties in accounts which have been granted as security in favor of the Collateral Agent pursuant
to Collateral Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Loan Documents</B>&rdquo;
means, collectively, this Agreement, the Disclosure Letter, the Term Loan Notes, the Security Agreement, the IP Agreements, the Perfection
Certificate, any Control Agreement, any Collateral Access Agreement, any other Collateral Document, any guaranties executed by a Guarantor
in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties in connection with this Agreement, and any
other present or future agreement between or among a Credit Party, the Collateral Agent and any Lender in connection with this Agreement,
including in each case, for the avoidance of doubt, any annexes, exhibits or schedules thereto, and any related ancillary documents,
accessions, agreements, waivers or consents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Logistics Agreement</B>&rdquo;
means any agreement between the Borrower or its Subsidiaries, on the one hand, and a Person acting solely as a Logistics Provider, on
the other hand, including agreements with specialty pharmacies and specialty distributors, in each case (x)&#8239;entered into in the
ordinary course of business and (y)&#8239;that does not substantively constitute an out-licensing or sale transaction with respect to
the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Logistics Provider</B>&rdquo;
means a Person that has the right, option or obligation to distribute, transport, warehouse, package, import, or provide similar logistics
services with respect to the Product pursuant to a Logistics Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Makewhole Amount</B>&rdquo;
means the Tranche A Makewhole Amount or the Tranche B Makewhole Amount (as applicable) or the combination thereof, as the context dictates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Managed Care Plans</B>&rdquo;
means all health maintenance organizations, preferred provider organizations, individual practice associations, competitive medical plans
and similar arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Manufacturing Agreement</B>&rdquo;
means (a)&#8239;any manufacturing or supply contract or agreement entered into by any Credit Party or any of its Subsidiaries with third
parties for (i)&#8239;the commercial supply in the Territory of the Product for any indication or (ii)&#8239;the commercial manufacture
or in-bound supply of any raw materials or component(s)&#8239;(including component raw materials and other component materials) incorporated
into the Product which such raw materials or component(s)&#8239;are not readily replaceable (with the Manufacturing Agreements in effect
as of the Effective Date being set forth in <U>Schedule 13.1</U> of the Disclosure Letter), and (b)&#8239;any future contract or agreement
entered into after the Effective Date by any Credit Party or any of its Subsidiaries with third parties for (i)&#8239;the clinical or
commercial manufacture or in-bound supply in the Territory of the Product for any indication or (ii)&#8239;the commercial manufacture
or in-bound supply of any raw materials or component(s)&#8239;(including component raw materials and other component materials) incorporated
into the Product which such raw materials or component(s)&#8239;are not readily replaceable. For the avoidance of doubt, each of the agreements
or contracts between a Credit Party or any of its Subsidiaries, on the on hand, and one or more of Catalent Maryland,&#8239;Inc., Catalent
Pharma Solution or Catalent Pharma Solutions LLC, on the other hand, included in the Virtual Data Room made available to Lenders and
the Collateral Agent prior to the Effective Date in connection with the transactions contemplated hereby constitutes a Manufacturing
Agreement for all purposes hereunder. Notwithstanding the foregoing, agreements or contracts entered into by any Credit Party or any
of its Subsidiaries with third parties for the performance of services relating to the manufacture or supply of the Product for any indication
or the commercial manufacture or in-bound supply of any raw materials or component(s)&#8239;incorporated into the Product are not Manufacturing
Agreements hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Margin Stock</B>&rdquo;
means &ldquo;margin stock&rdquo; within the meaning of Regulations U and X of the Federal Reserve Board as now and from time-to-time
hereafter in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Change</B>&rdquo; means any material adverse change in or material adverse effect on: (a)&#8239;the business, financial condition, properties
or assets (including all or any material portion of the Collateral), liabilities (actual or contingent), operations or performance of
the Credit Parties, taken as a whole, since December&#8239;31, 2024; (b)&#8239;without limiting the generality of <U>clause (a)</U>&#8239;above,
(i)&#8239;any of the rights or remedies of the Credit Parties, taken as a whole, in or related to the research, development, manufacture,
production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Product in
the U.S., or (ii)&#8239;the period of regulatory exclusivity granted by the applicable Regulatory Agency for the Product in the U.S. (including
Orphan Drug exclusivity); (c)&#8239;any ability of the Credit Parties, taken as a whole, to fulfill the payment or performance obligations
under the Loan Agreement or any other Loan Document; (d)&#8239;the binding nature or validity of, or the ability of the Collateral Agent
or any Lender to enforce, any of the Loan Documents or any of its material rights or remedies under any of the Loan Documents; or (e)&#8239;the
validity, perfection (except to the extent expressly permitted under the Loan Documents) or priority of Liens in favor of the Collateral
Agent, for the benefit of the Lenders and the other Secured Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Contract</B>&rdquo;
means any contract or other arrangement to which any Credit Party or any of its Subsidiaries is a party (other than the Loan Documents)
or by which any of its assets or properties are bound, in each case, relating to any aspect of the research, development, manufacture,
production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Product in
the Territory, for which the breach of, default or nonperformance under, cancellation or termination of or the failure to renew could
reasonably be expected to result in a Material Adverse Change. For the avoidance of doubt, (x)&#8239;each Manufacturing Agreement and
(y)&#8239;each Company IP Agreement is deemed to be a Material Contract for all purposes hereunder. Notwithstanding the foregoing, the
following agreements are not Material Contracts: (a)&#8239;any customer contracts, (b)&#8239;any purchase orders or statements of work
entered into from time to time in the ordinary course of business pursuant to Manufacturing Agreements, except, in each case if any such
order or statement is in the form of an amendment to or otherwise amends any material terms of any Manufacturing Agreement, (c)&#8239;agreements
or other contractual arrangements in connection with capital expenditures in the ordinary course of business, (d)&#8239;agreements or
other contractual arrangements entered into in the ordinary course of business in connection with the purchase of materials or the sale
of third-party products for further distribution and (e)&#8239;distribution agreements entered into in the ordinary course of business
with third parties for the sale of the Product in a specific territory outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Medicaid</B>&rdquo;
means the health care assistance program established by Title XIX of the SSA (42 U.S.C. &sect; 1396 et seq.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Medicare</B>&rdquo;
means the health insurance program for the aged and disabled established by Title XVIII of the SSA (42 U.S.C. 1395 et seq.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Mortgage</B>&rdquo;
means any deed of trust, leasehold deed of trust, mortgage, leasehold mortgage, deed to secure debt, leasehold deed to secure debt or
other document creating a Lien on real estate or any interest in real estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Multiemployer Plan</B>&rdquo;
means a multiemployer plan within the meaning of Section&#8239;4001(a)(3)&#8239;or Section&#8239;3(37) of ERISA (a)&#8239;to which Borrower
or its Subsidiaries or their respective ERISA Affiliates is then making or accruing an obligation to make contributions; (b)&#8239;to
which Borrower or its Subsidiaries or their respective ERISA Affiliates has within the preceding five (5)&#8239;plan years made contributions;
or (c)&#8239;with respect to which Borrower or its Subsidiaries could incur material liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Net Sales</B>&rdquo;
means, for any period, net sales of the Product in the Territory occurring during such period, determined by a Responsible Officer of
Borrower in good faith in accordance with GAAP and as presented in Borrower&rsquo;s financial statements (including, with respect of
any portion of such period covered by financial statements filed with the SEC (if any), such filed financial statements); <U>provided</U>,
<U>however</U>, that &ldquo;Net Sales&rdquo; shall exclude any milestone payments, any non-recurring payments and any non-sales-based
revenues or proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Note Register</B>&rdquo;
is defined in <U>Section&#8239;2.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Obligations</B>&rdquo;
means, collectively, the Credit Parties&rsquo; obligations to pay when due any and all debts, principal, interest, Lender Expenses, the
Additional Consideration, the Exit Consideration, the Makewhole Amount, the Prepayment Premium and any other fees, expenses, indemnities
and amounts any Credit Party owes any Lender or the Collateral Agent now or later, under this Agreement or any other Loan Document, including
interest accruing after Insolvency Proceedings begin (whether or not allowed), and to perform Borrower&rsquo;s duties under the Loan
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>OFAC</B>&rdquo;
is defined in <U>Section&#8239;4.18(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Operating Documents</B>&rdquo;
means, collectively with respect to any Person, such Person&rsquo;s formation and constitutional documents and, (a)&#8239;if such Person
is a corporation, its bylaws (or similar organizational regulations), (b)&#8239;if such Person is an exempted company or a company limited
by shares, its memorandum and articles of association (or similar organizational regulations), (c)&#8239;if such Person is a limited liability
company, its limited liability company agreement (or similar agreement), and (d)&#8239;if such Person is a partnership, its partnership
agreement (or similar agreement), in each case including all amendments, restatements, amendment and restatements, supplements and other
modifications thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ordinary course
of business</B>&rdquo; means, in respect of any transaction involving any Person, the ordinary course of such Person&rsquo;s business,
undertaken by such Person in good faith and not for purposes of evading any covenant, prepayment obligation or restriction in any Loan
Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Orphan Drug</B>&rdquo;
means a drug or biologic that meets the definition for &ldquo;orphan drug&rdquo; provided in 21 C.F.R. &sect; 316.3(b)(10)&#8239;that
has been granted an orphan drug designation by the Secretary of U.S. Department of Health and Human Services under 21 U.S.C. &sect; 360bb,
and any foreign equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Other Connection
Taxes</B>&rdquo; means, with respect to any Lender, Taxes imposed as a result of a present or former connection (including present or
former connection of its agents) between such Lender and the jurisdiction imposing such Tax (other than connections arising solely from
such Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected
a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest
in any Term Loan or Loan Document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Other Taxes</B>&rdquo;
means all present or future stamp, court or documentary, intangible, recording, excise, filing, value added Taxes, mortgage or property
Taxes, charges or similar levies or similar Taxes that arise from any payment made hereunder, from the execution, delivery, performance,
enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document,
except any such Taxes that are Other Connection Taxes imposed with respect to a Lender Transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Participant Register</B>&rdquo;
is defined in <U>Section&#8239;11.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Patents</B>&rdquo;
means all patents and patent applications (including any improvements, continuations, continuations-in-part, divisions, provisionals
or any substitute applications), any patent issued with respect to any of the foregoing patent applications, any reissue, reexamination,
renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent, and any confirmation
patent or registration patent or patent of addition based on any such patent, and all foreign and international counterparts of any of
the foregoing. For the avoidance of doubt, patents and patent applications under this definition include individual patent claims and
include all those filed with the U.S. Patent and Trademark Office</FONT> or which could be nationalized in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Patriot Act</B>&rdquo;
is defined in <U>Section&#8239;3.1(h).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Payment Date</B>&rdquo;
means (a)&#8239;the last Business Day of each March, June, September&#8239;and December&#8239;of each year, commencing on the Initial Payment
Date, and continuing through (b)&#8239;the Term Loan Maturity Date (provided, that if any such date is not a Business Day, then on the
immediately preceding Business Day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Perfection Certificate</B>&rdquo;
is defined in <U>Section&#8239;4.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Periodic Term SOFR
Determination Day</B>&rdquo; has the meaning specified in the definition of &ldquo;Term SOFR&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Acquisition</B>&rdquo;
means any Acquisition, so long as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no
Default or Event of Default shall have occurred and be continuing as of, or could reasonably be expected to result from, the consummation
of such Acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
properties or assets being acquired or licensed, or the Person whose Equity Interests are being acquired, are useful in or engaged in,
as applicable, (i)&#8239;the same or a related line of business as that then-conducted by Borrower or its Subsidiaries, or (ii)&#8239;a
line of business that is ancillary to and in furtherance of a line of business as that then-conducted by Borrower or its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the case of an Asset Acquisition, the subject assets are being acquired or licensed by a Credit Party, and within the timeframes expressly
set forth in <U>Section&#8239;5.12</U> with respect to all assets constituting Collateral, such Credit Party shall have executed and delivered
or authorized, as applicable, any and all security agreements, financing statements and any other documentation required by <U>Section&#8239;5.12</U>
or reasonably requested by the Collateral Agent, in order to include the newly acquired or licensed assets within the Collateral, as
applicable, to the extent required by <U>Section&#8239;5.12</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the case of a Stock Acquisition, the subject Equity Interests are being acquired in such Acquisition directly or indirectly by a Credit
Party, and such Credit Party shall have complied with its obligations under <U>Section&#8239;5.13</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Indebtedness or Liens assumed in connection with such Acquisition are otherwise permitted under <U>Section&#8239;6.4</U> or <U>6.5</U>,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Distributions</B>&rdquo;
means, in each case subject to <U>Section&#8239;6.8</U> if applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>dividends,
distributions or other payments by any Wholly Owned Subsidiary of Borrower on its Equity Interests to, or the redemption, retirement
or purchase by any Wholly Owned Subsidiary of Borrower of its Equity Interests from, Borrower or any other Wholly Owned Subsidiary of
Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>dividends,
distributions or other payments by any non-Wholly Owned Subsidiary on its Equity Interests to, or the redemption, retirement or purchase
by any non-Wholly Owned Subsidiary of its Equity Interests from, Borrower or any other Subsidiary or each other owner of such non-Wholly
Owned Subsidiary&rsquo;s Equity Interests based on their relative ownership interests of the relevant class of such Equity Interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>exchanges,
redemptions or conversions by Borrower in whole or in part any of its Equity Interests for or into another class of its Equity Interests
or rights to acquire its Equity Interests or with proceeds from substantially concurrent equity contributions or issuances of new Equity
Interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
such payments arising from (i)&#8239;a Permitted Acquisition or (ii)&#8239;other Permitted Investment, in each case of this <U>clause (d)</U>&#8239;by
Borrower or any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
payment of dividends by Borrower solely in non-cash pay and non-redeemable capital stock (including, for the avoidance of doubt, dividends
and distributions payable solely in Equity Interests);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>cash
payments in lieu of the issuance of fractional shares arising out of stock dividends, splits or combinations or in connection with the
exercise of warrants, options or other securities convertible into or exchangeable for Equity Interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
connection with any Acquisition or other Investment by Borrower or any of its Subsidiaries, (i)&#8239;the receipt or acceptance of the
return to Borrower or any of its Subsidiaries of Equity Interests of Borrower constituting a portion of the purchase price consideration
in settlement of indemnification claims, or as a result of a purchase price adjustment (including earn-outs or similar obligations) and
(ii)&#8239;payments or distributions to equity holders pursuant to appraisal rights required under Requirements of Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
distribution of rights pursuant to any shareholder rights plan or the redemption of such rights for nominal consideration in accordance
with the terms of any shareholder rights plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>dividends,
distributions or payments on its Equity Interests by any Subsidiary to any Credit Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>dividends,
distributions or payments on its Equity Interests by any Subsidiary that is not a Credit Party to any other Subsidiary that is not a
Credit Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>purchases
of Equity Interests of Borrower or its Subsidiaries in connection with net settlements, the exercise of stock options by way of cashless
exercise, or in connection with the satisfaction of withholding tax obligations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>issuance
to directors, officers, employees or contractors of Borrower or its Subsidiaries of awards or common stock of Borrower pursuant to awards,
of restricted stock, restricted stock units, or other rights to acquire common stock of Borrower, in each case pursuant to plans or agreements
approved by Borrower&rsquo;s Board of Directors (or committee thereof) or stockholders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
repurchase, retirement or other acquisition or retirement for value of Equity Interests of Borrower or any of its Subsidiaries held by
any future, present or former employee, consultant, officer or director (or spouse, ex-spouse or estate of any of the foregoing or trust
for the benefit of any of the foregoing or any lineal descendants thereof) of Borrower or any of its Subsidiaries pursuant to any management
equity plan or stock option plan or any other management or employee benefit plan or agreement, or any stock subscription or shareholder
agreement or employment agreement; <U>provided</U>, <U>however</U>, that the aggregate payments made under this <U>clause (m)</U>&#8239;do
not exceed in any calendar year the sum of (i)&#8239;$3,000,000 <I>plus</I> (ii)&#8239;the amount of any payments received in such calendar
year under key-man life insurance policies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>dividends
or distributions on its Equity Interests by Borrower or any of its Subsidiaries payable solely in additional shares of its common stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>additional
Restricted Payments in an aggregate amount not to exceed $5,000,000 in the aggregate; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Restricted
Payments with respect to the Borrower&rsquo;s Series&#8239;A Preferred Stock in an aggregate amount not to exceed $10,000,000 per annum;
<U>provided</U>, <U>however</U>, that all such payments occur after such time as Borrower can no longer make paid-in-kind dividends or
distributions in accordance with the terms of such Series&#8239;A Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Holders</B>&rdquo;
means (i)&#8239;Randal J. Kirk and his controlled Affiliates and family members (including any fund, estate, trust, partnership or other
bona fide estate-planning vehicle the only beneficiaries of which are any of the foregoing individuals) and (ii)&#8239;any Person with
which one or more of the Persons in clause (i)&#8239;above form a &ldquo;group&rdquo; (within the meaning of Section&#8239;14(d)&#8239;of
the Exchange Act) so long as, in the case of this clause (ii), the relevant Persons under clause (i)&#8239;directly or indirectly collectively
beneficially own more than 50% of the relevant voting stock beneficially owned by the group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Indebtedness</B>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
of the Credit Parties to Secured Parties under this Agreement and the other Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
existing on the Effective Date and shown on <U>Schedule 13.2</U> of the Disclosure Letter;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&#8239;Indebtedness
incurred to finance the purchase, construction, repair, or improvement of fixed assets and (ii)&#8239;Capital Lease Obligations; <U>provided</U>,
<U>however</U>, that all such Indebtedness and Capital Lease Obligations (other than that which directly relates to the purchase, construction,
repair, leasing or improvement of manufacturing facilities) shall not exceed $10,000,000 in the aggregate at any time outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
in connection with trade credit, corporate credit cards, purchasing cards or bank card products, <U>provided</U>, <U>that</U>, any such
Indebtedness that is secured shall not exceed $5,000,000 in the aggregate at any time outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>guarantees
of Permitted Indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
assumed in connection with any Permitted Acquisition or Permitted Investment, so long as (i)&#8239;such Indebtedness was not incurred
in connection with, or in anticipation of, such Acquisition or Investment and (ii)&#8239;such Indebtedness is at all times Subordinated
Debt or Capital Lease Obligations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
of Borrower or any of its Subsidiaries with respect to letters of credit, bank guarantees, bankers&rsquo; acceptances, warehouse receipts
or similar instruments outstanding and to the extent secured, secured solely by cash or Cash Equivalents, in each case entered into in
the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
owed: (i)&#8239;by a Credit Party to another Credit Party; (ii)&#8239;by a Subsidiary of Borrower that is not a Credit Party to another
Subsidiary of Borrower that is not a Credit Party; (iii)&#8239;by a Credit Party to a Subsidiary of Borrower that is not a Credit Party;
or (iv)&#8239;by a Subsidiary of Borrower that is not a Credit Party to a Credit Party, not to exceed $10,000,000 in the aggregate at
any time outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
consisting of Contingent Obligations described in <U>clause (a)</U>&#8239;of the definition thereof: (i)&#8239;of a Credit Party of Permitted
Indebtedness of another Credit Party (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder);
(ii)&#8239;of a Subsidiary of Borrower which is not a Credit Party of Permitted Indebtedness (or obligations that do not constitute Indebtedness
hereunder and are not prohibited hereunder) of another Subsidiary of Borrower which is not a Credit Party; (iii)&#8239;of a Subsidiary
of Borrower which is not a Credit Party of Permitted Indebtedness (or obligations that do not constitute Indebtedness hereunder and are
not prohibited hereunder) of a Credit Party; or (iv)&#8239;of a Credit Party of Permitted Indebtedness (or obligations that do not constitute
Indebtedness hereunder and are not prohibited hereunder) of a Subsidiary of Borrower which is not a Credit Party not to exceed $5,000,000
in the aggregate at any time outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
consisting of Contingent Obligations described in <U>clause (b)</U>&#8239;of the definition thereof, incurred in connection with any Permitted
Acquisition, Permitted Transfer, Permitted Investment or any in-licensing or any collaboration, co-promotion or co-marketing arrangement;
provided such Indebtedness is due and payable upon the occurrence of an event or the performance of an act (and not solely with the passage
of time);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
of any Person that becomes a (direct or indirect) Subsidiary of Borrower (or of any Person not previously a Subsidiary that is merged
or consolidated with or into a Subsidiary of Borrower in a transaction permitted hereunder after the Effective Date); <U>provided</U>,
<U>that</U>, all such Indebtedness was not made in contemplation of or in connection with such Person becoming a (direct or indirect)
Subsidiary of Borrower (or merging or consolidating with or into a Subsidiary of Borrower) or the Permitted Acquisition of any related
assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&#8239;Indebtedness
with respect to workers&rsquo; compensation claims, payment obligations in connection with health, disability or other types of social
security benefits, unemployment or other insurance obligations, reclamation and statutory obligations or (ii)&#8239;Indebtedness related
to employee benefit plans, including annual employee bonuses, accrued wage increases and 401(k)&#8239;plan matching obligations; in each
case, incurred in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
in respect of performance bonds, bid bonds, appeal bonds, surety bonds and completion guarantees and similar obligations arising in the
ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
in respect of netting services, overdraft protection and other cash management services, in each case in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
consisting of the financing of insurance premiums in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
consisting of guarantees resulting from endorsement of negotiable instruments for collection by any Credit Party in the ordinary course
of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>unsecured
Indebtedness incurred in connection with any items of Permitted Distributions in <U>clause (m)</U>&#8239;of the definition of Permitted
Distributions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
under any (i)&#8239;unsecured Hedging Agreements entered into for hedging and not speculative purposes, and (ii)&#8239;Hedging Agreements
with respect to interest rates that are secured only by cash or Cash Equivalents and entered into for hedging and not speculative purposes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Indebtedness
in an aggregate principal amount not to exceed $5,000,000; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>subject
to the proviso immediately below, extensions, refinancings, renewals, modifications, amendments, restatements and, in the case of any
items of Permitted Indebtedness in <U>clause (b)</U>&#8239;of the definition thereof or Permitted Indebtedness constituting notes governed
by an indenture, exchanges, of any items of Permitted Indebtedness in <U>clauses (a)</U>&#8239;through <U>(s)</U>&#8239;above, <U>provided</U>,
<U>that</U>, in the case of <U>clause (b)</U>&#8239;above, the principal amount thereof is not increased (other than by any reasonable
amount of premium (if any), interest (including post-petition interest), fees, expenses, charges or additional or contingent interest
reasonably incurred in connection with the same and the terms thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing
or anything in this Agreement to the contrary: (x)&#8239;no direct or indirect synthetic royalty or similar financing transaction involving
the sale of revenues or royalties, in each case, based on net sales of any product (including the Product) in the Territory entered into
after the Tranche A Closing Date (including, for the avoidance of doubt, any Indebtedness constituting such synthetic royalty or other
similar payment); and (y)&#8239;except to the extent incurred in connection with any Permitted Acquisitions, Permitted Investments, Permitted
Licenses, in-licensing agreements or any collaboration, co-promotion or co-marketing arrangements, no Indebtedness constituting royalty
payments or milestone payments based on net sales, in each case, based on the research, development, manufacture, production, use, commercialization,
marketing, importing, storage, transport, offer for sale, distribution or sale of any product (including the Product) in the Territory,
that is, directly or indirectly, created, incurred, assumed or guaranteed after the Tranche A Closing Date; in each case of <U>sub-clause
(x)</U>&#8239;or <U>(y)</U>&#8239;above, by a Credit Party or any of its Subsidiaries, shall in any instance be permitted under this Agreement
without the prior written consent of the Collateral Agent or the Required Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Investments</B>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Investments
(including Investments in Borrower and Subsidiaries) existing on the Effective Date and shown on <U>Schedule 13.3</U> of the Disclosure
Letter, and any extensions, renewals or reinvestments thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of cash and Cash Equivalents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of deposit accounts or securities accounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
in connection with Permitted Transfers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of (i)&#8239;travel advances and employee relocation loans and other employee advances in the ordinary course of business,
and (ii)&#8239;loans to employees, officers or directors relating to the purchase of equity securities of Borrower pursuant to employee
stock purchase plans or agreements approved by Borrower&rsquo;s Board of Directors (or committee thereof);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement
of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of accounts or notes receivable of, or prepaid royalties and other credit extensions, to customers, suppliers and manufacturers
who are not Affiliates, in the ordinary course of business; provided that this <U>clause (h)</U>&#8239;shall not apply to Investments
of any Credit Party in any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[Reserved];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
(i)&#8239;required in connection with a Permitted Acquisition (including the formation of any Subsidiary for the purpose of effectuating
such Permitted Acquisition, the capitalization of such Subsidiary whether by capital contribution or intercompany loans, in each case,
to the extent otherwise permitted by the terms of this Agreement, related Investments in Subsidiaries necessary to consummate such Permitted
Acquisition, and the receipt of any non-cash consideration in a Permitted Acquisition), and (ii)&#8239;consisting of earnest money deposits
required in connection with a Permitted Acquisition or other acquisition of properties or assets not otherwise prohibited hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
constituting the formation of any Subsidiary for the purpose of consummating a merger or acquisition transaction permitted by <U>Section&#8239;6.3(a)(i)</U>&#8239;through
<U>(iii)</U>&#8239;hereof, which such transaction is otherwise a Permitted Investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
of any Person that (i)&#8239;becomes a Subsidiary of Borrower (or of any Person not previously a Subsidiary of Borrower that is merged
or consolidated with or into a Subsidiary of Borrower in a transaction permitted hereunder) after the Effective Date, or (ii)&#8239;are
assumed after the Effective Date by any Subsidiary of Borrower in connection with an acquisition of assets from such Person by such Subsidiary,
in either case, in a Permitted Acquisition; <U>provided</U>, <U>that</U>, in each case any such Investment (w)&#8239;does not constitute
Indebtedness of such Person, (x)&#8239;exists at the time such Person becomes a Subsidiary of Borrower (or is merged or consolidated with
or into a Subsidiary of Borrower) or such assets are acquired, (y)&#8239;was not made in contemplation of or in connection with such Person
becoming a Subsidiary of Borrower (or merging or consolidating with or into a Subsidiary of Borrower) or such acquisition of assets,
and (z)&#8239;could not reasonably be expected to result in a Default or an Event of Default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
arising as a result of the licensing of Intellectual Property in the ordinary course of business and not otherwise prohibited hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Investments
by: (i)&#8239;any Credit Party in any other Credit Party; (ii)&#8239;any Subsidiary of Borrower which is not a Credit Party in another
Subsidiary of Borrower which is not a Credit Party; (iii)&#8239;any Subsidiary of Borrower which is not a Credit Party in any Credit Party;
and (iv)(A)&#8239;any Credit Party or a Subsidiary of Borrower which is not a Credit Party as of the Effective Date and shown on <U>Schedule
13.3</U> of the Disclosure Letter, and (B)&#8239;any Credit Party in a Subsidiary of Borrower which is not a Credit Party not to exceed
$10,000,000 in the aggregate outstanding at any time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>repurchases
of capital stock of Borrower or any of its Subsidiaries deemed to occur upon the exercise of options, warrants or other rights to acquire
capital stock of Borrower or such Subsidiary solely to the extent that shares of such capital stock represent a portion of the exercise
price of such options, warrants or such rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Investments
consisting of non-cash consideration received for any Permitted Transfer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Investments
consisting of acquisitions of assets from third parties used in the ordinary course of business, including inventory, raw materials,
vehicles, equipment, office supplies, software and other similar assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Investments
consisting of in-licensing agreements, <U>provided</U>, <U>that</U>, no Indebtedness that is not Permitted Indebtedness is incurred or
assumed in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the extent constituting an Investment, any Permitted License;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&#8239;unsecured
Hedging Agreements entered into for hedging and not speculative purposes, and (ii)&#8239;Hedging Agreements with respect to interest rates
that are secured only by cash or Cash Equivalents and entered into for hedging and not speculative purposes; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
Investments, not to exceed $5,000,000 in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>provided</U></FONT>,
<U>however</U>, that, none of the foregoing Investments shall be a &ldquo;Permitted Investment&rdquo; if any Indebtedness or Liens assumed
in connection with such Investment are not otherwise permitted under <U>Section&#8239;6.4</U> or <U>6.5</U>, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Licenses</B>&rdquo;
means, collectively: (a)&#8239;any exclusive or non-exclusive license, sublicense or covenant not to sue with respect to the Product or
to any Intellectual Property (including, for clarity, any Company IP) in any geography outside of the Territory; (b)&#8239;without limiting
clauses (d)&#8239;&ndash; (g)&#8239;below, any Permitted Non-Product Platform License that does not require any Credit Party to pay to
the licensee any royalties, milestones or similar compensatory payments based on such licensee&rsquo;s exploitation of the applicable
licensed Intellectual Property; (c)&#8239;without limiting clauses (d)&#8239;&ndash; (g)&#8239;below, any exclusive or non-exclusive license,
sublicense or covenant not to sue with respect to any (i)&#8239;Intellectual Property that is not Covered Company IP or (ii)&#8239;any
Platform Intellectual Property, in each case of (i)&#8239;and (ii), whether within or outside the Territory, that (A)&#8239;is not related
to, or does not interfere with or impede the ability of Borrower or any Subsidiary of Borrower to conduct the research, development,
manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the
Product in the Territory or enforce its rights with respect to any of the foregoing within the Territory and (B)&#8239;does not require
any Credit Party to pay to the licensee any royalties, milestones or similar compensatory payments based on such licensee&rsquo;s exploitation
of the applicable licensed Intellectual Property; (d)&#8239;licenses or sublicenses pursuant to any Logistics Agreements, Manufacturing
Agreements or otherwise with a logistics provider or contract manufacturer (or other contractor or service provider), in each case solely
with respect to the services provided under such agreement, whether within or outside the Territory; (e)&#8239;any non-exclusive licenses
or sublicenses with respect to any research and development, whether within or outside the Territory (including with any contract research
organization or other contractor or service provider); (f)&#8239;any intercompany license or other similar arrangement described in clause
(k)&#8239;of the definition of Permitted Transfers among Credit Parties and Subsidiaries, whether within or outside the Territory; and
(g)&#8239;any intercompany license or other similar arrangement among Credit Parties, whether within or outside of the Territory. Notwithstanding
the foregoing or any other provision of this Agreement, no Excluded License with respect to the Product entered into after the Effective
Date shall be a &ldquo;Permitted License&rdquo; hereunder without the prior written consent of the Collateral Agent or the Required Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Liens</B>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
in favor and for the benefit of any Lender and the other Secured Parties securing the Obligations pursuant to any Loan Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
existing on the Effective Date and set forth on <U>Schedule 13.4</U> of the Disclosure Letter;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
for Taxes, assessments or governmental charges which (i)&#8239;are not yet due and payable or (ii)&#8239;if due and payable, are being
contested in good faith and by appropriate proceedings; <U>provided</U> that, in each case, adequate reserves therefor have been set
aside on the books of the applicable Person and maintained in conformity with GAAP;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&#8239;pledges
or deposits made in the ordinary course of business (other than Liens imposed by ERISA) in connection with workers&rsquo; compensation,
payroll taxes, unemployment insurance, old-age pensions, or other similar social security legislation, (ii)&#8239;pledges or deposits
made in the ordinary course of business securing liability for reimbursement or indemnification obligations of (including obligations
in respect of letters of credit or bank guarantees for the benefit of) insurance carriers providing property, casualty or liability insurance
to Borrower or any of its Subsidiaries, (iii)&#8239;subject to <U>Section&#8239;6.2(b)</U>, statutory or common law Liens of landlords,
(iv)&#8239;pledges or deposits to secure performance of tenders, bids, leases, statutory or regulatory obligations, surety and appeal
bonds, government contracts, performance and return-of-money bonds and other obligations of like nature, in each case other than for
borrowed money and entered into in the ordinary course of business, (v)&#8239;Liens otherwise arising by operation of law in favor of
the owner or sublessor of leased premises and confined to the property rented, (vi)&#8239;Liens that are restrictions on transfer of securities
imposed by applicable securities laws, and (vii)&#8239;Liens resulting from a filing by a lessor as a precautionary filing for a true
lease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
arising from attachments or judgments, orders, or decrees in circumstances not constituting an Event of Default under either <U>Section&#8239;7.4</U>
or <U>Section&#8239;7.7</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
(including the right of set-off) in favor of banks or other financial institutions incurred on deposits made in accounts held at such
institutions in the ordinary course of business; <U>provided</U> that such Liens (i)&#8239;are not given in connection with the incurrence
of any Indebtedness, (ii)&#8239;relate solely to obligations for administrative and other banking fees and expenses incurred in the ordinary
course of business in connection with the establishment or maintenance of such accounts and (iii)&#8239;are within the general parameters
customary in the banking industry;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
that are contractual rights of set-off (i)&#8239;relating to pooled deposit or sweep accounts of Borrower or any of its Subsidiaries to
permit satisfaction of overdraft or similar obligations incurred in the ordinary course of business or (ii)&#8239;relating to purchase
orders and other agreements entered into with customers of Borrower or any of its Subsidiaries in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
solely on any cash earnest money deposits made by Borrower or any of its Subsidiaries in connection with any Permitted Acquisition, Permitted
Investment or other acquisition of assets or properties not otherwise prohibited under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
existing on assets or properties at the time of its acquisition or existing on the assets or properties of any Person at the time such
Person becomes a Subsidiary of Borrower, in each case after the Effective Date; <U>provided</U> that (i)&#8239;neither such Lien was created
nor the Indebtedness secured thereby was incurred in contemplation of such acquisition or such Person becoming a Subsidiary of Borrower,
(ii)&#8239;such Lien does not extend to or cover any other assets or properties (other than the proceeds or products thereof and other
than after-acquired assets or properties subject to a Lien securing Indebtedness and other obligations incurred prior to such time and
which Indebtedness and other obligations are permitted hereunder that requires, pursuant to its terms and conditions in effect at such
time, a pledge of after-acquired assets or properties, it being understood that such requirement shall not be permitted to apply to any
assets or properties to which such requirement would not have applied but for such acquisition), (iii)&#8239;the Indebtedness and other
obligations secured thereby is permitted under <U>Section&#8239;6.4</U> hereof and (iv)&#8239;such Liens are of the type otherwise permitted
under <U>Section&#8239;6.5</U> hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
securing Indebtedness permitted under <U>clause (c)</U>&#8239;of the definition of &ldquo;Permitted Indebtedness&rdquo; (including any
extensions, refinancings, modifications, amendments or restatements of such Indebtedness permitted under <U>clause (t)</U>&#8239;of the
definition of Permitted Indebtedness); <U>provided</U>, <U>that</U>, such Lien does not extend to or cover any assets or properties other
than those described in <U>clause (c)</U>&#8239;of the definition of Permitted Indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>servitudes,
easements, rights-of-way, restrictions and other similar encumbrances on real property imposed by Requirements of Law and encumbrances
consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor defects or other irregularities
in title which, in the aggregate, are not material, and which do not in any case materially detract from the value of the property subject
thereto or interfere with the ordinary conduct of the business of any Credit Party or any Subsidiary of any Credit Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the extent constituting a Lien, escrow arrangements securing indemnification obligations associated with any Permitted Acquisition or
Permitted Investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&#8239;leases
or subleases of real property granted in the ordinary course of business (including, if referring to a Person other than a Credit Party
or a Subsidiary, in the ordinary course of such Person&rsquo;s business), (ii)&#8239;licenses, sublicenses, leases or subleases of personal
property (other than Intellectual Property) granted to third parties in the ordinary course of business, in each case which do not interfere
in any material respect with the operations of the business of any Credit Party or any of its Subsidiaries and do not prohibit granting
the Collateral Agent a security interest in any Credit Party&rsquo;s personal property held at such location for the benefit of the Lenders
and other Secured Parties, (iii)&#8239;Permitted Licenses, and (iv)&#8239;retained interests of lessors or licensors or similar parties
under any in-licenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
on cash or other current assets pledged to secure: (i)&#8239;Indebtedness in respect of corporate credit cards, purchasing cards or bank
card products, <U>provided</U>, <U>that</U>, the portion of such Indebtedness secured pursuant to this clause (n)&#8239;shall not exceed
$5,000,000 in the aggregate at any time outstanding; or (ii)&#8239;Indebtedness in the form of letters of credit or bank guarantees entered
into in the ordinary course of business, <U>provided</U>, <U>that</U>, any such Indebtedness is secured solely by cash or Cash Equivalents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
on any properties or assets of Borrower or any of its Subsidiaries which do not constitute Collateral under the Loan Documents, other
than (i)&#8239;Liens on Equity Interests of any Subsidiary that does not constitute Collateral under the Loan Documents, or (ii)&#8239;Liens
that interfere with or impede the ability of Borrower or any Subsidiary of Borrower to conduct the research, development, manufacture,
production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Product in
the Territory or enforce its rights with respect to any of the foregoing within the Territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
on any properties or assets of Borrower or any of its Subsidiaries imposed by law or regulation which were incurred in the ordinary course
of business, including landlords&rsquo;, carriers&rsquo;, warehousemen&rsquo;s, mechanics&rsquo;, materialmen&rsquo;s, contractors&rsquo;,
suppliers of materials&rsquo;, architects&rsquo; and repairmen&rsquo;s Liens, and other similar Liens arising in the ordinary course
of business; <U>provided</U> that such Liens (i)&#8239;do not materially detract from the value of such properties or assets subject thereto
or materially impair the use of such properties or assets subject thereto in the operations of the business of Borrower or such Subsidiary
or (ii)&#8239;are being contested in good faith by appropriate proceedings, which conclusively operate to stay the sale or forfeiture
of any portion of such properties or assets subject thereto and for which adequate reserves have been set aside on the books of the applicable
Person and maintained in conformity with GAAP, if required;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
in favor of customs and revenue authorities arising as a Requirement of Law which were incurred in the ordinary course of business, to
secure payment of customs duties in connection with the importation of goods in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
on any goods sold to Borrower or any of its Subsidiaries in the ordinary course of business in favor of the seller thereof, but only
to the extent securing the unpaid purchase price for such goods and any related expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
securing Permitted Indebtedness of a Credit Party in favor of any other Credit Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
securing Indebtedness owed by a Subsidiary of Borrower that is not a Credit Party permitted under <U>clause (i)</U>&#8239;of the definition
of Permitted Indebtedness, in favor of a Credit Party or another Subsidiary of Borrower that is not a Credit Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
on insurance policies and the proceeds thereof; provided, <U>that</U>, such Liens are not given in connection with the incurrence of
any Indebtedness, secure only the financing of the insurance premiums with respect thereto, and are within the general parameters customary
in the insurance industry;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liens
solely on cash and Cash Equivalents in each case securing Hedging Agreements with respect to interest rates that are entered into for
hedging and not speculative purposes; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>additional
Liens on assets or properties, in each case so long as the aggregate principal amount of the Indebtedness and other obligations secured
thereby do not exceed $2,500,000 in the aggregate for all such Liens at any time outstanding; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>subject
to the provisos immediately below, the modification, replacement, extension or renewal of the Liens described in <U>clauses (a)</U>&#8239;through
<U>(w)</U>&#8239;above; <U>provided</U>, <U>however</U>, that any such modification, replacement, extension or renewal must (i)&#8239;be
limited to the assets or properties encumbered by the existing Lien (and any additions, accessions, parts, improvements and attachments
thereto and the proceeds thereof) and (ii)&#8239;not increase the principal amount of any Indebtedness secured by the existing Lien (other
than by any reasonable premium or other reasonable amount paid and fees and expenses reasonably incurred in connection therewith); <U>provided</U>,
<U>further</U>, that to the extent any of the Liens described in <U>clauses (a)</U>&#8239;through <U>(w)</U>&#8239;above secure Indebtedness
of a Credit Party, such Liens, and any such modification, replacement, extension or renewal thereof, shall constitute Permitted Liens
if and only to the extent that such Indebtedness is permitted under <U>Section&#8239;6.4</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Negative
Pledges</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations with regard to specific properties or assets encumbered by Permitted Liens, if and only to the extent each such prohibition
or limitation applies only to such properties or assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations set forth in any lease, license or other similar agreement entered into in the ordinary course of business and not prohibited
hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations relating to Permitted Indebtedness, in each case if and only to the extent such prohibitions or limitations, taken as
a whole, are not materially more restrictive than the prohibitions and limitations set forth in this Agreement and the other Loan Documents,
taken as a whole (as reasonably determined by a Responsible Officer of Borrower in good faith);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
provisions restricting assignments, subletting, sublicensing or other transfer of properties or assets subject thereto set forth in leases,
subleases, licenses and other similar agreements that are not otherwise prohibited under this Agreement or any other Loan Document, if
and only to the extent each such restriction applies only to the properties or assets subject to such leases, subleases, licenses or
agreements, and customary provisions restricting assignment, pledges or transfer of any agreement entered into in the ordinary course
of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations imposed by Requirements of Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations that exist as of the Effective Date under Indebtedness existing on the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
prohibitions or limitations arising in connection with any Permitted Transfer or contained in any agreement relating to any Permitted
Transfer pending the consummation of such Permitted Transfer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
provisions in shareholders&rsquo; agreements, joint venture agreements, organizational documents or similar binding agreements relating
to, or any agreement evidencing Indebtedness of, any joint venture entity or non-Wholly Owned Subsidiary and applicable solely to such
joint venture entity or non-Wholly Owned Subsidiary and the Equity Interests issued thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
net worth provisions set forth in real property leases entered into by Subsidiaries of Borrower, so long as such net worth provisions
could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably
determined by a Responsible Officer of Borrower in good faith);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
net worth provisions set forth in customer agreements entered into in the ordinary course of business that are not otherwise prohibited
under this Agreement or any other Loan Document, so long as such net worth provisions could not reasonably be expected to impair the
ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower
in good faith);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>restrictions
on cash or other deposits (including escrowed funds) imposed by agreements entered into in the ordinary course of business that are not
otherwise prohibited under this Agreement or any other Loan Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations set forth in any agreement in effect at the time any Person becomes a Subsidiary (but not any amendment, modification,
restatement, renewal, extension, supplement or replacement expanding the scope of any such restriction or condition); <U>provided</U>
that such agreement was not entered into in contemplation of such Person becoming a Subsidiary and each such prohibition or limitation
does not apply to Borrower or any other Subsidiary (other than such Person and any other Person that is a Subsidiary of such first Person
at the time such first Person becomes a Subsidiary);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations imposed by any Loan Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
provisions set forth in joint venture agreements or agreements governing minority investments that are not otherwise prohibited under
this Agreement or any other Loan Document, if and only to the extent each such prohibition or limitation applies only to the joint venture
entity or minority investment that is the subject of such agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>limitations
imposed with respect to any license acquired in a Permitted Acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
provisions restricting assignments or other transfer of properties or assets subject thereto set forth in any agreement entered into
in the ordinary course of business, if and only to the extent each such restriction applies only to the properties or assets subject
to such agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations imposed by any agreement evidencing any Permitted Indebtedness of the type described in <U>clause (c)</U>&#8239;of the
definition of Permitted Indebtedness; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations imposed by any amendments, modifications, restatements, renewals, extensions, supplements or replacements of any of the
agreements referred to in <U>clauses (a)</U>&#8239;through <U>(r)</U>&#8239;above, except to the extent that any such amendment, modification,
restatement, renewal, extension, supplement or replacement expands the scope of any such prohibition or limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Non-Product
Platform License</B>&rdquo; means any exclusive or non-exclusive license, sublicense or covenant not to sue with respect to any Platform
Intellectual Property for use in connection with the research, development, manufacture, production, use, commercialization, marketing,
importing, storage, transport, offer for sale, distribution or sale of any product other than the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Subsidiary
Distribution Restrictions</B>&rdquo; means, in each case notwithstanding <U>Section&#8239;6.8</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations with regard to specific properties or assets encumbered by Permitted Liens, if and only to the extent each such prohibition
or limitation applies only to such properties or assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations set forth in any lease, license or other similar agreement entered into in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations relating to Permitted Indebtedness, in each case if and only to the extent such prohibitions or limitations, taken as
a whole, are not materially more restrictive than the prohibitions and limitations set forth in this Agreement and the other Loan Documents,
taken as a whole (as reasonably determined by a Responsible Officer of Borrower in good faith);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
provisions restricting assignments, subletting, sublicensing or other transfer of properties or assets subject thereto set forth in leases,
subleases, licenses and other similar agreements that are not otherwise prohibited under this Agreement or any other Loan Document, if
and only to the extent each such restriction applies only to the properties or assets subject to such leases, subleases, licenses or
agreements, and customary provisions restricting assignment, pledges or transfer of any agreement entered into in the ordinary course
of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations on the transfer or assignment of any properties, assets or Equity Interests set forth in any agreement entered into in
the ordinary course of business that is not otherwise prohibited under this Agreement or any other Loan Document, if and only to the
extent each such prohibition or limitation applies only to such properties, assets or Equity Interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations imposed by Requirements of Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations that exist as of the Effective Date under Indebtedness existing on the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
prohibitions or limitations arising in connection with any Permitted Transfer or contained in any agreement relating to any Permitted
Transfer pending the consummation of such Permitted Transfer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
provisions in shareholders&rsquo; agreements, joint venture agreements, organizational documents or similar binding agreements relating
to, or any agreement evidencing Indebtedness of, any joint venture entity or non-Wholly Owned Subsidiary and applicable solely to such
joint venture entity or non-Wholly Owned Subsidiary and the Equity Interests issued thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
net worth provisions set forth in real property leases entered into by Subsidiaries of Borrower, so long as such net worth provisions
could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably
determined by a Responsible Officer of Borrower in good faith);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
net worth provisions set forth in customer agreements entered into in the ordinary course of business that are not otherwise prohibited
under this Agreement or any other Loan Document, so long as such net worth provisions could not reasonably be expected to impair the
ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower
in good faith);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>restrictions
on cash or other deposits (including escrowed funds) imposed by agreements entered into in the ordinary course of business that are not
otherwise prohibited under this Agreement or any other Loan Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations set forth in any agreement in effect at the time any Person becomes a Subsidiary (but not any amendment, modification,
restatement, renewal, extension, supplement or replacement expanding the scope of any such restriction or condition); provided that such
agreement was not entered into in contemplation of such Person becoming a Subsidiary and each such prohibition or limitation does not
apply to Borrower or any other Subsidiary (other than such Person and any other Person that is a Subsidiary of such first Person at the
time such first Person becomes a Subsidiary);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations imposed by any Loan Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
provisions set forth in joint venture agreements or agreements governing minority investments that are not otherwise prohibited under
this Agreement or any other Loan Document, if and only to the extent each such prohibition or limitation applies only to the joint venture
entity or minority investment that is the subject of such agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>customary
provisions restricting assignments or other transfer of properties or assets subject thereto set forth in any agreement entered into
in the ordinary course of business, if and only to the extent each such restriction applies only to the properties or assets subject
to such agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations imposed by any agreement evidencing any Permitted Indebtedness of the type described in <U>clause (c)</U>&#8239;of the
definition of Permitted Indebtedness; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>prohibitions
or limitations imposed by any amendments, modifications, restatements, renewals, extensions, supplements or replacements of any of the
agreements referred to in <U>clauses (a)</U>&#8239;through <U>(r)</U>&#8239;above, except to the extent that any such amendment, modification,
restatement, renewal, extension, supplement or replacement expands the scope of any such prohibition or limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Transfers</B>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
of any properties or assets which do not constitute Collateral under the Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
of Inventory in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
of surplus, damaged, worn out or obsolete equipment or immaterial property or assets that is, in the reasonable judgment of a Responsible
Officer of Borrower exercised in good faith, no longer economically practicable to maintain or useful in the ordinary course of business,
and Transfers of other properties or assets in lieu of any pending or threatened institution of any proceedings for the condemnation
or seizure of such properties or assets or for the exercise of any right of eminent domain;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
made in connection with, or constituting, Permitted Liens, Permitted Acquisitions or Permitted Investments;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
of cash and Cash Equivalents in the ordinary course of business for equivalent value and in a manner that is not prohibited under this
Agreement or the other Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers:
(i)&#8239;to a Credit Party, <U>provided</U> that, with respect to any properties or assets constituting Collateral under the Loan Documents,
any and all steps as may be required to be taken in order to create and maintain a first priority security interest in and Lien upon
such properties and assets in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties, including as required
pursuant to <U>Section&#8239;5.12</U>, are taken contemporaneously with the completion of any such Transfer; (ii)&#8239;between or among
non-Credit Parties; or (iii)&#8239;to a non-Credit Party, so long as such Transfer (x)&#8239;is on arm&rsquo;s length terms and is otherwise
permitted hereunder, (y)&#8239;constitutes an Investment that is otherwise permitted hereunder and (z)&#8239;does not include or otherwise
involve the transfer of any Covered Company IP to a non-Credit Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
sale or issuance of Equity Interests of any Subsidiary of Borrower to any Credit Party or Subsidiary, <U>provided</U>, <U>that</U>, any
such sale or issuance by a Credit Party shall be to another Credit Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
discount without recourse or sale or other disposition of unpaid and overdue accounts receivable arising in the ordinary course of business
in connection with the compromise, collection or settlement thereof and not part of a financing transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
abandonment, disclaimer, forfeiture, dedication to the public, cancellation, non-renewal or discontinuance of use or maintenance of Intellectual
Property (including, for clarity, any Company IP) that a Responsible Officer of Borrower reasonably determines in good faith (i)&#8239;is
no longer economically practicable to maintain or useful in the ordinary course of business and that (ii)&#8239;could not reasonably be
expected to be adverse to the rights, remedies and benefits available to, or conferred upon, the Collateral Agent or any Lender under
any Loan Document in any material respect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>without
limiting <U>clause (a)</U>&#8239;above, Transfers by Borrower or any of its Subsidiaries pursuant to any Permitted License;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>intercompany
licenses or grants of rights of distribution, co-promotion or similar commercial rights: (i)&#8239;between or among the Credit Parties;
(ii)&#8239;between or among the Credit Parties and Subsidiaries that are not Credit Parties and, in the case of any such licenses or grant
of rights that relates to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing,
storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of the Product within the Territory
entered into prior to the Effective Date, listed on <U>Schedule 13.5</U> of the Disclosure Letter; and (iii)&#8239;between or among Subsidiaries
that are not Credit Parties, together, in each case, with renewals, replacements and extensions thereof (including additional licenses
or grants in relation to new territories) on comparable terms in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
involuntary loss, damage or destruction of property or any involuntary condemnation, seizure or taking, by exercise of the power of eminent
domain or otherwise, or confiscation or requisition of use of property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>licenses,
sublicenses, leases or subleases, in each case other than relating to any Company IP, granted to third parties in the ordinary course
of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
abandonment disclaimer, forfeiture, dedication to the public, or other disposition of any Intellectual Property (including, for clarity,
any Company IP) that is (i)&#8239;not material to any aspect of the research, development, manufacture, production, use (by any Credit
Party or its Subsidiaries), commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising,
offer for sale, distribution or sale of the Product in the Territory, (ii)&#8239;expiring in accordance with its statutory term or (iii)&#8239;no
longer used or useful in any material respect in the Product line of business of Borrower and its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
involuntary disposition or any sale, lease, license or other disposition of property (other than, for the avoidance of doubt, any Company
IP or Covered Regulatory Materials) in settlement of, or to make payment in satisfaction of, any property or casualty insurance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>sales,
leases, licenses, transfers or other dispositions of property to the extent that (i)&#8239;such property is exchanged for credit against
the purchase price of similar replacement property or (ii)&#8239;the proceeds of such sale, lease, license, transfer or other disposition
are promptly applied to the purchase price of similar replacement property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
Transfers on commercially reasonable arm&rsquo;s length terms (i)&#8239;made in the ordinary course of business or (ii)&#8239;that otherwise
do not interfere with or impede the ability of Borrower or any Subsidiary of Borrower to conduct the research, development, manufacture,
production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of Product in the
Territory or enforce its rights with respect to any of the foregoing within the Territory on commercially reasonable arm&rsquo;s length
terms;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
Transfers of properties or assets, in each case so long as (i)&#8239;the fair market value of such properties or assets (as reasonably
determined in good faith by a Responsible Officer of Borrower) does not exceed, individually or together with any other such Transfers
under this <U>clause (r)</U>, $5,000,000 at any time and (ii)&#8239;such Transfer is not otherwise prohibited hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
Transfers of properties or assets not constituting Collateral (including, for clarity,&#8239;Intellectual Property or Equity Interests
which do not constitute Collateral) made on arms&rsquo; length terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing
or any other provision of this Agreement, but subject to the proviso at the end of this paragraph, no direct or indirect Transfer (other
than a Permitted License) (i)&#8239;of Product-Exclusive Intellectual Property registered, issued or filed for, as applicable, in the
Territory that is owned by Borrower or any of its Subsidiaries, or of any license held by Borrower or any of its Subsidiaries to any
Product-Exclusive Intellectual Property registered, issued or filed for, as applicable, in the Territory, (ii)&#8239;of Equity Interests
in any Person that owns or has a license to Product-Exclusive Intellectual Property that is, registered, issued or filed for, as applicable,
in the Territory, or (iii)&#8239;that has or would have the effect of interfering with or impeding the ability of Borrower or any Subsidiary
of Borrower to conduct the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport,
offer for sale, distribution or sale of the Product in the Territory or enforce its rights with respect to any of the foregoing within
the Territory or that requires any Credit Party to pay to the counterparty any royalties, milestones or similar payments that are based
on the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale,
distribution or sale of the Product in the Territory, shall, in any case, be a &ldquo;Permitted Transfer&rdquo; hereunder without the
prior written consent of the Collateral Agent or the Required Lenders; <U>provided</U> that, for the avoidance of doubt and notwithstanding
anything herein to the contrary, in no event shall this paragraph or any other provision in this Agreement prohibit or otherwise restrict
Borrower or any of its Subsidiaries from entering into any Permitted Non-Product Platform License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization,
association, corporation, exempted company, institution, public benefit corporation, firm, joint stock company, estate, entity or government
agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Personal Data</B>&rdquo;
means information protected under applicable Data Protection Laws as &ldquo;personal data,&rdquo; &ldquo;personal information,&rdquo;
 &ldquo;personally identifiable information,&rdquo; &ldquo;protected health information,&rdquo; &ldquo;medical information,&rdquo; &ldquo;health
information,&rdquo; &ldquo;sensitive information,&rdquo; &ldquo;individually identifiable health information,&rdquo; &ldquo;identifiable
private information,&rdquo; &ldquo;bulk sensitive personal data,&rdquo; &ldquo;United States government-related data,&rdquo; or any similar
terms under applicable Data Protection Laws, including customer, consumer, patient, clinical trial participant and employee information
collected, created, received, maintained, stored, transmitted, or otherwise processed by or for Borrower or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Personal Data Breach</B>&rdquo;
is defined in <U>Section&#8239;4.22(b).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Plan</B>&rdquo;
means any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section&#8239;412
of the IRC or Section&#8239;302 of ERISA which is maintained or contributed to by Borrower or its Subsidiaries or their respective ERISA
Affiliates or with respect to which Borrower or its Subsidiaries have any liability (including under Section&#8239;4069 of ERISA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Platform</B>&rdquo;
means Borrower&rsquo;s and its Affiliates&rsquo; proprietary technology platform, known as of the Effective Date as the &ldquo;AdenoVerse&rdquo;
platform, which utilizes a library of proprietary adenovectors for the efficient gene delivery of vaccine antigens and cytokines to modulate
the immune system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Platform Intellectual
Property</B>&rdquo; means any Intellectual Property that (a)&#8239;is owned by or licensed to Borrower or any of its Affiliates and (b)&#8239;Covers
the Platform. For the avoidance of doubt, Platform Intellectual Property includes but is not necessarily limited to the Intellectual
Property listed on <U>Schedule 13.6</U> of the Disclosure Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Premium</B>&rdquo;
means the Tranche A Prepayment Premium or the Tranche B Prepayment Premium (as applicable) or the combination thereof, as the context
dictates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Product</B>&rdquo;
means, collectively: (a)&#8239;PAPZIMEOS (zopapogene imadenovec-drba) (and foreign-named equivalents), and any modification or improvements
thereto, in each case developed for the treatment of recurrent respiratory papillomatosis (RRP) and owned or controlled by Borrower or
any of its Subsidiaries, in any form, dosage form, dosing regimen, strength or route of administration; (b)&#8239;any proposed or approved
pharmaceutical product owned or controlled by Borrower or any of its Subsidiaries that contains zopapogene imadenovec-drba, in the same
formulation approved as of the date hereof by the FDA, for any indication, or any formulation as may be approved by the FDA hereafter
for recurrent respiratory papillomatosis (RRP); (c)&#8239;any proposed or approved pharmaceutical product owned or controlled by Borrower
or any of its Subsidiaries that contains the immunogenic payload of zopapogene imadenovec-drba, in any form, in any dosage form, dosing
regimen, strength or route of administration, in each case developed for the treatment of recurrent respiratory papillomatosis (RRP);
and (d)&#8239;any successor product(s)&#8239;of PAPZIMEOS (zopapogene imadenovec-drba) (and foreign-named equivalents), under development
or hereinafter developed, including in conjunction with out-licensing partners, in each case developed for the treatment of recurrent
respiratory papillomatosis (RRP) and owned or controlled by Borrower or its Subsidiaries, in any dosage form, dosing regimen, strength
or route of administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Product-Exclusive
Intellectual Property</B>&rdquo; means any Intellectual Property that (a)&#8239;Covers the Product (and no other product of Borrower or
any of its Subsidiaries) and (b)&#8239;is not Platform Intellectual Property. For the avoidance of doubt, Product-Exclusive Intellectual
Property includes but is not necessarily limited to the Intellectual Property listed on <U>Schedule 13.7</U> of the Disclosure Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registered Organization</B>&rdquo;
means any &ldquo;registered organization&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Agency</B>&rdquo;
means a U.S. or foreign Governmental Authority with responsibility for the approval of the marketing and sale of biologics or other regulation
of biologics or otherwise having authority to regulate the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Approvals
or Licensures</B>&rdquo; means all approvals, authorizations, designations, licensures or clearances and any product or establishment
licenses, registrations or authorizations of any Regulatory Agency necessary for the manufacture, use, storage, import, export, transport,
offer for sale, or distribution or sale of the Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Submission
Material</B>&rdquo; means all regulatory filings, submissions, approvals, licensures, and authorizations related to any research, development,
manufacture, production, use, commercialization, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable)
monitoring and reporting (including post-marketing safety reports), marketing, importing, storage, transport, offer for sale, distribution
or sale of the Product in the Territory, including all data and information provided in, and used to develop, any of the foregoing, and
any other material that is exempt from disclosure under 5 U.S.C. &sect;&#8239;552.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Related Parties</B>&rdquo;
means, with respect to any Person, such Person&rsquo;s Affiliates and the partners, directors, officers, employees, agents, trustees,
administrators, managers, advisors and representatives of such Person and of such Person&rsquo;s Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Release</B>&rdquo;
means any release, spill, emission, leaking, pumping, pouring, injection, escaping, deposit, disposal, discharge, dispersal, dumping,
leaching or migration of any Hazardous Material into the indoor or outdoor environment (including the abandonment or disposal of any
barrels, containers or other closed receptacles containing any Hazardous Material), including the movement of any Hazardous Material
through the air, soil, surface water or groundwater.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Relevant Governmental
Body</B>&rdquo; means the Board of Governors of the Federal Reserve System or the Federal Reserve Bank of New York, or a committee officially
endorsed or convened by the Board of Governors of the Federal Reserve System or the Federal Reserve Bank of New York, or any successor
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Required Lenders</B>&rdquo;
means Lenders representing greater than fifty percent (50%) of the principal amount of the Term Loans outstanding as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Requirements of
Law</B>&rdquo; means, as to any Person, the organizational or governing documents of such Person, and any law (statutory or common, foreign
or domestic), treaty, order, policy, rule&#8239;or regulation or determination of an arbitrator or a court or other Governmental Authority
(including Environmental Laws, Health Care Laws, Data Protection Laws, FDA Laws, EU Laws, and all other applicable statutes, rules, regulations,
standards, guidelines, policies and orders administered or issued by any foreign Governmental Authority), in each case, applicable to
and binding upon such Person or any of its assets or properties or to which such Person or any of its assets or properties are subject,
including, with respect to Borrower, the rules&#8239;or requirements of any applicable U.S. national securities exchange applicable to
Borrower or any of its Equity Interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Responsible Officers</B>&rdquo;
means, with respect to any Credit Party or any of its Subsidiaries, collectively, each of the Executive Chairman of the Board, President,
Chief Executive Officer, Senior Vice Presidents, Chief Financial Officer, Chief Operating Officer, Chief Commercial Officer, Data Protection
Officer, Chief Legal Officer, and Vice Presidents of such Credit Party or, in each case, if none, of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Restricted License</B>&rdquo;
means any material license or other material agreement of the kind or nature subject or purported to be subject from time to time to
a Lien under any Collateral Document, with respect to which a Credit Party is the licensee and pursuant to which such Credit Party in-licenses
any of the Company IP that is necessary for the research, development, manufacture, production, use, commercialization, marketing, importing,
storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of the Product in the Territory,
(a)&#8239;that prohibits or otherwise restricts such Credit Party from granting a security interest in its interest therein to the Collateral
Agent, for the benefit of Lenders and the other Secured Parties (other than as a result of customary anti-assignment provisions) in a
manner enforceable under Requirements of Law, or (b)&#8239;for which a breach of or default thereunder remains uncured and could reasonably
be expected to materially interfere with the Collateral Agent&rsquo;s or any Lender&rsquo;s right to sell or otherwise dispose of any
Collateral (other than the license or agreement itself). For the avoidance of doubt, software, open source code, application programming
interfaces or trademarks, copyrights or patents of others that are commercially available to the public under the shrinkwrap licenses,
clickwrap licenses, online terms of service or other terms of use or similar agreements and intellectual property rights of customers
used by Borrower in the course of providing service to third parties in the ordinary course of business shall not constitute a Restricted
License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Restricted Payments</B>&rdquo;
is defined in <U>Section&#8239;6.8(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Sanctioned Country</B>&rdquo;
means, at any time, a country or territory which is itself the subject or target of comprehensive Sanctions (including Cuba,&#8239;Iran,
North Korea, Crimea, the so-called Donetsk People&rsquo;s Republic and so-called Luhansk People&rsquo;s Republic, Kherson, Zaporizhzhia
and other regions of Ukraine that are the subject or target of comprehensive Sanctions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Sanctions</B>&rdquo;
is defined in <U>Section&#8239;4.18(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC</B>&rdquo;
means the Securities and Exchange Commission and any analogous Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Secretary&rsquo;s
Certificate</B>&rdquo; means, with respect to any Person, a certificate of such Person executed by its Secretary, authorized signatory
or director certifying as to the various matters set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Section&#8239;5
of the FTC Act</B>&rdquo; means the Section&#8239;5(a)&#8239;of the U.S. Federal Trade Commission Act (15 U.S.C. &sect; 45), which prohibits
unfair and deceptive acts or practices in or affecting commerce and serves as the primary basis for U.S. Federal Trade Commission authority
on privacy and security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Secured Parties</B>&rdquo;
means each Lender, each other Indemnified Person and each other holder of any Obligation of a Credit Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities Account</B>&rdquo;
means any &ldquo;securities account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Security Agreement</B>&rdquo;
means the Guaranty and Security Agreement, dated as of the Tranche A Closing Date, by and among the Credit Parties and the Collateral
Agent, in form and substance substantially similar to <U>Exhibit&#8239;C</U> attached hereto or in such form or substance as the Credit
Parties and the Collateral Agent may otherwise agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Security Incidents</B>&rdquo;
is defined in <U>Section&#8239;4.22(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Security Program</B>&rdquo;
is defined in <U>Section&#8239;4.22(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Sensitive Information</B>&rdquo;
means, collectively, (a)&#8239;any Personal Data that is subject to any Data Protection Law(s), (b)&#8239;any confidential or proprietary
information in which Borrower or any of its Subsidiaries have IP Ancillary Rights or any other Intellectual Property rights (including
Company IP), (c)&#8239;any information with respect to which Borrower or any of its Subsidiaries have contractual non-disclosure obligations,
and (d)&#8239;Regulatory Submission Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Series&#8239;A Preferred
Stock</B>&rdquo; means Borrower&rsquo;s 8.00% Series&#8239;A Convertible Perpetual Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SOFR</B>&rdquo;
means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SOFR Administrator</B>&rdquo;
means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Software</B>&rdquo;
is defined in the definition of &ldquo;Intellectual Property&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Solvent</B>&rdquo;
means as of any date of determination, that, as of such date, (a)&#8239;the value of the assets (including goodwill minus disposition
costs) of such Person (both at fair value and present fair saleable value), on a going concern basis, is greater than the total amount
of liabilities (including contingent and unliquidated liabilities) of such Person, (b)&#8239;such Person is able to generally pay all
liabilities (including trade debt) of such Person as such liabilities become absolute and mature in the ordinary course of business consistent
with past practice and (c)&#8239;such Person does not have unreasonably small capital after giving due consideration to the prevailing
practice in the industry in which it is engaged or will be engaged. In computing the amount of contingent or unliquidated liabilities
at any time, such liabilities shall be computed at the amount that, in light of all the facts and circumstances existing at such time,
represents the amount that can reasonably be expected to become an actual or matured liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SSA</B>&rdquo;
means the Social Security Act of 1935, codified at Title 42, Chapter 7, of the United States Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Stock Acquisition</B>&rdquo;
means the purchase or other acquisition by Borrower or any of its Subsidiaries of (or resulting in the ownership of) any Equity Interests
(by merger, stock purchase or otherwise) in any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subordinated Debt</B>&rdquo;
means any Indebtedness in the form of or otherwise constituting term debt incurred by any Credit Party or any Subsidiary thereof (including
any Indebtedness incurred in connection with any Acquisition or other Investment) that: (a)&#8239;is subordinated in right of payment
to the Obligations at all times until all of the Obligations have been paid, performed or discharged in full and Borrower has no further
right to obtain any Credit Extension hereunder, pursuant to a subordination, intercreditor or other similar agreement that is in form
and substance reasonably satisfactory to the Collateral Agent (which agreement shall include turnover provisions that are reasonably
satisfactory to the Collateral Agent); (b)&#8239;except as permitted by <U>clause (d)</U>&#8239;below, is not subject to scheduled amortization,
redemption (mandatory), sinking fund or similar payment and does not have a final maturity, in each case, before a date that is at least
120 days following the Term Loan Maturity Date; (c)&#8239;does not include covenants (including financial covenants) and agreements (excluding
agreements with respect to maturity, amortization, pricing and other economic terms) that, taken as a whole, are more restrictive or
onerous on the Credit Parties in any material respect than the comparable covenants and agreements, taken as a whole, in the Loan Documents
(as reasonably determined by a Responsible Officer of such Credit Party in good faith); (d)&#8239;is not subject to repayment or prepayment,
including pursuant to a put option exercisable by the holder of any such Indebtedness, prior to a date that is at least 120 days following
the final maturity thereof except in the case of an event of default or change of control (or, in each case, the equivalent thereof,
however described); and (e)&#8239;does not provide or otherwise include provisions having the effect of providing that a default or event
of default (or the equivalent thereof, however described) under or in respect of such Indebtedness shall exist, or such Indebtedness
shall otherwise become due prior to its scheduled maturity or the holder or holders thereof or any trustee or agent on its or their behalf
shall be permitted (with or without the giving of notice, the lapse of time or both) to cause any such Indebtedness to become due, or
to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity, in any such case upon the occurrence
of a Default or Event of Default hereunder unless and until the Obligations have been declared, or have otherwise automatically become,
immediately due and payable pursuant to <U>Section&#8239;8.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiary</B>&rdquo;
means, (a)&#8239;with respect to any Person not incorporated in England and Wales, a corporation, partnership, limited liability company
or other entity of which more than fifty percent (50.0%) of whose shares of stock or other ownership interests having ordinary voting
power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect
a majority of the Board of Directors (or similar body) of such corporation, partnership or other entity are at the time owned, directly
or indirectly through one or more intermediaries, or both, by such Person, and (b)&#8239;with respect to any Person incorporated in England
and Wales, any subsidiary incorporated in England and Wales within the meaning of section 1159 of the Companies Act 2006. Unless the
context otherwise requires, each reference to a Subsidiary herein shall be a reference to a Subsidiary of a Credit Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Systems</B>&rdquo;
is defined in <U>Section&#8239;4.22(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tax</B>&rdquo;
means any present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees
or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan</B>&rdquo;
means each of the Tranche A Loan or the Tranche B Loan, as applicable, and &ldquo;<B>Term Loans</B>&rdquo; means, collectively, the Tranche
A Loan, and, to the extent funded, the Tranche B Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan Commitment</B>&rdquo;
means, each of the Tranche A Commitment or the Tranche B Commitment, as applicable, and &ldquo;<B>Term Loan Commitments</B>&rdquo; means,
collectively, the Tranche A Commitment and the Tranche B Commitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan Maturity
Date</B>&rdquo; means the 5<SUP>th</SUP>-year anniversary of the Tranche A Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan Note</B>&rdquo;
means the Tranche A Note or the Tranche B Note, as applicable, and &ldquo;<B>Term Loan Notes</B>&rdquo; means collectively, the Tranche
A Note and the Tranche B Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan Rate</B>&rdquo;
is defined in <U>Section&#8239;2.3(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term SOFR</B>&rdquo;
means, for any day in any calendar month, the Term SOFR Reference Rate for a tenor of three (3)&#8239;months to the applicable Interest
Period on the day (such day, the &ldquo;<B>Periodic Term SOFR Determination Day</B>&rdquo;) that is two (2)&#8239;U.S. Government Securities
Business Days&rsquo; prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; <U>provided</U>,
<U>however</U>, that if as of 5:00 p.m.&#8239;(New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference
Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to
the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the
Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such
tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more
than three (3)&#8239;U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day; <U>provided</U>, <U>further</U>,
that if Term SOFR determined as provided above (including pursuant to the proviso above) shall ever be less than the Floor, then Term
SOFR shall be deemed to be the Floor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term SOFR Administrator</B>&rdquo;
means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the
Collateral Agent in its reasonable discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term SOFR Reference
Rate</B>&rdquo; means the forward-looking term rate based on SOFR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Territory</B>&rdquo;
means the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Third-Party IP</B>&rdquo;
is defined in <U>Section&#8239;4.6(l)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Third-Party Regulatory
Materials</B>&rdquo; is defined in <U>Section&#8239;4.20(a)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trademarks</B>&rdquo;
means (a)&#8239;all trademarks, trade names, corporate names, company names, business names, fictitious business names, service marks,
elements of package or trade dress of goods or services, logos and other source or business identifiers, together with the goodwill associated
therewith, including all registrations and recordings thereof, and all applications in connection therewith, in the United States Patent
and Trademark Office or in any similar office or agency of the United States or any state thereof or in any similar office or agency
anywhere in the world in which foreign counterparts are registered or issued, and (b)&#8239;all renewals thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Additional
Consideration</B>&rdquo; is defined in <U>Section&#8239;2.7(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Closing
Date</B>&rdquo; means the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Commitment</B>&rdquo;
means, with respect to any Lender, the commitment of such Lender to make the Credit Extensions relating to the Tranche A Loan on the
Tranche A Closing Date in the aggregate principal amount set forth opposite such Lender&rsquo;s name on <U>Exhibit&#8239;D</U> attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Exit
Consideration</B>&rdquo; means, with respect to any prepayment or repayment of the Tranche A Loan by Borrower pursuant to <U>Section&#8239;2.2(c)</U>&#8239;or
as a result of the acceleration of the maturity of the Tranche A Loan pursuant to <U>Section&#8239;8.1(a)</U>, or any repayment of the
Tranche A Loan by Borrower pursuant to <U>Section&#8239;2.2(b)</U>&#8239;or otherwise (including, for the avoidance of doubt, on the Term
Loan Maturity Date), in any such case, an amount equal to the product of (a)&#8239;the amount of principal so prepaid or repaid, <I>multiplied
by</I> (b)&#8239;0.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Loan</B>&rdquo;
is defined in <U>Section&#8239;2.2(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Loan
Amount</B>&rdquo; means an original principal amount equal to One Hundred Million Dollars ($100,000,000.00).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Makewhole
Amount</B>&rdquo; means, as of the date of any prepayment of the Tranche A Loan occurring prior to the 3<SUP>rd</SUP>-year anniversary
of the Tranche A Closing Date, pursuant to <U>Section&#8239;2.2(c)</U>&#8239;or as a result of the acceleration of the maturity of the
Term Loans pursuant to <U>Section&#8239;8.1(a)</U>, an amount equal to the sum of all interest that would have accrued and been payable
from such date of prepayment through the 3<SUP>rd</SUP>-year anniversary of the Tranche A Closing Date on the amount of principal prepaid.
For purposes of calculating the Tranche A Makewhole Amount: (a)&#8239;the date of determination shall be such date of prepayment, using
the interest rate as in effect on such date, <U>provided</U>, <U>that</U>, for purposes of any such prepayment pursuant to <U>Section&#8239;2.2(c)(ii)</U>,
the date of determination shall be the date on which the Change in Control is consummated; and (b)&#8239;the Default Rate shall not apply
to any interest that would have accrued and been payable from and after such date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Note</B>&rdquo;
means a promissory note in substantially the form attached hereto as <U>Exhibit&#8239;B-1</U>, as it may be amended, restated, supplemented
or otherwise modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche A Prepayment
Premium</B>&rdquo; means, with respect to any prepayment of the Tranche A Loan by Borrower pursuant to <U>Section&#8239;2.2(c)</U>, or
as a result of the acceleration of the maturity of the Term Loans pursuant to <U>Section&#8239;8.1(a)</U>, an amount equal to the product
of the amount of any principal so prepaid, <I>multiplied by</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
such prepayment occurs prior to the 3<SUP>rd</SUP>-year anniversary of the Tranche A Closing Date, 0.03;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
such prepayment occurs on or after the 3<SUP>rd</SUP>-year anniversary of the Tranche A Closing Date but prior to the 4<SUP>th</SUP>-year
anniversary of the Tranche A Closing Date, 0.02; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
such prepayment occurs on or after the 4<SUP>th</SUP>-year anniversary of the Tranche A Closing Date but prior to the Term Loan Maturity
Date, 0.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
no Tranche A Prepayment Premium shall be due and owing for any payment of principal of the Tranche A Loan made on the Term Loan Maturity
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Additional
Consideration</B>&rdquo; is defined in <U>Section&#8239;2.7(a)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Closing
Date</B>&rdquo; means the date on which the Tranche B Loan is advanced by Lenders, which, as indicated in the Advance Request Form&#8239;in
the form of <U>Exhibit&#8239;A</U> hereto for the Tranche B Loan and subject to the satisfaction of the conditions precedent to the Tranche
B Loan set forth in <U>Section&#8239;3.2</U>, <U>Section&#8239;3.3</U>, <U>Section&#8239;3.4</U> and <U>Section&#8239;3.5</U>, shall be sixty
(60) days (or such shorter period as may be agreed to by Lenders) following the delivery by Borrower to the Collateral Agent of the completed
Advance Request Form&#8239;for the Tranche B Loan and in no event later than June&#8239;29, 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Commitment</B>&rdquo;
means, with respect to any Lender, the commitment of such Lender to make the Credit Extensions relating to the Tranche B Loan on the
Tranche B Closing Date in the aggregate principal amount set forth opposite such Lender&rsquo;s name on <U>Exhibit&#8239;D</U> attached
hereto; <U>provided</U>, <U>however</U>, that the parties hereto agree that such commitment, and any obligations of such Lender hereunder
with respect thereto, shall terminate automatically without any further action by any party hereto and be of no further force and effect
if the Tranche B Closing Date does not occur on or before June&#8239;29, 2027 (at such time, for purposes of this Agreement, such Lender&rsquo;s
Tranche B Commitment equals zero).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Exit
Consideration</B>&rdquo; means, with respect to any prepayment or repayment of the Tranche B Loan by Borrower pursuant to <U>Section&#8239;2.2(c)</U>&#8239;or
as a result of the acceleration of the maturity of the Tranche B Loan pursuant to <U>Section&#8239;8.1(a)</U>, or any repayment of the
Tranche B Loan by Borrower pursuant to <U>Section&#8239;2.2(b)</U>&#8239;or otherwise (including, for the avoidance of doubt, on the Term
Loan Maturity Date), in any such case, an amount equal to the product of (a)&#8239;the amount of principal so prepaid or repaid, <I>multiplied
by</I> (b)&#8239;0.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Loan</B>&rdquo;
is defined in <U>Section&#8239;2.2(a)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Loan
Amount</B>&rdquo; means an original principal amount equal to Twenty-Five Million Dollars ($25,000,000.00); <U>provided</U>, <U>however</U>,
that if the Tranche B Closing Date does not occur on or before June&#8239;29, 2027, then the Tranche B Loan Amount, from and after such
time for purposes of this Agreement, equals zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Makewhole
Amount</B>&rdquo; means, as of the date of any prepayment of the Tranche B Loan occurring prior to the 3<SUP>rd</SUP>-year anniversary
of the Tranche B Closing Date pursuant to <U>Section&#8239;2.2(c)</U>&#8239;or as a result of the acceleration of the maturity of the Term
Loans pursuant to <U>Section&#8239;8.1(a)</U>, an amount equal to the sum of all interest that would have accrued and been payable from
such date of prepayment through the 3<SUP>rd</SUP>-year anniversary of the Tranche B Closing Date on the amount of principal prepaid.
For purposes of calculating the Tranche B Makewhole Amount: (a)&#8239;the date of determination shall be such date of prepayment, using
the interest rate as in effect on such date, <U>provided</U>, <U>that</U>, for purposes of any such prepayment pursuant to <U>Section&#8239;2.2(c)(ii)</U>,
the date of determination shall be the date on which the Change in Control is consummated; and (b)&#8239;the Default Rate shall not apply
to any interest that would have accrued and been payable from and after such date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Net Sales
Trigger</B>&rdquo; means, with respect to the delivery of a completed Advance Request Form&#8239;in the form of <U>Exhibit&#8239;A</U>
hereto for the Tranche B Loan, TTM Net Sales having equaled or exceeded (a)&#8239;$75,000,000 for the trailing twelve-month period ended
September&#8239;30, 2026 or (b)&#8239;$100,000,000 for the trailing twelve-month period ended December&#8239;31, 2026, in either case as
reasonably determined by a Responsible Officer of Borrower in good faith in accordance with GAAP and as presented in Borrower&rsquo;s
financial statements (including, with respect of any portion of such trailing twelve-month period covered by financial statements filed
with the SEC (if any), such filed financial statements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Note</B>&rdquo;
means a promissory note in substantially the form attached hereto as <U>Exhibit&#8239;B-2</U>, as it may be amended, restated, supplemented
or otherwise modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tranche B Prepayment
Premium</B>&rdquo; means, with respect to any prepayment of the Tranche B Loan by Borrower pursuant to <U>Section&#8239;2.2(c)</U>&#8239;or
as a result of the acceleration of the maturity of the Term Loans pursuant to <U>Section&#8239;8.1(a)</U>, an amount equal to the product
of the amount of any principal so prepaid<I>, multiplied by</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
such prepayment occurs prior to the 3<SUP>rd</SUP>-year anniversary of the Tranche B Closing Date, 0.03;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
such prepayment occurs on or after the 3<SUP>rd</SUP>-year anniversary of the Tranche B Closing Date but prior to the 4<SUP>th</SUP>-year
anniversary of the Tranche B Closing Date, 0.02; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
such prepayment occurs on or after the 4<SUP>th</SUP>-year anniversary of the Tranche B Closing Date but prior to the Term Loan Maturity
Date, 0.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
no Tranche B Prepayment Premium shall be due and owing for any payment of principal of the Tranche B Loan made on the Term Loan Maturity
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer</B>&rdquo;
is defined in <U>Section&#8239;6.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Treasury Regulations</B>&rdquo;
mean those regulations promulgated pursuant to the IRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>TRICARE</B>&rdquo;
means, collectively, a program of medical benefits covering former and active members of the uniformed services and certain of their
dependents, financed and administered by the United States Departments of Defense, Health and Human Services and Transportation, and
all laws applicable to such programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>TTM Net Sales</B>&rdquo;
means, as of any date of determination, the sum of trailing twelve-month Net Sales and royalty revenue of the Product as of such date,
as determined by a Responsible Officer of Borrower in good faith in accordance with GAAP and as presented in Borrower&rsquo;s financial
statements (including, with respect of any portion of such trailing twelve-month period covered by financial statements filed with the
SEC (if any), such filed financial statements). For the avoidance of doubt, TTM Net Sales shall not include any milestone payments, non-recurring
payments or non-sales-based revenues or proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Unadjusted Benchmark
Replacement</B>&rdquo; means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>United States</B>&rdquo;
or &ldquo;<B>U.S.</B>&rdquo; means the United States of America, its fifty (50) states, the District of Columbia, Puerto Rico and any
other jurisdiction within the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>U.S.&#8239;Government
Securities Business Day</B>&rdquo; means any day except for (a)&#8239;a Saturday, (b)&#8239;a Sunday or (c)&#8239;a day on which the Securities
Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for
purposes of trading in United States government securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Wholly Owned Subsidiary</B>&rdquo;
means, with respect to any Person, a Subsidiary of such Person, all of the Equity Interests of which (other than directors&rsquo; qualifying
shares or nominee or other similar shares required pursuant to Requirements of Law) are owned by such Person or another Wholly Owned
Subsidiary of such Person. Unless the context otherwise requires, each reference to a Wholly Owned Subsidiary herein shall be a reference
to a Wholly Owned Subsidiary of a Credit Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Withdrawal
Event</B>&rdquo; means, as applicable, (a)&#8239;any voluntary withdrawal or removal of </FONT>the Product in the Territory by any Credit
Party or any of its Subsidiaries, (b)&#8239;the loss of marketing authorization for the Product in the Territory, (c)&#8239;the receipt
by any Credit Party or any of its Subsidiaries of any written notice from the FDA or any other Regulatory Agency of pending recommendation
to withdraw marketing authorization for the Product in the Territory that has not been rescinded or otherwise withdrawn within sixty
(60) days of the receipt thereof, or (d)&#8239;the receipt by any Credit Party or any of its Subsidiaries of any written notice from the
FDA or any other Regulatory Agency of final decision to withdraw marketing authorization for the Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Withdrawal Liability</B>&rdquo;
means liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such terms are
defined in Part&#8239;I of Subtitle E of Title IV of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Withholding Agent</B>&rdquo;
is defined in <U>Section&#8239;2.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page&#8239;follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have caused this Agreement to be executed as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PRECIGEN,&#8239;INC.,<BR> as Borrower
    and a Credit Party</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-size: 10pt">Donald Lehr</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Donald Lehr</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Chief Legal Officer &amp; Secretary</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">GENVEC, LLC<BR> as an additional
    Credit Party</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-size: 10pt">Donald Lehr</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Donald Lehr</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">President</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PRECIGEN ACTOBIO,&#8239;INC.,<BR>
    as an additional Credit Party</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-size: 10pt">Donald Lehr</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Donald Lehr</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Secretary</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">EXEMPLAR GENETICS, LLC.,<BR>
    as an additional Credit Party</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-size: 10pt">Donald Lehr</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Donald Lehr</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Vice President</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Signature Page&#8239;to Loan Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BIOPHARMA CREDIT PLC,<BR> as Collateral Agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">By:</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Pharmakon Advisors, LP,<BR> its
    Investment Manager</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">By: Pharmakon Management I, LLC,<BR> its General Partner</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Pedro Gonzalez de Cosio</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Pedro Gonzalez de Cosio</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Managing Member</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BPCR LIMITED PARTNERSHIP,<BR>
as a Lender</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left">By:</TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Pharmakon Advisors, LP,<BR> its
    Investment Manager</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">By: Pharmakon Management I, LLC,<BR> its General Partner</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Pedro Gonzalez de Cosio</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Pedro Gonzalez de Cosio</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Managing Member</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP,<BR>
as Lender</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%; text-align: left">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; padding-left: 0.125in">BioPharma Credit Investments V GP LLC,<BR> its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">By: Pharmakon Advisors, LP,<BR> its
    Investment Manager</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Pedro Gonzalez de Cosio</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Pedro Gonzalez de Cosio</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Managing Member</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Signature Page&#8239;to Loan Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT&#8239;A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>LOAN
ADVANCE REQUEST FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reference is made to that
certain Loan Agreement, dated as of September 3, 2025, by and among PRECIGEN,&#8239;INC., Virginia corporation (&ldquo;<B>Borrower</B>&rdquo;),
the Guarantors signatory thereto or otherwise party thereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC (in
its capacity as &ldquo;<B>Collateral Agent</B>&rdquo;), BPCR LIMITED PARTNERSHIP (a &ldquo;<B>Lender</B>&rdquo;) and BIOPHARMA CREDIT
INVESTMENTS V (MASTER) LP (a &ldquo;<B>Lender</B>&rdquo;), acting by its general partner, BioPharma Credit Investments V GP LLC (the
 &ldquo;<B>Loan Agreement</B>&rdquo;); with any capitalized term not otherwise defined herein having the meaning ascribed to such term
in the Loan Agreement. This Loan Advance Request is being delivered pursuant to Section&#8239;3.6 of the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
undersigned, being the duly elected and acting ______________ of Borrower does hereby certify to each Lender and the Collateral Agent,
solely in his/her capacity as an authorized officer of Borrower and not in his/her personal capacity, that, </FONT>on [_____________,
20__] (the &ldquo;<B>Tranche [A][B]</B><FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT> <B>Closing Date</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Borrower
hereby requests a borrowing of the Tranche [A][B]<FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT> Loan in the original principal amount
of $[INSERT TRANCHE [A] [B] AMOUNT];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
representations and warranties made by the Credit Parties in <U>Section&#8239;4</U> of the Loan Agreement and in the other Loan Documents
are true and correct in all material respects, unless any such representation or warranty is stated to relate to a specific earlier date,
in which case such representation or warranty shall be true and correct in all material respects as of such earlier date (it being understood
that any representation or warranty that is qualified as to &ldquo;materiality,&rdquo; &ldquo;Material Adverse Change,&rdquo; or similar
language shall be true and correct in all respects on the Tranche [A][B] Closing Date<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT>
or as of such earlier date, as applicable);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no
Default or Event of Default has occurred and is continuing as of the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
of the Credit Parties is in compliance with the covenants and requirements contained in <U>Sections 5</U> and <U>6</U> of the Loan Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>assuming
the Collateral Agent&rsquo;s and the Lenders&rsquo; satisfaction with each matter in respect of which such satisfaction is required,
all conditions referred to in <U>Section&#8239;3</U> of the Loan Agreement to the making of the Tranche [A][B]<FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT>
Loan to be made on the Tranche [A][B]<FONT STYLE="font-size: 10pt"><SUP>5</SUP></FONT> Closing Date have been satisfied (or waived in
writing by the Required Lenders);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no
Withdrawal Event has occurred since the [Effective Date]<FONT STYLE="font-size: 10pt"><SUP>6</SUP></FONT> [Tranche A Closing Date]<FONT STYLE="font-size: 10pt"><SUP>7</SUP></FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
undersigned is a Responsible Officer of Borrower; [and]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
proceeds of the Tranche [A][B]<FONT STYLE="font-size: 10pt"><SUP>8</SUP></FONT> Loan shall be disbursed as set forth on <U>Attachment
A</U> hereto[; and][.]<FONT STYLE="font-size: 10pt"><SUP>9</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1</SUP> As applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>2</SUP> As applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>3</SUP> As applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>4</SUP> As applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>5</SUP> As applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>6</SUP> To be included in Advance Request
Form for Tranche A Loan only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>7</SUP> To be included in Advance Request
Form for Tranche B Loan only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>8</SUP> As applicable.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><SUP>9</SUP> To be prepared by Lenders&rsquo; counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">[9.&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Evidence
as to the occurrence of the [Tranche B Net Sales Trigger]<FONT STYLE="font-size: 10pt"><SUP>10</SUP></FONT> is attached hereto as <U>Attachment
B</U>.]<FONT STYLE="font-size: 10pt"><SUP>11</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: ___________________, 202_</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page&#8239;follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>10</SUP> To be included in Advance Request
Form for Tranche B Loan only.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>11</SUP></FONT>
To be included in Advance Request Form for Tranche B Loan only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PRECIGEN,&#8239;INC.,<BR> as Borrower</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT&#8239;B-1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">THIS TRANCHE A
NOTE HAS BEEN ISSUED WITH &ldquo;ORIGINAL ISSUE DISCOUNT&rdquo; (WITHIN THE MEANING OF SECTION&#8239;1273 OF THE INTERNAL REVENUE CODE
OF 1986, AS AMENDED). </FONT>HOLDERS OF THIS TRANCHE B NOTE SHOULD CONTACT HARRY THOMASIAN JR., CHIEF FINANCIAL OFFICER, PRECIGEN,&#8239;INC.,
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MARYLAND 20876 IN WRITING TO OBTAIN (1)&#8239;THE ISSUE PRICE AND ISSUE DATE OF THIS TRANCHE
A NOTE, (2)&#8239;THE AMOUNT OF ORIGINAL ISSUE DISCOUNT ON THIS TRANCHE A NOTE AND (3)&#8239;THE YIELD TO MATURITY OF THIS TRANCHE A NOTE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>TRANCHE
A SECURED TERM LOAN PROMISSORY NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">$[______________]</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: right; width: 49%; font: 10pt Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;Dated: ____________,
    2025</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the undersigned,
PRECIGEN,&#8239;INC., a Virginia corporation (&ldquo;<B>Borrower</B>&rdquo;), HEREBY PROMISES TO PAY to [BPCR LIMITED PARTNERSHIP] [BIOPHARMA
CREDIT INVESTMENTS V (MASTER) LP] (&ldquo;<B>Lender</B>&rdquo;), or its registered assignees, the principal amount of [______________________]
($[____________]), <I><U>plus</U></I> interest on the aggregate unpaid principal amount of this Tranche A Secured Term Loan Promissory
Note (this &ldquo;<B>Tranche A Note</B>&rdquo;) at a <I>per annum</I> rate equal to Term SOFR <I>plus</I> the Applicable Margin, and
in accordance with the terms of the Loan Agreement dated as of September 3, 2025 by and among Borrower, the Guarantors from time to time party
thereto, BioPharma Credit PLC, as Collateral Agent, and the Lenders from time to time party thereto (as may be amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;). If not sooner paid, the entire principal amount, all
accrued and unpaid interest hereunder, all due and unpaid Lender Expenses and any other amounts payable under the Loan Documents shall
be due and payable on the Term Loan Maturity Date. Any capitalized term not otherwise defined herein shall have the meaning attributed
to such term in the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All unpaid principal with respect to the Tranche
A Loan (and, for the avoidance of doubt, all accrued and unpaid interest, all due and unpaid Lender Expenses and any other amounts payable
under the Loan Documents) is due and payable in full on the Term Loan Maturity Date. Interest shall accrue on this Tranche A Note commencing
on, and including, the date of this Tranche A Note, and shall accrue on this Tranche A Note, or any portion thereof, for the day on which
this Tranche A Note or such portion is paid. Interest on this Tranche A Note shall be payable in accordance with <U>Section&#8239;2.3</U>
of the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Principal, interest and all other amounts due
with respect to this Tranche A Note are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement
and this Tranche A Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loan Agreement, among other things, (a)&#8239;provides
for the making of secured Term Loans by Lender to Borrower, and (b)&#8239;contains provisions for acceleration of the maturity hereof
upon the happening of certain stated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Tranche A Note may not be prepaid except
as set forth in <U>Section&#8239;2.2(c)</U>&#8239;of the Loan Agreement or as expressly provided in <U>Section&#8239;8.1</U> of the Loan
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Tranche A Note and the obligation of Borrower
to repay the unpaid principal amount of this Tranche A Note, interest thereon, and all other amounts due Lender under the Loan Agreement
are secured pursuant to the Collateral Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presentment for payment, demand, notice of protest
and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement of this Term Loan
Note are hereby waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS TRANCHE A NOTE SHALL BE GOVERNED BY, AND
CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Note Register;
Ownership of Note</U></FONT>. The ownership of an interest in this Tranche A Note shall be registered on a record of ownership maintained
by the Collateral Agent. Notwithstanding anything else in this Term Loan Note to the contrary, the right to the principal of, and stated
interest on, this Tranche A Note may be transferred only if the transfer is registered on such record of ownership and the transferee
is identified as the owner of an interest in the obligation. Borrower shall be entitled to treat the registered holder of this Tranche
A Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any
equitable or other claim to or interest in this Term Loan Note on the part of any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Balance of Page&#8239;Intentionally Left
Blank]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, Borrower
has caused this Tranche A Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BORROWER:</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">PRECIGEN,&#8239;INC.,<BR> as Borrower</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&#8239;</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT&#8239;B-2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">THIS TRANCHE B
NOTE HAS BEEN ISSUED WITH &ldquo;ORIGINAL ISSUE DISCOUNT&rdquo; (WITHIN THE MEANING OF SECTION&#8239;1273 OF THE INTERNAL REVENUE CODE
OF 1986, AS AMENDED). HOLDERS OF THIS TRANCHE B NOTE SHOULD CONTACT </FONT>HARRY THOMASIAN JR., CHIEF FINANCIAL OFFICER, PRECIGEN,&#8239;INC.,
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MARYLAND 20876 IN WRITING TO OBTAIN (1)&#8239;THE ISSUE PRICE AND ISSUE DATE OF THIS TRANCHE
B NOTE, (2)&#8239;THE AMOUNT OF ORIGINAL ISSUE DISCOUNT ON THIS TRANCHE B NOTE AND (3)&#8239;THE YIELD TO MATURITY OF THIS TRANCHE B NOTE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>TRANCHE
B SECURED TERM LOAN PROMISSORY NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">$[______________]</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: right; width: 49%; font: 10pt Times New Roman, Times, Serif">Dated: [___], 202[_]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the undersigned,
PRECIGEN,&#8239;INC., a Virginia corporation (&ldquo;<B>Borrower</B>&rdquo;), HEREBY PROMISES TO PAY to [BPCR LIMITED PARTNERSHIP] [BIOPHARMA
CREDIT INVESTMENTS V (MASTER) LP] (&ldquo;<B>Lender</B>&rdquo;), or its registered assignees, the principal amount of [______________________]
($[____________]), <I><U>plus</U></I> interest on the aggregate unpaid principal amount of this Tranche B Secured Term Loan Promissory
Note (this &ldquo;<B>Tranche B Note</B>&rdquo;) at a <I>per annum</I> rate equal to Term SOFR <I>plus</I> the Applicable Margin, and
in accordance with the terms of the Loan Agreement dated as of September 3, 2025 by and among Borrower, the Guarantors from time to time party
thereto, BioPharma Credit PLC, as Collateral Agent, and the Lenders from time to time party thereto (as may be amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;). If not sooner paid, the entire principal amount, all
accrued and unpaid interest hereunder, all due and unpaid Lender Expenses and any other amounts payable under the Loan Documents shall
be due and payable on the Term Loan Maturity Date. Any capitalized term not otherwise defined herein shall have the meaning attributed
to such term in the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All unpaid principal with respect to the Tranche
B Loan (and, for the avoidance of doubt, all accrued and unpaid interest, all due and unpaid Lender Expenses and any other amounts payable
under the Loan Documents) is due and payable in full on the Term Loan Maturity Date. Interest shall accrue on this Tranche B Note commencing
on, and including, the date of this Tranche B Note, and shall accrue on this Tranche B Note, or any portion thereof, for the day on which
this Tranche B Note or such portion is paid. Interest on this Tranche B Note shall be payable in accordance with <U>Section&#8239;2.3</U>
of the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Principal, interest and all other amounts due
with respect to this Tranche B Note are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement
and this Tranche B Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loan Agreement, among other things, (a)&#8239;provides
for the making of secured Term Loans by Lender to Borrower, and (b)&#8239;contains provisions for acceleration of the maturity hereof
upon the happening of certain stated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Tranche B Note may not be prepaid except
as set forth in <U>Section&#8239;2.2(c)</U>&#8239;of the Loan Agreement or as expressly provided in <U>Section&#8239;8.1</U> of the Loan
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Tranche B Note and the obligation of Borrower
to repay the unpaid principal amount of this Tranche B Note, interest thereon, and all other amounts due Lender under the Loan Agreement
are secured pursuant to the Collateral Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presentment for payment, demand, notice of protest
and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement of this Term Loan
Note are hereby waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS TRANCHE B NOTE SHALL BE GOVERNED BY, AND
CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Note Register;
Ownership of Note</U></FONT>. The ownership of an interest in this Tranche B Note shall be registered on a record of ownership maintained
by the Collateral Agent. Notwithstanding anything else in this Term Loan Note to the contrary, the right to the principal of, and stated
interest on, this Tranche B Note may be transferred only if the transfer is registered on such record of ownership and the transferee
is identified as the owner of an interest in the obligation. Borrower shall be entitled to treat the registered holder of this Tranche
B Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any
equitable or other claim to or interest in this Term Loan Note on the part of any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Balance of Page&#8239;Intentionally Left
Blank]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, Borrower
has caused this Tranche B Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BORROWER:</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">PRECIGEN,&#8239;INC.,<BR> as Borrower</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&#8239;</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT&#8239;C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>FORM&#8239;OF
SECURITY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GUARANTY AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Dated as of September&nbsp;</FONT>3,
2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">PRECIGEN,&nbsp;INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">(as <I>Borrower</I></FONT>
and a <I>Grantor</I>),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Each OTHER
Grantor From Time to Time Party Hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">in favor of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BIOPHARMA CREDIT PLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(as <I>Collateral Agent</I> on behalf of Lenders
and the other Secured Parties)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;1</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINED TERMS</FONT></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Other Terms</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 5pt; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;2</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GUARANTY</FONT></TD>
    <TD STYLE="padding-top: 5pt; text-align: right; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guaranty</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitation of Guaranty</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization; Other Agreements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guaranty Absolute and Unconditional</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waivers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliance</FONT></TD>
    <TD STYLE="text-align: right">8</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contribution</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 5pt; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;3</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANT OF SECURITY INTEREST</FONT></TD>
    <TD STYLE="padding-top: 5pt; text-align: right; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant of Security Interest in Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 5pt; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;4</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS AND WARRANTIES</FONT></TD>
    <TD STYLE="padding-top: 5pt; text-align: right; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title; No Other Liens</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perfection and Priority</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pledged Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pledged Debt Instruments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 5pt; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;5</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVENANTS</FONT></TD>
    <TD STYLE="padding-top: 5pt; text-align: right; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance of Perfected Security Interest; Further
    Documentation and Consents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pledged Collateral and Pledged Investment Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 5pt; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;6</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REMEDIAL PROVISIONS</FONT></TD>
    <TD STYLE="padding-top: 5pt; text-align: right; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code and Other Remedies</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts and Payments in Respect of General Intangibles</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pledged Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to be Turned over to and Held by Collateral
    Agent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of Pledged Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficiency</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral Accounts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directions, Notices or Instructions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 5pt; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;7</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL RIGHTS OF COLLATERAL AGENT</FONT></TD>
    <TD STYLE="padding-top: 5pt; text-align: right; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral Agent&rsquo;s Appointment as Attorney-in-Fact</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization to File Financing Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority of Collateral Agent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duty; Obligations and Liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;8</FONT>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS</FONT></TD>
    <TD STYLE="text-align: right; padding-bottom: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.1</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reinstatement</FONT></TD>
    <TD STYLE="text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Release of Collateral and Guarantee Obligations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Obligations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Waiver by Course of Conduct</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments in Writing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Grantors and Guarantors; Additional Pledged
    Collateral</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors and Assigns</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Choice of Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jury Trial Waiver</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>Annex 1</U></FONT> &ndash; Form&nbsp;of
Pledge Amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>Annex 2</U></FONT> &ndash; Form&nbsp;of
Joinder Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>Annex 3</U></FONT> &ndash; Form&nbsp;of
[Patent] [Trademark][Copyright] Security Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><U>Annex 4</U></FONT> &ndash; Form&nbsp;of
Uncertificated Stock Control Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">GUARANTY
AND SECURITY AGREEMENT, dated as of September&nbsp;3</FONT>, 2025, by and among PRECIGEN,&nbsp;INC., a Virginia corporation (&ldquo;<U>Borrower</U>&rdquo;
and a Grantor), and each Person that becomes a party hereto in the capacity as a Guarantor pursuant to <U>Section&nbsp;8.6</U> (together
with Borrower and such Guarantors, &ldquo;<U>Grantors</U>&rdquo;), in favor of BIOPHARMA CREDIT PLC, a public limited company incorporated
under the laws of England and Wales (as the &ldquo;<U>Collateral Agent</U>&rdquo;) on behalf of Lenders and each other Secured Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">W I T
N E S S E T H:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to the Loan Agreement dated as of September&nbsp;3</FONT>, 2025 (as the same may be amended, restated, amended and restated,
supplemented or otherwise modified from time to time, the &ldquo;<U>Loan Agreement</U>&rdquo;) by and among Borrower, the Collateral
Agent, the Lenders and the other parties thereto, Lenders have agreed to make extensions of credit to Borrower upon the terms and subject
to the conditions set forth therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">WHEREAS,
each </FONT>Grantor other than Borrower agrees to guaranty, jointly and severally, the Obligations (as defined in the Loan Agreement)
of Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, each Grantor will
derive substantial direct and indirect benefits from the making of the extensions of credit under the Loan Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">WHEREAS,
it is a condition precedent to the obligation of Lenders to </FONT>make Term Loans to Borrower under the Loan Agreement that the Grantors
shall have executed and delivered this Agreement to the Collateral Agent and each Lender for the benefit of Lenders and the other Secured
Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual </FONT>promises herein contained and for valuable consideration the receipt and sufficiency
of which is hereby acknowledged and to induce each of the Collateral Agent, Lenders and the Credit Parties to enter into the Loan Agreement
and to induce each Lender to make extensions of credit to Borrower thereunder, each Grantor hereunder hereby agrees with the Collateral
Agent, each intending to be legally bound, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>DEFINED TERMS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Definitions</U>.
Capitalized terms used herein without definition are used as defined in the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
following terms have the meanings given to them in the Code and terms used herein without definition that are defined in the Code have
the meanings given to them in the Code (such meanings to be equally applicable to both the singular and plural forms of the terms defined):
&ldquo;<U>account</U>&rdquo;, &ldquo;<U>account debtor</U>&rdquo;, &ldquo;<U>as-extracted collateral</U>&rdquo;, &ldquo;<U>certificated
security</U>&rdquo;, &ldquo;<U>chattel paper</U>&rdquo;, &ldquo;<U>check</U>&rdquo;, &ldquo;<U>commercial tort claim</U>&rdquo;, &ldquo;<U>commodity
account</U>&rdquo;, &ldquo;<U>commodity contract</U>&rdquo;, &ldquo;<U>documents</U>&rdquo;, &ldquo;<U>deposit account</U>&rdquo;, &ldquo;<U>electronic
chattel paper</U>&rdquo;, &ldquo;<U>encumbrance</U>&rdquo;, &ldquo;<U>entitlement holder</U>&rdquo;, &ldquo;<U>equipment</U>&rdquo;,
&ldquo;<U>farm products</U>&rdquo;, &ldquo;<U>financial asset</U>&rdquo;, &ldquo;<U>fixture</U>&rdquo;, &ldquo;<U>general intangible</U>&rdquo;,
&ldquo;<U>goods</U>&rdquo;, &ldquo;<U>health-care-insurance receivable</U>&rdquo;, &ldquo;<U>instruments</U>&rdquo;, &ldquo;<U>inventory</U>&rdquo;,
&ldquo;<U>investment property</U>&rdquo;, &ldquo;<U>letter of credit</U>&rdquo;, &ldquo;<U>letter-of-credit right</U>&rdquo;, &ldquo;<U>money</U>&rdquo;,
&ldquo;<U>proceeds</U>&rdquo;, &ldquo;<U>promissory note</U>&rdquo;, &ldquo;<U>record</U>&rdquo;, &ldquo;<U>securities account</U>&rdquo;,
&ldquo;<U>security</U>&rdquo;, &ldquo;<U>security entitlement</U>&rdquo;, &ldquo;<U>supporting obligation</U>&rdquo;, &ldquo;<U>tangible
chattel paper</U>&rdquo; and &ldquo;<U>uncertificated security</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Agreement</U>&rdquo;
means this Guaranty and Security Agreement, as it may be amended, restated, </FONT>amended and restated, supplemented or otherwise modified
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Applicable
IP Office</U>&rdquo; means</FONT>, as applicable, the United States Patent and Trademark Office or the United States Copyright Office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Collateral</U>&rdquo;
has the meaning specified in <U>Section</U></FONT><U>&nbsp;3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Collateral Agent</U>&rdquo;
means BioPharma Credit PLC, together with its successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Excluded Property</U>&rdquo;
means, collectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
&ldquo;intent-to-use&rdquo; application for registration of a United States Trademark for which a &ldquo;Statement of Use&rdquo; pursuant
to Section&nbsp;1(d)&nbsp;of the Lanham Act, 15 U.S.C. &sect; 1051 (or any successor provision) or an &ldquo;Amendment to Allege Use&rdquo;
pursuant to Section&nbsp;1(c)&nbsp;of the Lanham Act, 15 U.S.C. &sect; 1051 (or any successor provision) has not been filed with and
accepted by the Applicable IP Office, solely to the extent, if any, that, and only during the period, if any, in which, the grant of
a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use United
States Trademark application under Requirements of Law; <U>provided</U>, <U>however</U>, that upon filing and acceptance by the Applicable
IP Office of such statement of use or amendment to allege use (as applicable), such intent-to-use application shall be considered Collateral
for all purposes under the Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
rights or interests in any permit, lease, license, contract, instrument or other agreement held by any Grantor with respect to which,
the grant to the Collateral Agent, in favor of and for the benefit of Lenders and the other Secured Parties, of a security interest therein
and Lien thereupon, and the pledge to the Collateral Agent thereof, in favor of and for the benefit of Lenders and the other Secured
Parties, to secure the Obligations (and any guaranty thereof) are prohibited by the terms thereof, but only, in each case, to the extent,
and for so long as, such prohibition is not terminated or rendered unenforceable or otherwise deemed ineffective by the Code (including
Sections 9-406(d), 9-407(a), 9-408(a)&nbsp;and 9-409 of the Code) or by any applicable Requirements of Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
rights or interests in any permit, lease, license, contract, instrument or other agreement held by any Grantor with respect to which,
the grant to the Collateral Agent, in favor of and for the benefit of Lenders and the other Secured Parties, of a security interest in
and Lien thereupon, and the pledge to the Collateral Agent thereof, in favor of and for the benefit of Lenders and the other Secured
Parties, to secure the Obligations (and any guaranty thereof) require the consent, authorization, approval or waiver of any Governmental
Authority or other third party (other than Borrower or an Affiliate of Borrower) not obtained, in each case after giving effect to the
applicable anti-assignment provisions of the Code and other Requirements of Law and other than Proceeds and receivables thereof, the
assignment of which is expressly deemed effective under the Code or other Requirements of Law notwithstanding such prohibition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
other asset or property subject or purported to be subject to a Lien under any Collateral Document held by any Grantor with respect to
which, the grant to the Collateral Agent, in favor of and for the benefit of Lenders and the other Secured Parties, of a security interest
in and Lien thereupon, and the pledge to the Collateral Agent thereof, in favor of and for the benefit of Lenders and the other Secured
Parties, to secure the Obligations (and any guaranty thereof) require the consent, authorization, approval or waiver of any Governmental
Authority or other third party (other than Borrower or an Affiliate of Borrower) not obtained, in each case after giving effect to the
applicable anti-assignment provisions of the Code and other Requirements of Law and other than Proceeds and receivables thereof, the
assignment of which is expressly deemed effective under the Code or other Requirements of Law notwithstanding such prohibition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
property or asset subject or purported to be subject to a Lien under any Collateral Document held by any Grantor that is a non-Wholly
Owned Subsidiary with respect to which, the grant to the Collateral Agent, in favor of and for the benefit of Lenders and the other Secured
Parties, of a security interest therein and Lien thereupon, and the pledge to the Collateral Agent thereof, in favor of and for the benefit
of Lenders and the other Secured Parties, to secure the Obligations (and any guaranty thereof) are validly prohibited by, or would give
any third party (other than Borrower or an Affiliate of Borrower) the right to terminate its obligations under, the Operating Documents
of, the joint venture agreement or shareholder agreement with respect to, or any other contract with such third party relating to such
non-Wholly Owned Subsidiary (other than customary non-assignment provisions which are ineffective under Article&nbsp;9 of the Code or
other Requirements of Law), but only, in each case, to the extent, and for so long as such Operating Documents, joint venture agreement,
shareholder agreement or other contract is in effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
asset or property subject or purported to be subject to a Lien under any Collateral Document held by any Grantor with respect to which,
the cost, difficulty, burden or consequences (including adverse Tax consequences to Borrower or any of its Subsidiaries) of granting
the Collateral Agent, in favor of and for the benefit of Lenders and the other Secured Parties, a security interest therein and Lien
thereupon, and pledging to the Collateral Agent thereof, in favor of and for the benefit of Lenders and the other Secured Parties, to
secure the Obligations (and any guaranty thereof) are excessive relative to the value to be afforded to Secured Parties thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
rights under any Federal or state governmental license, permit, franchise or authorization to the extent that the granting of a security
interest therein is specifically prohibited or restricted by any Requirements of Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
asset or property subject to a Permitted Lien to the extent the documents governing such Permitted Lien or the Permitted Indebtedness
secured thereby prohibit other Liens on such assets or property, but only, in each case, to the extent, and for so long as, such prohibition
is not terminated or rendered unenforceable or otherwise deemed ineffective by the Code (including Sections 9-406(d), 9-407(a), 9-408(a)&nbsp;and
9-409 of the Code) or by any applicable Requirements of Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>leasehold
interests in real property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>fee
interests in real property (1)&nbsp;in the case of such real property located in the United States, with a fair market value less than
$5,000,000, and (2)&nbsp;in the case of such real property located in any non-U.S. jurisdiction, all such real property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Vehicles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
letter of credit with an amount less than $5,000,000 and all letter-of-credit rights with respect thereto to the extent not perfected
by the filing of a UCC-1 financing statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xiii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>commercial
tort claims with a predicted value of less than $5,000,000 (as reasonably determined by a Responsible Officer of Borrower in good faith
and based upon reasonable assumptions);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xiv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Excluded
Equity Interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Excluded
Accounts; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xvi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
other asset or property held by any Grantor (including any asset or property not located in the United States) with respect to which
the grant to Collateral Agent, in favor of and for the benefit of Lenders and the other Secured Parties, of a security interest therein
and Lien thereupon, and the pledge to Collateral Agent, in favor of and for the benefit of Lenders and the other Secured Parties, thereof,
to secure the Obligations (and any guaranty thereof) are specifically prohibited by Requirements of Law, but only, in each such case,
to the extent, and for so long as, such prohibition is not rendered or deemed ineffective by the Code (or any other applicable Requirements
of Law) notwithstanding such prohibition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><U>provided</U></FONT>,
<U>however</U>, that &ldquo;<U>Excluded Property</U>&rdquo; shall not include any proceeds, products, substitutions or replacements of
Excluded Property unless such proceeds, products, substitutions or replacements would otherwise constitute Excluded Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Fraudulent Transfer
Laws</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Guaranteed
Obligations</U>&rdquo; has the meaning set forth in <U>Section</U></FONT><U>&nbsp;2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Guarantor</U>&rdquo;
means each Grantor other than Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Guaranty</U>&rdquo;
means the guaranty of the Guaranteed Obligations made by Guarantors as set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&ldquo;<U>IP
License</U>&rdquo; means all express and implied grants or rights to make, have made, use, sell, reproduce, distribute, modify, or otherwise
exploit any Intellectual Property</FONT> in the U.S., as well as all covenants not to sue and co-existence agreements (and all related
IP Ancillary Rights) relating to any Intellectual Property in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>IP Security Agreement</U>&rdquo;
means an intellectual property security agreement in the form attached hereto as <U>Annex&nbsp;3</U>, and &ldquo;<U>IP Security Agreements</U>&rdquo;
means, collectively, all such intellectual property security agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Maximum Guaranteed
Amount</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>NDA</U>&rdquo; means
a new drug application filed with the FDA pursuant to Section&nbsp;505(b)&nbsp;of the U.S. Federal Food, Drug, and Cosmetic Act, along
with all supplements and amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Pledged
Certificated Stock</U>&rdquo; means all of the Equity Interests (other than Excluded Equity Interests) </FONT>in any Subsidiary, evidenced
by a certificate or instrument or other document of title (in each case, as defined in the Code), in each case owned by any Grantor,
including a Grantor&rsquo;s right, title and interest resulting from its ownership of any such Equity Interests as a limited or general
partner in any partnership that has issued Pledged Certificated Stock or as a member of any limited liability company that has issued
Pledged Certificated Stock, and a Grantor&rsquo;s right, title and interest resulting from its ownership of any such Equity Interests
in, to and under any Operating Document or shareholder agreement of any corporation, partnership or limited liability company to which
it is a party, and any distribution of property made on, in respect of or in exchange for the foregoing from time to time, including
all certificated Equity Interests listed on <U>Schedule 1</U> of the Security Disclosure Letter. &ldquo;Pledged Certificated Stock&rdquo;
includes, for the avoidance of doubt, any Pledged Uncertificated Stock that subsequently becomes certificated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Pledged Collateral</U>&rdquo;
means, collectively, the Pledged Stock and the Pledged Debt Instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Pledged Debt Instruments</U>&rdquo;
means all right, title and interest of any Grantor in instruments evidencing any Indebtedness owed to such Grantor or other obligations
owed to such Grantor, and any distribution of property made on, in respect of or in exchange for the foregoing from time to time, including
all Indebtedness described on <U>Schedule 3</U> of the Security Disclosure Letter, issued by the obligors named therein. &ldquo;Pledged
Debt Instruments&rdquo; excludes any Excluded Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Pledged Investment
Property</U>&rdquo; means any investment property of any Grantor, and any distribution of property made on, in respect of or in exchange
for the foregoing from time to time, other than any Pledged Stock or Pledged Debt Instruments. &ldquo;Pledged Investment Property&rdquo;
excludes any Excluded Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Pledged Stock</U>&rdquo;
means all Pledged Certificated Stock and all Pledged Uncertificated Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Pledged
Uncertificated Stock</U>&rdquo; means all of the Equity Interests (other than Excluded Equity Interests) </FONT>in any Subsidiary that
is not Pledged Certificated Stock, in each case owned by any Grantor, including Grantor&rsquo;s right, title and interest resulting from
its ownership of any such Equity Interests as a limited or general partner in any partnership not constituting Pledged Certificated Stock
or as a member of any limited liability company not constituting Pledged Certificated Stock, a Grantor&rsquo;s right, title and interest
resulting from its ownership of any such Equity Interests in, to and under any Operating Document or shareholder agreement of any partnership
or limited liability company to which it is a party, and any distribution of property made on, in respect of or in exchange for the foregoing
from time to time, including in each case those interests set forth on <U>Schedule 1</U> of the Security Disclosure Letter, to the extent
such interests are not certificated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&ldquo;<U>Secured
Obligations</U>&rdquo; has the meaning set forth in <U>Section</U></FONT><U>&nbsp;3.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Security Disclosure
Letter</U>&rdquo; means the security agreement disclosure letter, dated as of the date hereof, delivered by the Grantors to the Collateral
Agent and each Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Vehicles</U>&rdquo;
means rolling stock, motor vehicles, vessels, aircraft and other assets subject to certificates of title.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Other Terms</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
the purposes of and as used in this Agreement: (i)&nbsp;references to any Person include its successors and assigns and, in the case
of any Governmental Authority, any Person succeeding to its functions and capacities; (ii)&nbsp;each authorization herein shall be deemed
irrevocable and coupled with an interest; and (iii)&nbsp;where the context requires, provisions relating to any Collateral when used
in relation to a Grantor shall refer to such Grantor&rsquo;s Collateral or any relevant part thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Interpretive Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Defined
Terms</U>. Unless otherwise specified herein or therein, all terms defined in this Agreement shall have the defined meanings when used
in any certificate or other document made or delivered pursuant hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>This
Agreement</U>. The words &ldquo;hereof&rdquo;, &ldquo;herein&rdquo;, &ldquo;hereunder&rdquo; and words of similar import when used in
this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Common Terms</U>. The words &ldquo;include&rdquo;, &ldquo;included&rdquo; and &ldquo;including&rdquo; are not limiting and mean &ldquo;including
without limitation.&rdquo; The word &ldquo;or&rdquo; has the inclusive meaning represented by the phrase &ldquo;and/or&rdquo;. The word
&ldquo;shall&rdquo; is mandatory. The word &ldquo;may&rdquo; is permissive. The singular includes the plural and the plural includes
the singular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Performance;
Time</U>. Whenever any performance obligation hereunder (other than a payment obligation) shall be stated to be due or required to be
satisfied on a day other than a Business Day, such performance shall be made or satisfied on the next succeeding Business Day. In the
computation of periods of time from a specified date to a later specified date, the word &ldquo;from&rdquo; means &ldquo;from and including&rdquo;;
the words &ldquo;to&rdquo; and &ldquo;until&rdquo; each mean &ldquo;to but excluding&rdquo;, and the word &ldquo;through&rdquo; means
&ldquo;to and including.&rdquo; If any provision of this Agreement refers to any action taken or to be taken by any Person, or which
such Person is prohibited from taking, such provision shall be interpreted to encompass any and all means, direct or indirect, of taking,
or not taking, such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Contracts</U>.
Except as the context otherwise requires (including to the extent otherwise expressly provided herein), references to any contract, agreement,
instrument or other document, including this Agreement and the other Loan Documents, shall be deemed to include any and all amendments,
amendments and restatements, supplements or modifications thereto or restatements or substitutions thereof, in each case which are in
effect from time to time, but only to the extent such amendments, amendments and restatements, supplements, modifications, restatements
or substitutions are not prohibited by the terms of any Loan Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Laws</U>.
Except as the context otherwise requires (including to the extent otherwise expressly provided herein), references to any law, statute,
treaty, order, policy, rule&nbsp;or regulation include any amendments, supplements and successors thereto, and references to any law,
statute, treaty, order, policy, rule&nbsp;or regulation are to be construed as including all statutory and regulatory provisions related
thereto or consolidating, amending, replacing, supplementing or interpreting such law, statute, treaty, order, policy, rule&nbsp;or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Excluded
Property</U>. Notwithstanding anything to the contrary herein, the representations, warranties and covenants set forth herein in relation
to the assets of the Grantors shall not apply to any Excluded Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 126; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>GUARANTY</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Guaranty</U>.
To induce Lenders to make the Term Loans to Borrower in accordance with the terms and conditions of the Loan Agreement, each Guarantor,
jointly and severally with each other Guarantor, absolutely, unconditionally and irrevocably guarantees, as primary obligor and not merely
as surety, the full and punctual payment when due, whether at stated maturity or earlier, by reason of acceleration, mandatory prepayment
or otherwise in accordance with any Loan Document, of all the Obligations of Borrower existing on the date hereof or thereafter incurred
or created pursuant to any Loan Document (the &ldquo;<U>Guaranteed Obligations</U>&rdquo;). This Guaranty by each Guarantor hereunder
constitutes a guaranty of payment and not of collection. Each Guarantor hereby acknowledges and agrees that the Guaranteed Obligations,
at any time and from time to time, may exceed the Maximum Guaranteed Amount of such Guarantor and may exceed the aggregate of the Maximum
Guaranteed Amounts of all Guarantors, in each case without discharging, limiting or otherwise affecting the obligations of any Guarantor
hereunder or the rights, powers and remedies of any Secured Party hereunder or under any other Loan Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitation
of Guaranty</U>. Any term or provision of this Guaranty or any other Loan Document to the contrary notwithstanding, the maximum aggregate
amount for which any Guarantor shall be liable hereunder (the &ldquo;<U>Maximum Guaranteed Amount</U>&rdquo;) shall not exceed the maximum
amount for which such Guarantor can be liable without rendering this Guaranty or any other Loan Document, as it relates to such Guarantor,
subject to avoidance under applicable Requirements of Law relating to fraudulent conveyance or fraudulent transfer (including the Uniform
Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act and Section&nbsp;548 of title 11 of the United States Code or any applicable
provisions of comparable Requirements of Law) (collectively, &ldquo;<U>Fraudulent Transfer Laws</U>&rdquo;). Any analysis of the provisions
of this Guaranty for purposes of Fraudulent Transfer Laws shall take into account the right of contribution established in <U>Section&nbsp;2.7</U>
below and, for purposes of such analysis, give effect to any discharge of intercompany debt as a result of any payment made under the
Guaranty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization;
Other Agreements</U>. The Collateral Agent, on behalf of Lenders and the other Secured Parties, is hereby authorized, without notice
to or demand upon any Guarantor and without discharging or otherwise affecting the obligations of any Guarantor hereunder and without
incurring any liability hereunder, from time to time, to do each of the following but subject in all cases to the terms and conditions
of the other Loan Documents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>subject
to compliance with <U>Section&nbsp;11.5</U> of the Loan Agreement and <U>Section&nbsp;8.4</U> hereof (as applicable), (i)&nbsp;modify,
amend, supplement or otherwise change, (ii)&nbsp;accelerate or otherwise change the time of payment or (iii)&nbsp;waive or otherwise
consent to noncompliance with, any Guaranteed Obligation or any Loan Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>apply
to the Guaranteed Obligations any sums by whomever paid or however realized to any Guaranteed Obligation in such order as provided in
the Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>refund
at any time any payment received by any Secured Party in respect of any Guaranteed Obligation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
accordance with the terms of the Loan Documents: (i)&nbsp;sell, exchange, enforce, waive, substitute, liquidate, terminate, release,
abandon, fail to perfect, subordinate, accept, substitute, surrender, exchange, affect, impair or otherwise alter or release any Collateral
for any Guaranteed Obligation or any other guaranty therefor in any manner, (ii)&nbsp;receive, take and hold additional Collateral to
secure any Guaranteed Obligation, (iii)&nbsp;add, release or substitute any one or more other Guarantors, makers or endorsers of any
Guaranteed Obligation or any part thereof and (iv)&nbsp;otherwise deal in any manner with Borrower or any Guarantor, maker or endorser
of any Guaranteed Obligation or any part thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>subject
to Section&nbsp;11.1 of the Loan Agreement, settle, release, compromise, collect or otherwise liquidate the Guaranteed Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Guaranty
Absolute and Unconditional</U>. Each Guarantor hereby waives and agrees not to assert any defense (other than payment in full of the
Guaranteed Obligations (other than inchoate indemnity obligations)), whether arising in connection with or in respect of any of the following
<U>clauses (a)</U>&nbsp;through <U>(f)</U>&nbsp;or otherwise, and hereby agrees that its obligations under this Guaranty are irrevocable,
absolute and unconditional and shall not be discharged as a result of or otherwise affected by any of the following <U>clauses (a)</U>&nbsp;through
<U>(f)</U>&nbsp;(which may not be pleaded and evidence of which may not be introduced in any proceeding with respect to this Guaranty,
in each case except as otherwise agreed in writing by the Collateral Agent):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
invalidity or unenforceability of any obligation of Borrower or any Guarantor under any Loan Document or any other agreement or instrument
relating thereto (including any amendment, consent or waiver thereto), or any security for, or other guaranty of, any Guaranteed Obligation
or any part thereof, or the lack of perfection or continuing perfection or failure of priority of any security for the Guaranteed Obligations
or any part thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
absence of (i)&nbsp;any attempt to collect any Guaranteed Obligation or any part thereof from Borrower or any Guarantor or other action
to enforce the same or (ii)&nbsp;any action to enforce any Loan Document or any Lien thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
failure by any Person to take any steps to perfect and maintain any Lien on, or to preserve any rights with respect to, any Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
workout, insolvency, bankruptcy proceeding, reorganization (by way of voluntary arrangement, scheme of arrangement or otherwise), examinership,
arrangement, liquidation, administration, receivership, rescue process or dissolution (in each case howsoever described, and including
any analogous process, steps and/or proceedings in any applicable jurisdiction) by or against Borrower, any Guarantor or any of Borrower&rsquo;s
other Subsidiaries or any procedure, agreement, order, stipulation, election, action or omission thereunder, including any discharge
or disallowance of, or bar or stay against collecting, any Guaranteed Obligation (or any interest thereon) in or as a result of any such
proceeding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
foreclosure, whether or not through judicial sale, and any other sale or other disposition of any Collateral or any election following
the occurrence of an Event of Default and during the continuance thereof by the Collateral Agent, on behalf of Lenders and any other
Secured Party, to proceed separately against any Collateral in accordance with the Collateral Agent&rsquo;s rights and the rights of
any Lender or other Secured Party under any applicable Requirements of Law; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
other defense, setoff, counterclaim or any other circumstance that might otherwise constitute a legal or equitable discharge of Borrower,
any Guarantor or any other Subsidiary of Borrower, in each case other than payment in full of the Guaranteed Obligations (other than
inchoate indemnity obligations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Waivers</U>.
To the fullest extent permitted by Requirements of Law, each Guarantor hereby unconditionally and irrevocably waives and agrees not to
assert any claim, defense, setoff or counterclaim based on diligence, promptness, presentment, requirements for any demand or notice
hereunder,&nbsp;including any of the following: (a)&nbsp;any demand for payment or performance and protest and notice of protest; (b)&nbsp;any
notice of acceptance; (c)&nbsp;any presentment, demand, protest or further notice or other requirements of any kind with respect to any
Guaranteed Obligation (including any accrued but unpaid interest thereon) becoming immediately due and payable; and (d)&nbsp;any other
notice in respect of any Guaranteed Obligation or any part thereof, and any defense arising by reason of any disability or other defense
of Borrower or any Guarantor. Until payment in full of the Guaranteed Obligations (other than inchoate indemnity obligations), each Guarantor
further unconditionally and irrevocably agrees not to (x)&nbsp;enforce or otherwise exercise any right of subrogation or any right of
reimbursement or contribution or similar right against Borrower or any Guarantor by reason of any Loan Document or any payment made thereunder
or (y)&nbsp;assert any claim, defense, setoff or counterclaim it may have against any other Credit Party or set off any of its obligations
to such other Credit Party against obligations of such Credit Party to such Guarantor. No obligation of any Guarantor hereunder shall
be discharged other than by complete performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reliance</U>.
Each Guarantor hereby assumes responsibility for keeping itself informed of the financial condition of Borrower, each other Guarantor
and any other guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and of all other circumstances bearing upon
the risk of nonpayment of any Guaranteed Obligation or any part thereof that reasonable and diligent inquiry would reveal, and each Guarantor
hereby agrees that neither the Collateral Agent nor any Lender or other Secured Party shall have any duty to advise any Guarantor of
information known to it regarding such condition or any such circumstances. In the event the Collateral Agent, in its sole discretion,
undertakes at any time or from time to time to provide any such information to any Guarantor, such Person shall be under no obligation
to (a)&nbsp;undertake any investigation not a part of its regular business routine, (b)&nbsp;disclose any information that any Lender
or other Secured Party, pursuant to accepted or reasonable commercial finance or banking practices, wishes to maintain confidential or
(c)&nbsp;make any future disclosures of such information or any other information to any Guarantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Contribution</U>.
To the extent that any Guarantor shall be required hereunder to pay any portion of any Guaranteed Obligation exceeding the greater of
(a)&nbsp;the amount of the value actually received by such Guarantor and its Subsidiaries from the Term Loans and other Obligations and
(b)&nbsp;the amount such Guarantor would otherwise have paid if such Guarantor had paid the aggregate amount of the Guaranteed Obligations
(excluding the amount thereof repaid by Borrower) in the same proportion as such Guarantor&rsquo;s net worth on the date enforcement
is sought hereunder bears to the aggregate net worth of all Guarantors on such date, then such Guarantor shall be reimbursed by such
other Guarantors for the amount of such excess, <I>pro rata</I>, based on the respective net worth of such other Guarantors on such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>GRANT OF SECURITY INTEREST</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Collateral</U>.
For the purposes of this Agreement, the following tangible and intangible assets and property now owned or at any time hereafter acquired,
developed or created by a Grantor or in which a Grantor now has or at any time in the future may acquire any right, title or interest,
in each case, wherever located, is collectively referred to as the &ldquo;<U>Collateral</U>&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
accounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
as-extracted collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
chattel paper, including electronic chattel paper or tangible chattel paper;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
checks;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
deposit accounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
encumbrances;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
equipment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
fixtures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
general intangibles (including all Company IP Agreements, Manufacturing Agreements and any other agreements or contracts of any kind);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
goods;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
Intellectual Property and IP Licenses (including any IP Licenses under the Company IP Agreements to which a Grantor is a party and the
rights of such Grantor thereunder, and all of a Grantor&rsquo;s right, title and interest in, to and under any Internet Domain Names
and Software), including any similar or equivalent rights to those set forth in any of clauses (a)&nbsp;through (g)&nbsp;of the definition
of &ldquo;Intellectual Property&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
instruments (including all promissory notes and similar instruments);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
right, title and interest in, to and under any NDA relating to the research, development, manufacture, production, use, commercialization,
marketing, importing, storage, transport, offer for sale or lease, distribution, sale or lease of Product in the Territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
inventory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
investment property (including Pledged Collateral, Pledged Investment Property, Equity Interests, securities, securities accounts and
security entitlements with respect thereto and financial assets carried therein, and all commodity accounts and commodity contracts);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
money (including cash and cash equivalents);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
letters of credit with an amount greater than or equal to $5,000,000 and all letter-of-credit rights and supporting obligations with
respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>fee
interests in real property located in the United States with a fair market value greater than or equal to $5,000,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
commercial tort claims with a predicted value of $5,000,000 or more (as reasonably determined by a Responsible Officer of Borrower in
good faith and based upon reasonable assumptions) described on <U>Schedule 4</U> of the Security Disclosure Letter;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
books, records, ledger cards, files, correspondence, customer lists, blueprints, technical specifications, manuals, computer software,
computer printouts, tapes, disks and other electronic storage media and related data processing software and similar items that at any
time pertain to or evidence or contain information relating to any of the other property described in this <U>Section&nbsp;3.1</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
property of such Grantor held by the Collateral Agent for the benefit of Lenders and any other Secured Party, including all property
of every description, in the custody of or in transit to the Collateral Agent for the benefit of Lenders and any other Secured Party
for any purpose, including safekeeping, collection or pledge, for the account of such Grantor or as to which such Grantor may have any
right or power, including cash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
proceeds, products, accessions, rents and profits of or in respect of any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the extent not otherwise included, all personal property of such Grantor, whether tangible or intangible and wherever located, and all
proceeds, products, accessions, rents, issues and profits of any and all of the foregoing and all collateral security, supporting obligations
and guarantees given by any Person with respect to any of the foregoing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>to
the extent not otherwise included, all other properties or assets of whatever kind and nature subject or purported to be subject from
time to time to a Lien under any Collateral Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><U>excluding</U></FONT>,
<U>however</U>, in all cases, all Excluded Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Grant
of Security Interest in Collateral</U>. Without limiting any other security interest granted to the Collateral Agent, in favor of and
for the benefit of Lenders and the other Secured Parties, each Grantor, as collateral security for the prompt and complete payment and
performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations of such Grantor (the &ldquo;<U>Secured
Obligations</U>&rdquo;), hereby pledges, hypothecates and grants to the Collateral Agent, in favor and for the benefit of Lenders and
the other Secured Parties, to secure the payment and performance in full of all of the Obligations for the benefit of Lenders and the
other Secured Parties, a first priority Lien (subject only to Permitted Liens) on and continuing security interest in, all of its right,
title and interest in, to and under the Collateral of such Grantor, wherever located, whether now owned or hereafter acquired or arising;
<U>provided</U>, <U>however</U>, notwithstanding the foregoing, no Lien or security interest is hereby granted on, and &ldquo;Collateral&rdquo;
shall not include, any Excluded Property; <U>provided</U>, <U>further</U>, that if and when any property or asset shall cease to be Excluded
Property, a first priority Lien (subject only to Permitted Liens) on and security interest in such property or asset shall be deemed
granted therein and, therefore, &ldquo;Collateral&rdquo; shall then include any such property or asset. For the avoidance of doubt, notwithstanding
anything herein to the contrary, no Grantor or Subsidiary of any Grantor shall be required to take any action under laws outside the
United States, or enter into agreements governed or purported to be governed by laws outside of the United States, to attach, maintain,
perfect, protect or enforce any Lien of the Collateral Agent in favor and for the benefit of the Secured Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 130; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>REPRESENTATIONS AND WARRANTIES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">To
induce</FONT> each of the Collateral Agent and Lenders to enter into the Loan Documents, each Grantor, jointly and severally with each
other Grantor, represents and warrants each of the following to the Collateral Agent, each Lender and the other Secured Parties, that
the following statements are true and correct as of the Effective Date and each applicable Closing Date on which a Term Loan is made
(both with and without giving effect to the Term Loans) except as otherwise specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Title;
No Other Liens</U>. Except for the Lien granted to the Collateral Agent for the benefit of Lenders and the other Secured Parties pursuant
to this Agreement and any other Permitted Liens under any Loan Document (including <U>Section&nbsp;4.2</U> hereof), such Grantor owns
or otherwise has the rights it purports to have in each item of the Collateral, free and clear of any and all Liens or claims of others.
Such Grantor (a)&nbsp;is the record and beneficial owner of the Collateral pledged by it hereunder constituting instruments or certificates
and (b)&nbsp;except for Permitted Subsidiary Distribution Restrictions, has rights in or the power to transfer each other item of Collateral
in which a Lien is granted by it hereunder, free and clear of any other Lien other than any Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Perfection
and Priority</U>. Other than in respect of any fixtures to the extent the underlying property is not subject to a Mortgage, as-extracted
collateral and in respect of money and other Collateral subject to Section&nbsp;9-311(a)(1)&nbsp;of the Code, the security interest granted
to the Collateral Agent pursuant to this Agreement constitutes a valid and continuing first priority perfected security interest (subject,
in the case of priority only, to Permitted Liens that are expressly permitted (if at all) by the terms of the Loan Agreement or this
Agreement to, or that by operation of law, have superior priority to the Lien and security interest granted to the Collateral Agent for
the benefit of Lenders and the other Secured Parties) in favor of and for the benefit of Lenders and the other Secured Parties in all
Collateral, subject, for the following Collateral, to the occurrence of the following: (a)&nbsp;in the case of all Collateral in which
a security interest may be perfected by filing a financing statement under the Code, the completion of the filings and other actions
specified on <U>Schedule&nbsp;2</U> of the Security Disclosure Letter (which, in the case of all filings and other documents referred
to on such schedule, have been duly authorized by the applicable Grantor); (b)&nbsp;with respect to any account over which a Control
Agreement is required pursuant to Section&nbsp;5.5 of the Loan Agreement, the execution of Control Agreements; (c)&nbsp;in the case of
all United States Trademarks, United States Patents and United States Copyrights (or exclusive IP Licenses with respect to United States
Copyrights) for which Code filings are insufficient to effectuate perfection, all appropriate filings having been made with the Applicable
IP Office, as applicable; (d)&nbsp;in the case of all Pledged Certificated Stock, Pledged Debt Instruments and Pledged Investment Property
(other than any Pledged Debt Instrument or Pledged Investment Property that is not evidenced by a physical copy as of the date hereof),
the delivery to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of such Pledged Certificated Stock, Pledged
Debt Instruments and Pledged Investment Property consisting of instruments and certificates, in each case, properly endorsed for transfer
to the Collateral Agent or in blank; (e)&nbsp;in the case of all Pledged Uncertificated Stock, the delivery to the Collateral Agent,
for the benefit of the Lenders and the other Secured Parties, of an executed uncertificated stock control agreement among the issuer,
the registered owner and the Collateral Agent in the form attached as <U>Annex 4</U> hereto; (f)&nbsp;in the case of letter-of-credit
rights which constitute Collateral hereunder and are not supporting obligations of Collateral, the execution of a contractual obligation
granting control to Collateral Agent, for the benefit of the Lenders and the other Secured Parties, over such letter-of-credit rights;
(g)&nbsp;in the case of electronic chattel paper, the completion of all steps necessary to grant control to Collateral Agent, for the
benefit of the Lenders and the other Secured Parties, over such electronic chattel paper; and (h)&nbsp;in the case of all other instruments
that are not Pledged Stock, if any, the delivery thereof to the Collateral Agent, for the benefit of Lenders and the other Secured Parties,
of such instruments. Such Lien on and security interest in Pledged Stock shall be prior to all other Liens on such Collateral, subject
to Permitted Liens having priority over the Collateral Agent&rsquo;s Lien by operation of law or as and to the extent expressly permitted
(if at all) by any Loan Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 131; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pledged
Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Pledged Stock issued by any Subsidiary of any Grantor pledged by such Grantor hereunder (i)&nbsp;consist of the number and types of Equity
Interests listed on <U>Schedule 1</U> of the Security Disclosure Letter (or any update thereof or supplement thereto permitted to be
made pursuant to the Loan Agreement and received by the Collateral Agent in accordance with the Loan Agreement) and constitutes that
percentage of the issued and outstanding equity of all classes of each issuer thereof as set forth on <U>Schedule 1</U> of the Security
Disclosure Letter, (ii)&nbsp;has been duly authorized, validly issued and (where required by Requirements of Law to be) is fully paid
and nonassessable (other than Pledged Stock in limited liability companies and partnerships), and (iii)&nbsp;if and to the extent applicable,
constitutes the legal, valid and binding obligation of the issuer thereof with respect thereto, enforceable in accordance with its terms,
subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors&rsquo; rights generally
and subject to equitable principles (regardless of whether enforcement is sought in equity or at law). As of the date any Joinder Agreement
or Pledge Amendment is delivered pursuant to <U>Section&nbsp;8.6</U>, the Pledged Stock pledged by each applicable Grantor thereunder
(x)&nbsp;is listed on the applicable schedule attached to such Joinder Agreement or Pledge Amendment, as applicable, and constitutes
that percentage of the issued and outstanding equity of all classes of each issuer thereof as set forth on such schedule, (y)&nbsp;has
been duly authorized, validly issued and (where required by Requirements of Law to be) is fully paid and non-assessable (other than Pledged
Stock in limited liability companies and partnerships) and (z)&nbsp;if and to the extent applicable, constitutes the legal, valid and
binding obligation of the issuer thereof with respect thereto, enforceable in accordance with its terms, subject to applicable bankruptcy,
insolvency, reorganization, moratorium or other similar laws affecting creditors&rsquo; rights generally and subject to equitable principles
(regardless of whether enforcement is sought in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
Pledged Certificated Stock has been delivered to (or otherwise in accordance with the written direction of) the Collateral Agent, for
the benefit of Lenders and the other Secured Parties, in accordance with <U>Section&nbsp;5.2(a)</U>, and (ii)&nbsp;with respect to all
Pledged Uncertificated Stock, uncertificated stock control agreements in the form attached as <U>Annex 4</U> hereto have been delivered
to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, in accordance with <U>Section&nbsp;5.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the occurrence and during the continuance of an Event of Default, the Collateral Agent for the benefit of Lenders and the other Secured
Parties shall be entitled to exercise all of the rights of the Grantor granting the security interest in any Pledged Stock, and a transferee
or assignee of such Pledged Stock shall become a holder of such Pledged Stock to the same extent as such Grantor and, upon the transfer
of the entire interest of such Grantor, such Grantor shall, by operation of law, cease to be a holder of such Pledged Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pledged
Debt Instruments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;To
the Knowledge of the Borrower, all Pledged Debt Instruments constituting Indebtedness owed to a Grantor have been duly authorized, authenticated
or issued and delivered by the issuer(s)&nbsp;of such Indebtedness, and is the legal, valid and binding obligation of such issuer(s)&nbsp;and
such issuer(s)&nbsp;is not in default thereunder, subject as to the enforcement of remedies to applicable bankruptcy, insolvency, reorganization,
fraudulent conveyance or transfer, moratorium or similar laws affecting creditors&rsquo; rights generally and subject to general principles
of equity, regardless of whether considered in a proceeding in equity or at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Schedule 3</U> of the Security Disclosure Letter (or any update thereof or supplement thereto permitted to be made
pursuant to the Loan Agreement and received by the Collateral Agent in accordance with the Loan Agreement), none of the Pledged Debt
Instruments constituting Indebtedness owed to such Grantor is subordinated in right of payment to any other Indebtedness or subject to
the terms of an indenture (or similar agreement or instrument).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
Pledged Debt Instruments constituting Indebtedness owed to such Grantor (other than any Pledged Debt Instrument that is not evidenced
by a physical copy as of the date hereof) evidencing Indebtedness or other monetary obligations in an amount, individually or together
with one or more other Pledged Debt Instruments, exceeding $5,000,000 (as reasonably determined by a Responsible Officer of Borrower
in good faith) and required to be delivered on or prior to the date hereof have been delivered to the Collateral Agent, for the benefit
of Lenders and the other Secured Parties, in accordance with <U>Section&nbsp;5.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>COVENANTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Each
Grantor agrees with the Collateral Agent to the following, until payment in full of the</FONT> Secured Obligations (other than inchoate
indemnity obligations) and unless the Collateral Agent, on behalf of Lenders and the other Secured Parties, otherwise consents in writing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Maintenance
of Perfected Security Interest; Further Documentation and Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as otherwise (i)&nbsp;mutually agreed in writing between Borrower and the Collateral Agent not to be required under this Agreement or
the other Loan Documents, (ii)&nbsp;mutually agreed in writing between Borrower and the Collateral Agent to be effected solely by filings
of financing statements under the Code or amendments thereto to be made by the Collateral Agent or any Lender or its Related Party pursuant
to <U>Section&nbsp;7.2</U>, or (iii)&nbsp;expressly provided in Section&nbsp;5.14 of the Loan Agreement, such Grantor, in order to grant
and maintain a security interest in favor of the Collateral Agent pursuant to this Agreement which constitutes a valid and continuing
first priority perfected security interest as described in <U>Section&nbsp;4.2</U> (subject only to Permitted Liens):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>after
the creation or acquisition of any U.S. deposit account over which a Control Agreement is required pursuant to Section&nbsp;5.5 of the
Loan Agreement, execute and deliver to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, in accordance
with Section&nbsp;5.5 of the Loan Agreement, Control Agreements in form and substance reasonably satisfactory to the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
accordance with the requirements in <U>Section&nbsp;5.3</U> (as applicable), with respect to any registered or applied-for U.S. Trademarks,
U.S. Patents, U.S. Copyrights, or any exclusive IP Licenses under registered U.S. Copyrights to which such Grantor is the licensee, in
each case of this clause (ii), constituting Collateral, execute and deliver to the Collateral Agent, for the benefit of Lenders and the
other Secured Parties, all appropriate IP Security Agreements, in the form attached hereto as <U>Annex 3</U>, for the filing thereof
by the Collateral Agent or its Related Party, and such Grantor hereby duly authorizes the Collateral Agent and its Related Party to file
such IP Security Agreements with the Applicable IP Office;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
accordance with the requirements in <U>Section&nbsp;5.2</U> (as applicable), with respect to any Pledged Certificated Stock, deliver
to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, such Pledged Certificated Stock consisting of instruments
and certificates, in each case, properly endorsed for transfer to the Collateral Agent or in blank and in form and substance reasonably
satisfactory to the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
accordance with the requirements in <U>Section&nbsp;5.2</U> (as applicable), with respect to any Pledged Uncertificated Stock, deliver
to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, an executed uncertificated stock control agreement
among the issuer, the registered owner and the Collateral Agent in the form attached as <U>Annex 4</U> hereto (and otherwise in form
and substance reasonably satisfactory to the Collateral Agent), pursuant to which, <I>inter alia</I>, such issuer agrees to comply with
the Collateral Agent&rsquo;s instructions with respect to such Pledged Uncertificated Stock without further consent by such Grantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
accordance with the requirements in <U>Section&nbsp;5.2</U> (as applicable), with respect to any Pledged Debt Instruments and Pledged
Investment Property, deliver to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, such Pledged Debt Instruments
or Pledged Investment Property (as applicable) consisting of instruments and certificates, in each case, properly endorsed for transfer
to the Collateral Agent and in form and substance reasonably satisfactory to the Collateral Agent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 133; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>maintain
the security interest created by this Agreement as a first priority perfected security interest as described in <U>Section&nbsp;4.2</U>
(subject to Permitted Liens) and shall take commercially reasonable efforts to warrant and defend the Collateral covered by such security
interest and such priority (subject to Permitted Liens) against the claims and demands of all Persons (other than Secured Parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Such
Grantor shall furnish to the Collateral Agent at any time and from time to time statements and schedules further identifying and describing
the Collateral and such other documents in connection with the Collateral as the Collateral Agent may reasonably request in writing,
in all cases in reasonable detail and in form and substance reasonably satisfactory to the Collateral Agent (including in the case of
any commercial tort claim constituting Collateral, for the avoidance of doubt, reasonable detail identifying the specific claims subject
to the security interest granted in such commercial tort claims to the Collateral Agent pursuant to this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
any time and from time to time, upon the reasonable written request of the Collateral Agent, such Grantor shall, for the purpose of obtaining
or preserving the full benefits of this Agreement and the other Collateral Documents and of the rights and powers herein and therein
granted, (i)&nbsp;promptly and duly execute and deliver, and have recorded, such further documents, including an authorization to file
(or, as applicable, the filing) of any financing statement or amendment under the Code (or other filings under similar Requirements of
Law) in effect in the U.S. and (ii)&nbsp;take such further action as the Collateral Agent may reasonably request in writing that is consistent
with the requirements hereof and of the other Loan Documents, including&nbsp;executing and delivering any Control Agreements required
by Section&nbsp;5.5 of the Loan Agreement with respect to the Collateral Accounts, in each case of <U>sub-clause (i)</U>&nbsp;and <U>(ii)</U>&nbsp;above,
subject to the terms of Section&nbsp;5.12 of the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pledged
Collateral and Pledged Investment Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of Pledged Collateral and Pledged Investment Property</U>. Without limitation to <U>Section&nbsp;5.1</U> above, such Grantor shall promptly,
and no later than sixty (60) days after acquiring any Pledged Collateral not owned on the Tranche A Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>deliver
to the Collateral Agent, properly endorsed, in blank or otherwise in suitable form for transfer and in form and substance reasonably
satisfactory to the Collateral Agent, (A)&nbsp;all such Pledged Stock that is Pledged Certificated Stock, (B)&nbsp;each Pledged Debt
Instrument (other than any Pledged Debt Instrument that is not evidenced by a physical copy) evidencing Indebtedness or other monetary
obligations in an amount, individually or together with one or more other Pledged Debt Instruments, exceeding $5,000,000 (as reasonably
determined by a Responsible Officer of Borrower in good faith), and (C)&nbsp;all certificates and instruments evidencing Pledged Investment
Property with a fair market value, individually or together with one or more other such certificates or instruments, exceeding $5,000,000
(as reasonably determined by a Responsible Officer of Borrower in good faith);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>subject
all Collateral Accounts required to be subject to a Control Agreement pursuant to Section&nbsp;5.5 of the Loan Agreement to a Control
Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>cause
the issuer of any such Pledged Stock that has been issued by any Subsidiary of any Grantor and is Pledged Uncertificated Stock to execute
an uncertificated stock control agreement in the form attached hereto as <U>Annex 4</U>, pursuant to which, <I>inter alia</I>, such issuer
agrees to comply with the Collateral Agent&rsquo;s instructions with respect to such Pledged Uncertificated Stock without further consent
by such Grantor, and, for the avoidance of doubt, if any such Pledged Uncertificated Stock becomes certificated, promptly (but in any
event within thirty (30) days thereof, or such longer period as the Collateral Agent may agree in writing and in its sole discretion,
taking into account reasonable good faith efforts) deliver to the Collateral Agent, in suitable form for transfer and in form and substance
reasonably satisfactory to the Collateral Agent, all such certificates, instruments or other similar documents (as defined in the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Event
of Default</U>. During the continuance of any Event of Default and in connection with the exercise of rights or remedies hereunder or
under any other Loan Document, the Collateral Agent shall have the right, at any time in its discretion and without prior notice to any
Grantor, to (i)&nbsp;transfer to or to register in its name or in the name of its nominees any Pledged Stock and (ii)&nbsp;exchange any
certificate or instrument representing or evidencing any Pledged Stock for certificates or instruments of smaller or larger denominations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 134; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cash
Distributions with respect to Pledged Collateral and Pledged Investment Property</U>. Except as provided in <U>Article&nbsp;6</U> and
subject to any limitations set forth in the Loan Agreement, such Grantor shall be entitled to receive all cash distributions paid in
respect of the Pledged Collateral and the Pledged Investment Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voting
Rights</U>. Except as provided in <U>Article&nbsp;6</U>, such Grantor shall be entitled to exercise all voting, consent and corporate,
partnership, limited liability company and similar rights with respect to the Pledged Collateral and Pledged Investment Property; <U>provided</U>,
<U>however</U>, that no vote shall be cast, consent, waiver or ratification given or right exercised (or failed to be exercised) or other
action taken (or failed to be taken) by such Grantor in any manner that would reasonably be expected to (i)&nbsp;violate or be inconsistent
with any of the terms of this Agreement or any other Loan Document or (ii)&nbsp;have the effect of materially impairing such Collateral
or the position of any Secured Party or their rights or interests in such Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Intellectual
Property</U>. If such Grantor shall at any time after the date hereof acquire any registered, issued or applied-for, as applicable, U.S.
Copyright, U.S. Trademark or U.S. Patent, or any exclusive IP License under registered U.S. Copyrights to which such Grantor is the licensee,
in each case, that constitutes Collateral, such Grantor shall, promptly (and no later than thirty (30) days (or such longer period as
the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after delivery
of financial statements pursuant to Section&nbsp;5.2(a)&nbsp;of the Loan Agreement) (or such longer period as Collateral Agent may agree
in its sole discretion), execute and deliver to the Collateral Agent, the IP Security Agreement(s)&nbsp;in the form attached hereto as
<U>Annex 3</U> (or in any other form and substance reasonably acceptable to the Collateral Agent and suitable for filing in the Applicable
IP Office), as required by the Applicable IP Office, in respect of any such newly-acquired Copyright(s), Trademark(s)&nbsp;or Patent(s)&nbsp;or
any such newly-acquired IP License(s)&nbsp;(as applicable) of such Grantor for recordation in the Applicable IP Office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>REMEDIAL PROVISIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Code
and Other Remedies</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Code
Remedies</U>. During the continuance of an Event of Default, the Collateral Agent, on behalf of Lenders and the other Secured Parties,
may exercise, in addition to all other rights and remedies granted to it in this Agreement, any IP Agreement, any other Loan Document
or in any other instrument or agreement securing, evidencing or relating to any Secured Obligation, all rights, powers and remedies of
a secured party under the Code or any other Requirements of Law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Disposition
of Collateral</U>. During the continuance of an Event of Default, without limiting the generality of the foregoing, the Collateral Agent
may (personally or through its agents or attorneys), without demand of performance or other demand, presentment, protest, advertisement
or notice of any kind (except any notice required by Requirements of Law referred to below) to or upon any Grantor or any other Person
(all and each of which demands, defenses, advertisements and notices are hereby waived): (i)&nbsp;enter upon the premises where any Collateral
is located, without any obligation to pay rent, through self-help, without judicial process, without first obtaining a final judgment
or giving Grantor or any other Person notice or opportunity for a hearing on the Collateral Agent&rsquo;s or any Lender&rsquo;s claim
or action; (ii)&nbsp;collect, receive, appropriate and realize upon any Collateral; (iii)&nbsp;store, process, repair or recondition
the Collateral or otherwise prepare any Collateral for disposition in any manner to the extent the Collateral Agent deems appropriate;
and (iv)&nbsp;sell, assign, license out, convey, transfer, grant option or options to purchase or license and deliver any Collateral
(or enter into contractual obligations to do any of the foregoing), in one or more parcels at public or private sale or sales, at any
exchange, broker&rsquo;s board or office of the Collateral Agent or any Lender or other Secured Party or elsewhere upon such terms and
conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery without assumption
of any credit risk. The Collateral Agent, on behalf of Lenders and the other Secured Parties, shall have the right, upon any such public
sale or sales and, to the extent permitted by the Code and other Requirements of Law, upon any such private sale or sales, to purchase
or license the whole or any part of the Collateral so sold or licensed, free of any right or equity of redemption of any Grantor, which
right or equity is hereby waived and released. The Collateral Agent, as representative of all Lenders and other Secured Parties, shall
be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral
sold at any such sale made in accordance with the Code, to use and apply any of the Secured Obligations as a credit on account of the
purchase price for any Collateral payable by the Collateral Agent on behalf of Lenders and the other Secured Parties, at such sale. If
the Collateral Agent on behalf of any Lender sells any of the Collateral upon credit, Grantor will be credited only with payments actually
made by purchaser and received by such Lender and applied to indebtedness of the purchaser. In the event the purchaser fails to pay for
the Collateral, the Collateral Agent may resell the Collateral and Grantor shall be credited with proceeds of the sale. Neither the Collateral
Agent nor any Lender shall have an obligation to marshal any of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 135; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Management
of the Collateral</U>. Each Grantor further agrees, that, during the continuance of any Event of Default, (i)&nbsp;at the Collateral
Agent&rsquo;s request, it shall assemble the Collateral and make it available to the Collateral Agent at places that the Collateral Agent
shall reasonably select, whether at such Grantor&rsquo;s premises or elsewhere, (ii)&nbsp;without limiting the foregoing, the Collateral
Agent also has the right to require that such Grantor store and keep any Collateral pending further action by the Collateral Agent and,
while any such Collateral is so stored or kept, provide such guards and maintenance services as shall be necessary to protect the same
and to preserve and maintain such Collateral in good condition, normal wear and tear excepted, (iii)&nbsp;until the Collateral Agent
is able to sell, assign, license out, convey or transfer any Collateral, the Collateral Agent shall have the right to hold or use such
Collateral to the extent that it deems appropriate for the purpose of preserving the Collateral or its value or for any other purpose
deemed appropriate by the Collateral Agent and (iv)&nbsp;the Collateral Agent may, if it so elects, seek the appointment of a receiver
or keeper to take possession of any Collateral and to enforce any of the Collateral Agent&rsquo;s or any Lender&rsquo;s remedies, with
respect to such appointment without any prior written notice or hearing as to such appointment. The Collateral Agent shall not have any
obligation to any Grantor to maintain or preserve the rights of any Grantor as against other Persons with respect to any Collateral while
such Collateral is in the possession of the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Application
of Proceeds</U>. The Collateral Agent shall apply the cash proceeds received by it in respect of any sale of, any collection from, or
other realization upon all or any part of the Collateral, after deducting all reasonable costs and expenses of every kind incurred in
connection therewith or incidental to the care or safekeeping of any Collateral or in any way relating to the Collateral or the rights
of Lenders and the other Secured Parties, including reasonable and documented out-of-pocket attorneys&rsquo; fees and disbursements,
to the payment in whole or in part of the Secured Obligations, as set forth in the Loan Agreement and, and only after such application
and after the payment by the Collateral Agent or Lenders of any other amount required by any Requirements of Law, need the Collateral
Agent or any Lender account for the surplus, if any, to any Grantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Direct
Obligation</U>. Neither the Collateral Agent nor any Lender or other Secured Party shall be required to make any demand upon, or pursue
or exhaust any right or remedy against, any Grantor or any other Person with respect to the payment of the Obligations or to pursue or
exhaust any right or remedy with respect to any Collateral therefor or any direct or indirect guaranty thereof. All of the rights and
remedies of the Collateral Agent and Lenders and any other Secured Party shall be cumulative, may be exercised individually or concurrently
and not exclusive of any other rights or remedies provided by any Requirements of Law. To the extent it may lawfully do so, each Grantor
absolutely and irrevocably waives and relinquishes the benefit and advantage of, and covenants not to assert against the Collateral Agent,
Lenders or any other Secured Party, any valuation, stay, appraisement, extension, redemption or similar laws and any and all rights or
defenses it may have as a surety, now or hereafter existing, arising out of the exercise by any of them of any rights or remedies hereunder.
If any notice of a proposed sale (public or private) or other disposition of any Collateral shall be required by Requirements of Law,
such notice shall be deemed reasonable and proper if given at least ten (10)&nbsp;days before such sale or other disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Commercially
Reasonable</U>. To the extent that applicable Requirements of Law impose duties on the Collateral Agent or any Lender or other Secured
Party to exercise remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is not commercially unreasonable
for the Collateral Agent or any Lender to do any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>fail
to incur significant costs, expenses or other liabilities reasonably deemed as such by the Collateral Agent or such Lender to prepare
any Collateral for disposition or otherwise to complete raw material or work in process into finished goods or other finished products
for disposition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 136; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>fail
to obtain permits, licenses or other consents for access to any Collateral to sell or license or for the collection or sale or licensing
of any Collateral, or, if not required by other Requirements of Law, fail to obtain permits, licenses or other consents for the collection
or disposition of any Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>fail
to exercise remedies against account debtors or other Persons obligated on any Collateral or to remove Liens on any Collateral or to
remove any adverse claims against any Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>advertise
dispositions of any Collateral through publications or media of general circulation, whether or not such Collateral is of a specialized
nature, or to contact other Persons, whether or not in the same business as any Grantor, for expressions of interest in acquiring any
such Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>exercise
collection remedies against account debtors and other Persons obligated on any Collateral, directly or through the use of collection
agencies or other collection specialists, hire one or more professional auctioneers to assist in the disposition of any Collateral, whether
or not such Collateral is of a specialized nature, or, to the extent deemed appropriate by the Collateral Agent or such Lender, obtain
the services of other brokers, investment bankers, consultants and other professionals to assist the Collateral Agent or such Lender
in the collection or disposition of any Collateral, or utilize Internet sites that provide for the auction of assets of the types included
in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets to dispose of any Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>dispose
of assets in wholesale rather than retail markets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclaim
warranties, such as title, merchantability, possession, non-infringement or quiet enjoyment; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>purchase
insurance or credit enhancements to insure the Collateral Agent or any Lender or other Secured Party against risks of loss, collection
or disposition of any Collateral or to provide to the Collateral Agent and Lenders a guaranteed return from the collection or disposition
of any Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>IP
Licenses</U>. To the extent permitted, and only for the purpose of enabling the Collateral Agent to exercise rights and remedies under
this <U>Section&nbsp;6.1</U> or Section&nbsp;8.1 of the Loan Agreement during the continuance of an Event of Default (including in order
to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, license out, convey, transfer
or grant options to purchase any Collateral) at such time as the Collateral Agent on behalf of Lenders and the other Secured Parties
shall be lawfully entitled to exercise such rights and remedies, each Grantor hereby grants to the Collateral Agent: (i)&nbsp;an irrevocable,
non-exclusive, assignable, royalty-free license or other right to use (and for its agents or representatives to use) in the Territory
(exercisable without payment of royalty or other compensation to such Grantor), including the right to sublicense, use and practice,
any and all Intellectual Property included in the Collateral and now owned or held or hereafter acquired or held by such Grantor and
access to all media in which any of the licensed items may be recorded or stored and to all Software and programs used for the compilation
or printout thereof; and (ii)&nbsp; an irrevocable license (without payment of rent or other compensation to such Grantor) to use, operate
and occupy all real property owned, operated, leased, subleased or otherwise occupied by such Grantor; <U>provided</U> that, in each
case of <U>sub-clauses (i)</U>&nbsp;and <U>(ii)</U>&nbsp;above, such license and sublicenses with respect to Trademarks will be subject
to the maintenance of quality standards with respect to the goods and services on which such Trademarks are used sufficient to preserve
the validity of such Trademarks; <U>provided</U>, <U>further</U>, that nothing in this <U>clause (g)</U>&nbsp;shall require a Grantor
to grant any license that (x)&nbsp;violates the express terms of any license agreement between a Grantor and a third party governing
such Grantor&rsquo;s use of such Intellectual Property or (y)&nbsp;is prohibited by applicable Requirement of Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Grantor acknowledges that the purpose of
this <U>Section&nbsp;6.1</U> is to provide a non-exhaustive list of actions or omissions that are commercially reasonable when exercising
remedies against any Collateral and that other actions or omissions by the Collateral Agent, Lenders or any other Secured Party shall
not be deemed commercially unreasonable solely on account of not being indicated in this <U>Section&nbsp;6.1</U>. Without limitation
upon the foregoing, except as expressly provided in this <U>Section&nbsp;6.1</U>, nothing contained in this <U>Section&nbsp;6.1</U> shall
be construed to grant any rights to any Grantor or to impose any duties on the Collateral Agent or any Lender or other Secured Party
that would not have been granted or imposed by this Agreement or by applicable Requirements of Law in the absence of this <U>Section&nbsp;6.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 137; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accounts
and Payments in Respect of General Intangibles</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
addition to, and not in substitution for, any similar requirement in the Loan Agreement, if required by the Collateral Agent at any time
during the continuance of an Event of Default, any payment of accounts or payment in respect of general intangibles relating to the Collateral,
when collected by any Grantor, shall promptly (and, in any event, within two (2)&nbsp;Business Days of such collection) be deposited
by such Grantor in the exact form received (unless the Collateral Agent otherwise agrees in writing), duly indorsed by such Grantor to
the Collateral Agent for the benefit of Lenders and the other Secured Parties, segregated from other funds of such Grantor (unless the
Collateral Agent otherwise agrees in writing) in a Collateral Account, subject to withdrawal by the Collateral Agent as provided in <U>Section&nbsp;6.4</U>.
Until so turned over, such payment shall be held by such Grantor in trust for the Collateral Agent for the benefit of Lenders and the
other Secured Parties, segregated from other funds of such Grantor. Each such deposit of proceeds of accounts and payments in respect
of general intangibles relating to the Collateral shall, upon the Collateral Agent&rsquo;s request, be accompanied by a report identifying
in reasonable detail the nature and source of the payments included in the deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
any time during the continuance of an Event of Default, in each case to the extent not prohibited under Section&nbsp;8.1 of the Loan
Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Grantor shall, upon the Collateral Agent&rsquo;s request, assemble and hold for the benefit of Lenders and the other Secured Parties
all original and other documents evidencing, and relating to, the contractual obligations and transactions that gave rise to any account
or any payment in respect of general intangibles, including all IP Licenses, original orders, invoices and shipping receipts and notify
account debtors that the accounts or general intangibles have been collaterally assigned to the Collateral Agent for the benefit of Lenders
and the other Secured Parties and that payments in respect thereof shall be made directly to the Collateral Agent for the benefit of
Lenders and the other Secured Parties or to any Lender on behalf of itself and the other Secured Parties, as the Collateral Agent shall
direct; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Grantor shall take all actions, deliver all documents and provide all information necessary or reasonably requested by the Collateral
Agent to ensure any Internet Domain Name is registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Anything
herein to the contrary notwithstanding, each Grantor shall remain liable under each account and each payment in respect of general intangibles
included in the Collateral to observe and perform all the conditions and obligations to be observed and performed by it thereunder, all
in accordance with the terms of any agreement giving rise thereto. Neither the Collateral Agent nor any Lender or other Secured Party
shall have any obligation or liability under any agreement giving rise to an account or a payment in respect of a general intangible
included in the Collateral by reason of or arising out of any Loan Document or the receipt by the Collateral Agent or any Lender or other
Secured Party of any payment relating thereto, nor shall the Collateral Agent nor any Lender or other Secured Party be obligated in any
manner to perform any obligation of any Grantor under or pursuant to any agreement giving rise to an account or a payment in respect
of a general intangible included in the Collateral, to make any payment, to make any inquiry as to the nature or the sufficiency of any
payment received by it or as to the sufficiency of any performance by any party thereunder, to present or file any claim, to take any
action to enforce any performance or to collect the payment of any amounts that may have been assigned to it or to which it may be entitled
at any time or times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pledged
Collateral</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voting
Rights</U>. During the continuance of an Event of Default, upon written notice from the Collateral Agent to the relevant Grantor(s),
all rights of each Grantor to exercise or refrain from exercising the voting and other consensual rights which it would otherwise be
entitled to exercise pursuant hereto shall cease and all such rights shall thereupon become vested in the Collateral Agent or a nominee
on behalf of Lenders or the other Secured Parties, who shall thereupon have the sole right to exercise such voting and other consensual
rights, including the right to exercise (i)&nbsp; any voting, consent, corporate and other right pertaining to the Pledged Collateral
at any meeting of shareholders, partners or members, as the case may be, of the relevant issuer or issuers of Pledged Collateral or otherwise,
and (ii)&nbsp;any right of conversion, exchange and subscription and any other right, privilege or option pertaining to the Pledged Collateral
as if it were the absolute owner thereof (including the right to exchange at its discretion any Pledged Collateral upon the merger, amalgamation,
consolidation, reorganization, recapitalization or other fundamental change in the corporate or equivalent structure of any issuer of
Pledged Collateral, the right to deposit and deliver any Pledged Collateral with any committee, depositary, transfer agent, registrar
or other designated agency upon such terms and conditions as the Collateral Agent (or such nominee) on behalf of Lenders or the other
Secured Parties may determine), all without liability except to account for property actually received by it; <U>provided</U>, <U>however</U>,
that the Collateral Agent (or such nominee) shall have no duty to any Grantor to exercise any such right, privilege or option and shall
not be responsible for any failure to do so or delay in so doing; <U>provided further</U>, that the failure of the Collateral Agent (or
such nominee) to deliver such notice shall not limit, affect or diminish any right of the Collateral Agent or the Lenders hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 138; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Proxies</U>.
During the continuance of an Event of Default, in order to permit the Collateral Agent on behalf of Lenders and the other Secured Parties
to exercise the voting and other consensual rights that it may be entitled to exercise pursuant hereto and to receive all dividends and
other distributions that it may be entitled to receive hereunder, (i)&nbsp;each Grantor shall promptly execute and deliver (or cause
to be executed and delivered) to the Collateral Agent all such proxies, dividend payment orders and other instruments as the Collateral
Agent may from time to time reasonably request in writing and (ii)&nbsp;without limiting the effect of <U>clause&nbsp;(i)</U>&nbsp;above,
such Grantor hereby grants to the Collateral Agent for the benefit of Lenders and the other Secured Parties an irrevocable proxy to vote
all or any part of the Pledged Collateral and to exercise all other rights, powers, privileges and remedies to which a holder of the
Pledged Collateral would be entitled (including giving or withholding written consents of shareholders, partners or members, as the case
may be, calling special meetings of shareholders, partners or members, as the case may be, and voting at such meetings), which proxy
shall be effective, automatically and without the necessity of any action (including any transfer of any Pledged Collateral on the record
books of the issuer thereof) by any other Person (including the issuer of such Pledged Collateral or any officer or agent thereof) during
the continuance of an Event of Default and which proxy shall only terminate upon (A)&nbsp;the cure or waiver of any and all Events of
Default or (B)&nbsp;payment in full of the Secured Obligations (other than inchoate indemnity obligations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization
of Issuers</U>. Each Grantor hereby expressly and irrevocably authorizes and instructs, without any further instructions from such Grantor,
each issuer of any Pledged Collateral pledged hereunder by such Grantor to, and each Grantor that is an issuer of Pledged Collateral
so pledged hereunder hereby agrees to: (i)&nbsp;comply with any instruction received by it from the Collateral Agent in writing that
states that an Event of Default is continuing and is otherwise in accordance with the terms of this Agreement, and each Grantor agrees
that such issuer shall be fully protected from liabilities to such Grantor in so complying; and (ii)&nbsp;during the continuance of such
Event of Default, unless otherwise permitted hereby or by the Loan Agreement, pay any dividend or make any other payment with respect
to the Pledged Collateral directly to the Collateral Agent for the benefit of Lenders and the other Secured Parties or to any Lender
on behalf of itself and the other Secured Parties, as the Collateral Agent shall direct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Proceeds
to be Turned over to and Held by Collateral Agent</U>. Unless otherwise expressly provided in the Loan Agreement or this Agreement, during
the continuance of an Event of Default and, upon written notice by the Collateral Agent to the relevant Grantor or Grantors, all proceeds
of any Collateral received by any Grantor hereunder in cash or Cash Equivalents shall be held by such Grantor in trust for Lenders and
the other Secured Parties, segregated from other funds of such Grantor (unless the Collateral Agent otherwise agrees in writing), and
shall, promptly upon receipt by any Grantor, be turned over to the Collateral Agent for the benefit of Lenders and the other Secured
Parties in the exact form received (unless the Collateral Agent otherwise agrees in writing), with any necessary endorsement. All such
proceeds of Collateral and any other proceeds of any Collateral received by the Collateral Agent in cash or Cash Equivalents shall be
held by the Collateral Agent for the benefit of itself and the other Secured Parties in a Collateral Account. All proceeds being held
by the Collateral Agent in a Collateral Account (or by such Grantor in trust for Lenders and the other Secured Parties) shall continue
to be held as collateral security for the Secured Obligations and shall not constitute payment thereof until applied as provided in the
Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Sale
of Pledged Collateral</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Grantor recognizes that the Collateral Agent may be unable to effect a public sale of any Pledged Collateral by reason of certain prohibitions
contained in the Securities Act and applicable state or foreign securities laws or otherwise or may determine that a public sale is impracticable,
not desirable or not commercially reasonable and, accordingly, may resort to one or more private sales thereof to a restricted group
of purchasers that shall be obliged to agree, among other things, to acquire such securities for their own account for investment and
not with a view to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in
prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such
private sale shall be deemed to have been made in a commercially reasonable manner. The Collateral Agent shall be under no obligation
to delay a sale of any Pledged Collateral for the period of time necessary to permit the issuer thereof to register such securities for
public sale under the Securities Act or under applicable state securities laws even if such issuer would agree to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Grantor agrees to use commercially reasonable efforts to do or cause to be done all such other acts as may be reasonably necessary to
make such sale or sales of any portion of the Pledged Collateral pursuant to <U>Section&nbsp;6.1</U>, this <U>Section&nbsp;6.5</U> and
Section&nbsp;8.1 of the Loan Agreement valid and binding and in compliance with all applicable Requirements of Law. Each Grantor further
agrees that a breach of any covenant contained herein will cause irreparable injury to the Collateral Agent, Lenders and the other Secured
Parties, that the Collateral Agent, Lenders and the other Secured Parties have no adequate remedy at law in respect of such breach and,
as a consequence, that each and every covenant contained herein shall be specifically enforceable against such Grantor, and such Grantor
hereby waives and agrees not to assert any defense against an action for specific performance of such covenants except for a defense
that no Event of Default has occurred and is continuing under the Loan Agreement or a defense of payment in full of the Secured Obligations
(other than inchoate indemnity obligations). Each Grantor waives any and all rights of contribution or subrogation upon the sale or disposition
of all or any portion of the Pledged Collateral by the Collateral Agent on behalf of Lenders and the other Secured Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Deficiency</U>.
Each Grantor shall remain liable for any deficiency if the proceeds of any sale or other disposition of any Collateral are insufficient
to pay the Secured Obligations and the reasonable and documented fees and disbursements of any attorney employed by the Collateral Agent
or any Lender to collect such deficiency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Collateral
Accounts</U>. If any Event of Default shall have occurred and be continuing, the Collateral Agent may apply the balance from any Collateral
Account of a Grantor or instruct the bank at which any Collateral Account is maintained to pay the balance of any Collateral Account
to the Collateral Agent for the benefit of Lenders and the other Secured Parties or to any Lender on behalf of itself and the other Secured
Parties, as the Collateral Agent shall direct, to be applied to the Secured Obligations in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Directions,
Notices or Instructions</U>. Neither the Collateral Agent nor any Lender or any Related Party thereof or any other Secured Party shall
take any action under or issue any directions, notice or instructions pursuant to any Control Agreement or similar agreement or any acknowledgement
from a landlord or third party bailee with respect to any Collateral Access Agreement unless an Event of Default has occurred and is
continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;7</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ADDITIONAL RIGHTS OF COLLATERAL AGENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Collateral
Agent&rsquo;s Appointment as Attorney-in-Fact</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Grantor hereby irrevocably constitutes and appoints the Collateral Agent and any Related Party thereof, with full power of substitution,
as its true and lawful attorney-in-fact with full irrevocable power and authority in the place and stead of such Grantor and in the name
of such Grantor or in its own name, for the purpose of carrying out the terms of the Loan Documents, to take any appropriate action and
to execute any document or instrument that may be necessary or desirable to accomplish the purposes of the Loan Documents, in each case
during the continuance of an Event of Default, and, without limiting the generality of the foregoing, each Grantor hereby gives the Collateral
Agent and its Related Party the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do any of
the following when an Event of Default shall be continuing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
the name of such Grantor, in its own name or otherwise, take possession of and indorse and collect any check, draft, note, acceptance
or other instrument for the payment of moneys due under any account or general intangible or with respect to any other Collateral and
file any claim or take any other action or proceeding in any court of law or equity or otherwise deemed appropriate by the Collateral
Agent for the purpose of collecting any such moneys due under any account or general intangible or with respect to any other Collateral
whenever payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 140; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
the case of any Intellectual Property (including any IP Ancillary Rights) or any IP Licenses, in each case, included in the Collateral,
execute, deliver and have recorded any document that the Collateral Agent may request to evidence, effect, publicize or record the Collateral
Agent&rsquo;s security interest, in favor of and for the benefit of Lenders and the other Secured Parties, in such Intellectual Property
or IP Licenses and the goodwill and general intangibles of such Grantor relating thereto or represented thereby and the Collateral Agent&rsquo;s
(on behalf of Lenders and the other Secured Parties) rights and remedies with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>pay
or discharge taxes and Liens levied or placed on or threatened against any Collateral, effect any repair or obtain or pay any insurance
called for by the terms of the Loan Agreement (including all or any part of the premiums therefor and the costs thereof);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>execute,
in connection with any sale provided for in <U>Section&nbsp;6.1</U> or <U>6.5</U>, any document to effect or otherwise necessary or appropriate
in relation to evidence the sale of any Collateral; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;direct
any party liable for any payment under any Collateral to make payment of any moneys due or to become due thereunder directly to the Collateral
Agent or as the Collateral Agent shall direct, (B)&nbsp;ask or demand for, and collect and receive payment of and receipt for, any moneys,
claims and other amounts due or to become due at any time in respect of or arising out of any Collateral, (C)&nbsp;commence and prosecute
any suit, action or proceeding at law or in equity in any court of competent jurisdiction to collect any Collateral and to enforce any
other right in respect of any Collateral, (D)&nbsp;defend any actions, suits, proceedings, audits, claims, demands, orders or disputes
brought against such Grantor with respect to any Collateral, (E)&nbsp;settle, compromise or adjust any such actions, suits, proceedings,
audits, claims, demands, orders or disputes and, in connection therewith, give such discharges or releases as the Collateral Agent may
deem appropriate, (F)&nbsp;assign or license any Intellectual Property included in the Collateral on such terms and conditions and in
such manner as the Collateral Agent shall in its sole discretion determine, including the execution and filing of any document necessary
to effectuate or record such assignment or license and (G)&nbsp;generally, sell, assign, license, convey, transfer or grant a Lien on,
make any contractual obligation with respect to and otherwise deal with, any Collateral as fully and completely as though the Collateral
Agent on behalf of Lenders and the other Secured Parties were the absolute owner thereof for all purposes and do, at the Collateral Agent&rsquo;s
option, at any time or from time to time, all acts and things that the Collateral Agent deems necessary to protect, preserve or realize
upon any Collateral and the Collateral Agent&rsquo;s, in favor of and for the benefit of Lenders and the other Secured Parties, security
interests therein and to effect the intent of the Loan Documents, all as fully and effectively as such Grantor might do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any Grantor fails to perform or comply with any contractual obligation contained herein, the Collateral Agent, at its option, but without
any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such contractual obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
accordance with, and without limiting the generality of, Section&nbsp;2.4 of the Loan Agreement, each Grantor agrees to promptly pay
or reimburse the Lender Expenses and any other reasonable and documented out-of-pocket expenses of the Collateral Agent and any Lender
and other Secured Party incurred in connection with the taking of any actions pursuant to or as otherwise contemplated by this <U>Section&nbsp;7.1</U>,
together with, solely in the event any Grantor fails to pay any of the Obligations when due or upon the commencement and during the continuance
of an Insolvency Proceeding of the Borrower or, at the election of the Required Lenders, upon the occurrence and during the continuance
of any other Event of Default, interest thereon at the Default Rate from the date any such expenses were paid by the Collateral Agent
or any Lender through the date such expenses are reimbursed by the relevant Grantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue of this <U>Section&nbsp;7.1</U>. All
powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until payment in full
of the Secured Obligations (other than inchoate indemnity obligations), this Agreement is terminated and the security interests created
hereby are released</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 141; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization
to File Financing Statements</U>. Each Grantor authorizes the Collateral Agent and its Related Party, at any time and from time to time,
without notice to any Grantor, to file or record financing statements and other filing or recording documents or instruments with respect
to any Collateral, and amendments thereto, in each case in such form, in such jurisdictions and in such offices as the Collateral Agent
reasonably determines appropriate to perfect or protect the security interests of the Collateral Agent, in favor of and for the benefit
of Lenders and the other Secured Parties, under this Agreement or any other Loan Document (and the Collateral Agent&rsquo;s and each
Lender&rsquo;s and each other Secured Party&rsquo;s rights in respect thereof), and such financing statements, documents and instruments,
and amendments thereto, may describe the Collateral covered thereby as &ldquo;<U>all assets of the debtor</U>&rdquo; or words of similar
effect and may include a notice that any disposition of the Collateral, by any Grantor or other Person, shall be deemed to violate the
rights of the Collateral Agent and Lenders and other Secured Parties under the Code (or other Requirements of Law in the applicable jurisdiction)
to the extent not permitted under this Agreement or any other Loan Document. Save as otherwise required by Requirements of Law, a photographic
or other reproduction of this Agreement shall be sufficient as a financing statement or other filing or recording document or instrument
for filing or recording in any jurisdiction. Notwithstanding anything to the contrary herein or in the Loan Agreement, Lender Expenses
shall not include, and the Collateral Agent and Lenders shall be solely responsible for, any filing fees or other expenses incurred by
the Collateral Agent or any Lender in connection with any filings, recordings or other actions taken in jurisdictions <U>other than</U>
the United States or with respect to any Grantor that is not a Domestic Subsidiary, the jurisdiction of such Grantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authority
of Collateral Agent</U>. Each Grantor acknowledges that, as between the Collateral Agent and the Grantors, the Collateral Agent shall
be conclusively presumed to be acting as agent for each Lender and all of the other Secured Parties with full and valid authority so
to act or refrain from acting, and no Grantor shall be under any obligation or entitlement to make any inquiry respecting such authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Duty;
Obligations and Liabilities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Duty
of Collateral Agent</U>. The Collateral Agent&rsquo;s sole duty with respect to the custody, safekeeping and physical preservation of
the Collateral in its possession shall be to deal with it in the same manner as it deals with similar property for its own account, but
in no event in less than a commercially reasonable manner. The powers conferred on the Collateral Agent hereunder are solely to protect
each Lender&rsquo;s and the other Secured Parties&rsquo; interest in the Collateral and shall not impose any duty upon the Collateral
Agent to exercise any such powers. The Collateral Agent shall be accountable only for amounts that it receives as a result of the exercise
of such powers, and neither it nor any of its Related Parties shall be responsible to any Grantor for any act or failure to act hereunder,
except for its or their own gross negligence, bad faith or willful misconduct as finally determined by a court of competent jurisdiction.
In addition, the Collateral Agent shall not be liable or responsible for any loss or damage to any Collateral, or for any diminution
in the value thereof, by reason of the act or omission of any warehousemen, carrier, forwarding agency, consignee or other bailee if
such Person has been selected by the Collateral Agent in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Obligations
and Liabilities with respect to Collateral</U>. Neither the Collateral Agent nor Lenders or any other Secured Parties nor any of their
respective Related Parties shall be liable for failure to demand, collect or realize upon any Collateral or for any delay in doing so
or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or
to take any other action whatsoever with regard to any Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Article&nbsp;8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>MISCELLANEOUS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reinstatement</U>.
Each Grantor agrees that, if any payment made by any Credit Party or other Person and applied to the Secured Obligations is at any time
annulled, avoided, set aside, rescinded, invalidated, declared to be fraudulent or preferential or otherwise required to be refunded
or repaid, or the proceeds of any Collateral are required to be returned by any Secured Party to such Credit Party, its estate, trustee,
receiver or any other party, including any Grantor, under any bankruptcy law, state or federal law, common law or equitable cause, in
each case as finally determined by a court of competent jurisdiction, then, to the extent of such payment or repayment, any Lien or other
Collateral securing such liability shall be and remain in full force and effect, as fully as if such payment had never been made. If,
prior to any of the foregoing, (a)&nbsp;any Lien or other Collateral securing such Grantor&rsquo;s liability hereunder shall have been
released or terminated by virtue of the foregoing or (b)&nbsp;any provision of the Guaranty hereunder shall have been terminated, cancelled
or surrendered, such Lien, other Collateral or provision shall be reinstated in full force and effect and such prior release, termination,
cancellation or surrender shall not diminish, release, discharge, impair or otherwise affect the obligations of such Grantor in respect
of any Lien or other Collateral securing such obligation or the amount of such payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 142; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Release
of Collateral and Guarantee Obligations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>When
all Secured Obligations (other than inchoate indemnity obligations) have been paid in full, the Collateral shall be automatically released
from the Lien created hereby and this Agreement and all obligations (other than those expressly stated to survive such termination) of
each Lender and any other Secured Party and each Grantor and Guarantor hereunder shall automatically terminate, all without delivery
of any instrument or performance of any act by any party (except as required hereunder), and all rights of the Collateral Agent, Lenders
and any other Secured Parties to the Collateral shall automatically revert to the Grantors. Upon the sale, transfer or other disposition
of any Collateral to any Person (other than a Credit Party) that is permitted under the Loan Documents or to which Required Lenders have
otherwise consented (including the sale, transfer or other disposition of Pledged Stock of a Grantor to any Person (other than a Credit
Party)), such Collateral shall be automatically released from the Lien created hereby. Notwithstanding any Liens granted to the Collateral
Agent, in favor of and for the benefit of Lenders and the other Secured Parties, under the Loan Documents, to the extent any Intellectual
Property is or becomes subject to a Permitted License or other license of Intellectual Property permitted pursuant to the Loan Agreement,
the use of such Intellectual Property shall be subject to the terms of such Permitted License or other license, including the rights
of the licensee thereunder to the continued use of such Intellectual Property subject to the terms thereof, and in connection with any
Permitted License or other license of Intellectual Property permitted pursuant to the Loan Agreement, the Collateral Agent, on behalf
of the Lenders and the other Secured Parties, shall, upon the written request of the licensee thereunder, enter into customary non-disturbance
and similar agreements, in each case in form and substance reasonably satisfactory to the Collateral Agent and the other party or parties
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
connection with any termination or release pursuant to this <U>Section&nbsp;8.2</U>, the Collateral Agent shall, and to the extent required,
each Secured Party hereby authorizes the Collateral Agent to, promptly execute and deliver to any Grantor all instruments, documents
and agreements which such Grantor shall reasonably request in writing to evidence and confirm such termination or release (including
termination statements under the Code and customary payoff letters), and will duly assign, transfer and deliver to such Grantor (or its
designee), such of the Collateral that may be in the possession of the Collateral Agent, all without further consent or joinder of the
Collateral Agent or any Lender or other Secured Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
termination or release pursuant to this <U>Section&nbsp;8.2</U> is subject to reinstatement as provided in <U>Section&nbsp;8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
the release of the Liens on any Collateral or of a Grantor from all of its obligations as a Credit Party under the Loan Agreement and
as a Grantor hereunder, any representation, warranty or covenant contained in any Loan Document relating to any such Collateral or such
Grantor, as applicable, shall no longer be deemed to be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
accordance with, and without limiting the generality of, Section&nbsp;2.4 of the Loan Agreement, each Grantor agrees to pay or reimburse
promptly the Lender Expenses and any other reasonable and documented out-of-pocket expenses of the Collateral Agent and any Lender and
other Secured Party incurred in connection with the taking of any actions pursuant to or as otherwise contemplated by this <U>Section&nbsp;8.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Independent
Obligations</U>. The obligations of each Grantor and Guarantor hereunder are independent of and separate from the Secured Obligations
and the Guaranteed Obligations. Upon any Event of Default and during the continuance thereof, the Collateral Agent for the benefit of
Lenders and the other Secured Parties may, at its sole election, proceed directly and at once, without notice, against any Grantor and
Guarantor and any Collateral to collect and recover the full amount of any Secured Obligation or Guaranteed Obligation then due, without
first proceeding against any other Guarantor, Grantor, any other Credit Party or any other Collateral and without first joining any other
Guarantor, Grantor or any other Credit Party in any proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 143; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Waiver by Course of Conduct</U>. Neither the Collateral Agent nor any Secured Party shall by any act (except by a written instrument
pursuant to <U>Section&nbsp;8.5</U>), delay, indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder
or to have acquiesced in any Default or Event of Default. No failure to exercise, nor any delay in exercising, on the part of the Collateral
Agent or any Secured Party, any right, power or privilege hereunder shall operate as a waiver thereof. No single or partial exercise
of any right, power or privilege hereunder shall preclude any other or further exercise thereof or the exercise of any other right, power
or privilege. A waiver by the Collateral Agent or any Secured Party of any right or remedy hereunder on any one occasion shall not be
construed as a bar to any right or remedy that the Collateral Agent or any Secured Party would otherwise have on any future occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments
in Writing</U>. None of the terms or provisions of this Agreement may be waived, amended, supplemented or otherwise modified except in
accordance <U>with</U> Section&nbsp;11.5 of the Loan Agreement; <U>provided</U>, <U>however</U>, that annexes to this Agreement may be
supplemented (but no existing provisions may be modified and no Collateral may be released) through Pledge Amendments and Joinder Agreements,
in substantially the form of <U>Annex&nbsp;1</U> and <U>Annex&nbsp;2</U> attached hereto, respectively, in each case, duly executed by
the Collateral Agent and each Grantor or Guarantor, as applicable, directly affected thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Grantors and Guarantors; Additional Pledged Collateral</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Joinder
Agreements</U>. If, at the option of Borrower pursuant to Section&nbsp;5.12 of the Loan Agreement or as otherwise required pursuant to
Section&nbsp;5.12 or Section&nbsp;5.13 of the Loan Agreement, Borrower shall cause any Subsidiary (other than an Excluded Subsidiary,
unless Borrower has elected to join such Excluded Subsidiary pursuant to Section&nbsp;5.12 of the Loan Agreement) that is not a Grantor
or Guarantor hereunder (as applicable) on the Tranche A Closing Date to become a Grantor or Guarantor hereunder (as applicable), such
Subsidiary shall execute and deliver to the Collateral Agent a Joinder Agreement substantially in the form of <U>Annex&nbsp;2</U> attached
hereto and shall thereafter for all purposes be a party hereto and have the same rights, benefits and obligations as a Grantor or Guarantor
party hereto on the Tranche A Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pledge
Amendments</U>. To the extent any Pledged Collateral has not been delivered as of the Tranche A Closing Date, each relevant Grantor shall,
promptly after such Pledged Collateral is acquired (and in any case, subject to the timing requirements set forth under Section&nbsp;5.12
or Section&nbsp;5.13 of the Loan Agreement, as applicable), deliver a pledge amendment duly executed by such Grantor in substantially
the form of <U>Annex&nbsp;1</U> attached hereto (each, a &ldquo;<U>Pledge Amendment</U>&rdquo;). Such Grantor authorizes the Collateral
Agent to attach each Pledge Amendment to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
All notices, requests and demands hereunder to or upon the Collateral Agent or any other party hereto shall be effected in the manner
provided for in Section&nbsp;9 of the Loan Agreement; <U>provided</U>, <U>however</U>, that any such notice, request or demand to or
upon any Grantor or any other party hereto (other than the Collateral Agent) hereunder shall be addressed to Borrower&rsquo;s notice
address set forth in Section&nbsp;9 of the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. This Agreement shall be binding upon the successors and assigns of each Grantor and Guarantor and shall inure to the
benefit of the Collateral Agent and each Secured Party and their respective successors and assigns; <U>provided</U>, <U>however</U>,
that no Grantor or Guarantor may assign, transfer or delegate any of its rights or obligations under this Agreement without the prior
written consent of the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so
executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages&nbsp;may
be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page&nbsp;of
this Agreement by facsimile transmission or by electronic transmission shall be as effective as delivery of a manually executed counterpart
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 144; Options: NewSection; Value: 23 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
Any provision of this Agreement being held illegal, invalid or unenforceable in any jurisdiction shall not affect any part of such provision
not held illegal, invalid or unenforceable, any other provision of this Agreement or any part of such provision in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Choice
of Law</U>. THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS EXCLUDING THOSE LOAN DOCUMENTS THAT BY THEIR OWN TERMS ARE EXPRESSLY GOVERNED
BY THE LAWS OF ANOTHER JURISDICTION, AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO AND THERETO, SHALL BE GOVERNED BY, AND CONSTRUED
AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT COULD
REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, <U>PROVIDED</U>, <U>HOWEVER</U>, THAT IF THE LAWS OF ANY JURISDICTION OTHER
THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS
AFFECTING ENFORCEMENT OF ANY LIENS IN COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Jury
Trial Waiver</U>. TO THE FULLEST EXTENT PERMITTED BY REQUIREMENTS OF LAW, EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ITS RIGHT TO A
JURY TRIAL IN ANY CLAIM, SUIT, ACTION OR PROCEEDING WITH RESPECT TO, OR DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION
WITH, THIS AGREEMENT, ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREIN AND THEREIN OR RELATED HERETO OR THERETO (WHETHER
FOUNDED IN CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A)&nbsp;CERTIFIES THAT NO OTHER PARTY AND NO RELATED PARTY OF ANY
OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT,&nbsp;IN THE EVENT OF LITIGATION, SEEK TO ENFORCE
THE FOREGOING WAIVER, (B)&nbsp;ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY THE
MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION&nbsp;8.12</U> AND (C)&nbsp;HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">THE
</FONT>TERMS OF SECTION&nbsp;10 OF THE LOAN AGREEMENT ARE INCORPORATED HEREIN BY REFERENCE, <I>MUTATIS MUTANDIS</I>, AS IF SET FORTH
IN FULL HEREIN AND THE PARTIES HERETO AGREE TO SUCH TERMS AND TO BE BOUND BY SUCH TERMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Pages&nbsp;Follow]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 145; Value: 23 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, each of
the undersigned has caused this Guaranty and Security Agreement to be duly executed and delivered as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PRECIGEN,&nbsp;INC.,<BR>
as Borrower and a Grantor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>GENVEC LLC,<BR>
as a Grantor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PRECIGEN ACTOBIO,&nbsp;INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>as a Grantor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EXEMPLAR GENETICS, LLC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>as a Grantor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Signature Page&nbsp;to Guaranty and Security
Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 146 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACCEPTED AND AGREED<BR>
as of the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIOPHARMA CREDIT PLC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as Collateral Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Pharmakon Advisors, LP,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">its Investment Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Pharmakon Management I, LLC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">its General Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Pedro Gonzalez de Cosio</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Member</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Signature Page&nbsp;to Guaranty and Security
Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">ANNEX
1<BR>
TO GUARANTY AND SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">FORM&nbsp;OF
PLEDGE AMENDMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Pledge Amendment, dated
as of __________, 20__, is delivered pursuant to <U>Section&nbsp;8.6(b)</U>&nbsp;of the Guaranty and Security Agreement, dated as of
September&nbsp;3, 2025, by PRECIGEN,&nbsp;INC., a Virginia corporation, as Borrower and the other Persons from time to time party thereto
as Grantors in favor of BIOPHARMA CREDIT PLC, as Collateral Agent on behalf of Lenders and each of the other Secured Parties (as such
agreement may be amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<U>Guaranty and Security Agreement</U>&rdquo;).
Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The undersigned hereby agrees
that this Pledge Amendment may be attached to the Guaranty and Security Agreement and that the Pledged Collateral listed on <U>Annex&nbsp;1-A</U>
to this Pledge Amendment shall be and become part of the Collateral referred to in the Guaranty and Security Agreement and shall secure
all Secured Obligations of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[GRANTOR]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 148; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Annex 1-A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">PLEDGED STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center; padding-left: 5.4pt">ISSUER</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center; padding-left: 5.4pt">CLASS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center; padding-left: 5.4pt">CERTIFICATE
    NO(S).</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center; padding-left: 5.4pt">PAR
    VALUE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center; padding-left: 5.4pt">NUMBER
    OF<BR>
    SHARES, <BR>
    UNITS OR <BR>
    INTERESTS</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PLEDGED DEBT INSTRUMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COMMERCIAL TORT CLAIMS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACKNOWLEDGED AND AGREED<BR>
as of the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIOPHARMA CREDIT PLC,<BR>
as Collateral Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Pharmakon Advisors, LP,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">its Investment Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Pharmakon Management I, LLC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">its General Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;Pedro Gonzalez de Cosio</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Managing Member</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">ANNEX
2<BR>
TO<BR>
GUARANTY AND SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">FORM&nbsp;OF
JOINDER AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This JOINDER AGREEMENT, dated
as of _________ __, 20__, is delivered pursuant to <U>Section&nbsp;8.6(a)</U>&nbsp;of the Guaranty and Security Agreement, dated as of
September&nbsp;3, 2025, by and among PRECIGEN,&nbsp;INC., a Virginia corporation (&ldquo;<U>Borrower</U>&rdquo;), and the other Persons
from time to time party thereto as Grantors or Guarantors, in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted
assigns, the &ldquo;<U>Collateral Agent</U>&rdquo;) on behalf of Lenders and each of the other Secured Parties, (as such agreement may
be amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<U>Guaranty and Security Agreement</U>&rdquo;).
Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By executing and delivering
this Joinder Agreement, the undersigned, as provided in <U>Section&nbsp;8.6</U> of the Guaranty and Security Agreement, (a)&nbsp;hereby
becomes a party to the Guaranty and Security Agreement as a &ldquo;Grantor&rdquo; and a &ldquo;Guarantor&rdquo; thereunder with the same
force and effect as if originally named as a &ldquo;Grantor&rdquo; and a &ldquo;Guarantor&rdquo; therein and, without limiting the generality
of the foregoing, hereby assumes all obligations and liabilities of a &ldquo;Grantor&rdquo; and a &ldquo;Guarantor&rdquo; thereunder
and (b)&nbsp; as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration
or otherwise) of the Secured Obligations of the undersigned, hereby pledges and hypothecates to the Collateral Agent for the benefit
of Lenders and the other Secured Parties, and grants to the Collateral Agent for the benefit of Lenders and the other Secured Parties,
a lien on and security interest in, all of its right, title and interest in, to and under the Collateral of the undersigned. The undersigned
hereby agrees to be bound as a &ldquo;Grantor&rdquo; and a &ldquo;Guarantor&rdquo; for the purposes of the Guaranty and Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In connection with this Joinder
Agreement, the undersigned has delivered to the Collateral Agent a completed Perfection Certificate duly executed by the undersigned.
The information set forth in <U>Annex&nbsp;1-A</U><FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT> is hereby added to the information
set forth in <U>Schedules 1</U> and <U>3</U> to the Security Disclosure Letter. By acknowledging and agreeing to this Joinder Agreement,
the undersigned hereby agrees that this Joinder Agreement may be attached to the Guaranty and Security Agreement, the Perfection Certificate
delivered herewith by the undersigned shall constitute a &ldquo;Perfection Certificate&rdquo; referred to in Section&nbsp;4.6 of the
Loan Agreement and that the Pledged Collateral listed on <U>Annex&nbsp;1-A</U> to this Joinder Agreement, if any, shall be and become
part of the Collateral referred to in the Guaranty and Security Agreement and shall secure all Secured Obligations of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The undersigned hereby represents
and warrants that each of the representations and warranties contained in <U>Article&nbsp;4</U> of the Guaranty and Security Agreement
applicable to it, if any, is true and correct on and as the date hereof as if made on and as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In witness whereof, the undersigned
has caused this Joinder Agreement to be duly executed and delivered as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Additional Grantor]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Use same Annex 1-A as is attached in Annex 1 to the Guaranty and Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 151; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACKNOWLEDGED AND AGREED<BR>
as of the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIOPHARMA CREDIT PLC,<BR>
as Collateral Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Pharmakon Advisors, LP,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">its Investment Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Pharmakon Management I, LLC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">its General Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;Pedro Gonzalez de Cosio</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Managing Member</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">ANNEX
3<BR>
TO<BR>
GUARANTY AND SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">FORM&nbsp;OF
[COPYRIGHT] [PATENT] [TRADEMARK] SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS [COPYRIGHT] [PATENT] [TRADEMARK]
SECURITY AGREEMENT, dated as of _______, 20__, is made by __________________ (&ldquo;<U>Grantor</U>&rdquo;), in favor of BIOPHARMA CREDIT
PLC (together with its successors and permitted assigns, the &ldquo;<U>Collateral Agent</U>&rdquo;) on behalf of Lenders and the other
Secured Parties (as defined in the Loan Agreement referred to below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">W I T
N E S S E T H:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, pursuant to the Loan
Agreement, dated as of September&nbsp;3, 2025 (as the same may be amended, amended and restated, supplemented or otherwise modified from
time to time, the &ldquo;<U>Loan Agreement</U>&rdquo;), by and among PRECIGEN,&nbsp;INC., a Virginia corporation (&ldquo;<U>Borrower</U>&rdquo;),
the other parties thereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, as Collateral Agent, BPCR LIMITED PARTNERSHIP,
(as a &ldquo;<U>Lender</U>&rdquo;) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting
by its general partner, BioPharma Credit Investments V GP LLC (as a &ldquo;<U>Lender</U>&rdquo;), each Lender has agreed to make extensions
of credit to Borrower upon the terms and subject to the conditions set forth therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, each of the Grantors
has agreed, pursuant to a Guaranty and Security Agreement dated as of September&nbsp;3, 2025 in favor of the Collateral Agent for the
benefit of Lenders and the other Secured Parties (as such agreement may be amended, amended and restated, supplemented or otherwise modified
from time to time, the &ldquo;<U>Guaranty and Security Agreement</U>&rdquo;), to guarantee the Obligations (as defined in the Loan Agreement)
of Borrower; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, each of the Grantors
is party to the Guaranty and Security Agreement pursuant to which such Grantor is required to execute and deliver this [Copyright] [Patent]
[Trademark] Security Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">NOW, THEREFORE, in consideration
of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section&nbsp;1.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Defined
Terms</U>. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section&nbsp;2.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Grant
of Security Interest in [Copyright] [Trademark] [Patent] Collateral</U>. Each of the Grantors, as collateral security for the prompt
and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations,
hereby mortgages, pledges and hypothecates to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and grants
to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a Lien on and security interest in, all of its right,
title and interest in, to and under the following Collateral of such Grantor, in each case, solely to the extent constituting Collateral
(and excluding any Excluded Property) (the &ldquo;<U>[Copyright] [Patent] [Trademark] Collateral</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[all
of its Copyrights and all IP Licenses and IP Ancillary Rights providing for the grant by such Grantor of any right under any Copyright,
including, without limitation, those U.S. Copyrights and exclusive IP Licenses under registered U.S. Copyrights to which such Grantor
is the licensee, in each case, referred to on <U>Schedule&nbsp;1</U> hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
renewals, reversions and extensions of the foregoing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 153; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including,
without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation,
dilution, violation or other impairment thereof.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[all
of its Patents and IP Ancillary Rights providing for the grant by or to such Grantor of any right under any Patent, including, without
limitation, those U.S. Patents referred to on <U>Schedule&nbsp;1</U> hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
reissues, reexaminations, continuations, continuations-in-part, divisionals, substitutes, renewals and any patent term extension or adjustment
(including any supplementary protection certificate) of the foregoing, and any Patent issued with respect to any of the foregoing, and
any confirmation patent or registration patent or patent of addition based on any such Patent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including,
without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation,
dilution, violation or other impairment thereof.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[all
of its Trademarks and IP Ancillary Rights providing for the grant by or to such Grantor of any right under any Trademark, including,
without limitation, those U.S. Trademarks referred to on Schedule&nbsp;1 hereto, but excluding any &ldquo;intent-to-use&rdquo; application
for registration of a United States Trademark for which a &ldquo;Statement of Use&rdquo; pursuant to Section&nbsp;1(d)&nbsp;of the Lanham
Act, 15 U.S.C. &sect; 1051 (or any successor provision) or an &ldquo;Amendment to Allege Use&rdquo; pursuant to Section&nbsp;1(c)&nbsp;of
the Lanham Act, 15 U.S.C. &sect; 1051 (or any successor provision) has not been filed with and accepted by the Applicable IP Office (but
only excluding such intent-to-use application until such statement of use or amendment to allege use (as applicable) is filed with and
accepted by the Applicable IP Office);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
renewals and extensions of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
goodwill of the business connected with the use of, and symbolized by, each such Trademark; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including,
without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation,
dilution, violation or other impairment thereof.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section&nbsp;3.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Guaranty
and Security Agreement</U>. The security interest granted pursuant to this [Copyright] [Patent] [Trademark] Security Agreement is granted
in conjunction with the security interest granted to the Collateral Agent for the benefit of Lenders and the other Secured Parties, pursuant
to the Guaranty and Security Agreement and each of the Grantors hereby acknowledges and agrees that the obligations, rights and remedies
of such Grantor and of the Collateral Agent on behalf of Lenders and the other Secured Parties with respect to the security interest
in the [Copyright] [Patent] [Trademark] Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement,
the terms and provisions of which are incorporated by reference herein as if fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section&nbsp;4.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Grantor
Remains Liable</U>. Each of the Grantors hereby agrees that, anything herein to the contrary notwithstanding, Grantors shall assume full
and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their
[Copyrights] [Patents] [Trademarks] and IP Licenses subject to a security interest hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section&nbsp;5.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This [Copyright] [Patent] [Trademark] Security Agreement may be executed in any number of counterparts and by different parties in separate
counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and
the same agreement. Signature pages&nbsp;may be detached from multiple separate counterparts and attached to a single counterpart. Delivery
of an executed signature page&nbsp;of this [Copyright] [Patent] [Trademark] Security Agreement by facsimile transmission or electronic
transmission shall be as effective as delivery of a manually executed counterpart hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section&nbsp;6.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. THIS [COPYRIGHT] [PATENT] [TRADEMARK] SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED
BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS
OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, <U>PROVIDED</U>, <U>HOWEVER</U>, THAT IF THE LAWS OF
ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD
TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN [COPYRIGHT] [PATENT] [TRADEMARK] COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS
SHALL APPLY TO THAT EXTENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THE TERMS OF SECTION&nbsp;10
OF THE LOAN AGREEMENT ARE INCORPORATED HEREIN BY REFERENCE, <I>MUTATIS MUTANDIS</I>, AS IF SET FORTH IN FULL HEREIN AND THE PARTIES HERETO
AGREE TO SUCH TERMS AND TO BE BOUND BY SUCH TERMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section&nbsp;7.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.
Upon payment in full of the Secured Obligations (other than inchoate indemnity obligations) in accordance with the provisions of the
Loan Agreement and the expiration or termination of the Term Loan Commitments, the security interest in the [Copyright] [Patent] [Trademark]
Collateral granted hereby shall automatically terminate, without delivery of any instrument or performance of any act by any party, and
all rights to the [Copyright] [Patent] [Trademark] Collateral shall automatically revert to Grantors or any other Person entitled thereto.
At such time, the Collateral Agent authorizes the filing by such Grantor of an appropriate termination hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, each of
the Grantors has caused this [Copyright] [Patent] [Trademark] Security Agreement to be executed and delivered by its duly authorized
officer as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[GRANTOR]<BR>
&#8239;&#8239;as Grantor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Signature Page&nbsp;to [Copyright] [Patent]
[Trademark] Security Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACCEPTED AND AGREED<BR>
as of the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIOPHARMA CREDIT PLC,<BR>
as Collateral Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Pharmakon Advisors, LP,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">its Investment Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Pharmakon Management I, LLC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">its General Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;Pedro Gonzalez de Cosio</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Managing Member</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Signature Page&nbsp;to [Copyright] [Patent]
[Trademark] Security Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE&nbsp;I<BR>
TO<BR>
[COPYRIGHT] [PATENT] [TRADEMARK] SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>[Copyright] [Patent] [Trademark] Registrations</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD>REGISTERED U.S. [COPYRIGHTS] [PATENTS] [TRADEMARKS]</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Include Registration Number and Date]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD>U.S. [COPYRIGHT] [PATENT] [TRADEMARK] APPLICATIONS</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Include Application Number and Date]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD>[EXCLUSIVE IP LICENSES OF U.S. REGISTERED COPYRIGHTS]</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Include complete legal description of agreement (name of agreement,
parties and date)]]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">ANNEX
4<BR>
TO<BR>
GUARANTY AND SECURITY AGREEMENT<BR>
FORM&nbsp;OF UNCERTIFICATED STOCK CONTROL AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This UNCERTIFICATED STOCK CONTROL
AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;), dated as of _________ __, 20__, is made by and among [APPLICABLE GRANTOR], a [JURISDICTION
OF ORGANIZATION] [ENTITY TYPE] (the &ldquo;<B>Grantor</B>&rdquo;), BIOPHARMA CREDIT PLC, a public limited company organized under the
laws of England and Wales, as collateral agent on behalf of the Secured Parties (together with its successors and permitted assigns,
the &ldquo;<B>Collateral Agent</B>&rdquo;), and [APPLICABLE INTEREST ISSUING COMPANY], a [JURISDICTION OF ORGANIZATION] [ENTITY TYPE]
(the &ldquo;<B>Issuer</B>&rdquo;). All capitalized terms used but not otherwise defined herein shall have the meanings assigned to such
terms in the Security Agreement (as defined below) or the Loan Agreement (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, PRECIGEN,&nbsp;INC.,
a Virginia corporation (&ldquo;<B>Borrower</B>&rdquo;), the other Credit Parties from time to time party thereto, the Collateral Agent
and the Lenders have entered into that certain Loan Agreement, dated as of September&nbsp;3, 2025 (as may be amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, the Grantor is the
registered holder of [DESCRIBE PLEDGED UNCERTIFICATED STOCK] issued by the Issuer (the &ldquo;<B>Pledged Stock</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, pursuant to the Guaranty
and Security Agreement, dated as of September&nbsp;3, 2025, by and among the Grantor, the Collateral Agent and the other parties thereto
(as amended, amended and restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Security Agreement</B>&rdquo;),
the Grantor has granted a continuing Lien on and security interest (the &ldquo;<B>Security Interest</B>&rdquo;) in, all of its right,
title and interest in, to and under the Pledged Stock (other than Excluded Equity Interests), whether now existing or hereafter arising
or acquired; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, it is a condition
precedent to the making and maintaining of the Term Loans by Lenders under the Loan Agreement that the parties hereto execute and deliver
this Agreement in order to perfect a first priority Security Interest in the Pledged Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">NOW, THEREFORE, in consideration
of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Issuer confirms that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Pledged Stock is Equity Interests that are not represented by certificates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Issuer is the issuer of the Pledged Stock and the Grantor is registered on the books and records of the Issuer as the registered holder
of the Pledged Stock; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Security Interest in the Pledged Stock is registered on the books and records of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Grantor hereby irrevocably agrees that, for so long as this Agreement remains in effect, the Collateral Agent, for the benefit of the
Lenders and the other Secured Parties under the Loan Agreement shall have exclusive control of the Pledged Stock. In furtherance of such
agreement, the Grantor hereby irrevocably authorizes and directs the Issuer, and the Issuer hereby agrees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the provisions of <U>Section&nbsp;3</U> hereof, to comply with any and all written instructions delivered to the Issuer which directs
that the transfer of any or all of the Pledged Stock to the Collateral Agent be registered on the books and records of the Issuer in
the name of the Collateral Agent as the holder thereof, for the benefit of Lenders and the other Secured Parties, without further consent
by the Grantor or any other Person; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the provisions of <U>Section&nbsp;3</U> hereof, not to comply with any instructions relating to any or all of the Pledged Stock originated
by any Person other than the Collateral Agent, for the benefit of Lenders and the other Secured Parties, or a court of competent jurisdiction.
In the event of any conflict between any instruction originated by the Collateral Agent and any instruction originated by any other Person,
the Issuer shall comply only with the instruction originated by the Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
addition to, and not in lieu of, the obligation of the Issuer to honor instructions as agreed in <U>Section&nbsp;2</U> hereof, the Issuer
and the Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the rights of the Grantor described herein, the Issuer agrees that, from and after the date hereof, the Pledged Stock shall be under
the exclusive dominion and control of the Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>So
long as the Issuer has not received a written notice from the Collateral Agent that it is exercising exclusive control over the Pledged
Stock (a &ldquo;<B>Notice of Exclusive Control</B>&rdquo;), the Issuer may comply with instructions of the Grantor concerning the Pledged
Stock, which Notice of Exclusive Control shall only be given by the Collateral Agent following the occurrence and during the continuance
of an Event of Default. After the Issuer receives a Notice of Exclusive Control from the Collateral Agent, the Issuer will not accept
any instructions concerning the Pledged Stock from any Person other than the Collateral Agent, unless otherwise ordered by a court of
competent jurisdiction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Until
the Issuer receives a Notice of Exclusive Control, the Grantor shall be entitled to direct the Issuer with respect to voting the Pledged
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement shall not subject the Issuer to any obligation or liability except as expressly set forth herein and under any Requirements
of Law. In particular, the Issuer need not investigate whether the Collateral Agent is entitled under the Security Agreement, or otherwise
to give an instruction or Notice of Exclusive Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Issuer hereby represents, warrants and covenants with the Collateral Agent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement has been duly authorized, executed and delivered by the Issuer and constitutes a legal, valid and binding obligation of the
Issuer enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar
laws affecting creditors&rsquo; rights generally and subject to equitable principles (regardless of whether enforcement is sought in
equity or at law);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Issuer has not entered into, and until termination of this Agreement will not enter into, any agreement with any other Person relating
to the Pledged Stock pursuant to which it has agreed, or will agree, to comply with instructions provided by such Person. The Issuer
has not entered into any other agreement with the Grantor purporting to limit or condition the obligation of the Issuer to comply with
instructions as agreed in <U>Section&nbsp;3</U> hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
for the claims and interests of the Collateral Agent, on behalf of the Lenders and the other Secured Parties, and the Grantor in the
Pledged Stock, the Issuer does not know of any claim to, or interest in, the Pledged Stock (except to the extent constituting Permitted
Liens). If any Person asserts any Lien or adverse claim (including any writ, garnishment, judgment, attachment, execution or similar
process) against the Pledged Stock (other than Permitted Liens), the Issuer will promptly notify the Collateral Agent and the Grantor
thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
is no agreement (except this Agreement) between the Issuer and the Grantor or among the Issuer, the Grantor and any third Person with
respect to the Pledged Stock [except for [IDENTIFY RELEVANT AGREEMENTS] (the &ldquo;<B>Existing Agreements</B>&rdquo;)]. In the event
of any conflict between this Agreement (or any portion hereof) and any other such agreement (including any Existing Agreement) with respect
to the Pledged Stock, whether now existing or hereafter entered into, the terms of this Agreement shall prevail; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
granting by the Grantor of the Security Interest in the Pledged Stock to the Collateral Agent for the benefit of the Lenders and the
other Secured Parties does not violate the Operating Documents or any other agreement governing the Issuer or the Pledged Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 160; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A4-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
notice, request or other communication to a party hereto under this Agreement shall be in writing, will be sent to such party&rsquo;s
address set forth under its name below or to such other address as such party may notify the other parties hereto and will be effective
on receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
amendment or modification of this Agreement or waiver of any right hereunder shall be binding on any party hereto unless it is in writing
and is signed by all the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
rights and powers granted herein to the Collateral Agent (a)&nbsp;have been granted in order to perfect the Security Interest in the
Pledged Stock, (b)&nbsp;are powers coupled with an interest and (c)&nbsp;will not be affected by any bankruptcy of the Grantor or any
lapse in time. The obligations of the Issuer hereunder shall continue in effect until the Collateral Agent has notified the Issuer in
writing that the Security Interest in the Pledged Stock has been terminated pursuant to the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement shall be governed by and construed in accordance with the laws of the [ISSUER&rsquo;S JURISDICTION OF ORGANIZATION], WITHOUT
REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, <U>PROVIDED</U>,
<U>HOWEVER</U>, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN [ISSUER&rsquo;S JURISDICTION OF ORGANIZATION] SHALL GOVERN IN REGARD
TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS
IN THE PLEDGED STOCK, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed
shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages&nbsp;may
be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page&nbsp;of
this Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page&nbsp;Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 161; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A4-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[GRANTOR]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Signature Page&nbsp;to Uncertificated Stock
Control Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[ISSUER]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Signature Page&nbsp;to Uncertificated Stock
Control Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 163 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIOPHARMA CREDIT PLC,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a public limited company</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Pharmakon Advisors, LP,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its Investment Manager</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Pharmakon Management I, LLC,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its General Partner</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;Pedro Gonzalez de Cosio</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Managing Member</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioPharma Credit PLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">51 Lime Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">19th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">London, United Kingdom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EC3M 7DQ</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Company Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">with copies (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pharmakon Advisors, LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">110 East 59th Street, #2800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Pedro Gonzalez de Cosio</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: +1 (212) 883-2296</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: +1 (917) 210-4048</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: pharmakon@pharmakonadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10036-6745</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Geoffrey E. Secol</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: +1 (212) 872-8081</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: gsecol@akingump.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Signature Page&nbsp;to Uncertificated Stock
Control Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 164 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT&#8239;D</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>COMMITMENTS;
NOTICE ADDRESSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lender</FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Commitments</U></FONT></TD>
    <TD STYLE="width: 54%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
    Address</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BPCR
    Limited Partnership</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tranche A Loan Commitment:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$50,000,000.00</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tranche B Loan Commitment:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$12,500,000.00</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BPCR LIMITED PARTNERSHIP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">51 Lime Street</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19th Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">London, United Kingdom</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EC3M 7DQ</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Company Secretary</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">with copies (which shall not constitute notice)
    to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PHARMAKON ADVISORS, LP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">110 East 59th Street, #2800</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Pedro Gonzalez de Cosio</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +1 (212) 883-2296</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fax: +1 (917) 210-4048</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: pharmakon@pharmakonadvisors.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AKIN GUMP STRAUSS HAUER&#8239;&amp; FELD LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One Bryant Park</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10036-6745</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Geoffrey E. Secol</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +1 (212) 872-8081</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: gsecol@akingump.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPharma
    Credit Investments V (Master) LP</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tranche A Loan Commitment:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$50,000,000.00</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tranche B Loan Commitment:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$12,500,000.00</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o BioPharma Credit Investments V GP LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Walkers Corporate Limited</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">190 Elgin Avenue,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">George Town</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grand Cayman KY1-9008</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Pedro Gonzalez de Cosio</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">with copies (which shall not constitute notice) to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PHARMAKON ADVISORS, LP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">110 East 59th Street, #2800</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Pedro Gonzalez de Cosio</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: +1 (212) 883-2296</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: +1 (917) 210-4048</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: pharmakon@pharmakonadvisors.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AKIN GUMP STRAUSS HAUER&#8239;&amp; FELD LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Bryant Park</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10036-6745</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Geoffrey E. Secol</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: +1 (212) 872-8081</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: gsecol@akingump.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 165 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT&#8239;E</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>form
of COMPLIANCE CERTIFICATE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif">TO:</TD>
    <TD STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; text-align: left">BIOPHARMA CREDIT PLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: left">&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">FROM:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">PRECIGEN,&#8239;INC.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned
authorized officer of </FONT>PRECIGEN,&#8239;INC., a Virginia corporation, hereby certifies, solely in his/her capacity as a Responsible
Officer of Precigen,&#8239;Inc. and not in his/her personal capacity, that in accordance with the terms and conditions of the Loan Agreement
(the &ldquo;<B>Loan Agreement</B>&rdquo;; capitalized terms used, but not defined herein having the meanings given them in the Loan Agreement)
dated as of September 3, 2025 by and among PRECIGEN,&#8239;INC. (as &ldquo;<B>Borrower</B>&rdquo;), the Guarantors from time to time party thereto,
BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the
 &ldquo;<B>Collateral Agent</B>&rdquo;) and the Lenders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
my knowledge, the Credit Parties are in complete compliance for the period ending ________, 202_ with all required covenants, except
as noted below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
my knowledge, no Default or Event of Default has occurred and is continuing, except as noted below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Set
forth below is a list of all new deposit accounts established by the Borrower or any Credit Party that has not previously been reported
to the Collateral Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[_]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[Except
as set forth below, each] Credit Party and each of its Subsidiaries has timely filed all required Tax returns and reports or extensions
therefor of each Credit Party and each of its Subsidiaries required to be filed by any of them and such returns and reports are correct
in all material respects, and has timely paid all Taxes, assessments, deposits and contributions imposed upon it or any of its properties
or assets or in respect of any of its income, businesses or franchises, except as otherwise permitted pursuant to the terms of <U>Section&#8239;5.3</U>
of the Loan Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[Except
as set forth below,] no Liens have been levied or claims made against any Credit Party or any of its Subsidiaries relating to unpaid
employee payroll or benefits of which (a)&#8239;such Credit Party has not previously provided written notification to the Collateral Agent
or (b)&#8239;which do not constitute Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attached are the required documents, if any,
supporting our certification(s). The undersigned Responsible Officer on behalf of Borrower further certifies that the attached financial
statements (which shall not be attached if such financial statements are deemed delivered by filing with the SEC on Form&#8239;10-Q or
10-K as applicable) fairly present, in all material respects, the consolidated financial condition, results of operations and cash flows
of Borrower and its Subsidiaries as of applicable the dates and for the applicable periods in accordance with GAAP consistently applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[signature page&#8239;follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 166 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">PRECIGEN,&#8239;INC.,<BR> as Borrower</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&#8239;</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&#8239;to Compliance Certificate]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 167 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Please indicate compliance status since the
last Compliance Certificate by circling Yes, No, or N/A under &ldquo;Complies&rdquo; column.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#8239;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Reporting Covenant</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Requirement</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Complies</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: left">1)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="width: 27%; font: 10pt Times New Roman, Times, Serif; text-align: left">Annual Financial Statements</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left">90 days after year end</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; width: 11%; font: 10pt Times New Roman, Times, Serif">Yes</TD><TD STYLE="text-align: center; width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; width: 11%; font: 10pt Times New Roman, Times, Serif">No</TD><TD STYLE="text-align: center; width: 1%; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; width: 11%; font: 10pt Times New Roman, Times, Serif">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Quarterly Financial Statements</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">45 days after quarter end</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Yes</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">No</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">3)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other Information after an Event of Default</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">5 Business Days after request</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Yes</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">No</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal Action Notice</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Promptly</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Yes</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">No</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">5)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Notice of Default,&#8239;etc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Promptly (within 5 Business Days) after knowledge</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Yes</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">No</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounting Changes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Promptly (within 5 Business Days) after occurrence</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Yes</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">No</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">7)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Material Statements and Reports</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Promptly (within 5 Business Days)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">Yes</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">No</TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">N/A</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Deposit and Securities Accounts</U></B></FONT></TD>
    <TD STYLE="width: 55%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(Please
    list all accounts and indicate each Excluded Account with an asterisk (*); attach separate sheet if additional space needed)</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bank</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Account Number</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    Account?</B></FONT></TD>
    <TD STYLE="text-align: center">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acct
    Control Agmt in place?</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 25%">&#8239;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&#8239;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 25%">&#8239;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&#8239;</TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top; width: 1%">&#8239;</TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&#8239;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&#8239;</TD>
    <TD STYLE="vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&#8239;</TD>
    <TD STYLE="vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4)</B></FONT></TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center">&#8239;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5)</B></FONT></TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center">&#8239;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&#8239;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&#8239;</TD>
    <TD STYLE="vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top">&#8239;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 5%">&#8239;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other Matters</U></B></FONT></TD>
    <TD STYLE="width: 10%">&#8239;</TD>
    <TD STYLE="width: 10%">&#8239;</TD>
    <TD STYLE="width: 1%">&#8239;</TD>
    <TD STYLE="width: 10%">&#8239;</TD>
    <TD STYLE="width: 10%">&#8239;</TD>
    </TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&#8239;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have there been any changes
    in management since the last Compliance Certificate?</FONT></TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: center">Yes</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: center">No</TD>
    <TD>&#8239;</TD>
    </TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&#8239;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have there been any prohibited
    Transfers?</FONT></TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: center">Yes</TD>
    <TD>&#8239;</TD>
    <TD STYLE="text-align: center">No</TD>
    <TD>&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exceptions</U></B></FONT></TD>
    <TD STYLE="width: 50%">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please explain any exceptions
    with respect to the certification above:&#8239;(If no exceptions exist, state &ldquo;No exceptions.&rdquo; Attach separate sheet if
    additional space needed.)</FONT></TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>
        <P STYLE="border-top: Black 1pt solid; margin-top: 0; margin-bottom: 0">&#8239;</P>
        <P STYLE="border-top: Black 1pt solid; margin-top: 0; margin-bottom: 0">&#8239;</P>
        <P STYLE="border-top: Black 1pt solid; margin-top: 0; margin-bottom: 0">&#8239;</P>
        <P STYLE="border-top: Black 1pt solid; margin-top: 0; margin-bottom: 0">&#8239;</P>
</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 70%"></TD><TD STYLE="padding-left: 2pt; border-top: Black 1pt solid; border-left: Black 1pt solid; width: 20%; text-align: left">LENDER USE ONLY</TD><TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; text-align: justify; width: 10%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="padding-left: 2pt; border-left: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="padding-left: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">Compliance Status</TD><TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">Yes</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 168; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2524946d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="tm2524946d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Precigen Announces Up to $125 Million Non-Dilutive Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>$100 million funded at close fortifies balance
sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit
of pediatric and other HPV-related indications</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GERMANTOWN, MD, September 3, 2025 --
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to
improve the lives of patients, today announced that it has entered into a credit facility agreement with&nbsp;investment funds
managed by <U>Pharmakon Advisors, LP</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&ldquo;I am pleased to
announce this non-dilutive financing with Pharmakon, a respected leader in strategic life sciences funding,&rdquo; said Helen Sabzevari,
PhD, President and CEO of Precigen. &ldquo;This fortifies our position for robust US commercialization of PAPZIMEOS, our groundbreaking
novel immunotherapy, while also supporting efforts to expand to international markets and pursue pediatric and additional HPV-related
indications. Precigen has demonstrated the strength of our innovative therapeutic platforms and is now advancing into the next stage as
a commercial company. With the potential for revenue from PAPZIMEOS on the horizon, we are well-positioned to deliver meaningful growth
and establish Precigen as a leading biopharma innovator.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Harry Thomasian, Jr.,
Chief Financial Officer of Precigen adds, &ldquo;Strengthening our balance sheet provides us with the financial flexibility to commercialize
PAPZIMEOS while advancing our broader strategic objectives as Precigen enters a period of projected significant growth.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The credit facility provides Precigen with up to&nbsp;$125 million&nbsp;committed
across two tranches, subject to the terms and conditions of the agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The first tranche of&nbsp;$100 million&nbsp;was funded at closing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A second tranche of $25 million can be drawn at Precigen&rsquo;s discretion
through June&nbsp;29, 2027, subject to certain conditions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The credit facility will mature on the fifth anniversary
of the closing date of the first tranche. The credit facility bears interest at a variable rate per year equal to 6.50%&nbsp;plus three-month
secured overnight financing rate (SOFR) with a SOFR floor of 3.75%. The credit facility can be prepaid in whole at Precigen&rsquo;s discretion
at any time, subject to prepayment fees. Additional information on the agreement is filed as a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evercore served as financial advisor and Davis Polk &amp; Wardwell LLP served as legal advisor to Precigen. Akin Gump Strauss Hauer &amp;
Feld LLP served as legal advisor to Pharmakon Advisors, LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the
BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors, LP have committed over $10 billion across 59 investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Precigen: Advancing Medicine with Precision<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><SUP>&nbsp;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Precigen (Nasdaq: PGEN) is a biopharmaceutical
company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient
need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment
to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology,
autoimmune disorders, and infectious diseases. For more information about Precigen, visit <U>www.precigen.com</U>&nbsp;or follow us on
<U>LinkedIn</U>&nbsp;or <U>YouTube</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><SUP>&nbsp;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Trademarks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>Precigen, PAPZIMEOS, AdenoVerse, and Advancing Medicine with Precision are trademarks of&nbsp;Precigen and/or its affiliates. Other
names may be trademarks of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Statement Regarding Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking&rdquo;
statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;goal,&rdquo; &ldquo;seek,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;strategy,&rdquo; &ldquo;future,&rdquo; &ldquo;likely,&rdquo;
 &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; and similar references to future periods. These statements are subject to numerous
risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking
statements include, among others, information relating to the Company&rsquo;s business and business plans, the success of efforts to commercialize
PAPZIMEOS&trade; (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company&rsquo;s
ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS and
the Company&rsquo;s other product candidates, the timing of clinical trials and their results, the Company&rsquo;s ability to commence clinical studies
or complete ongoing clinical studies, and the ability of PAPZIMEOS to treat RRP. The Company has no obligation to provide any updates
to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety
by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which
could cause the Company&rsquo;s actual results to differ from those contained in the forward-looking statements, see the section entitled &ldquo;Risk
Factors&rdquo; in the Company&rsquo;s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:<BR>
</B>Steven M. Harasym<BR>
Tel: +1 (202) 365-2563<BR>
<U>investors@precigen.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:<BR>
</B>Donelle M. Gregory<BR>
<U>press@precigen.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pgen-20250903.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWauDibOdzZR+CYkxtmBzbXlqzy4roxIAcSB1tcNW4XsJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:PGEN="http://precigen.com/20250903" elementFormDefault="qualified" targetNamespace="http://precigen.com/20250903">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://precigen.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="pgen-20250903_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pgen-20250903_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pgen-20250903_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pgen-20250903_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pgen-20250903.xsd#Cover" roleURI="http://precigen.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://precigen.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2524946d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2524946d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 * # 2(  A$! Q$!_\0
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M .\/_0%IU-7J_P#O#_T!:=6E/9^OZ( I,\X]LTHZ#_\ 5^G:J[,2S Y   #
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M0FBT'QIXEFG-[:W4R3PW5E%;R6[LK2MGRQ[H8E+;LMTQC)]<D_B>3[D^M1M
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MT^Z-T?MOA#Q#-INI2:%J@$CJ+*:YC;Z\:VC8Y8L3E6(#%5)5@PR,_=! P,G
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H ****8!1110 4444GNO7]& 4444P"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 03, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  03,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRECIGEN,
INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001356090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0084895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20374 Seneca Meadows Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Germantown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">556-9900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, No Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PGEN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2524946d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precigen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pgen-20250903.xsd</File>
    <File>pgen-20250903_lab.xml</File>
    <File>pgen-20250903_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2524946d1_8k.htm">tm2524946d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2524946d1_8k.htm": {
   "nsprefix": "PGEN",
   "nsuri": "http://precigen.com/20250903",
   "dts": {
    "schema": {
     "local": [
      "pgen-20250903.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pgen-20250903_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pgen-20250903_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2524946d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://precigen.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2524946d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2524946d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://precigen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-25-086669-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-086669-xbrl.zip
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ME;67K, 3)A5D: 8?J)(P#=YW,^<,E"R$'F104D #/(>3&#DC_NIJA\;O[A?
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M9$XS898'P0)@RF2@D"&E0X702\_KNP0L4P\Q@LTQ96X)L)ML4M#4!$2"U1A
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M?(AR(NO%SV3 +3 XP@58G\]LDYDYWP'AC /+IS9S F'-B  ,*@8SV5-W</I
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MPTXXJJQY^_)(%,1DVR^H\AP(3M7+J,= &B'?1+X;!Z4(!D3Q&!R@QMBZVR;
M.9!C >944 /D-'83$@E2TBCBE6@BF,T=_ &)%.)&YHV5M <0E2V Y<A!X"+(
M_-]JK5&J$(@N%L<W2B":=! T(N2[<>06#IZ+4>@3(*S8)"L<[8#(^$&MG'Z
M::%4*.ALB) W/B=,QX@Z<<C_A2">)*?$< /B&@02X\(\47!)H]Z2"ESA2!5R
M4(O.H)WIT1L24\[=33D]3T484]X)Y19&MP(:\A76!D LVL0Q*S(EX@:I(W"V
MR*? 9J2V(7UQC:R( +00BJ8@%8[(><(L0/]I SI'-:!9IVRH1,ZA5?P,CV&
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MA5*4_CU=8C1:GHDK9!!W'<_$]ZE*VCK)5'I'4XI,<6FX1CI#".E,;VI!C)$
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M'+JL(I6YQC^&]SOPQFUOU G?.G1[\2!\F=[:O9HU*N^R\4L&_66O-GDZ=>Q
MG]OJ@7>M(<LX+(LRV<7#,Y!+EB A''F/4L CWNWR_#*;G]>];?=M3*\SXFP
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M25K=.@&]IW5:YGFV#I& 54FS2<3I0^RZ\[0<2Y:C_;[BH+HFTMTM\_X,L)\
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MGX?9.$#?YK?]=T<G_>-NI__[V6#PD0 ?^^^LA7@(+RTG@GP8)5@CLZ3^VU&
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M82K'<# $R:T7)>K]PDFW0^WE:+@QMI^#R1XDES&]$[%5Q2!#U-!._3Q9X$+
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MK/^Y_S)';2ZSR24'N%RD1B4#7:>*RM']E[MO>*DHU6WC=*A'18R1.GU?1.V
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M6%8V$G^.6&+:-O;-MW@O/!!:&P<ER;[BD&>?2V?J?1IQG4JP3T.FN=/0\XH
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M6$:G4-@65Z0U(#<)6>FI^$@P'E2.]F.Z'?V<NA*)TMRAQO.]$UH-*T)8.H5
M<R91?M4X&#MQX[8Y]P7+(/90H^E#,@&'9I0P*DQ;?J1QV9(*M+<@S(9T#)2X
MT72 2K,?&G,=Y!5.SGP*2C3-&@=C>HC+K2WZ+Z3D+AC:I!Y87HLB^"(N((^C
M000>O?)IE:QP.&7<N*-KG.BC.+K8QU<2^(*\L@CHK%.!E]YFH>-#O5'ID*F
MN'%-,[^:4M$ZI129$#O?"D?8"!61R,J >QJC1KJ8%2 G61M5LEAOCJEHA5A<
MG6RUS*@?@6@(-0M2&^6\?F:FQNG@O>Q^AJ6+S3YBI^<P"=^,C7VE?,N[L-NI
MWW8K:D2G0X48B70.H./CE;(WK,!Y]O6LEU\.M+("(EFU7.PZ.^I#3Y5?GD3+
M,2N-P!%5;5$:D]4Y24OQDA!S#&RR^U;"FT-:+!/!*J/:*8-.M7&,SEPEX67W
MIB>)-!Z]8U,L]63>2%Y,<6"*2(LWJ!DYD&J#4:A>$A:T4HI:'"F^&1ISDRY
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MV.-1SK@R&VI6RS06J2P650I:,VAUL\-JZB(JB.)>85D:'H*40D[[DFF-":.
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M*@=_X%1 M)HFP6#<:GD2K\TT"=E&=F9;!W8H'6&P79+M$@IK[L_7L$*,"K!
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M^F8J91EX6)/PQ,O1&@%+KDS7M;VZ;DUBUTZG5!&["V[$) MA5:2CR9<LF)@
MCLXDQ#9(TS"TX&;&D<8EPY:^H_ V91,WRC TD](Z76:(\9=6,U,CS#4BVNV
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M+X^"$==RW-I?&XBUW86=-MM1<//X)3QO4\+_I 55V/EF:!S&7X2,#^;]5-%
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MAU?L./>BTV;7&<,]S-PN$\Z8:YX?=]BK&8AJ^.ZK1C4\_(9J^&M=Z>MR")_
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M&&Z3,DX.!?#E[[_9G=A_LQL,8GK%O1WY8]600_8==#&HHIE/K].(@[?QZ7[
MG>)S508<]20U=UU66]6]&^DOE_K:>G]4A.[6Y<1KG/M+&#@%K[':P"<G45E4
M?4P^[B26E^J!Y./T>@T_K2N/>8<WU<"JZN.ON:KZZ/ZWJNI=M.2G=\*2GPZR
MY#N\;<=_V^5S&;?T8/![E-00ROT]*1P%I.[)^YDXJWWMU .L^]VY +UI.U]/
MM<JQ91C$BVKGP/J'(70G<8PL ^'"8V:H#[%TXR];98I'>([$%,+[O[ER&S5R
MMO#(<4TAB4H*.%I<3O"_Q$XF6K-&:+3%FQT'?%64C1N8L;V[A]K>X/-'U[09
M)U/.VB)0[:WC-BU9-Q6[W["!MO@FE'P#EOF$&R6(4RQ6=]=T^GODD8/_GL0*
M[\HAML.D/QJ(7L]FQ"]U"N$FW$'"/X8KUYO%PCQ;:O? DC$S;#'"(P<?73G9
MP)S6OLEC'=B6P4I,\S%\CF)#3$V->9<B,G69HS2O$&,,R:5W:L5&=X O^[^@
M)0R*[G2O8;CV5&G1MMSLR]\&MPK[DFW M-UNF?M9WK89]EEE)GPKR\TO@7[?
MY)K+S31Q]UAWWY;=;=?/MUO?ZUK>8;7=I5*7#\IV(_19&RP;E8 QBE' TF*'
M]Y_@$$?]=E_!6KG5NI^L%6KINH*%VJNFL6N6L0FW;YIM?:+I:_\9G6:LKH,'
MO3*3TCJWO_RU\JDJ%X$0Q#>2D\7YR*00R0FX6L^%)Z"FMMA^F]0Z(>.SK\I/
M!=(*!HF%)N I@C?&\6!96:I>Q"CL(ZYA211[PI]<=)@Z+N9H>3*"4JDDR@OL
M_SLK5D9<_N+/#<>+8/MRE6(MXI8Z".56%,]/D]6FJI$#*:B<HA0W%K_#B-W]
MM=H,T[8M3(CAGMS&RNQ9KC__I$D_^.GWGTY>OGSU]O7)^U?_?G%X\.RW?[_X
M]>37]^_P&../WO&!'A(DOVA*PP1!*\%OXX)GS)JQ)DPY0.K;E1L(A['?]7+!
M35C,2H6G!?SG-U=).'*G10'G1,E=]=-\L22T>/@HPOU;*C9)C6KW0BJ /PH!
M66\U95W^[8N8--P5Q]<E7>W\S^N,6BZYP@1#^.*CJ(Y0<B/!Z)_>^@WF0:IS
M F@LX?6BOD6=<9(P83O-$;1")S.A=.BJEL[S4S!GN=[W\( AY;C4WC8*7;]D
M%W)ZQ(6C/S9544\+"<F) 2V 5:B[HJQ6I<*'B:==0GJ_(+.Z(6'5\A/XR=#1
MY8(0#\UWQ]HC/WJ:8)S(I2E2 Y_/^QLR)@J]MW'$C_.)E%+5JH"Q8?QQR&BN
M:Z:+PTYQUFJ3LP&6#2/'J9!&+E#A&2:86P\VBA^MT2B5]ZN5R4HJ9#-RY K\
MIQ.Q$2F-ROH-2>2+)[@'\4<'(98/D:-K4FXJSH?B1[50;CY;0^@<1EJYGGP:
MAR>-NAJ6+:HG=3!'B615]0KC9F[5:V(UAA .9<="/RV3NNS+PM)*V8<0OJ&K
MYD[XS*>6MKFGDE^?&(9J06S*#(J8SSOWC?CN/6T<<'<&R!6T:H17K,'43SVT
M0X8%_/,NL'\;T*$ T]-3K#&OA2.GETK_[MKR@:77)U]UZ?7!M]+K7^I 7)>6
M)_[/RP*]!NKG)Q$0"=]^990%NP_/&2'>$;X@>=WZ,W?._NKB"1QNG9. Y]P=
MMI4WKXY]RX-\LEQN<(1ML)/&6"?_8<SY$KP9;$GX\?XHF6:7M8N:<F;XIDAE
M5M2(L&9&7T_1/,YAE"BI8%@O_]F<'+[#@^?@CZ'XCE+SILA9]B1ECE(Z K@:
ME<T)JEZ?H:;:@$Y82[S(P[(,3GB U(IR@A#@1AJ[86VCP@RB2(">HC,'5YF7
M%\*>LRXG'\[*.>+$-03(.2MB',O1/5%\63JTF:#*:29/4*L)VUR(EB_K8EQN
MD&"SY%?&7<\4",@PGUKW.&$[JOR\*#=UX_7GV'J3P]>%P+I!!O>/DY,WVJ;.
M9-%^>&:V?-Q <;Z'.E6D\YYD>U<0OK#G9^6:3-MNB*=O52S[>B%QYZQRVCXP
M03I"@HRCRV^89F16,%\TMKN?+HGXAJ6R^!$EO&"_L./>'(&/\YU#0GF%SEQ"
MB(T2\-*7',5W\!_^OJ3A8;&I5.Z,/N<XCTB#P<$E00 #(V8TPM+?=%K2]J'H
MJ%J&#BC]>Q#9Q.D(/<C4MT\I/8@+9(%V3"6XQA6&BXP82)L<6AJDU"DS./:L
M#>L:2\5KYH#6-:UB:UG84SM)M\*VGI)4%P5WNLSAR4KDL<(GXV72MZPYY- R
M'G'-PE)8P@L7[@D:J4ROWZ54 =62WQ*[D+F5H&9Q,XF$",4<!=B/[S^V)JZL
M&F<0,M[[[>,\OZ34,?SEX?W[#^6^W$&39&ML'),\,"]=-6AN>R1;=@<"WJM%
M>C,7XZW&B[%CO\:#4ONT+YSK^P\%/[  F4(/C]TQ0YJU>F&QKKQ*\S%(B[,)
M.+:*8?_];S*LNO.^QVT['__?)JM@8C"HWNE_X!%Y>8\AB8^?;/5!9!)A75(5
MHLKA*X]D<[_D,T_N7#?\%E%JV.:XN'0,WB2^GK@QR?_9+'/Q8.Y?Q8/IZI[M
M=F'B^[>\F&2G$].TN6I"6:*A\7H,?5S:(,@#U3E:=KDWMJ]VC'+3^1F9H8;_
M+>_!XZZP@$9*E-V'/UJM0;[38$](/D1 >CHMJ%^=SPU#PG9Y2W#J#W"7OBY;
M\0F-Q;/0J_J,#R9PB7(V%[^#DZS=VY?$=2Q-LS&:^6?M8WJ.=F0&P7MYH1VJ
M4\Q$3NTB(UR,75[1X8'/<#93YT\H=1YA8<MV@ET_I5P;63+=$&$'<E;AGNU^
MUT1(?3 R0"CGCM" C^]+%LM=E%C9E=H _*H6?9RC$QF;*[N!@4I5=58_M1L8
M2@*'!VV7T!4,W"[OVKJN+WLN?=#$2X-6C@F&MOOF:$!UV @KT/#4D[:C'GOH
M25R\&5ZQN=*RX^KHT<]!3>6%,E,^SV<9IOWA(OIC6Z])S#L\Z]#O(<TJNN67
MBB> Z QLLW3>6[E'E;89%<_"""3X(P4FPGHSR<B* !@<<_+OX_,:+[8NJ;SP
M-=GE\ULVR[]QO<IUIL=NVQ:K&[PW5SI4=179T,VT*L_C#%<=+SE#M'M2/C1$
MVM<7$2Q1\9'DT\FG"D4Z,+%$ZU9P#T3@-SD*=LNC84:[K5*H;$K:I.$ZAE<;
M:1=LQ,"P-OI]&@M?)(NE!GXI4<DKH(R:OE#&'I"O83&Y! UX3_[Z*=H,I:_E
MLPE^@0<%_\/>/4I8",I!2(X%%I6PS$2+0HR."Q(S4DVQCM)>%;5.!L02%P2C
M%I^CNDSF>+@A?%-25/9-KYN$DFCXP'2U*07E>D1(LF""<2I:%))?JXB!%Q>3
M:]O44KZ?EQ'3\6:^T*@##(%K62WSRWN3.5&B6Q%<WE$TJ1&I(I\D8D75A[_#
M2>_/ 84.:_=7H80(AQ-M]1?GNM[DMVGRXNVK=R?RAY0LV;3*+F 1R6=9VK>S
MCJM!:]S6E=5&A\P_$Z$+NRE'PL02-%MW.ZPCL9V]6>&6-#KO4N(%*,<(R( M
M]\&:Z^2D36EP(M%2:E:#21XH$R"W[A)XIVCY^4ELNMHR77@%Y#CG0!K3MXL%
M*IBH6Y4)3],4]FDM(),+F2%<EA]R)L@6-L' E=*5>CU^=]R@;J#3PK1TF4A;
MOMPGL<M)Y,&<@ SNM=2W\Y-:OE,X0=(@ 9.=EP5[JTBL4&[&:[YB<YGB%7L6
MZ2AJ6W"K_0X;F8$HA.^^:A3"PV\HA+MXLMUJHPN<;+\@S/#PX(2]&S[G^!QZ
MHZ?.U4Z9S:I<MLX22[7KV>#]8M135'6Q?[7.E^;!( 4XJ[9)YN44GFF9-(!K
M,$L$,L0,H4IF!XG!'^[]*PG@2L7?TY@DCKD93DGA7'WWXIF]R(OG_SAY*\H4
ME#(2PBB$!F)DSG_(IN7*(&MT@5':Z22?P2EYK@)QZ V*-KJ\=/-M@ZHVO#2X
ML/SV+9G'SD"G.T9:9)?^))*0"EDJN:2%0#CEU-X216&,\S=/9U8Q5?>4C(JU
ML=OI#B-"H^?2JAD?ZK+P?'9&)!6/8\BFYD6".)UK<J= OZS9V6G]A1T*JT@6
M2PPF+G&V^!7Y24)<. OP$ONVQ8D<,&AJJNGYF,MSZ?_ZM$T"Q?C?3.B6,;P\
M-=QN\\60["WG:%&]'U/@RY>\XH7?P B\![ED_"<;F'*SOM?2=:U#]B\P'&-\
MMIOB>+-$?7I,!4VS17:J\7.]CBJ".Z@S,<NUP((B!:\?)R)ZM7;2*D0BC<-1
M(\*BUJ1<Y)GVB-A%[3A,/<K5D8K=3TLZ$C* ".&):I]#P%H?.K8J;(EDFBQU
MQB(F<P(W1TJ?,^GIRN;P4,\PB<@,BN@2\T\O?I<?.BG&([?9;R3,,VX(.E!M
M2,7'O50:WBA-3C<%IK27>5-A@'P=[F7U=*A=FJ?*K)]7HFF$G*PX!]P"A ZU
M@-#INSV(W!T4:$F# 8WW+XZIOM4V9YO"^0%8Y:=*@=E/99%TI%$[B"Q24PEJ
M&%,D/7=X?*^X#*9W4A5,D$8%-4N 37,X/^<-X=C JQ:8U$94=-]M_W$;<TZ-
M;C2W@X/SH8-.L"T]CO3KCEBSD0TZ/-B5#O+SV<R=U'5N=<&MB90H=W+OJ\F=
MW&I[+,($'79D6Z)C0*U-,A=^48MU%NLML!(S46A/+ =K5M?3XG8D)\(1_>5/
M_JWVN\+DO[;R7L!FD/%\2Y-17RGA+QKJDLU7I[IIRM#4KUQB*50:K;S&DNR$
M7)IMP'.LSP*]$V,QF8%RO%8"9KG>%J^NV9MJ:7@13(;;LL3&'%/OZ.^P_2L[
M>FN__/5WJTR56+G,6-M.FCA/P#[<>TU\'[]D%/.AN2 GR5<0N+/UK@[]9P<4
MYQ/^\("/^%:YCV 7NJO[-S.<XMQ4V1 "E>*5]P>4YK].6KVRO [0)8>S'\Z%
M548R5-SDY2YM02X^#<=BRTP@3ZI$8-0TWH-I7Y[# W3OV.&)BHVL:(/:WAGB
M2+J=,FOQ_R7G/$6I[WCIQ=4[0AA;_\GVY7^'+<WGATW\>5Y./F TP41Y45;M
MUX:^5-&>71>L6^7G:+Q9=^;@&AC%CB0<AU=#BSUCK)I0Z$"RM!R3-C_4D<NH
MDA.XZIPT.;JN6Y!BGHR,, CBMZY[W9 ;:+4_3PN$?!#=/C/R$_&^7HTU-9"C
MK+S,F6'8TE4%$9B=<W494RZN,76>9U,L <]+)CG#*<N)^\)Q^!)=\31\G[([
MY^&/R)7'*"Q";)[E$))BO(L91O!HJU-*;9R7<^)=8X*J>=BQE/,A.6T8%8@%
M%SE+JS8^=X<W]>"M#/L%5[KU71 6LX0(M^32%H'N GY!G;PZ-5YCR] 57CN(
M%G9 N0U9XKUX?M2[YH:^)JZJ3B),%07($68/_SUV/T]0VVW:P8&9-S,'';E@
M6$B6#":I=@57%22T&\JXX1,AM^WT03!?KJC6T '!=QV0 N=)N<$<>+/_'2\O
M06.#("9([]!,P$+M *]-VDF8?7+L-&Y72K$?'FS+L2=[IMCO\.X>6'#]_JLN
MN#[Z5G#]2]N^KTN(&__G??91NKL/#]YSO1$<#:8Z,2/EVB8:)2?X.JJ<;JJE
M"IQ1>@2/(2IB<B^8I3RH78+OL@)C@C>A!TA=#Q,2E$[A,K6RS1"DK0!'DJY5
M+!CU2G7:8MTHL@2D(_T!+KH63FG?P.&^H&VM"HN4Y)NQI2#W!:Y5^LXJ!UO&
MA^P,/HU12[714N]2V34ZV$<&4VWTJ)J$=%0SH3\PE5VR1<;ID@$COFVJ^= ,
M\.>8WHTF>[KA"8=Y,L%A0C/C[!,E"*^)Y)<"\<A2,P\1H!U'32ZTK)CB:6%4
M1$Q1,LX%(HZM;ESY(UX<&#4XL<:7D=AQ*!QB0X+&&H7B";DM1Q3'(BW0-'%X
M23@/_]S@Y80+R:U3=W#F2(V)A0Y:;O"@9?FACOB2Z&FI 13/."KV&*:>,.;*
M(01V/:?GC+T"G16>$9L''N@D'F>M@L:#G0;L)Q6]W?A0=7D.BQN53$T)#:8"
M/%-V:.ILGDL!:Y87:Y+GX"WB&I,:DXO?A\.\UCC>O\$=/M_W-;6/;]34OL*:
M<:9<7(<'KY4GBI:+Y?NQ%$3<IV)/-VNA>PJMJ85>*='>\IHU@\&?P!"<(L;P
MH:;3%QM*SBR9R)&N,-1.9D%*K'!K9?H#/ :J[-9P,&=5P;N.*N'ZO;'R[%.>
MR>$B2$@S7YYFIX$TLL;45,@@@U4Q=+KVSZW!&ZFU;LEN)57-(>SEW'J+Y)LU
MF.>S>V$$&L+I^OS"4< WQW&'Y<]$"%=^!7^0P";>"I>G:B9F*_QX3B#&+D(@
MH)>=%!4$BQA.2O7')>;D88_QXKZ$""<M TICC'D[MGCP&,\*!).3@6H%"<M+
M@?-8@0IKR#S@H1&IFRMVQ$&JE"5KZSJ@4U2D']TOPYQ%YM71!DA)QNL8M8X=
M2GEVYV--/% ?F[-7M;61.BT(S/ADTC=!!X:+9VC54RZ&=@H<DWG.GPIX@B,J
MY+:^E:AJ1$G=LR6<Y])KAJU["A3@#@;.P8YYXJ-R,=E?4F&\-*6PYNN.8$V$
M Z^KQ\F#I+6_B>P!ZS<5RPUUT'4U<[2;5;L6N9*"B,'A1'-[WF,%)P:4D*M8
M=RU'F21;CK'>)AV !'IN7W\4/7IW%PO'N4;A)PZ3.PVY29;.6"N12=.]KE[5
M@]S1+Z.+;F?JG.?)?!W8SD7$CZ>;C)_)@&J(4BG6G4,8/_#GKJ/KC^V;99S]
MC0%R6'X72, WI9#KEQM>+7E_^-Q8K',4&I0IFJK1#2KJLX48,$JFP7#XG</3
M@]:C=(BJ<;;\$+*I$EJ6E89QBHC4\ 'W^+R<9!*%1*TA3>(:.6_9+9&[$_/C
M,R%$.6DS4?M !N]9;0)S!S>(F8W?W;(F/"X1 M.C2YM\[HT7\(0N,2M(T )H
MJX9WT%;'.*NR8U;J3L+28\0S2S6R]16I,G;4*CD HGRON@EU["6X.>IA'5;<
M3A?)QI%25^'1B6Z89)6WH<\(_1 A5MEG1:./CA4UTL&QPFG\[ ,+6N%JD87C
MG%07^H*;A1F5$9THM@OPR_QFK5%+A46Y,6F#=D'2LPG:XXHM>[;+N S=B!%U
M-Q:U=^7@??./X%L)U;0DOM-0:^Z U75^@3<$$B.T=L05=E_S@.P96_P3BM=+
M=W4[1V[%!8S64VO"&H._,RO(;@UT-W6S= UH-^*7 #M8DZMRBAT4'= >#%RM
MTKR*7X+)QXG%"Y6;M3@W!<ZM -VP4U.L;M?J__)/PEMMTWR/J]@19YE_*20L
M@3)9LDC6?(R[F[A^CQX$97.VM?G'D/398+J4P-W9)2P$,'WR@V3^+*T+]D7*
MRLD%QOP<!_#*%39XJM=RLJBYL'M[9JQ6G29'#^5!_YM7I?$!Z5.WRVI4" L-
MV%KKNRC#E6*XG3R'F#>I)BZ]Q]MU9SDE]%O8R'PA_-5(A$[A569(S8@&H[V]
MTH!JL.EP\0E8',S?R5]&/#M^NG!H$2E=7J22&/#)'(HX9P5$-XK:([P^W/2Q
MW!09^,X0R!>&U;")]D"==VUVXS/^HMV@CA5;E^&FL>OZ'$SE63$NV*2<DLH>
M@@!FFLR4O#D\WW?-Y],&4TWI,C?*)%B>D- 7X<N@*,6F]^C[EC*YSI^=HA+K
MMC,-'03G006\XG51X36U*36#E?KJIS$<WS@Y^=__]]5/%N0J6WUN#?9\D"&?
M#5E>3!HLL=4":Z=3L_-#*#"]OV%%Y-YT0*J)YS/; 7"M8:T)& B[UH3(T$Q;
MVB:PA:*V@L,#F _>Q-,R9RH"+)? %_^?)RE86?R?]^NZ2^S!%!2SSG?Q#[=;
M</YZ[Y38*_&;U+VO8IW/4:! AOSP8%F*EQG7[I%&M&-1V/$NB3?.D=)=S!/0
M5*A6GAJ["G8II3;JUM7;]$[MMY5-51GE6)._(THWDC%C,U,N \RD:Q C0DJF
M8HM&JCT\7<Y1*7[35,5,&J0=30K+9G)4I[F1(7V"S]CF-(F7&[W!#TU3ADL]
M* IQ$\R834U31/:!&^'U655N3L\(1/-]6T?63"/N?)O'-YID.\)WC5?U'O?[
MH8TT0=/+^+3Y)9L1X7;Z^\\_Z>WC!(D2KMYA]W @WN.'KQKO\?@;WN,NQB2W
MVF#?0"^RNQ?@B^Q<!%\?4]FND,#Z46NA*+9>-^0M0M/T2.G4CU9P+I!C'4HD
MK0^%@KW4H!KPW&13<Y%K:_(D)!.C?%YWR:J+ZC@$:,*8VW],:#+AE+IJ>Y)A
M7JFH=0R/+-2.QY@:A4U8J=PFT4@I+#@,T*F=;BK+%SVZ?P^&55"2HT;VD#PJ
MN<C4(9=/)G!(UD7<=AXT8<G?[!^P7<?JS8W7X4%CP+*)(9@PF%A*=W%@=-_Q
M9G?X[-JW*/+=C=J)0-$I3A$V8WPKBUS;\#X3[2=5#Q-NT;"MNN)L4^R2IG8,
M""EG\,=&NFA2Y(XB'4#\[!^;Z:ET-(;\,/=TE)4"1#3>I80#0?$,3.= =BZQ
M\6)Y7E2E=KY+?S_R+*5;*0"Z.O_Y@'F93\D&O,P*B-A^ 4>TPNRSL!6<H)Z5
M\0<H7V9'![\RL8S2Q.FNM>U!D  EWHZ([1D18ED%43)"$ZT;'1Z3>=E33BN?
M(Q*+>2:P51),*7P)]T@:<W.EEGDIL-#EOJ%) ?K0JJQAM<J%R9[3;\+'(5JC
MC\37UL_YN_N9'F&_!:;^I2,#V<8*U?:V7N/43RU=+Q"-U=D,=5$$ZPF/0?(!
MER-L8UAN$)- +R-%>'X7\'6S4[KN/!LC)0/\M"'-#].,L#>P.]$U%B7_-D/D
MX[JHZ?>( I7GS#_JC]@A6U;@_*6LO(:_IQZ:G!.6B'1+L0QC<-)$?MNC4_$^
MKRHJDJAR6DPT:5D(!^U4\39:=+2N6DD((FK=2OP@US/6A^T8T6W$#]JZ_N6;
MY5O-T;]":FHA-O9*F1&G"*$OIL2V[B:+M[14OFC?MO.LP0I;WV.ZI>D1%OJ+
MCZ;?\HJV@MA!^M*SLJHV*V=-V_87O]AE>;_\=7*K<=.SIG3CL/E,NJ<S]+XV
M9O0SGR7OEGY_H],05C-%::C+36DK9,.UW-A;DF3]YJQ>>[4[7?BM9.U=DJW@
M V"!"W_?IZ@KP3L5.*V-E2<8/:59OHS+-YRE %^IF!:",\R7I&%LB-,9:0O@
M:?OJ36ABD?)@C\N71!Y?KX?3X\P<'CAOAKT69*BZ+3<E^&P\0(:(G&T8V0_^
M'C&ZPGNNJ-K)QHG4@N !*+7GV@?0(R3"J^8O\X\9 0=(VM;_Z>^O?J*+46\_
MMA:]^BG!4G9^$7T.'>D*7'3J>(XN0,XF50N[O@>.%SSB?-YQYRC>F8.9W% 8
MA.!MN-SJ+'GU;_C'VFD[<3L[ASCZ!4>I^,]L/3F[]Y_L(TPZQQMGL"3T9H[,
M3I%4N!#Q<*W&Q=K(UQ?P?)E%87"I:9WR8G[%$DV2^7I?95/"LX [7M?,Y1#?
M0V*X-"9&@X6R8C(T^,DH6/A3U)"!3X?)N7QYJF@Z(H:@X$.W2RI#(UL%Y=JC
MO<-OO,2V]+-B1;F2"R31HW\X!&S87T]=8LD<IC5+9,R8!H+(*7S'2=B2.!A(
M7E/E*F3O?R6RVES&%GJ!_3;LD.##!1FZ8\'&W.R6?>K;[PG4070:C*7J,U5H
M<F_!5NUX]Y:U8H+FZY@K*>2-87[!,9JF3#8/:Q9_EH8D9MV;"FW 5)&0(LH6
MB8=W(*,(?4=T@8AU0[B3<EOG'_'MZ[P[UZJP]26V+1/P&IF4Q.@H"1=WZ-B!
M%5(FFF&!N/'X])C3&?*6AE]5?+U0PG ,$)'#A<KP$HP<OWJTD[@?2!C$EX*)
M9POGKC<B^]9840$-)O(A 0B&N(-^NHI.E:X0P:01CJP)0 BM MT(LR.3V<1_
MX7;@I]LL742%-T#FB31(5N@:F6>7^70TM"L2+V3Z/1$LW@U4F(PUF3P>G^&C
M0W 2)@7D_E4L4(_OF5M4QXR+Q*O!G(LMTD6IL3#LB[KNXU;3P4_%91JR'&A'
MZ3+9!^5RG(1#$1,:Y+L1LRLEGO(\),J]$D77-2( A8MRPRG5%+M@NWZ'_?*!
M)>,?O^J2\9-O)>.[& S>:HK,!8,-.X1P8P^ X:,F5VQ\QP&:A//3(K\!D2*<
MMH6XQ,B@A(D8 NOI/]MM;$VSQC]K*VV;![$3WZKLZ8%S1_\T"I9.<D+BK2G5
M4]>]6P>J6E:*4:74HP;6 TNYI<#S;Q-$2=1]:,S$I^=(V1=__$O*0X5G'TEZ
MDZ0?4X7CIPHXI+\R:82+/HS<B &3BK17$%J&PF?+'*EV$&>),?Y)B/'K /B/
M')[;BMX/#V[();YF-- 0I7,4!I+O$%*+:OVU#(=TE3N.^QE&X(*TAD@Y-'30
M QK_."\[E]40MS9JF4Y(R;Q!R/"L7%VR'Y)R4(XO+4'H&_*N:\\Z%28AC>@9
M./9FU=D096^649S-;?N--)7;U/#08WQ?+4O.6?9"MO>,WM$/"*R836,@<,XY
MT\*#$B6&$@)0P"03]T3TK+36)D8  0[P\E[@M'.N'X>!TQRN4;&ND9IO_")^
MS3\C7I9_%^9FY',% U.";;^4TSAJP8VTPK:(A!,:8EJ F5IPV8@M<0 X:*-D
M"E;E8F/,HQ-9,1%.8PMKT6R51O0:53,8]$_IK_;%[&25VRRN/\W)=6?9X/'7
MG^;DJK/LQ&,^21KZ4Z>U(KQ63\.:\S]T/D-^X"IY%[,[H^/D1;MI])0 ,+Y=
M"IGS9MW$O:ZQ(G4<0[V:0IC%.'IP?[MRW=#PG&7<F?FG%D93DJJ3ID%X=[JB
M-4%]R/-5]VNXO ES\+$$"!-GN,X$(_J.+;4[3I4VBTV;)&![J$VC-R+&(TXF
MQ'O5$MG-8US/:J5;;6UR)6M4,79IR(*M)&SK++T4M104S17+;UJ'UZ25=9F\
MIZ--2)_?-*0J81:;3\L-2*TOWN$DQN=02G^789M#5C.K%1977&[2-WO1J3"X
MDKBM@"@P,O:OG2MW># N2B'B21/X.:#+S,MD/0>Z&P)O'%%(?_:;;7**4-O,
M$&Q-M1O5MB%WV.'&5(!%ZZQ=P$#MTKSSIX4VG\AO%ZSO^QIK0_BJ"&@^=E0G
M9,GI&/>%8;;0PVPZ/M&1C:!RY#7-F,]O1E6KB J=6-#'E)VM]&)F4**JU2J
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M42V/=I!<K$K#TJ[B:?-#:R,.:AT7>]+4%5-/F6F69]/%5"O,VT+3*/P@?IY
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MEF0<^M.QP6RBL8!M74P>]B$1=]UM\0?7_")K^#1S]KU8D%*TN^S,B5L+SP3
MXIL\_):.3D.ZXJ3R#,K^?-K<6+DW,RZ#DD=1"9/]B>G2H..Z\F#65Q28FM2^
M7BCM&6UK"F9EX[CFS-&F:GDXUW8EVKI6K_19\Y@WZF_48>G$O" EV*+B@G6-
MV[CUT9LVT#!@>' R5_WU+\^_@2+HJY[&-UN)^I^+T:D_A3<W#G,RC*9%R13#
MDSC*B_P1*.PTX:9U_]1?Q!P99!^5 X>5<V9- =J4FAR1YE?-&$)/W"I%6X/%
M/')M MAG9?W^94^M\9,34@(1G@7C&E&LJ$?=\)(3VY2,&:6SE.:=4!*C1[0#
M,(52+4J*8 _!^\VXOU3(D]Z\Y"QAVG)^)PZ;P:TQN3_)U,.5BD%^]C1W?00B
M4$S9U,>Z(XZ*S;D? WC0VD!5&X2Z%R34Y%5;IC=>1VZJ[U ?-WO.="4-=#OV
ML>"24* F1E(8N:KABP/8SA6 -S 3Y:7#W&QNA* ;ETGP^%:.@N-L%T3'C<M,
M1@0)=^S*QIRLZ6@LGB>L??L\RP+;0N+T^*@[K'+6!#D\_:Y!#J\>0 Y?]9Q[
M=:/GW+NL<LX+AW3EP&L4MHM!),HOX3"@AJ6#*S&D2[%G]%'0WB&DO"N##Y\7
M:\[STO=L]M3]6!QS0?'#A&.]#?89'_H(_"J)JN.W&CX-</NKH?H1J[,,(5W2
MLV3%#ZAGQ[RE1679-4K&9I)JO-JL9!@)'A8EM8&5]W3Q>;4^MTRS3NK4,_?6
M8M?C6IZ&R_C_%B"?XXQM WT0G75P?0<H/:[U@MQF5@/"7-)QKY(A0,P[?#!<
M=8_^=*-[%$5F<\-%#%X;.?0D%!YL:+F:&J5!8HKHON7.,W"HD!E(2W$.;TDE
M0=& ,_L1-Q%,<_@17 BV+AA:!IS<0,PT% (_LRHDNVE2&E2?ROD$UY2PB,@M
M);_+]CBB+ +;6%DJO:3(OWOM8J!F@RY_81O-L67HE#IKS49(*(1[ZXCIM.TG
M;DC^%39 Y/EK;6C4!>6NZ19*N)1SMSG4+*>G#BZ=/=9\AGM7=A%NYF5E@/6P
ME969A,K+J-\A20X3=I%)2$KB.K/AFF)Q[[#8?5#DS&SQP0T;@?15/0+E7YY0
M5HDVS_:.M^F(N581E^;=%F7:,MZ.D\'7^8*T^CI?-<*[VFW=(Z7XY/$U]6#_
M:/^X)_55JO@B^C LH>*VIK8C*)WE2QN"FMLP!!QDHV*4P8K>GB)'!)'H+,_B
MI<VF0:<Q+OS@E0]*_IX]?K;U28*MV/6<QE;D=177?,]U.Y_*1EGV;M%ZKW:?
MY/.Z?%'[J-P40]#(Y'B@4L\VR15Z!F%N<4W2:[9W/9JI:XD^I,0%!>6BSW>&
M'&A?09WXBN)ZD:$8]J)&@["\]O<3@!.%0N6A<.D>7-A25Z%CF&GBD>/]>,B'
M8VC5G6"WBN*$8X8"I8T"7YHTBI&XW*0[K$C"$^\AU-"&5/O46O>$CVH4/H7V
M,]U;EZQTZ[BFO@CV%-H*79LJ>EMT]P%M"$]::2#X..62;&MV=7 *&4ZXS0UG
M2MW][7Q%?L*;]98[DBHU?L*C_5]_0W["WON]Z*C_KK^WWS^./GXX?!_UWD=$
M7AC=4^I"G/ ;IMT[HM:D'-H]DN:DK$__.!.T6EV>55WB3QP)0=RN:Z:)^"Q,
MFE<RB$]URA'\F>&&$G44(RGM9!([UES?$7V4(N?=-\Z>^+7S]:,4%#/RU:#B
M,EQL)K6]ND>R;VF,.97*I<=7$9VEVZZ.M/'=.#PFVBC07@K6I=81<CL@*&ZD
M[#&QDXU;I;B.LZFQ0A")%!A\).MQ5)NQ!DWAG9J4F#((R6)>())J2"8Z%08L
MF2K=<O@VO.UBV71U\-2:7!S;PGE"C8'K L<TET+0&;>3!7HTU5+Q)-3M7RN?
M+=>XE6 OV,BGI15MS#K,I"M\U160R*$#Z4IV49<C-J7ML[*8"\>F=%O6%2/:
M([D*9^53QB0TE(U'X8 Q^=#$19*=^[A$+5'&89'[CVV\54Q(-2]F6'9UGA#[
MNF2G*6$XEWP@F_6TY VB>@5IMU$*W_^5N57X;I7.YQ/!>8YPB-2RG'PQLG P
MQUQ)5 NW"OI5O>&0  5[4@Q"X4_1-^AJDJ\DI5CD0Y6\;&(&-13G4*AK*Q*1
MK&(ECCMX?&G30D14[36&"%%[C,S)3B,Z&+=A_RDVQF98'5%GW9Y,NJ\SY1.R
MAG"2Y1Q7_])V8VX9%L]:=8<%=LT4];/O.D7]TT.*^BYJR5O%YF-ZF;,>CN :
MM_VHT/!^%65&CT5YBC@K*6MVX1JFB4:C9=C0A**25JHQA$0MT6-&AT7+55CX
MM!VO5MEBPQJO*0TY'!5#;K%$L6G]MCFUZO164@OW*<692LZ3C(%M0D'?N!WX
M)R /5,3>=6=WR<[FQDF'08YION2460O+("]]#G<&_UR2ZF1X8\R.B0KK+UU%
MDV*(,4FF59%W86(F0P_C2N!L,;2_3ZS&;XSF^/ LD2*).:TFA?=<+1=Y$AC!
MIV.3P%)<Z8%LBX2&HD0=0;@92C"_:2&1P:JQG.85$>(0A'2T$_6Y7.L\17V-
M/M5%/63BZ*([8B9.Y$Y+H@]L%01$Z,$#SPOQ[<KB,IG,+Q^-L60:W P<EO<
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MG[,30#Z +U/9W!A0$0Z'X:M/%,(I$)8F:TIKY5 MS;>_1XKR9IOAOB\V-_[
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M!GET"@MHCMA[E-DO( 0/20RI_IW9KHL&PW( PW,D=5J?;<HJM-F<])J)$L]
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M;]7&6=J,(H[6=^Z5 P@-&G]L-7[# M3DM'HA9I_P:F&R:I#B'>@'U;PH)!.
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M-<G$-I0X1JU3J)\_F1NDU,UJ'5C1UX '4C<RO=R/D <(_YO.YTP,*4&D%N'
M6\,KB@AX.!#YI5-9=U([(FM(XBO JL"D?C[>>?+XV:,GGI:Q#9%Y@AS>BY*
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MN.34?DWXM&\6WK;V%><J:&?14<0SGW[.JM!$N/]*_U9A7!P-$@%)/J6N45(
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M,]S:94>O%\?N?KG?5V?+[4]@CLLBSX:;&WT"LXM/W%(B?0&'>:5PHE0OCI6
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MLS2A$BEE<,,35#:.IC-(@$!)GZ=YIC$P.2OQCUP:\'E?R92S</<)27<[U)"
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M%^,UO0JM2G/-/9FQY;EV,Y\B3Q@<W$7BR1$Y1L'LTAG.E!W2G90Y?X<%H;K
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MTVJ:?,ZF"^(K!56EL6Q#E:%Z>5C@F:&I$NEXQT5H >7WM@20TNB<0ZX,N9/
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M1OK):$F]@N?>4__7UV@NBVXW\]Q[ 0V6T? B3:]"5<J>3W]+.2U5\')./7Y
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M_4FQ8NK%2#$8U6G,73?JAC:+;$A;7$$O1Y%)H@F(8Y^M/-8>&;DBNI-R,9:
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M@59S.?D^_9/)HQ1H@.XOQ/KTCE_?W0,GLL^#%+:-9[N)?:"O2\WQX-9KY1.
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M4L"K>8??;;_-8ER%+@.!GC20G4BO$+Z)$^M-!0*C.I0A7Y9SM+PBZ*,_FLM
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M+! X'=/0].6R+*:JYZ?E9KQ6KNUE_HD]DHMB7'# KYY<Y%/P,P:TD0Y)[;.
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M"F#\K-X,7+Q-C$RPVMCL4E\9T0SPCXFP4(HH]:J,:A_0J;*11B,S^YT\U0W
M-W*3Y*&0!R<>+\HYW3'QN=(4N(WCBSQW&SWEIJDJRG5RVH \WZ(^3YSVO(#]
M]-M?=F]&V+A _>V-E T0CGGF#OT?%(#X*KOVO05^9A#U?V^6.0:W6MMZ,$AE
MHT1,?P?H0JK4NH2_8#%\@SWB-H0,;S@(C4U%SS(@MT*3*XO!B,C[?D;A#BP6
MJB[>4S=8$L4&M<JMZ0LF,LJB5TP9'E(*.U*Q0-V-NQHE,1Z587^P>W9V8#-,
M#)GAW3(\SW;(]HAFIBB=4\LR]^&7']\[2;74HQ (Z[@KC9.BH@3.&O2O.1_<
M'I$G^;O+;79Q'J6XS'1V[\$+FBM2YQ,G<^*'K+]U@OKB_@++$M+KJT=>7XJ9
MI9\Q@H9X:AG1),#7<6Z5,A&XI%QM#$/CUH(1^)ZITE?YUB24:B'=;!;\:^8$
M_L!%OJ<V$71 F9JH4$DNC88PD4(RS6Q\TE%US92UR!Y=D8GYFOL=OQ%'7\JK
MHIND]-FFSF>;N512AWA7RFV 3.NOF-ZFSA:,IO75U_-BV: :E'@ 3M]](=EG
M;-DM=(Q1*70V'+3NS(=_G32Z(9,*EO('S^S]M<:U*X([N1?!U?(VTTWC%((;
MZWH2G,WX=SB_(M=ML;2RS7#*F#@8ZVR M2B.FE79@DB3I=09I(<-DJG(F'EZ
M<'1,3%,M=QPY=AY8 &&XL04HD^ W(OR3T:J>M]DTLT*,&3MEXYR_"IY:JZN>
M18GY&)VE$0Y]0 P8,X9O^3"HM%"0R703V/OZ-"RCW*4O0W][&2%<D")X]6MQ
MY3*_ CEJUQ+*?)HEL[.9 5QFIB(N7M_J-1[RSMPR<?W]HTM</_F6N/X#E/_T
M7Z/\F1ZI7_=O89Q TS1MQV3JOIFLY]?,;N7_,H?$<&!.B1LU-1!?\T+#<)VI
MQ$Z5<T(J)]F9=FBA*O2K_H<HT]#V:NS.$S*[D,TD.A%W(&P6W;W_6BL.P0B9
MJ2:#26M]GAT\809)^N[9P5,I,PB%.O/=*WD)KO<K4]?;"5*-H(6Z&]V1VS&1
M!/FG")L_G;\YZ%_LH%.> +7Q*34H#JL5"#H\:D'("/_WPIE+U\DO5PC-Q2W
M@K^R) W6TJNFW:53@P#NDBY&.]7*M'33@O.[/''6_40.!5A'*IBH_?<-I5$/
MV9C[-VDR^1DRAH*HWM7Y7-E*C&@1(/S6)WV&3-F?5\+LRD4>[NZ5A^&&QPX'
MS>=Z<&[KP3XIJ>6> * C=G8E<&X/I/ 5A.Z:_#+C#&!=^^<W;_TXQ/Q^8@TB
MYODG9G*LZ7Q7 51V5W#6T)\VK-/1Y=?2$K4%K^10$)%'+X7]0]>UZQ?L43/%
M&W[#QFSWS9'-A<WCNY 1@L?WX,CFS*1.45IN>\:%"LMX0P,1@& 7C0DL/_P@
M&%^/2M;NQ[71OKVP9@65H+6D FND53/$EDEG)J01U&11"E>^H;[F6N9F;#0F
M>JDML^;4,FN.KTU5<3]IU^,0@?OQ9$0$.#2OI16SQ)^RD881D*M;0YPXU(D0
M]:!<PX&:9-!9$4>GLA,11W!4L'U3YS+_5 94Q\>[>Q+=.@RBJ71&CT,09O<I
M"%A4+PE$XC0O\HV>_ZJ.\?>L8I0P5IEJX;S2 (\N3 -:^V"O);5SM92@W/>(
MJ>6XZN"* @X3-':L*:Z(C8JZR:\:!I]$E9D0 H?CFL@)Z&2#W21G*8D/Y.]Q
MVBOG]RDWB))UM5ANG!*\7N% :.:E>KL/Q/DY@P)&;\+56H62I,89Z9N*"%&V
MN#7QM[2L%^,+1JF2K,EJ[;W+587V.Q-;L$Z@]SI?K^>YZM5"6Z5+=PM&TJ6<
M"FV60,2W[D8XYEFU1(/S"*MM8GTCH2,,I[/?VV75T+"@_N69 "<1R/RBQEFK
M5945=6#Y]>D+#E>]YS\][]_;[.IQ[*N+>S^88PK.F2Y M#I+*4GFI?.7S+G2
M(O9CO>,F5\V(,P"8H'DLP3%YBV?$RV.ZPY[G/H[5+_ZP8$?8R#TQ# E*F"""
M"(K-&CR.5?K]WVJ5! #"8,\HQ:.@^F9T*/K)</#X%OCC?2ZPGL0U@;YNM!:Z
M2,HZK%OBYO*6 3/B)-;:9>-9+5W03#.:&?;YG-A)]>JTWX!.:J?%ZUGFBZ3P
M!10U@9.S3]90>!QB,K]7&UB\(VIQS_E;ZFY;,DD:^(>8A3"/NC25U>TBA)/6
M.4!3]9X6Y5)%Q/PR,@CH\I0D5MD1G*U&/TI;GS@;KEC7H52N(\S7]]1&3,>.
M@5I-DFUKV(YA1Y:7,23-!ZFY"Q PG3I]1"2"9R.6E#.11SD;,8&S&XJ8J@]9
M?+>$R;QX=#"9I]]@,@].0R[NW9NI<CU/F_DTZ>$0APS,)?!3N+AYBV.XS]^_
MR%%==LU,D5QUG7;0#:BJ3AGU/5\3 4VI?)>55_#,=+3B[M7YIWW^)\6=A)57
M:_8:A9!PRT =3,0%S?XR?;]@&JHE6'VG>>WVZ!0Q,:,6MYN$INNXH+[%TE64
M)U9=1VN)^ ^#$1I^2:\LL^9?Q?\@D.!K82G=%QFA257X=N'&E[1L4O[63 *E
MG[=)-Y-.SDWFP7:_.L>">).<*M9-\:/)0RQL'F):#@>PK%$6'O@2)N#WF&85
M%8D) HR:!P2?\$\GZ>'A(?X_^?.;OZSFF_K/W[WY2[,75B8=MV>VG+X.A X*
M%M,'#@?T1![XQ_QZ'TPE\V*66Q9PI^LGCR8WLOR7N'>4_VPX>/U.W5;;L)73
MR (IID35Y7?6_'H<BUK>:\[3S_-P\#X8P^],X@,]0+S.D#T*+8 P*2N"/SWU
MVUO W_X'.X2AO&695O>Y3&%I@'V5M6G6-6#B6YX$7CJOY6ZG8(6=Y501QNC=
M[=;WZ- O\(JX@I:;Q4OB==[BT*%ZARBK3E5I0N9*WZ"\ X'_D&S(D%NEFD$Z
M6S_BM"JFH&OX6%!*5/.R(#R*=5$'T784JJ4GWCPM.XP>_8G]Q*X:<G\8OW=[
MUBG>_SY(_E94'RFO#;. ''40H$XM!3[UJ,T6Z,V]H-+Q%AW'C-I]L168:IL(
M0Y?I3=[A8.PT43)#EQB^?!]V$U7@7N87(!-E&L8E%2G"LIJ$P( T(*OR;J,Q
MT#=P,B@J/_,\CR0OVA^@T=8[E-]Q+$M,I' 7-$#EUDF9E@2?5^5FI57%>]OT
M6SAZ$E NRF_Q6C*W($08F6+:5/5M!"/Q RM&:0Q7T]&SR=1Z@1[DO26]=4ND
M\P[H4GFUY.DA0K"GA__10LA=EFNN:(*V:?XV%"'1/.WPMK,@^?;>^X:Y_N(3
MTDZPM,YJ4KGC1&MT)>WF)X\;F38:M3Z*I;I7Z'*\5/DG=WH;2I'7U)L; %QB
M Z$2GPOHF9)K/"<7^73C#H*CDP,N[Y2U?E74DWE9@SSN;;Y>/Q:0^;VB;\/1
M$*]9L11: 30QI*K5/$*!<+#(G?03A8L[ZXT9Z PW%Z&GBD^A>K1Q*I\)>.XM
MVD,EIH_#UCU&O.D9U2CA,;WW;K0[=3=A6\"?AEP)7ZO!W?/*%-ZC=T9S*PE:
M-=Y]$;5'=/^23O CJ6 SH19K@3==K"1C?#,9T8# 2!_,QR'_]XH(;DI].[E8
M43<G.F92S\JOGZ"_'P!_(B-8Y8DFK\;9\B/]Y?LZIIU!/(@@_Q%:=T;2K"GO
M6DZVMNST>^>/6W3N%4E\OLF(CEF2Y=V6X..8YWL%ZL9;](:J4_'QNE'[W2#]
MX&@9)ZE]GEQE##C14[%+4R@Z 44?( CUC*ZM8M@RPH4VCL3VPT&0P@?=FA;W
MPV;,70HH5O2*&RCV'W>/0P+O%?+;\CRVB7@W8W=S,EDICJ&G"9T008WP!^X:
M[4@5$+^@&*=T$=QYP01SE%Z1L 69)A)]"WI>>R(9,@XY1M)PGG!,?GQ-F!L6
MIIIKW839O8%\R./^PAS!N*'!\.,0P7M%QS9$\"J?_I?16"UZG<14ND40.:MJ
MZ%<]=<&W(?,DFG?G7], ;AGWW<<D_36+RZ_P:@V:HOXX>8>IQ:GV?R=;:SO$
MSHO#1X?8>?8-L?/@-.R](M!C#4O% 1*UFH$ '__$Z6D#"<"E5,784ZUJN#VS
MD H)7ADZ48&P6 5.93!Q,T;C43096&:=NIW@.5$32RBZ:4DJS-?VY+%QZ;L8
M2#^WG*YV/NI%,2;^:7_!Z&547,/\0-T:EN,IW2JVUU/ZG.$/!W<8OYVWNP\\
M/K@:;Q\;A?^RUV^O'J-W^E^_\4KQH7FS$'[.:!N">]?%^ASYZL,MD,OV+33R
MKZD3^8JZ=+R5+DV]:WYK8& XB/C,@GQKSY*T,U:@KIX[MYD2T< 4D3[-QKY;
MYZ3<=S*]*-79=W^C"T#.=96H[648X4OBB.5^8)UN/W<>GGKPU&8E&10A_55N
M5.>;7<H0*6 =&L[(UYES0?>T :&X>QXVL<KJVED0G%)SHO=(BLOOM8ZF%3$P
M^ -2E=P0"X6P>_^?O7=M:AS)UH6_.\+_03$Q,P$1*@:H2U=W]>D( ZXN]JX"
M7J"ZSYR.CAVR+8.F9,E;LJ'H7_^N6]YT,39@\.V<V-.%+4NIS)4KU^59S^*\
M@YV1WZY3?*1UG9NQ @UOHG2<QP6G1SDZ@S"[$O)2W(IH:1/3+TF YD6I>R:&
MM-Q>67IW6/J<D#[EY%Y=LW@KYEV9P%$!-\*M\HX>(2Q61=5J*H'L[ILTPUS)
M7#7%M;XKSC'.F.QO,V/XP513MFTQ.5<%(_O2!";F"!ZGQM9CT\VU*JDNEUF,
MQ-VFF1UE0P9)T.=NF7JY^6IE==LUM5%$/H]<M2#6Z/X1.)@,1\.^R#&2&0LE
ML$#&<VR>;H&]]2\-N-EZ/#5"BP.KOS3BI\:C%(7/&J7+4./L*BUR:"!5X==S
MJSL[80"#V+HP3<;449Z:M:/^0+\3KD?J88&)O=G=,XJ5$/$PWNXU[24[NROA
M1+ -*+%J']Z;6.*\:U-*.4^K4[)M.\""8VZS$_74/X/A$.LQY"]$8J TXU_2
M$ 9D)23Y-%%M%M4R7X,F48FDH<O:+_I<L?V3%CT)1PSADQZPOI?>A%DO@U/=
M;B.F>XYSGL"JAS$_+#0]W^SFN>/[)_E:A(_5G//$RJ++9K)P$(T'^6:1G@/=
M/VF1+%7)I#B:CBY,>BFLA4(3)>$5^)0!$SZ9;%^?K%0&\'(#Z"+S1<T:DV.R
M7HO\O_-<Y'$B&=5"V.N^T$0$KDWNQMJ.BO4.=05[Y8B(&SAV;K0>:YP]WT96
MP<P[*Y2OI<#[%/;(B]2PX]S-G./&O99K=' &SN2QT-,.QQFVV<W](D:D?..R
MDZ-; V>,950=?=7@N,*B/N5/SWS0<-=#RO)G-=:<"JYA!AHE&H(A?D^MWOJ4
MYHWFN1I"L$]N,P5,J7LP;#&K V4GC--;WW3J)7==FU[T%[7VS;%#>4_3XN'>
MA@W<$VZ<+'3[ I6J?XC MN*\*)PWLP?0BQ YZW8.+2"(&BSO%?H'"9XO9&UX
MO%C$+V#HG%6@:Y;AYH7DJ>HK"A? CK.^H$JL,IZV$%PLS%[=K,C->&T+>TO-
M3Z01@!3NZ#DH<K&Y= \F,*U,J;M8VJ# :3ZV?:.;K3(Z4)VC5T-PGH6-CJ^
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M,-_KL<7G6L52.MV=?<HG.$M7'6]I86/KX]^J-/-U6C.X2:.>"A7UTG%GY$2
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MRO_E37[B$7*W]+S/X76VDC(^!\E;C%LNYG22E?.T,KR1WY<7MK693G*AGUB
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MYCU3C]YNRV@_&HRID1PD?+:,TK2'1EXPHA>=, BZ!EZ4&RI%;(W"2XHF5D-
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M!"<8]SRF7(MTT?GC YZ!?_ZQ,\WC?W0>OVPR49V'/!_'X2N5;K/S?@*'V"?
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M\,0N%4&DK.(DI0<?^::,J*RK\>=\_13/H3,))P*.43I%1UR79%:@!^HEE3)
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M$[@4J@KU\;Z$"W3&=? DJJ@H8-Z%B2D<D"4%VR-B\PDD=T1X)G=&^<)<D9_
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M")QJN\9+ D=#8BEL7 (J=KMBC7WG>_]!I'',$I!3R"F.[WB5;9 ="G /FWC
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M?Y$/!)9NK.5PS:;ZB6?:G?!^&$Z::F]K3_:'IES*#9C&O31.N>!#KG109[[
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MSL);UQB!8\/%CX7MI!2!R]B,*[2A1C..G\CC&W4J3!-RKS9@PR7L.S L'7$
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M1;>/(;8,^RT3F2-:C?8&ZL=S&_H!7(=TC?*WA+_XA[A/^O.<QUM3Y EL2C)
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M+48/2573!I82#,/KXLIW?W1_,@^=!$>Y6R+8GM*%LZP"$] SVV1]UE5@+@[
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M6&[5KI-[L:J[+^4@\REY(ZJ $:8"EMI(HDU2X>XC6 0D08Z*0=Z(Q[6B5UR
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MK2W3?PL.]T8M?P:'8\>S[I#AJS\@("M%!G]<0!:+'B=.@EF9A1'JAPBMP")
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MK2!(9\A#I74VJDL"[#N;E>%!G+^E%PG3F>@4TL1\R/-IRQC(N:-@HTZ[RS9
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M/A7Y(7N'IC-$7\+ 1)GK)DAC'O04;ARLST&HV@]R Q/ QLK')=SE(!IGCJP
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M!;4X\MW5"#S>Z=NET:4Q>)*#)BD7W1%+5SGO&_AI09.0D^@\;-UN_&;=NS$
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ML0^R"+Z*?0RSZV&-$4^;N0XTD4*0;Z1,!,V+ZYS&Q8LD+;25 N&6WR4F#R3
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MIUWM9L_"):0RTZM\=H<L4YW;'[_PM*?=B;/='8;.PY&J.:2/"8VYB.TK+IG
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M^SB3A ,FKQJE(J*&^V M.Q<>_.GY8#Z20!68[F#:HH/<Z";NHY3\,[@.Y=M
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M^C9]^?KU_CT0)GVIAA'5\9;6''[0_58'(#T/:(L&]*B=WF5=?*9S]3R@3VY
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MN;+QN;+Q"6: SL'2_$*3"#:981,7KR*)"_I,2PM>XV%I)XGHQ]%" IUEF^7
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MN[643ST>NK)>@S^R'<1.D[(;BFAZD06+JNT%F@^#8K&":5DF7> 8V9R93Z]
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MI(@I4N"Z%Q01  ))QTDDU=KWEZ&0T;9JJ1,0F6D*P;Z5K%:M_[=N5[S3*-Z
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M=1KW$XN,3\S4*N?X6_#Q9CS2U;C0$5>(]XP13&0Z5CW1C^//S:=XQCQ*)?
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M4$L! A0#%     @ N3@C6UM&#3F7&P  .HL  !(              ( !%!8
M '1M,C4R-#DT-F0Q7SAK+FAT;5!+ 0(4 Q0    ( +DX(UM#M2%PD@(# )SR
M$P 6              "  =LQ  !T;3(U,C0Y-#9D,5]E>#$P+3$N:'1M4$L!
M A0#%     @ N3@C6]Z1/"\O#0  +"X  !8              ( !H30# '1M
J,C4R-#DT-F0Q7V5X.3DM,2YH=&U02P4&      8 !@"- 0  !$(#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2524946d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pgen-20250903.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2025-09-03</startDate>
            <endDate>2025-09-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-03" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-03" id="Fact000004">0001356090</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-03" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-03" id="Fact000010">2025-09-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-03" id="Fact000011">PRECIGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-03" id="Fact000012">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-03" id="Fact000013">001-36042</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-03" id="Fact000014">26-0084895</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-03" id="Fact000015">20374 Seneca Meadows Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-03" id="Fact000016">Germantown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-03" id="Fact000017">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-03" id="Fact000018">20876</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-03" id="Fact000019">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-03" id="Fact000020">556-9900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-03" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-03" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-03" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-03" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-03" id="Fact000025">Common Stock, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-03" id="Fact000026">PGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-03" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-03" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
